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  Summary 
Vitiligo is an acquired, non-contagious depigmenting skin disease results from epidermal 
melanocyte loss. Accumulating evidence suggests a role for autoimmunity in vitiligo 
aetiology, as antibodies and autoreactive T cells against melanocyte autoantigens can 
be detected in vitiligo patients. As part of determining the pathomechanisms involved 
in the development of vitiligo, identifying the specific targets of the immune reactivity 
in patients is a major goal in the vitiligo research field. A better understanding of vitiligo 
aetiology may help to develop successful treatment and diagnostic modalities.  
One of the main aims of this study was to identify novel autoantigens in vitiligo using 
phage-display technology; a melanocyte cDNA phage-display library was immuno-
screened with IgG from 22 vitiligo patients. Several autoantigens were enriched by this 
technique, including ones already known (tyrosinase, tyrosinase-related protein 1, 
melanocyte-specific protein PMEL, L-dopachrome tautomerase, heat-shock protein 90, 
ribosomal protein L24, and LaminA). Additionally, humoral immune reactivities were 
identified against previously unreported putative autoantigens glycoprotein non-
metastatic melanoma protein b (GPNMB), OCA2-encoded P protein (OCA2 protein), 
melanocortin-1 receptor, and GTP-binding protein Rab27A. 
The frequency of GPNMB, OCA2 protein, and LaminA antibodies in sera from healthy 
subjects (n = 100) and non-segmental (n = 231), segmental (n = 4) or focal (n = 11) vitiligo 
patients was investigated using radioligand binding assays (RLBAs). Healthy individuals 
were all negative for all antibodies tested. In the non-segmental vitiligo patient group, 
91/231 (39%) were positive for GPNMB antibodies and this was statistically significant 
when compared with healthy controls (P = < 0.0001). The frequency of GPNMB antibody 
was significantly higher in the non-segmental vitiligo patient group with active disease 
compared to those with stable disease (P = 0.006). OCA2 protein and LaminA antibodies 
were detected at an overall frequency of 22%. GPNMB, OCA2 protein, and LaminA were 
antibody targets in both patient groups with and without accompanying autoimmune 
disease. 
Overall, the study identified GPNMB, OCA2 protein, and LaminA as autoantigens in 
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1 General Introduction 
 The Skin 
Human skin is considered the largest organ of the body, comprising approximately 10% 
of the total body mass with an average surface area of 1.8 m2 (Sender et al., 2016). 
Although healthy skin is commonly taken for granted and not thought about in our 
everyday life, the importance of the skin is frequently underestimated (Menon, 2015). 
Skin diseases profoundly impact on physical comfort, psychologic well-being of patients 
and the quality of every aspect of personal and social life, affecting everyday functioning 
and socioeconomic status (Menon, 2015).   One study showed that 64% of patients with 
skin conditions suffered from experiencing embarrassment, anxiety, a lack of 
confidence, and depression (Jowett and Ryan, 1985). Moreover, 40% of interviewed 
patients reported limited employment opportunities and functional and interpersonal 
difficulties in the workplace (Jowett and Ryan, 1985). Even though not all systemic 
health problems result in skin diseases, skin is generally a mirror for overall health and 
provides a window on hereditary disorders of connective tissues (Holbrook and Byers, 
1989). Also, the skin is the main surface for medical treatment and nursing care ranging 
from delivery of transdermal drug to attaching devices to examine physiological 
functions (Menon, 2015).  
 Skin functions 
The skin has several functions; it provides an effective barrier against external chemical 
and physical assaults, ultraviolet (UV)-irradiation, and pathogen invasion (Rudikoff, 
1998, Proksch et al., 2008, Tay et al., 2014). The skin also regulates trans-epidermal 
water loss and body temperature, synthesises vitamin D3, and has significant cosmetic, 
social and sexual functions (Proksch et al., 2008, Menon, 2015). Additionally, the skin 
plays an important role in immunological surveillance as it encompasses a number of 
cellular immune components that reside in both the epidermis and dermis (Tay et al., 
2014). These immune cells afford protection against a wide range of pathogens while 
maintaining tolerance to innocuous antigens (Tay et al., 2014). However, they also 




 Structure of the skin 
Human skin consists of three structural layers; an outermost cellular avascular layer 
called the epidermis which arises from the embryonic ectoderm, the dermis, which is a 
dense vascularised tissue of mesodermal origin and an innermost layer called the 
subcutaneous layer which is composed primarily of fat and connective tissues (Figure 
1.1a). The epidermis comprises five histologically distinct layers, composed mostly of 
keratinocytes (Figure 1.1b). From the innermost outwards, these layers include the basal 
cell layer (stratum basale), the spinous cell layer (stratum spinosum), the granular cell 
layer (stratum granulosum), the transitional cell layer (stratum lucidum) and the horny 
layer (stratum corneum). 
The nomenclature of these layers is based on the differences in keratinocyte 
morphological appearance according to their stage in keratin maturation. The lower 
basal layer which is adjacent to the dermis comprises a single layer of columnar cells 
attached to the basement membrane via hemidesmosomes. The basal layer cells 
undergo a continual proliferation and differentiation as they move outwards to help 
form new keratinocytes that can replace the ones shed from stratum corneum. Above 
the basal cell layer are spinous keratinocytes that appear as prickles due to their 
protruding desmosomes which are filled with keratin filaments and which provide 
intracellular bridges. The granular cell layer consists of flattened keratinocytes. Their 
granular-like appearance is attributed to the aggregation of keratohyalin in their 
cytoplasm. The transitional keratinocytes constitute a thin layer and following full 
keratinisation and loss of their cellular contents, these form the outer squamous cell 
layer and are regularly shed off and substituted with new cells. 
As well as keratinocytes, the epidermis also contains Langerhans cells, Merkel cells and 
melanocytes. Langerhans cells are dendritic cells residing in the basal and suprabasal 
layers of the epidermis and are capable of antigen presentation to T cells (Friedmann, 
1981, Romani et al., 2003, Hunger et al., 2004, Wakim et al., 2008, Heath and Carbone, 
2009, Jiang et al., 2012, Seneschal et al., 2012, Doebel et al., 2017). Merkel cells are 
distributed throughout the epidermis and their function is associated with sensory 




2015, Schober et al., 2016). Melanocytes are responsible for the synthesis of skin 
pigments (Sulaimon and Kitchell, 2003, Goding, 2007, Videira et al., 2013, Reemann et 














Figure 1.1: Skin structure. 
(a) Human skin consists of a subcutaneous layer, the dermis, and the epidermis. The other main 
features are the sweat glands, sebaceous glands, and the hair follicles. (b) The epidermis consists 
of several layers based on the morphological appearance of the constituent keratinocytes. The 









Melanocytes are melanin-producing cells residing mainly in the cutaneous epidermis, 
hair follicle, uveal tract, inner ear, and leptomeninges, and are responsible for 
determining skin, hair and eye colour (Sulaimon and Kitchell, 2003, Goding, 2007, Plonka 
et al., 2009, Nishimura, 2011, Bastian, 2014, Hong et al., 2015, D'Mello et al., 2016). They 
are pyramidal cells with numerous dendritic projections (Figure 1.2), and arise from 
melanoblasts that originate in the embryonic neural crest (Fore, 2006, Santiago-Walker 
et al., 2009, Mull et al., 2015, Zonunsanga, 2015). Undifferentiated melanoblasts in 
approximately seven-week-old human embryos migrate into the developing epidermis 
and ultimately reside in the epidermal basal cell layer (Holbrook et al., 1989, 
Zonunsanga, 2015). In adult skin, melanocytes are found at a density of around 800-
2000 cells/mm2 (Staricco and Pinkus, 1957, Fitzpatrick and Szabo, 1959, Thingnes et al., 
2012), and account for approximately 5-10% of the cellular population in the epidermis 
(Holbrook et al., 1988, Chung et al., 2011, Thingnes et al., 2012, Zonunsanga, 2015). 
The principle function of melanocytes is the synthesis of melanin, which protects the 
genome of proliferating keratinocytes and melanocytes from UV-induced DNA damage 
(Gasparro, 2000, Kadekaro et al., 2003, Plonka et al., 2009, Abdel-Malek et al., 2010, 
Hong et al., 2015, D'Mello et al., 2016). Additionally, melanin efficiently absorbs reactive 
oxygen species (Korytowski et al., 1987, Abdel-Malek et al., 2010, Cichorek et al., 2013), 
and thus protects metabolically active keratinocytes and melanocytes from oxidative 
stress (Sulaimon and Kitchell, 2003, Hoogduijn et al., 2004). Melanin is synthesised in 
bound-membrane organelles called melanosomes (Setaluri, 2003, Barral and Seabra, 
2004, Raposo and Marks, 2007, Yamaguchi and Hearing, 2014, Zonunsanga, 2015), 
which are transported along dendritic projections to surrounding keratinocytes (Scott et 
al., 2002, Watabe et al., 2008, Ando et al., 2012, Thingnes et al., 2012, Cichorek et al., 
2013, Hong et al., 2015). 
Keratinocytes act on melanocytes by synthesising several factors that support the 
growth, melanisation and survival of adjacent melanocytes (Lee et al., 2005, Faria et al., 
2014). They generate the essential microenvironment for melanocyte proliferation, 




receptors of melanocytes (Carlson et al., 2007, Faria et al., 2014). Each melanocyte 
communicates with approximately thirty-six keratinocytes forming an epidermal 
melanin unit (Fitzpatrick et al., 1967, Seiberg, 2001, Lin and Fisher, 2007, Cichorek et al., 
2013). Such close interaction between melanocytes that synthesise melanin and 
keratinocytes that receive it contribute to skin pigmentation (Westerhof, 2006, Faria et 
al., 2014). 
Melanocytes are situated in the epidermal basal layer at a ratio of 1 to every 5 of basal 
keratinocytes (Lee et al., 2005, Faria et al., 2014). This balance is maintained via 
controlled induction of melanocyte division (Haass and Herlyn, 2005, Faria et al., 2014). 
To proliferate, melanocytes need to separate from the basement membrane and from 
keratinocytes, pull back their dendritic tips, divide, migrate via the basement membrane 
and finally attach themselves to the matrix and keratinocytes, forming another 
epidermal melanin unit (Haass and Herlyn, 2005, Faria et al., 2014). There is no 
difference in the epidermal melanin unit between ethnic groups (Cichorek et al., 2013), 
and the difference of skin colour among these groups is attributed to the different rates 
of melanin synthesis (Iwata et al., 1990, Cichorek et al., 2013), the different type of 
pigment produced (Cichorek et al., 2013), and the way in which melanin is scattered 
within keratinocytes (Szabo et al., 1988). Besides melanin synthesis, melanocytes also 
serve as accessory cells in the skin immune response (Das et al., 2001, Tam and Stepien, 
2007, Cichorek et al., 2013). They are capable of expressing cytokines which lead to the 
maturation of antigen-presenting cells and to the recruitment of immune cells into the 
skin (Zachariae et al., 1991, Swope et al., 1994, Lu et al., 2002, Cichorek et al., 2013). 
Moreover, melanocytes are able to behave as antigen-presenting cells due to the 
expression of intercellular adhesion molecule-1 (ICAM-1) and class I and class II antigens 
of the major histocompatibility complex (MHC) (Krasagakis et al., 1991, Le Poole et al., 












Figure 1.2: Melanocytes growing in culture. 
The image shows melanocytes in culture at x200 magnification. The dendritic projections of 
melanocytes are visible. The image was used with kind permission from Miss Chariklia Balafa 
















1.1.4.1 Key components of the melanin synthesis pathway 
To initiate melanogenesis, melanosomes and the enzymes responsible for melanin 
synthesis are made independently in the smooth and rough endoplasmic reticulum of 
melanocytes, respectively (Pawelek et al., 1980, Urabe et al., 1994).  Melanogenesis 
(Figure 1.3) is tightly regulated by a multi-enzyme complex (D'Mello et al., 2016) which 
includes tyrosinase, tyrosinase-related protein 1 (TYRP1) and L-dopachrome 
tautomerase (DCT), previously referred to as tyrosine-related protein 2 (TYRP2) (Gillbro 
and Olsson, 2011, D'Mello et al., 2016). The process begins with the hydroxylation of L-
tyrosine to L-dihydroxyphenylalanine (L-DOPA), which is subsequently oxidised to L-
dopaquinone (Gillbro and Olsson, 2011, D'Mello et al., 2016). These first two steps of 
melanin synthesis are catalysed by tyrosinase (Gillbro and Olsson, 2011, D'Mello et al., 
2016). Of particular note, the levels of L-tyrosine for melanin production depends on the 
conversion of L-phenylalanine by phenylalanine hydroxylase activity (Gillbro and Olsson, 
2011, Videira et al., 2013, D'Mello et al., 2016). 
Following L-dopaquinone formation, the melanogenesis pathway is divided into the 
production of brownish black eumelanin and red/yellow pheomelanin (Gillbro and 
Olsson, 2011, D'Mello et al., 2016). In the pheomelanin pathway, L-dopaquinone reacts 
with cysteine, if available, to form cysteinyl-dopa, which is the substrate for red-yellow 
pigment formation (Gillbro and Olsson, 2011, Pillaiyar et al., 2017b). L-dopaquinone can 
also cyclise to generate DOPAchrome, which can then spontaneously decarboxylate to 
5, 6-dihydroxyindole. This product immediately oxidises and polymerises to yield dark 
brown/black coloured pigment (D'Mello et al., 2016, Pillaiyar et al., 2017b). If DCT is 
available, DOPAchrome will form 5,6-dihydroxyindole-2-carboxylic acid, which can 
oxidise and polymerise to produce lighter brown pigment (D'Mello et al., 2016, Pillaiyar 




1.1.4.2 Regulation of melanin synthesis 
Melanin synthesis is regulated by signalling pathways and transcription factors and can 
be controlled at several levels (Pillaiyar et al., 2017b). During the development of 
embryos, melanoblasts (melanocyte precursor cells) are generated from the neural crest 
and migrate to different destinations such as the basal layer of skin epidermis and hair 
follicles (D'Mello et al., 2016, Pillaiyar et al., 2017b). The migration pattern of 
melanocytes is the first level of melanogenesis regulation (Pillaiyar et al., 2017b). 
Subsequently, melanogenesis is regulated at a cellular level through the formation of 
melanosomes, whose size, quantity and density are dependent on melanin content 
(Pillaiyar et al., 2017b). Finally, melanin synthesis is regulated at a subcellular level 
through control of the expression of genes encoding specific melanogenic enzymes such 
as tyrosinase (Pillaiyar et al., 2017b). 
A variety of extrinsic and intrinsic factors can influence the initiation and extension of 
melanin synthesis (Figure 1.3) (Pillaiyar et al., 2017b). Extrinsic factors encompass UVB 
radiation and chemicals, whereas intrinsic factors are various molecules secreted by 
keratinocytes, melanocytes, and fibroblasts, inflammatory, neural and endocrine cells 
(Videira et al., 2013). In UVB-induced melanogenesis, the paracrine cross-talk between 
melanocytes and keratinocytes within the epidermis is essential (Pillaiyar et al., 2017b). 
Following exposure to UVB, keratinocytes potently stimulate or secrete a variety of 
cytokines such as α-melanocyte-stimulating hormone (α-MSH) and its receptor, 
melanocortin 1 receptor (MC1R), endothelin-1 (EDN-1), interleukin (IL)-2, basic 
fibroblast growth factor (b-FGF), and adrenocorticotropic hormone (ACTH) (Pillaiyar et 
al., 2017a, Pillaiyar et al., 2017b). These factors that have a paracrine effect on 
melanocytes triggering melanin synthesis via various signalling pathways (Pillaiyar et al., 
2017a, Pillaiyar et al., 2017b).  
Signalling from MC1R has been established to be the main factor dictating melanin 
synthesis (D'Mello et al., 2016). There are three main ligands for MC1R, namely, α-MSH, 
ACTH and agouti signalling peptide (ASP) (Videira et al., 2013, D'Mello et al., 2016). 
Normally, ASP and α-MSH compete to bind to MC1R (Videira et al., 2013). When ASP 




MSH or ACTH binds (Videira et al., 2013, D'Mello et al., 2016). Both ACTH and  α-MSH 
are derived from a precursor peptide known as pro-opiomelanocortin (POMC) which is 
synthesised by both the pituitary gland and epidermal keratinocytes permitting local 
paracrine regulation (Videira et al., 2013, D'Mello et al., 2016, Pillaiyar et al., 2017b). 
Following MC1R ligand binding, melanogenesis is increased via activation of cyclic 
adenosine monophosphate (cAMP) pathway (Choi et al., 2016, Pillaiyar et al., 2017b). 
Production of cAMP leads to the activation of protein kinase A (PKA) and cAMP-
responsive element binding protein (CREB), which in turn induces microphthalmia-
associated transcription factor (MITF) expression (Choi et al., 2016, Pillaiyar et al., 
2017b). The MITF is a master regulator of melanin synthesis that upregulates the 
expression of the related melanogenic enzymes, tyrosinase, TYRP1 and DCT, and 
melanocyte development (Choi et al., 2016, Pillaiyar et al., 2017b). Furthermore, the 
MITF protein regulates the expression of GTP-binding protein Rab27A protein and 
melanocyte-specific protein (PMEL), previously known as Pmel17 or gp100) (Pillaiyar et 
al., 2017b). The former is important in melanosome transport, while the latter plays a 
vital role in the structural organisation of pre-melanosomes (Bissig et al., 2016, Pillaiyar 






Figure 1.3: Melanin synthesis. 
Eumelanin and pheomelanin are produced within melanosomes of melanocytes by a sequence 
of reactions that are catalysed by melanogenic enzymes. Synthesis of such enzymes is driven by 
the microphthalmia-associated transcription factor (MITF) whose activity is controlled by a 
number of signalling pathways such as protein kinase C (PKC), cyclic AMP (cAMP), mitogen-
activated protein (MAP) kinase (MEK), and Wingless-related integration site (WNT). These 
signalling pathways are activated upstream by receptors including KIT with ligand stem cell 
factor (SCF) and melanocortin 1 receptor (MC1R) with ligands α-melanocyte-stimulating 
hormone (α-MSH), adrenocorticotropic hormone (ACTH) and agouti signalling peptide (ASP). 
The image, from a paper by D'Mello et al. (2016), was used with kind permission from MDPI-
publisher of open access journals, St. Alban-Anlage 66, 4052 Basel, Switzerland. DAG, 
diacylglycerol; PAH, phenylalanine hydroxylase; PKA, protein kinase A; CREB, cAMP response 
element-binding protein; DCT, L-dopachrome tautomerase; GPCR, G protein-coupled receptors; 
ERK, extracellular signal–regulated kinases; POMC, pro-opiomelanocortin;  TYR, tyrosinase; 
TYRP1, tyrosinase-related protein-1; PMEL, melanocyte-specific protein PMEL; SOX10, 





 Clinical Characteristics, Epidemiology, and Treatment of Vitiligo  
 Definition of vitiligo 
Vitiligo is an acquired depigmenting skin disorder characterised by the development of 
circumscribed white macules (patches) as a consequence of the loss of functional 
melanocytes from the epidermis (Taïeb et al., 2007). 
 Signs of vitiligo  
The most apparent sign or symptom of vitiligo is the depigmented patches on the skin. 
The disease initially occurs as small patches but subsequently these patches are usually 
enlarged over time. The lesions typically and initially appear on the face, hand and wrist 
(Ghafourian et al., 2014, Roy, 2017). Rare signs of the disease are depigmentation or 
greying of scalp hair, eyebrows, eyelashes or other hair-bearing areas (Ezzedine et al., 
2012b, Roy, 2017). Also some patients may experience depigmentation on the tissues 
that line the eye membrane and the mucosal membranes such as the oral and/or genital 
mucosae (Farajzadeh et al., 2009, Roy, 2017). In addition, a number of vitiligo patients 
suffer from intense tactile sensation at depigmented areas throughout active stages 
(Birlea et al., 2008a, Roy, 2017). Patients suffering from vitiligo often suffer from 
depression (Al'Abadie et al., 1994a, Kent and Al'Abadie, 1996, Ghafourian et al., 2014). 
The diagnosis of vitiligo is primarily based on the clinical characteristics of pigmentation 
loss from the skin (Iannella et al., 2016). A Wood’s lamp can be used to optimally 
evaluate some uncertain patches, by which the specific milky fluorescent aspect of 
vitiliginous skin can more easily be observed (Picardo et al., 2015, Iannella et al., 2016). 
Given its high incidence in vitiligo patients, autoimmune thyroiditis should be screened 
for in patients suffering from vitiligo using thyroid function tests and the measurement 
of anti-thyroid antibodies (Picardo et al., 2015). In addition, a biopsy or other specific 
tests may be necessary to differentiate vitiligo from other conditions of decreased 
pigmentation like pityriasis versicolor, tuberous sclerosis, piebaldism, and 




undoubtedly diagnosed, vitiligo clinical type can be determined from the extent and 
distribution of depigmented patches. 
 Clinical types of vitiligo 
Even now, vitiligo clinical types have neither been uniformly understood nor reliably 
classified. The simplest classification of vitiligo was proposed by Koga (1977), in which 
vitiligo divided into segmental and non-segmental types based on the extent and 
distribution of the lesions. For decades there was no proper global joint effort to create 
a worldwide consensus on classification of vitiligo, until an article from the Vitiligo Global 
Issues Consensus Conference (VGICC) was published (Ezzedine et al., 2012b). The VGICC 
used the classification proposed by Taïeb et al. (2007) in order to achieve a broader 
international consensus on vitiligo classification. According to the consensus 
recommendations of the VGICC (Table 1.1) (Ezzedine et al., 2012b), vitiligo is classified 
in the clinical types which are described below. 
1.2.3.1 Non-segmental vitiligo 
Non-segmental vitiligo is characterised by symmetrical bilateral white macules (Figure 
1.4a) and includes a group of several patterns; acrofacial, mucosal, 
generalised/symmetrical, universal, and mixed types as well as rare variants (Figure 1.4). 
Acrofacial vitiligo affects the distal fingers and toes, and facial orifices (Figure 1.4b).  
Mucosal vitiligo affects the oral and/or genital mucosae involving more than one 
mucosal site (Figure 1.4 c), and it can be present in patients suffering from acrofacial, 
generalised, or universal forms. However, when only one mucosal site is affected, this 
type of vitiligo is classified as undetermined. 
Generalised/symmetrical vitiligo, formerly known as vitiligo vulgaris, is characterised by 
a bilateral, symmetrical distribution of patches (Figure 1.4a). It can affect any site of the 
body, but mostly the fingers, hands, and face. Universal vitiligo involves 80-90% of the 
body surface. It mostly occurs in adulthood and is usually preceded by the generalised 




vitiligo (Figure 1.4d). Mostly, the segmental type precedes the non-segmental form 
(Figure 1.4d). 
Rare variants of vitiligo were considered originally as unclassified. They include punctate 
vitiligo which has sharply demarcated depigmented punctate macules and can involve 
any site of the body (Figure 1.4e), minor vitiligo which is characterised by partial defects 
in skin pigmentation (Figure 1.4f), and follicular vitiligo which affects the follicular 
reservoir and limited skin area (Figure 1.4g). 
1.2.3.2 Segmental vitiligo 
Segmental vitiligo can affect one or more areas of the skin (Figure 1.4h and i). The most 
common form of segmental vitiligo is unisegmental which is characterised by one or 
more white lesions on one side of the body, often respecting the midline of the body, 
body hair involvement, and rapid development of the condition (Figure 1.4h). Rarely, it 
can affect more than one area with either a unilateral or bilateral distribution (Figure 
1.4i). In contrast to non-segmental vitiligo, segmental vitiligo demonstrates a rapidly 
progressive but limited course, early onset, and a lesser association with autoimmune 
diseases. It also shows stable results with autologous grafting and early involvement of 
the hair compartment after onset. There is often an undistinguishable pattern from 
nevus depigmentosus in patients with early onset segmental vitiligo (Table 1.2) (Kovacs, 
1998, Taieb and Picardo, 2009, Ezzedine et al., 2012b). 
1.2.3.3 Unclassifiable or undetermined vitiligo 
Unclassifiable or undetermined vitiligo includes focal vitiligo which is characterised by 
small isolated depigmented macules without a segmental distribution (Figure 1.4j). It 
can evolve into either segmental vitiligo or non-segmental vitiligo. Also, mucosal when 
only one mucosal site is affected. 
In addition, based on the clinical patterns, there are also some rare morphological 
variations of vitiligo namely inflammatory vitiligo and trichrome vitiligo. Inflammatory 
vitiligo presents with erythema at peri-lesional borders and frequent itching (Karelson 




or complete depigmentation within each lesion and hyperpigmentation of normally 
pigmented skin neighbouring the vitiligo lesions (Hann et al., 2000, Karelson et al., 2009). 
However, these two forms of vitiligo are not present in the vitiligo classification table of 
the latest international consensus conference (Ezzedine et al., 2012b), possibly because 
these are regarded as a temporary phenomenon of a restricted area of active spreading 




Table 1.1: Vitiligo classification of the Vitiligo Global Issue Consensus Conference 
 
Clinical type of 
vitiligoa 
Clinical subtypesa Remarksa 





Mixed (associated with 
segmental vitiligo) 
Rare variants 
Subtyping may not reflect discrete 




Often segmental vitiligo in mixed 




Further classification according to 
lesional distribution pattern is 





Mucosal (only one mucosal 
site)  
This category is meant to allow 
time, after sufficient observation to 
make a conclusive classification. 
 





Figure 1.4: Clinical subtypes of vitiligo. 
The figure shows vitiligo subtypes (a) generalised non-segmental, (b) acral, (c) mucosal (d) 
mixed, (e) punctate, (f) minor, (g) follicular, (h) unisegmental, (i) bisegmental, and (j) focal. Figure 
(a) was used with kind permission from Medknow Publications and Media Pvt. Ltd. (Mumbai, 
India) from an article by Attili and Attili (2013). Figures (b), (h) and (j) were used with kind 
permission from Medknow Publications and Media Pvt. Ltd. (Mumbai, India) from an article by 
Palit and Inamadar (2012). Figures (d), (e), (f), (g), and (i) were used from an article by Ezzedine 
et al. (2012b) with kind permission from John Wiley and Sons. Figure (c) is used from DermNet 





Table 1.2: Typical characteristics of segmental and non-segmental vitiligo  
 
Segmental vitiligoa Non-segmental vitiligoa 
Often manifests in childhood Later onset, at all ages 
Rapid onset with limited course 
Progressive onset with unpredictable 
course 
Rapid involvement of hair after onset Later stages of hair involvement 
Rarely associated with autoimmune 
diseases 
Common personal and/or family records 
of autoimmune diseases 
Good results with autologous grafting 
Usually relapses following autologous 
grafting 
Sometimes undistinguishable from nevus 









 Activity status of vitiligo  
The course of vitiligo is unpredictable, but is often episodically progressive with phases 
of stabilised depigmentation (Gawkrodger et al., 2010). Vitiligo is classified as stable if 
no new patches or growth of old lesions had appeared for the previous 12 months, and 
as active if existing macules were enlarged or new lesions were developed within the 
previous 12 months (Gawkrodger et al., 2010, Ezzedine et al., 2012b, Benzekri and 
Gauthier, 2017). In most cases, the course of segmental vitiligo is rapidly stabilised over 
a few months following partial or complete skin depigmentation of the affected skin 
segment, whereas the course of non-segmental vitiligo is usually unpredictable (Picardo 
et al., 2015). 
 Associated diseases 
Several studies have revealed that patients with vitiligo are more likely to suffer from 
autoimmune disorders than those in the general population (Table 1.3) (Cunliffe et al., 
1968, Tunbridge et al., 1977, Schallreuter et al., 1994b, Alkhateeb et al., 2003, Liu et al., 
2005, Birlea et al., 2008b, Narita et al., 2011). A survey of nearly 3,000 vitiligo patients 
showed one additional autoimmune disease was present in 30% of them, and increased 
frequencies of Addison’s disease, autoimmune thyroid disease, pernicious anaemia, and 
systemic lupus erythematosus were reported (Alkhateeb et al., 2003). Furthermore, 
vitiligo patients with a family history of vitiligo have been revealed to have a high 
frequency of other autoimmune disease (Laberge et al., 2005, Zhang et al., 2009). 
However, the occurrence of the overall concomitant autoimmune diseases in patients 
with vitiligo varies, and depends on the population studied. Even within a specific 
country, pockets of variance exist (Table 1.3). Furthermore, the frequency of an 
individual autoimmune disease in vitiligo patients is also variable (Table 1.4). Overall, 
the association of vitiligo with autoimmune disease suggest that in some patients an 
autoimmune mechanism might be involved in vitiligo pathogenesis (Kemp et al., 2001b). 
Of note, non-segmental vitiligo shows a greater association with autoimmune diseases 
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1.56% Taiwan (Chen et al., 2015) 
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 Psychological issues 
Since vitiligo is not a life threatening disease and does not cause any physical disabilities, 
it is often perceived as a minor cosmetic disorder (Salzes et al., 2016, Cupertino et al., 
2017). However, changes in physical appearance caused by the disease may induce 
serious psychological harm, particularly in dark-skinned patients in whom the pale 
patches are very apparent (Linthorst Homan et al., 2009, Ezzedine et al., 2015). In the 
event of social contact, vitiligo patients commonly experience feelings of stress, unease, 
embarrassment, negative self-image or self-consciousness (Kent and Al'Abadie, 1996, 
Ingordo et al., 2012, Picardo et al., 2015, Salzes et al., 2016, Grimes and Miller, 2018). 
More generally, perception of discrimination, social isolation, loss of self-esteem, and 
stigmatisation are common, particularly in patients with visible patches affecting areas 
such as the face and hands, and these can have a major negative impact on patient’s 
quality of life (Dolatshahi et al., 2008, Choi et al., 2010, Salzes et al., 2016, Cupertino et 
al., 2017, Yang et al., 2017c, Grimes and Miller, 2018).  
In some countries such as India, vitiligo is still confused with leprosy and patients are 
subjected to antagonism, insult, social stigma, or isolation (Parsad et al., 2003a, Ezzedine 
et al., 2015, Grimes and Miller, 2018). Furthermore, in patriarchal societies, with respect 
to marriage, for example, women’s beauty is of great value in the market of arranged 
marriages, thus the psychosocial burden on females is greater (Shenoi and Prabhu, 2013, 
Cupertino et al., 2017, Grimes and Miller, 2018). However, vitiligo can also have a 
negative impact on the marital status and sexual health in males owing to 
embarrassment and loss of self-esteem (Dolatshahi et al., 2008, Ezzedine et al., 2015). 
Moreover, previous reports have demonstrated that vitiligo patients with decreased 
quality of life at treatment initiation face a lower response rate to a given therapy 
(Parsad et al., 2003b, Salzes et al., 2016). Therefore, the development of specific 
psychological intervention and quality of life measures may affect positively the 
outcome of vitiligo treatment and enhance the patient’s self-esteem and confidence 





 Vitiligo prevalence 
Vitiligo is the most common cause of skin depigmentation worldwide (Picardo et al., 
2015). It has an estimated worldwide prevalence of less than 0.6% (Howitz et al., 1977, 
Das et al., 1985, Singh et al., 1985, Boisseau-Garsaud et al., 2000a, Wang et al., 2013). 
Some studies report a prevalence of 0.4% to 2% in certain population (Figure 1.5) (Kruger 
and Schallreuter, 2012), with peaks of up to 4% and 8.8% noted in Mexico and India, 
respectively (Sehgal and Srivastava, 2007). This may be due to an apparent colour 
contrast and social stigma that may force vitiligo patients to seek an early consultation, 
as well as to occupational factors where vitiligo may be related to chemically-induced 
depigmentation by industrial reagents (Sehgal and Srivastava, 2007). In addition, 
variability in epidemiological data could also be attributable to variances in disease 
classification, unavailable simple laboratory tests, inconsistent reporting by vitiligo 
patients, selection bias of hospital-based studies and varied populations with different 
ethnic backgrounds (Shah et al., 2008, Picardo et al., 2015). 
Non-segmental vitiligo is the most frequent type of the disease. The 
generalised/symmetrical subtype (previously called vitiligo vulgaris) has been the most 
frequently reported morphological pattern in several published studies, accounting for 
39-83% of the subjects (Handa and Kaur, 1999, Dogra et al., 2005, Liu et al., 2005, Mason 
and Gawkrodger, 2005, Singh and Pandey, 2011, Vora et al., 2014). The second most 
common subtype is acrofacial, which is reported to be between 17-35% of cases in 
different clinical studies (Dave et al., 2002, Martis et al., 2002, Nejad et al., 2013, Vora 
et al., 2014). Universal vitiligo has been shown to present in 0.5-18% of subjects with 
the disease (Dogra et al., 2005, Wang et al., 2013). Segmental vitiligo is less common 
than the non-segmental form and its prevalence ranges from 5-16% of overall vitiligo 
cases (Hann and Lee, 1996, Silverberg, 2010, Ezzedine et al., 2015). Only a few studies 
have reported cases of mixed vitiligo (Mulekar et al., 2006, Ezzedine et al., 2011, van 










Figure 1.5: Worldwide prevalence of vitiligo. 
The white and yellow boxes indicate the prevalence of vitiligo in the general population and 
children/adolescents, respectively. The image is used with kind permission from John Wiley & 





 Gender distribution 
Individuals of both genders can be affected by vitiligo (Sun et al., 2005, Taïeb and 
Picardo, 2010, Pradhan et al., 2013). However, epidemiological studies have reported 
contradictory views of the incidence of vitiligo in both genders. While some studies have 
demonstrated that vitiligo, like most autoimmune diseases, is more common in females 
(Shah et al., 2008, Singh and Pandey, 2011, Esfandiarpour and Farajzadeh, 2012, Vora et 
al., 2014, Zhang et al., 2016), others have shown a greater proportion of the male 
population is affected (Koranne et al., 1986, Handa and Kaur, 1999, Khaitan et al., 2012). 
The social stigma associated with vitiligo in women may contribute to the former 
findings (Patil et al., 2014). However, most studies have reported that both genders are 
affected almost equally (Dutta and Mandal, 1969, Howitz et al., 1977, Das et al., 1985, 
Dave et al., 2002, Alkhateeb et al., 2003, Liu et al., 2005, Shajil et al., 2006, Sehgal and 
Srivastava, 2007, Kyriakis et al., 2009, Taieb and Picardo, 2009, Ezzedine et al., 2015). 
 Onset age 
Vitiligo can appear at any age and disease onset age varies between studies from 
different countries (Sun et al., 2005, Taïeb and Picardo, 2010, Pradhan et al., 2013). The 
most common age for the onset of vitiligo is 10-30 years. In approximately half of 
patients, vitiligo manifests by the age of 20 years and 70-80% of cases develop the 
disorder before the age of 30 years (Herane, 2003, Zhang et al., 2004, Liu et al., 2005, 
Sehgal and Srivastava, 2007, Taïeb et al., 2007).  However, an epidemiological study in 
Denmark found that the age of onset of vitiligo most frequently ranged between 40-60 
years (Howitz et al., 1977). Segmental type vitiligo has been found to be more 
characteristic of children and young adults with a median age at onset of 12-16 years in 
most studies (Barona et al., 1995, Liu et al., 2005, Khaitan et al., 2012). It can account 
for nearly a third of paediatric cases (Halder et al., 1987, Nicolaidou et al., 2012, Shankar 
et al., 2012) and only for 0-4.5% of adult patients (Dogra et al., 2005, Mason and 
Gawkrodger, 2005). However, the segmental form has been reported to affect less than 
8% of children with vitiligo in a Jordanian study conducted on 71 children with vitiligo 




years) was reported in China (Wang et al., 2013). In contrast to segmental vitiligo, non-
segmental forms develop at all ages (Picardo et al., 2015). 
 Family history of vitiligo 
A number of studies have investigated the effects of a positive family history on the 
occurrence of vitiligo. These indicate that the familial occurrence of the disease varies 
from one region of the world to another and lies between 12% and 36% (Pradhan et al., 
2013). However, a family history as high as 40% has been found in some areas of India 
(Sehgal and Srivastava, 2007). Consanguineous  marriage may account for an increased 
incidence of family history of vitiligo in specific regions of the world (Silverberg, 2015). 
Vitiligo patients who had consanguineous cases affected with vitiligo showed an earlier 
age of onset of disease (Pajvani et al., 2006, Alzolibani, 2009). Family history and early 
onset imply a role for a genetic factor in vitiligo pathogenesis (Kumar et al., 2014). 
 Histopathology  
The depigmented area in vitiligo is histologically characterised by melanin loss and 
reduced numbers of melanocytes in the epidermis (Figure 1.6) (Husain et al., 1982, Tobin 
et al., 2000, Li et al., 2013, Ezzedine et al., 2015). This decrease varies according to the 
disease stage (Ezzedine et al., 2015). However, there are reports demonstrating that 
vitiligo lesions can be completely devoid of melanocytes (Le Poole et al., 1993c, Le Poole 
et al., 1996, Yaghoobi et al., 2011). Melanocytes from vitiligo patients also show 
morphological and physiological abnormalities (Li et al., 2009b). Those in peri-lesional 
borders are seen to be enlarged with longer dendritic ends (Le Poole et al., 1993c, Faria 
et al., 2014). Moreover, vacuolar degeneration of basal cell layer melanocytes, 
epidermal and dermal infiltration of lymphocytes (Figure 1.7), and melanin granules in 
the upper dermis can occur in the uninvolved skin adjacent to vitiligo macules (Hann et 
al., 1992, Pretti Aslanian et al., 2007, Anbar et al., 2009, Faria et al., 2014). In addition to 
melanocyte abnormalities, Benzekri et al. (2015) and Picardo et al. (2015) have 
demonstrated abnormalities in the keratinocyte phenotype in both the peri- lesional 










Figure 1.6: Loss of melanocytes in the vitiligo epidermis. 
The figure shows (a) melanocytes in the normal epidermis, and (b) melanocyte loss in the 
vitiliginous epidermis. Both sections had been treated with dihydroxyphenylalanine stain, which 
identifies tyrosinase activity and reveals melanocytes in brown. Taken with kind permission from 





















Figure 1.7: Lymphocyte infiltration at the edge of a vitiligo lesion. 
The skin section was treated with hematoxylin and eosin stain and is shown at a magnification 
of x400. The image is used with kind permission from Medknow Publications and Media Pvt. Ltd.  














 Treatment modalities 
As the exact aetiology of vitiligo is yet unknown, there are no efficient therapies 
available to alter the underlying cause of melanocyte loss. Therefore, the positive results 
of repigmenting treatments are usually unsustained, and patients have to use cosmetics 
to cover their depigmented patches. However, spontaneous repigmentation has been 
reported in 1%-25% of vitiligo patients (Iannella et al., 2016). Treatments available for 
vitiligo include topical and systemic medications, phototherapy and surgical procedures, 
which together may serve to arrest vitiligo progression, stabilize depigmented macules 
and obtain skin repigmentation (Rodrigues et al., 2017a) and these are listed in Table 
1.5. Often, medical treatments are combined for greater efficacy. 
1.2.12.1 Topical therapies 
This class of drugs includes topical corticosteroids, topical immunomodulators, and 
antioxidants (Table 1.5) (Garg et al., 2010, Iannella et al., 2016, Dillon et al., 2017). 
Topical corticosteroids decrease the activity of T lymphocytes and inhibit the secretion 
of a wide variety of cytokines by interfering with gene expression (Speeckaert et al., 
2015). The use of topical corticosteroids is considered to be the first-line vitiligo 
treatment in both children and adults with either segmental type or non-segmental type 
of recent onset (Garg et al., 2010, Iannella et al., 2016, Dillon et al., 2017). Potent 
corticosteroids such as betamethasone and very potent corticosteroids such as 
clobetasol can stimulate repigmentation of vitiliginous skin to variable degrees (Lakhani 
and Deshpande, 2014, Speeckaert et al., 2015, Dillon et al., 2017). However, regardless 
of corticosteroid efficacy, topical immunomodulators are preferable for treating vitiligo 
due to the potential for corticosteroids to induce cutaneous atrophy (Garg et al., 2010, 
Iannella et al., 2016, Dillon et al., 2017).  
Topical immunomodulators, also known as calcineurin inhibitors, include tacrolimus and 
pimecrolimus (Lakhani and Deshpande, 2014, Iannella et al., 2016, Dillon et al., 2017). 
These reagents also suppress T cell activation (Speeckaert et al., 2015). 
Topical antioxidants have also been tried to treat vitiligo patients, as several studies have 




and Picardo, 2006, Taieb et al., 2013). Antioxidants act by decreasing high levels of 
hydrogen peroxide in melanocytes and keratinocytes to restore the intracellular redox 
status, resulting in repigmentation of vitiliginous lesions (Schallreuter et al., 2001, Taieb 
et al., 2013). Antioxidants such as pseudocatalase alone or in combination with 
ultraviolet light have been used to treat vitiligo lesions and resulted in excellent 
repigmentation of vitiligo lesions in 90% of 33 vitiligo patients (Schallreuter et al., 1995). 
1.2.12.2 Systemic therapy 
Oral corticosteroids are very rarely considered as a therapeutic approach for the 
treatment of vitiligo (Table 1.5) (Iannella et al., 2016). Systemic corticosteroids are 
mainly used in rapidly progressive cases to arrest disease activity (Dillon et al., 2017). 
Oral administration of dexamethasone has been reported to halt progressive vitiligo, 
with some degree of repigmentation being observed (Lee et al., 2010, Manga et al., 
2016). However, oral corticosteroids are only used for a short duration due to their 
potential side effects (Manga et al., 2016). In addition, oral administration of 
antioxidants has been employed to treat vitiligo (Table 1.5) (Rodrigues et al., 2017a). In 
one study, vitiligo patients received an oral combination of the antioxidants α-lipoic acid 
and vitamins C and E before treatment with narrow band-ultraviolet B (NB-UVB). This 
demonstrated excellent repigmentation in 40% of the vitiligo patients treated (Dell'Anna 
et al., 2007, Rodrigues et al., 2017a). 
1.2.12.3 Phototherapy 
Phototherapy as a treatment for vitiligo includes three main types, namely psoralen plus 
ultraviolet A (PUVA), narrow band-ultraviolet B (NB-UVB), and laser therapy (Table 1.5) 
(Iannella et al., 2016). PUVA therapy has been reported to help reverse the destruction 
of melanocytes and keratinocytes around and within vitiligo lesions (Anbar et al., 2012). 
NB-UVB can trigger the release of EDN-1 and b-FGF from keratinocytes, which then 
induce melanocyte proliferation. It is also considered to be immunosuppressive (Wu et 
al., 2004, Rodrigues et al., 2017a, Dillon et al., 2017). Repigmentation rates of 40-100% 




2005, Arca et al., 2006, Welsh et al., 2009, Rodrigues et al., 2017a) and, compared to 
other phototherapies, it is more suitable for treatment in pregnancy and in children 
(Bhatnagar et al., 2007, Rath et al., 2008). Moreover, in combination with tacrolimus, 
NB-UVB was found to be more efficacious than NB-UVB alone in reducing the size of 
vitiligo lesions (Nordal et al., 2011, Iannella et al., 2016). In addition, one study showed 
that vitiligo patients treated with NB-UVB lost their new pigment two years after 
cessation of treatment (Sitek et al., 2007). 
Another effective therapeutic option in vitiligo is the use of excimer laser, which allows 
targeted treatment of individual vitiligo lesions, cosmetically prominent with a 
wavelength of 308 nm (Asawanonda et al., 2008, Taieb et al., 2013, Dillon et al., 2017). 
Excimer laser therapy is thought to induce proliferation and migration of melanocytes 
and T cell apoptosis (Abrouk et al., 2016). Several studies have reported a greater 
efficacy of excimer laser over other phototherapies in achieving more rapid and better 
repigmentation with lesser adverse side-effects (Casacci et al., 2007, Pacifico and Leone, 
2011, Taieb et al., 2013, Iannella et al., 2016, Ayob et al., 2018). However, Passeron and 
Ortonne (2005a) showed that repigmentation relapse occurred in 15% of vitiligo 
patients 1-3 years following the discontinuation of excimer laser treatment.  
1.2.12.4 Depigmenting treatments  
In cases of extensive disfiguring vitiligo, where greater than 90% of the body surface 
area is affected, depigmentation of the remaining normal skin with topical monobenzyl 
ether of hydroquinone or 4-methoxyphenol may be recommended to render all skin or 
skin that is socially visible an even colour (Table 1.5) (Ghafourian et al., 2014, Lakhani 
and Deshpande, 2014, Manga et al., 2016, Grimes and Nashawati, 2017). However, the 
treatment is irreversible and patients must adhere to sun-safety for life to prevent 
severe sunburn, ochronosis and melanoma (Phillips et al., 2001, Ghafourian et al., 2014, 




1.2.12.5 Surgical treatment   
The aim of surgical procedures is to replace lost melanocytes with ones obtained from 
a normally pigmented autologous donor site. These procedures are only performed in 
patients with lesions refractory to medical treatment (Taieb et al., 2013, Iannella et al., 
2016). Variety of surgical techniques have been established (Table 1.5). Surgical 
treatments offer better repigmentation outcomes for patients with stable segmental 
vitiligo (Kovacs, 1998, Taieb and Picardo, 2009, Ezzedine et al., 2012b, Rodrigues et al., 
2017a). When repigmentation is achieved in these cases, relapse is rare (van Geel et al., 
2010a, Gan et al., 2016, Rodrigues et al., 2017a). 
1.2.12.6 Camouflage techniques 
Given the negative impact of vitiligo on the patient’s appearance, camouflaging may be 
a significant part of disease management and it is offered to every patient (Table 1.5) 
(Ongenae et al., 2005, Gawkrodger et al., 2010, Taieb et al., 2013, Rodrigues et al., 
2017a). Self-tanning agents and highly pigmented creams could be employed to cover 
aesthetic skin disfigurement and these are easy to apply (Taieb et al., 2013, Rodrigues 
et al., 2017a). Additionally, cosmetic tattooing is another option to hide vitiligo macules, 
but particular caution should be considered with this technique because of the 







Table 1.5: Treatment options for vitiligo 
 
Medical treatments References 
Topical treatment  
Topical steroids e.g., betamethasone (Kandil, 1974, Taieb et al., 2013, Bilal and 
Anwar, 2014, Dillon et al., 2017) 
Topical immunomodulators e.g., 
tacrolimus 
(Boone et al., 2007, Radakovic et al., 2009, 
Dillon et al., 2017) 
Topical antioxidants e.g., 
pseudocatalase 
(Rodrigues et al., 2017a) 
Systemic treatment  
Steroids e.g., dexamethasone (Taieb et al., 2013, Bilal and Anwar, 2014, 
Rodrigues et al., 2017a) 
Antioxidants e.g., minocycline, 
vitamin E, vitamin C, and lipoic acid 
(Zhang et al., 2004, Dell'Anna et al., 2007, 
Middelkamp-Hup et al., 2007, Colucci et al., 
2015a, Roy, 2017) 
Phototherapy  
Narrow-band-ultraviolet B (NB-UVB) (Westerhof and Nieuweboer-Krobotova, 1997, 
Brazzelli et al., 2007, Rodrigues et al., 2017a) 
Topical or systemic psoralen plus 
ultraviolet A (PUVA) 
(Ortonne et al., 1979, Pathak and Fitzpatrick, 
1992, Wu et al., 2007, Taieb et al., 2013, Bilal 
and Anwar, 2014, Rodrigues et al., 2017a) 
Excimer laser  (Passeron and Ortonne, 2005a, Casacci et al., 
2007, Pacifico and Leone, 2011, Taieb et al., 
2013, Dillon et al., 2017) 
Depigmentation therapy  
Depigmenting agents e.g., 
hydroquinone monobenzyl ether, and 
4-methoxyphenol 
(Njoo et al., 2000b, AlGhamdi and Kumar, 
2011, Taieb et al., 2013, Bilal and Anwar, 
2014, Manga et al., 2016, Rodrigues et al., 
2017a) 
Surgical options 
Tissue grafting e.g., punch grafting, 
suction blister epidermal grafting, and 
split-thickness skin grafts 
(Falabella, 2003, Taieb et al., 2013, Faria et al., 
2014, Manga et al., 2016, Dillon et al., 2017, 
Rodrigues et al., 2017a) 
Cellular grafting technique e.g., 
transplantation of non-cultured 
melanocytes 
(Parsad and Gupta, 2008, Budania et al., 2012, 
Manga et al., 2016, Dillon et al., 2017, 
Rodrigues et al., 2017a)  
Skin camouflage 
Cosmetic creams (Kovacs, 1998, Gawkrodger et al., 2010, 
Lakhani and Deshpande, 2014, Rodrigues et 
al., 2017a) 




 Aetiology and Pathogenesis of Vitiligo 
The exact aetiopathogenesis of vitiligo still remains obscure, but there have been a 
number of proposed theories and these are discussed in the forthcoming sections. 
 Psychological stress 
Some studies have revealed that vitiligo can develop under conditions of extreme stress 
(Lerner, 1959, Papadopoulos et al., 1998). However, it has also been shown that vitiligo 
does not necessarily develop due to the stressing conditions themselves, but to an 
inability to endure effectively uncontrollable situations (Picardi et al., 2003). In terms of 
the pathogenic mechanism, physiological stress may elevate the production of 
neuropeptides Y (Al'Abadie et al., 1994b, Tu et al., 2001, Karia et al., 2015), which could 
initiate a cascade of immunological reactions leading to melanocyte destruction (Karia 
et al., 2015). 
 Koebner’s phenomenon 
The development of lesions in response to physical trauma of normal skin, also referred 
to as Koebner’s phenomenon, can possibly be an important initiating factor in the the 
loss of melanocytes in vitiligo (van Geel et al., 2011b, Ezzedine and Silverberg, 2016, 
Khurrum et al., 2017). It has been noted that the location of initial vitiliginous lesions is 
related to sites of friction (Gauthier, 1995, van Geel et al., 2011b). The prevalence of 
Koebner’s phenomenon in vitiligo has been reported to range from 21-62% (Barona et 
al., 1995, Gauthier, 1995, van Geel et al., 2011b, Khurrum et al., 2017). 
Currently, the exact pathomechanism of Koebner’s phenomenon in causing melanocyte 
loss is unclear, although several aetiological hypotheses have been suggested including 
oxidative stress, immunological mechanisms, and deficient adhesion of melanocytes 
(van Geel et al., 2011b).  Indeed, when the non-lesional skin of vitiligo patients is 
subjected to physical trauma, melanocytes show detachment from the basal cell layer 
of the epidermis followed by melanocyte death (Gauthier et al., 2003). Two steps of 




injury, inflammatory factors such as tumour necrosis factor-α (TNF-α), IL-1, IL-6, heat-
shock protein 70 (HSP70), and ICAM-1 are released (van Geel et al., 2011b). Secondly, 
these factors may trigger an autoimmune response via activating and recruiting 
melanocyte-specific T cells in the integument (van Geel et al., 2011b, Sanghavi et al., 
2013). 
 Infections and molecular mimicry 
Antigenic structural homology between foreign (microbial) proteins and self-proteins of 
the human host is a phenomenon referred as molecular mimicry, whereby an immune 
response to the foreign molecules for defensive purposes can turn against the self-
antigens and initiate autoimmune diseases (Cusick et al., 2012, Guarneri and Guarneri, 
2013). This mechanism has been suggested as a possible pathogenic factor for vitiligo. It 
has been speculated that viral or microbial infections may cause vitiligo by triggering 
immune responses which then adversely affect melanocytes due to their expression of 
cross-reacting antigens (Le Poole et al., 1993a, Guarneri and Guarneri, 2013). Suggested 
infectious agents have included cytomegalovirus (Grimes et al., 1996), human 
immunodeficiency virus (Ivker et al., 1994, Antony and Marsden, 2003, Guarneri and 
Guarneri, 2013), Mycobacterium leprae (Sehgal, 1973), and Candida albicans (Howanitz 
et al., 1981). However, a lack of amino acid homology between known vitiligo 
autoantigens and microbial or viral agents means there is, as yet, no definitive evidence 
for molecular mimicry as a possible trigger factor for vitiligo (Gavalas et al., 2009). 
 Neural factors 
The neural theory suggests that certain neurochemical mediators secreted by nearby 
nerve endings are cytotoxic to melanocytes in vitiligo. This hypothesis is supported by 
various histological, clinical, and biochemical observations in vitiligo patients.  
1.3.4.1 Clinical evidence 
Clinically, adverse effects of neurochemical mediators could explain the different 




the dermatomal distribution of macules in segmental vitiligo (Lerner, 1959, Choi et al., 
2014). According to the neural theory, segmental vitiligo results from dysfunctionally 
sympathetic nerves that supply the affected dermatome (Lerner, 1959, Choi et al., 
2014).  Moreover, vitiligo has been noted to spare denervated area of skin, for example, 
below the neurological damage level in some patients suffering from severe spinal cord 
injury (Lerner, 1959, Choi et al., 2014).  In addition, pathological diseases affecting the 
nervous system add further evidence to the neural hypothesis in the pathophysiology of 
vitiligo (Bellei et al., 2013, Choi et al., 2014). Patients with inflammatory diseases that 
affect the peripheral nervous system such as leprosy can develop vitiligo-like 
hypopigmented patches (Boisseau-Garsaud et al., 2000b, Choi et al., 2014). Moreover, 
vitiliginous depigmented lesions can appear with neurodysplasias sush as 
neurofibromatosis and tuberous sclerosis (Zvulunov and Esterly, 1995, Herane, 2003, 
Nanda, 2008, Choi et al., 2014).The arrest of such pathological conditions oftentimes 
results in repigmentation (Choi et al., 2014). Additional evidence for the engagement of 
nerves in vitiligo is that innervation for transplant skin is required to repigment an area 
(Lerner, 1959). Moreover, although no sensory abnormalities have been found in 
vitiliginous areas, autonomic abnormalities such as increased skin temperature and 
sweating have been reported in lesional skin of vitiligo patients in comparison to normal 
skin (Al'Abadie et al., 1994a, Nordlund, 2011). 
More recently, clinical observational studies of segmental vitiligo patches with respect 
to their distribution pattern suggest a possible role of cutaneous mosaicism in the 
aetiology of segmental vitiligo (van Geel and Speeckaert, 2017). van Geel and Speeckaert 
(2017) showed distinct pattern of segmental vitiligo lesions in some patients, which 
were not completely corresponding to unilateral or band-shaped dermatomes. In 
addition, increasing evidence of inflammation has recently been shown in some 
segmental vitiligo cases (van Geel et al., 2010b, Ezzedine et al., 2012b). Histopathological 
studies demonstrated an infiltrate of cytotoxic CD8+T lymphocytes around the dermo-
epidermal junction suggesting inflammatory or immune-related involvement in the 





1.3.4.2 Histological evidence  
Histologically, vitiligo patients can have dystrophic and degenerative changes in the 
dermal nerves and nerve endings (Choi et al., 2014). Electron-microscopic studies have 
revealed direct contact between nerve endings and melanocytes in vitiligo (Choi et al., 
2014). Moreover, melanocytes arise from the neural crest and, in a variety of vitiligo 
cases, marginal melanocytes seem increasingly more neural in their behaviour, in which 
they adapt a progressively dendritic morphology and they have the ability to secrete 
adrenaline (Iyengar and Misra, 1988, Choi et al., 2014). Furthermore, 
Immunohistochemical studies have shown alterations in the neuropeptide levels in the 
lesional and peri-lesional skin of vitiligo patients. The levels of neuropeptide Y (NPY) in 
the plasma and lesional and peri-lesional areas of patients with vitiligo were significantly 
higher in comparison to healthy controls (Tu et al., 2001, Al'Abadie et al., 1994a, 
Hristakieva et al., 2000). Additionally, the number of nerve fibres that innervate the skin 
and secrete neuropeptides e.g., calcitonin gene-related peptide (CGRP) and nerve 
growth factor (NGF) has been exhibited to be elevated in vitiligo lesions as opposed to 
unaffected and control skin (Al'Abadie et al., 1994a, Liu et al., 1996, Lazarova et al., 2000, 
Tu et al., 2001, Laddha et al., 2014b, Lotti et al., 2014).  
1.3.4.3 Neurotransmitter levels 
In addition to the high levels of nerve fibres immunoreactive to NPY, NGF and CGRP, 
various studies have described elevated amounts of catecholamine neurotransmitters 
such as adrenaline and noradrenaline in the sera and depigmented skin lesions of 
patients with vitiligo (Morrone et al., 1992, Schallreuter et al., 1996, Cucchi et al., 2000, 
Cucchi et al., 2003, Zaki and Elbatrawy, 2009). In addition, increased secretion of 
catecholamines by keratinocytes has been found in vitiliginous skin (Schallreuter et al., 
1992). Increased catecholamines levels can have a direct cytotoxic action on 
melanocytes. Indirectly, high levels of catecholamines as well as NPY can induce severe 
vasoconstriction leading to hypoxia with overproduction of oxyradicals, which can result 
in accumulation of melanocyte-damaging oxidative stress (Lundberg et al., 1983, 




2014b). The possible mechanisms of action of NGF and CGRP in vitiligo are still unclear. 
However, it has been shown that lymphocytes express NGF and CGRP receptors, which 
when stimulated might lead to inflammatory responses (Yu et al., 2012b). 
 Biochemical factors 
1.3.5.1 Accumulation of toxic metabolites 
Toxic metabolite accumulation has been suggested to play a part in vitiligo 
pathogenesis. For example, melanocytes synthesise 6-tetrahydrobiopterin (6-BH4), a 
phenylalanine hydroxylase cofactor required for the conversion of phenylalanine to 
tyrosine, the latter being needed for melanin production (Schallreuter et al., 1994a, 
Schallreuter et al., 1994b, Choi et al., 2014). In vitiligo patient skin, the activity of 
phenylalanine hydroxylase is low leading to the accumulation of 6-BH4, elevated 
concentrations of which are toxic to melanocytes (Schallreuter et al., 1994a, Schallreuter 
et al., 1994b, Choi et al., 2014). In addition, a decrease in the stability of TYRP1, which is 
required for melanin synthesis (Figure 1.3), has been observed in vitiligo melanocytes 
(Jimbow et al., 2001, Ghanem and Fabrice, 2011). This defect allows the accumulation 
of melanin intermediates which are toxic to melanocytes (Jimbow et al., 2001, Ghanem 
and Fabrice, 2011).  
1.3.5.2 Oxidative stress 
Oxidative stress is suggested to be a primary event in melanocyte destruction (Sravani 
et al., 2009, Speeckaert et al., 2015), resulting from an excessive accumulation of 
reactive oxygen species (Mohammed et al., 2015, Speeckaert et al., 2015, Xie et al., 
2016). Reactive oxygen species consist of a number of oxygen-based free radicals such 
as superoxide and hydrogen peroxide (Sravani et al., 2009, Choi et al., 2014), which are 
formed during multiple physiological and pathological processes (Knight, 1995, Sravani 
et al., 2009). Such free radicals are constantly scavenged by antioxidants such as 
superoxide dismutase, catalase, vitamin C, vitamin E, and other trace elements. In 




radicals, which cause damage to cellular components such as DNA, proteins, 
carbohydrates and lipids (Bickers and Athar, 2006, Lubos et al., 2011, Xie et al., 2016). 
Under normal circumstances, superoxide dismutase catalyses the first step of 
dismutation by converting the superoxide anion into oxygen and hydrogen peroxide and 
then catalase enzyme transforms hydrogen peroxide into water and oxygen (Ines et al., 
2006, Lobo et al., 2010).  In vitiligo patients, high levels of superoxide dismutase and low 
levels of catalase have been observed in their skin (Schallreuter et al., 1991, Schallreuter 
et al., 2001, Sravani et al., 2009). Hydrogen peroxide created from superoxide anion can 
easily cross melanocyte membranes causing cellular damage (Agrawal et al., 2004, Shajil 
and Begum, 2006, Sravani et al., 2009, Mohammed et al., 2015). 
A decrease in the levels of antioxidants such as vitamin C and vitamin E has also been 
observed in vitiligo patient skin (Haider et al., 2010, Deo et al., 2013, Korobko and 
Lomonosov, 2014), and this low antioxidant status could be responsible for increased 
concentrations of reactive oxygen species (Maresca et al., 1997, Sravani et al., 2009). 
Furthermore, successful repigmentation of skin with antioxidants such as 
pseudocatalase adds validity to the theory that oxidative stress is involved in vitiligo 
development (Schallreuter et al., 2001, Rashighi and Harris, 2017). 
Furthermore, there is much evidence suggesting that melanocytes in vitiligo have 
intrinsic defects that decrease their ability to manage cellular stress (Rashighi and Harris, 
2017). Cells in the epidermis including melanocytes, are regularly exposed to various 
environmental stressors e.g., UV radiation and oxidising chemicals, which can stimulate 
reactive oxygen species production that has been observed in vitiligo (Rashighi and 
Harris, 2017). Although normal pigment cells are capable of dealing with such stressors, 
melanocytes in vitiligo patients appear more vulnerable (Rashighi and Harris, 2017). For 
example, peri-lesional melanocytes exhibit a dilated endoplasmic reticulum, 
mitochondrial dysfunction, and an abnormal melanosome structure, all of which are 





1.3.5.3 Chemically-induced vitiligo 
Several chemicals, particularly aliphatic or aromatic derivatives of phenols or catechols, 
have been shown to be preferentially cytotoxic to melanocytes, in vitro and in vivo 
(Gellin et al., 1970, Lerner, 1971, Ortonne and Bose, 1993, Fisher, 1994, Cummings and 
Nordlund, 1995, Wu et al., 2015, Rashighi and Harris, 2017). As these compounds are 
structurally similar to tyrosine, they compete for hydroxylation via tyrosinase and so 
interfere with melanin synthesis (Figure 1.3) (Jimbow et al., 1974, Harris, 2016). How 
this subsequently promoted cells destruction is unclear. However, it has been proposed 
that semiquinone free radicals and reactive oxygen species formed by tyrosinase 
catalytic action on derivatives of phenols or catechols can lead to melanocyte damage 
in vitiligo (Boissy and Manga, 2004, Harris, 2016). In addition, it has recently been 
reported that melanocytes exposed to bleaching phenols secrete elevated amounts of 
HSP70 leading to melanocyte sensitisation to dendritic cell-mediated cytotoxicity 
(Mosenson et al., 2014, Harris, 2016). 
 Melanocyte growth factors 
Melanin synthesis is controlled by a variety of melanogenic cytokines and growth factors 
including EDN-1, stem cell factor (SCF) and granulocyte monocyte-colony stimulating 
factor (GM-CSF). Such factors that are synthesised by keratinocytes and fibroblasts have 
a paracrine action on melanocytes by interacting with their respective receptors to 
trigger melanogenesis (Pillaiyar et al., 2017b). The expression levels of these 
melanogenic cytokines have been reported to be altered in vitiligo patients. For 
instance, SCF mRNA and protein have been found at lower levels in the vitiliginous 
lesions (Moretti et al., 2002b, Lee et al., 2005, Picardo et al., 2015, Shi et al., 2016). 
Furthermore, decreased levels of GM-CSF, b-FGF and EDN-1 have been shown in lesions 
of vitiligo patients (Imokawa et al., 1997, Moretti et al., 2002a, Moretti et al., 2002b, 
Nada and Rashed, 2012, Seif El Nasr et al., 2013, Mohammed et al., 2015, Shi et al., 
2016). A decrease in the levels of such growth factors may contribute to the 




 Melanocortin hormones 
The melanocortin system in the skin comprises the melanocortin peptides α, β and γ-
MSH and ACTH (Kingo et al., 2007, Abdel-Malek et al., 2014, D'Mello et al., 2016). These 
peptides bind with varying affinities to five different melanocortin receptors (MC1, MC2, 
MC3, MC4 and MC5R) (Abdel-Malek et al., 2014). The MC1R is the most abundant 
melanocortin receptor expressed in melanocytes and exhibits the highest affinity for α-
MSH, which is shown to be the most prevalent melanocortin in the skin (Kingo et al., 
2007, Montero-Melendez, 2015). The α-MSH peptide has been detected at lower levels 
in the plasma of vitiligo patients compared with normal subjects (Pichler et al., 2006, 
Khan et al., 2018). Moreover, a reduction in the levels of α-MSH mRNA and peptide has 
also been reported in lesional and peri-lesional skin of patients with vitiligo compared 
to normal subjects (Graham et al., 1999, Amin et al., 2013). Moreover, a study of α-MSH-
positive melanocytes has revealed that low expression of α-MSH within vitiligo skin 
results from reduced expression of the peptide rather than a decrease in melanocyte 
number (Graham et al., 1999). Therefore, low expression levels of α-MSH may be 
considered a possible explanation for skin depigmentation in vitiligo. 
 Genetic factors 
Approximately 6-38% of vitiligo patients have a positive family history of the disease, 
suggesting a possible hereditary cause (Nath et al., 1994, Njoo and Westerhof, 2001, 
Mohammed et al., 2015, Spritz and Andersen, 2017). However, familial cases of vitiligo 
do not show a Mendelian mechanism of inheritance, indicating the disease is polygenic 
(Majumder et al., 1993, Alkhateeb et al., 2003, Zhang et al., 2004, Mohammed et al., 
2015, Patel et al., 2017, Spritz and Andersen, 2017). Indeed, several studies have shown 
that multiple loci contribute to vitiligo susceptibility (Table 1.6) (Majumder et al., 1993, 
Nath et al., 1994, Alkhateeb et al., 2003, Sun et al., 2006). More recently, genome-wide 
association studies have revealed that approximately half of vitiligo susceptibility genes 
encode immune-regulatory proteins, while the remainder encode melanocyte-specific 
proteins (Picardo et al., 2015, Spritz and Andersen, 2017). It must be noted, however, 




non-genetic factors are also involved in the aetiology of vitiligo (Alkhateeb et al., 2003, 
Spritz, 2013, Picardo et al., 2015). 
1.3.8.1 Major histocompatibility complex genes 
In humans, the genes of the MHC encode human leukocyte antigens (Shaker and El-
Tahlawi) (Shaker and El-Tahlawi), which are referred to as MHC class I, class II or class III 
antigens (Singh et al., 1997, Shaker and El-Tahlawi, 2008, Zhang and Xiang, 2014). 
Molecules encoded by this genetic region are implicated in antigen presentation as well 
as the regulation of inflammation and the complement system (Shiina et al., 2009, 
Matzaraki et al., 2017). Variability in the HLA region has been associated with 
susceptibility to a variety of autoimmune disorders (Choi et al., 2014). In terms of 
statistical significance and odds ratio, the strongest genetic associations of vitiligo have 
been found with the MHC class II. Even so, there are differences in the MHC loci and 
alleles associated with vitiligo when compared between different populations (Table 
1.6). 
In European-derived white subjects, significant associations of vitiligo are found with 
allelic variants of HLA class I and II molecules (Jin et al., 2010a, Jin et al., 2010b). 
Specifically, the HLA class I association is HLA-A*02:01, and the HLA class II gene 
association is HLA-DRB1*04 (Fain et al., 2006, Jin et al., 2010a, Jin et al., 2011, Jin et al., 
2012b, Cavalli et al., 2016, Hayashi et al., 2016). Similar to Europeans, vitiligo in patients 
from the Indian subcontinent is associated with MHC class II loci, one located upstream 
of HLA-DRA and the other located between HLA-DRB1 and HLA-DQA1, but no 
association detected in the MHC class I region (Birlea et al., 2013). Findings in Japanese 
vitiligo patients resemble those reported for the MHC class I region in vitiligo patients of 
European decent, specifically, HLA-A*02:01 and HLA-A*02:06 (Jin et al., 2015). In 
contrast, genome-wide association analysis of Han Chinese has provided evidence for 
the association of vitiligo susceptibility with HLA specificities in the class III region (Quan 
et al., 2010). Finally, and interestingly, HLA-A*02:01 is suggested to present the vitiligo 
autoantigen tyrosinase on the surface of melanocytes, resulting in activation and 
recruitment of cytotoxic T cells to the skin, which  then target and destroy pigment cells 




1.3.8.2 Other immune-regulatory genes 
Many immune-regulatory genes have been identified as risk factors for vitiligo which, 
taken together, provide evidence that the dysregulation of immunity can contribute to 
vitiligo development (Table 1.6). For example, the PTPN22 gene, which encodes 
lymphoid protein tyrosine phosphatase non-receptor type 22, an essential down-
regulator of T lymphocyte activation (Hill et al., 2002), is associated with vitiligo in 
English, North American, Romanian and Mexican populations (Canton et al., 2005, 
LaBerge et al., 2008a, Laberge et al., 2008b, Jin et al., 2010a, Garcia-Melendez et al., 
2014). So too, the NACHT leucine-rich-repeat protein 1 (NLRP1) gene which encodes 
nuclear localization leucine-rich-repeat protein 1, a key regulator of the innate immune 
system (Spritz et al., 2004, Jin et al., 2007a, Jin et al., 2007b, Martinon et al., 2007, 
Hoffman and Brydges, 2011, D'Osualdo and Reed, 2012, Levandowski et al., 2013). 
A further candidate susceptibility gene encodes the autoimmune regulator (AIRE), which 
has a role in central tolerance. Single-nucleotide polymorphisms (SNPs) in AIRE are 
associated significantly with vitiligo susceptibility (Tazi-Ahnini et al., 2008, Oftedal et al., 
2015). Similarly, SNPs in the gene encoding cytotoxic T lymphocyte antigen-4 (CTLA4) 
have been shown to associate with vitiligo (Kemp et al., 1999, Blomhoff et al., 2005, 
Spritz and Andersen, 2017). CTLA4 negatively regulates T cell activation and also controls 
T cell apoptosis (Das et al., 2001, Al-Shobaili, 2011, Spritz and Andersen, 2017). Recently, 
many vitiligo susceptibility genes e.g., X-box binding protein 1, forkhead box P1, 
cytokine-chemokine receptor, thymic stromal lymphopoietin and forkhead box P3, 
which encode regulating elements of the immune system, have also been identified and 
confirmed by the application of genome-wide association studies (Cheong et al., 2009, 
Ren et al., 2009, Jin et al., 2010b, Quan et al., 2010, Birlea et al., 2011). 
1.3.8.3 Genes related to melanocyte function 
Polymorphisms in non-immune genes such as OCA2, the gene encoding P protein (Jin et 
al., 2012a), MC1R, the gene encoding melanocortin 1 receptor (Jin et al., 2012a), PMEL, 
the gene encoding melanocyte-specific protein PMEL(Tang et al., 2013), and ZMIZ1, the 




identified as vitiligo susceptibility loci (Table 1.6). All of these genes contribute to the 
development, function and survival of melanocytes (Shen et al., 2016). Of particular 
interest, is the association found in European-derived whites between vitiligo and SNPs 
in TYR, the gene encoding tyrosinase (Jin et al., 2010a). The causal genetic variation of 
TYR is inversely correlated between vitiligo and malignant melanoma (Spritz, 2010a, Jin 
et al., 2012a, Jin et al., 2012b), thus suggesting vitiligo may develop from the 
dysregulation of normal immune surveillance against melanoma (Spritz, 2010a, Shen et 
al., 2016). Interestingly, a correlation between the minor TYR allele, 402Q and 
predisposition to malignant melanoma has been described (Gudbjartsson et al., 2008, 
Bishop et al., 2009), suggesting that such a variant may be less accessible to the immune 
defences. Therefore, in melanoma cases with the 402Q variant, these neoplastic 
melanocytes perhaps evade immune surveillance (Jin et al., 2010a, Spritz, 2010a). On 
the other hand, the TYR 402R variant possibly presented to the immune defences more 
effectively than 402Q variant leading to a more efficient immunological responses to 
neoplastic melanocytes, but equally contributes to susceptibility to vitiligo (Jin et al., 
2010a, Spritz, 2010a). 
1.3.8.4 Genes encoding metabolic proteins 
Many studies have been carried out to identify genes that regulate melanocyte 
metabolism, development or proliferation, and which could be associated with vitiligo 
susceptibility (Table 1.6). Such studies have included the genes encoding catalase (Casp 
et al., 2002, Park et al., 2006, Liu et al., 2010, Birlea et al., 2011, Lv et al., 2011, Lu et al., 
2014, Caputo et al., 2017) and catechol-O-methyltransferase (Tursen et al., 2002, Li et 
al., 2009a, Birlea et al., 2011). Several polymorphisms have been identified in both 
genes, which might impair the function of the enzymes they encode (Al-Shobaili, 2011, 
Picardo et al., 2015). Catalase and catechol-O-methyltransferase are critical enzymes 
that protect cells against oxidative damage via breaking down hydrogen peroxide and 
catecholamines, respectively (Al-Shobaili, 2011, Ezzedine et al., 2015). Therefore, it is 
plausible that abnormal expression of such proteins results in toxic radical accumulation 
and subsequently leads to melanocyte damage, which in turn results in vitiligo (Li et al., 




Polymorphic expression of methylene tetrahydrofolate reductase (MTHFR) gene has 
recently been reported in vitiligo patients (Chen et al., 2014). This enzyme regulates the 
levels of homocysteine, which has been detected at elevated levels in vitiligo patients 
(Shaker and El-Tahlawi, 2008, Silverberg and Silverberg, 2011, Singh et al., 2011). 
Increased levels of homocysteine have been shown to induce cell apoptosis via 
downregulating enzymes such as catalase leading to increased generation of reactive 
oxygen species, which in turn can cause damage to melanocyte in vitiligo (Chen et al., 
2014, Picardo et al., 2015). 
Polymorphisms in the EDN-1 gene has been correlated with an elevated risk of vitiligo 
(Kim et al., 2007). EDN-1, produced by keratinocytes, has been shown to activate 
melanocyte proliferation and stimulates melanogenesis through activating tyorsinase 
and stimulating expression of TYRP1 (Hara et al., 1995, Imokawa et al., 1997, Funasaka 
et al., 1998, Mou et al., 2004, Yamaguchi and Hearing, 2009, Aly et al., 2013, Lee et al., 
2013b, Bingül et al., 2016). 
Allelic variation in ACE, the gene encoding angiotensin-converting enzyme (ACE), has 
been associated with an increased risk of vitiligo (Jin et al., 2004, Deeba et al., 2009, 
Tippisetty et al., 2011, Patwardhan et al., 2013, Badran et al., 2015, Abdel Azeem et al., 
2016). ACE plays a crucial role in converting angiotensin I into angiotensin II which acts 
as an effective pro-inflammatory modulator (Song et al., 2015). Recent studies have 
suggested that the catalysis of angiotensin I conversion to angiotensin II by ACE may 
simultaneously increases the production of reactive oxygen species and secretion of 




Table 1.6: A summary of genes associated with susceptibility to vitiligo  
 
Type Gene Protein Function References 
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(Jin et al., 
2012a) 
C1QTNF6  Complement C1q 
tumour necrosis 
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CASP7 Caspase-7 Executor protein 
of apoptosis and 
inflammation 
(Jin et al., 
2012a) 
CCR6 Chemokine-
cytokine receptor 6 
Regulates 
differentiation 




(Jin et al., 
2010a, 
Quan et al., 
2010) 
CD44 CD44 antigen Involves in T cell 
development 






activation of T 
cells 










(Jin et al., 
2012a) 
CTLA4  Cytotoxic 
T-lymphocyte 
protein 4 









CXCR5 C-X-C chemokine 
receptor type 5  
Involves in B 
lymphocyte 
migration 
(Tang et al., 
2013) 
FASLG FAS ligand Regulate immune 
apoptosis 
(Li et al., 
2008) 
FOXP1  Forkhead box 
protein P1  
 
Regulates B cell 
development 
 
(Jin et al., 
2010b) 
FOXP3  Forkhead box 
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process of 
immune-induced 
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(Jin et al., 
2012a) 
IKZF4  Zinc finger protein 
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Regulates T cell 
activation 
 
(Jin et al., 
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i et al., 
2013) 
PTPN22 Lymphoid protein 
tyrosine 
phosphatase non-
receptor type 22 
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Jin et al., 
2010a, Song 
et al., 2013, 
Garcia-
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SH2B3 SH2B adapter 
protein 3 
Development of B 
and T 
lymphocytes 
(Jin et al., 
2012a) 
SLA  Src-like-adapter  Regulates antigen 
receptor 
signalling 
(Jin et al., 
2012a) 
TOB2 Protein TOB2 Involves in T cell 
tolerance 
(Jin et al., 
2012a) 
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(Ren et al., 
2009, Birlea 
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(Na et al., 
2003) 
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(Na et al., 
2003, Jin et 
al., 2012a) 
OCA2 OCA2 gene Melanosomal 
transporter 







(Tang et al., 
2013) 
TYR Tyrosinase Regulator of 
melanogenesis 







ZMIZ1 Zinc finger protein 






(Quan et al., 
2010, Sun 
et al., 2014) 
Metabolism-
related genes  
ACE Angiotensin-
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(Jin et al., 
2010a) 
RNASET2 Ribonuclease T2  Oxidative stress 
regulator 







 Autoimmunity  
Many studies have indicated a role for autoimmunity in the aetiology and pathogenesis 
of vitiligo, and the evidence for this will be described and discussed in the next sections. 
1.3.9.1 Autoimmune diseases 
The association between vitiligo and other autoimmune diseases has been discussed 
earlier in Section 1.2.5. 
1.3.9.2 Immunogenetic factors 
The association between vitiligo susceptibility and variability in respect of genes 
encoding factors that regulate the immune system has been discussed earlier in Section 
1.3.8. 
1.3.9.3 Animal models of vitiligo 
The study of animal models has provided persuasive evidence that immune mechanisms 
play a role in the pathogenesis of vitiligo. The Smyth line chicken is characterised by the 
spontaneous loss of pigment from feathers and ocular tissues due to an inherited 
melanocyte defect (Smyth, 1989). In the Smyth line chicken, abnormal melanocytes are 
destroyed by autoreactive T cells, and antibodies against TYRP1 constitute the major 
humoral immune response (Austin et al., 1992, Wang and Erf, 2004, Shi et al., 2012, 
Essien and Harris, 2014). In addition, the levels of interferon-γ (IFN-γ), IL-10, and IL-21 in 
growing feathers have been shown to increase at vitiligo onset, reaching a peak during 
active disease, and decreasing to near pre-vitiligo levels after the complete loss of 
melanocytes (Shi et al., 2012, Essien and Harris, 2014). These cytokine expression 
studies suggest that Smyth line chicken vitiligo is a T helper 1 (Th1) cell-polarised 
autoimmune disease (Shi et al., 2012). Sera from Smyth line chickens and other animal 
models of vitiligo, for example, horses and dogs also contain anti-melanocyte antibodies 




et al., 2007, Essien and Harris, 2014), although such antibodies may only be markers of 
the disease or a secondary phenomenon.  
Recent studies using mouse models of vitiligo have provided several lines of evidence 
which support a vital role for autoimmunity in the development of vitiligo (Chatterjee et 
al., 2014, Eby et al., 2014, Shi et al., 2014). A recent study of h3TA2 mice, which develop 
vitiligo spontaneously, showed that the adoptive transfer of T regulatory cells (Tregs) 
induced a lasting remission of vitiligo when the animals were treated at the onset of or 
after the establishment of the disease (Chatterjee et al., 2014). Further to this, in IFN-γ-
knockout h3TA2 mice, depigmentation was significantly impaired, confirming a central 
role for IFN-γ in the development of vitiligo. In Vitesse mice, which again develop vitiligo 
spontaneously, there is an increased level of IL-17-producing cells and a reduced Tregs 
abundance, although the significance of this has yet to be fully evaluated (Eby et al., 
2014). Taken together, these results show mounting evidence implicating autoimmune 
mechanisms in vitiligo pathogenesis.  
1.3.9.4 Immunosuppressive therapies  
Repigmentation in vitiligo patients receiving immunosuppressive treatments (Table 1.5) 
indirectly supports the notion that immune-mediated processes play a part in vitiligo 
pathogenesis (Parrish et al., 1976, Tsuji and Hamada, 1983, Ongenae et al., 2003, 
Sandoval-Cruz et al., 2011, Ezzedine et al., 2015). For example, topically-applied 
tacrolimus, a reagent that suppresses T cells by blocking the action of the cytokine gene-
activating cofactor calcineurin (Homey et al., 1998, Lubaki et al., 2010, Speeckaert et al., 
2015) has been used to treat vitiligo successfully (Hartmann et al., 2008). 
Topical corticosteroids which suppress T lymphocyte activity and B cell antibody 
responses, are also an effective first line treatment for vitiligo of recent onset (Abu Tahir 
et al., 2010, Gawkrodger et al., 2010). Corticosteroids inhibit the synthesis of a wide 
variety of cytokines including IL-1, IL-2, IL-3, IL4, IL-5, IL-6, IL-8, GM-CSF, TNF-α, and IFN-
γ by interfering with gene expression (Speeckaert et al., 2015). Although the exact 
mechanism of action is unclear, it is interesting to note that after treating vitiligo 




and in antibody-mediated anti-melanocyte cytotoxicity has been observed (Takei et al., 
1984, Hann et al., 1993a). 
With regard to the treatment of vitiligo using photochemotherapy, a decrease in 
Langerhans cell numbers and in the expression of vitiligo-associated melanocyte 
antigens has been demonstrated (Viac et al., 1997, Lee et al., 2013a). UV-irradiation 
itself can also lead to an increase in anti-inflammatory cytokines expression, regulate 
ICAM-1 expression and evoke apoptosis of skin-infiltrating T lymphocytes (Duthie et al., 
1999, Bulat et al., 2011, Lahiri and Malakar, 2012, Lee et al., 2013a). 
1.3.9.5 Immunological features of melanocytes 
A number of studies have demonstrated abnormal expression of MHC class II antigen 
HLA-DR and induced expression of ICAM-1 by peri-lesional melanocytes in vitiligo skin 
(al Badri et al., 1993, Ahn et al., 1994, van den Wijngaard et al., 2000, Dwivedi et al., 
2013b, Laddha et al., 2013). These molecules have vital roles in the presentation of 
antigens and in the activation of T cells (Hedley et al., 1998, Dwivedi et al., 2013b, 
Benzekri et al., 2015). Their expression by melanocytes may, therefore, contribute to 
the cellular immune response against pigment cells, as observed in vitiligo (al Badri et 
al., 1993, Ogg et al., 1998, van den Boorn et al., 2009, Dwivedi et al., 2013b). Both vitiligo 
and normal melanocytes can also express MHC class I molecules (Hedley et al., 1998) 
which may allow interaction with cytotoxic T cells (Le Poole et al., 1993b). In addition, 
peri-lesional melanocytes express CD68 and CD36 which attract macrophages (van den 
Wijngaard et al., 2000). They also express decreased amounts of membrane regulators 
of complement activation, such as membrane cofactor protein and decay acceleration 
factor (van den Wijngaard et al., 2002), implying a vulnerability of such cells to 
destruction by macrophages and the complement system. 
1.3.9.6 Immuno-regulatory micro RNAs 
Micro RNAs (miRNAs) are a class of non-coding RNAs that play a role in the negative 
regulation of gene expression (Ambros, 2003, Lai, 2003). A growing number of studies 




regulating cellular differentiation and proliferation of immune cells. Abnormal 
expression of miRNAs has been reported by several studies on vitiligo (Shi et al., 2013, 
Shi et al., 2014, Mansuri et al., 2016). 
In a mouse model of vitiligo, upregulation of miRNA-146a was observed (Shi et al., 2014). 
This miRNA is involved in the regulation of Tregs and natural killer cell functions (Lu et 
al., 2010) and contributes to the development of autoimmune disease in mice (Mueller 
et al., 2009). Interestingly, increased levels of miRNA-146a in rheumatoid arthritis have 
been suggested to cause prolonged production of the pro-inflammatory cytokine TNF-
α, and significantly upregulate phagocytic activity (Pauley et al., 2008, Shi et al., 2014). 
As TNF-α, Tregs and natural killer cells play a potential role in vitiligo development, it is 
plausible to suggest that highly expressed miR-146a in vitiligo could contribute to vitiligo 
pathogenesis (Shi et al., 2014). 
Shi et al. (2013) showed, in patients affected by vitiligo compared to controls, 
significantly increased expression of miR-19a and miR-19b, both of which have been 
shown to play a crucial role in Th1 cell responses, through inducing IFN-γ secretion and 
suppressing inducible Tregs (Jiang et al., 2011). Therefore, miR-19a and miR-19b may be 
implicated in vitiligo development by regulating Th1 cell responses (Shi et al., 2013). 
Furthermore, Mansuri et al. (2016) reported a decreased expression of miR-211 which 
downregulates IL-23A, IL-1B, and IL-1 receptor. The same study reported that lesional 
skin of vitiligo patients showed increased expression of IL-23, which is mainly 
synthesised by dendritic cells and macrophages and regulates IL-17A secreted by T 
helper 17 (Th17) cells (Bettelli et al., 2008, Vaccaro et al., 2015). As IL-23 is important in 
stimulating the effector function of Th17 cells to produce cytokines and initiate 
inflammatory responses (Vaccaro et al., 2015), it may contribute to melanocyte 
destruction in vitiligo. Interleukin-1B and IL-1 receptor are key mediators of the body’s 
cytokine-induced immune and inflammatory responses, and both were shown to be 
significantly upregulated in vitiligo patients (Mansuri et al., 2016). Interestingly the 
former was demonstrated to be upregulated in non-lesional skin of vitiligo patients 
compared to lesional skin, suggesting its vital involvement in the destruction of 
melanocytes rather than being a consequence of the disorder (Mansuri et al., 2016). 




downregulates PTPN22 expression that encodes a negative regulator of T cell activation 
(Mansuri et al., 2016). The same study found reduced expression of PTPN22 in the skin 
of vitiligo patients, suggesting that downregulation of PTPN22 by miR-577 may result in 
hyper-responsive T cells and hence an increased susceptibility to autoimmunity 
(Mansuri et al., 2016). Taken together, the upregulation of IL-1B, IL-1 receptor and IL-
23A, and the downregulation of PTPN22 in vitiligo patients indicates a potential role for 
miRNAs in the autoimmune pathogenesis of vitiligo (Mansuri et al., 2016). 
1.3.9.7 Cellular immunity in vitiligo 
1.3.9.7.1 Macrophages 
Macrophage-infiltration has been observed in vitiligo lesions with an elevated number 
in peri-lesional skin in comparison to normal skin (Le Poole et al., 1996, van den 
Wijngaard et al., 2000). Macrophages may be involved in the clearance of melanocytes 
which have been evoked to apoptosis by cytotoxic T lymphocytes (Rezaei et al., 2007). 
Serarslan et al. (2010) and Li et al. (2013) showed that serum concentrations of 
macrophage migration inhibitory factor, which can concentrate macrophages at the 
sites of inflammation and regulate the activation of macrophages and T cells, are 
significantly increased in vitiligo patients. Ma et al. (2013) also reported that 
macrophage migration inhibitory factor mRNA is over-expressed in the peripheral blood 
mononuclear cells and in the lesional skin of patients with progressive vitiligo. 
Additionally, the active participation of macrophages in vitiligo development is 
demonstrated by their expression of immunoglobulin receptors; in a model mouse of 
vitiligo, macrophages encoding the common γ-chain of the activating Fc receptors are 
able to mediate melanocyte loss (Trcka et al., 2002). All these data are suggestive of 
macrophage involvement in melanocyte destruction. 
1.3.9.7.2 Dendritic cells 
Dendritic cells are antigen-presenting cells which express a high density of MHC class II 
molecules. Dendritic cells also secrete key inflammatory cytokines such as IL-1, IL-6, IL-




involved in the activation of B cells and natural killer cells and induce the attraction of 
other innate immune effector cells (Blanco et al., 2008). Dendritic cell density in lesional 
skin has been variously observed as normal, reduced, and increased compared with non-
lesional skin from the same patients and with control groups (Riley, 1967, Claudy and 
Rouchouse, 1984, Hatchome et al., 1987, Searle et al., 1993). Such variation may be 
attributed to vitiligo clinical subtype, techniques of sampling or skin biopsy sites in the 
different studies. 
More recent studies have provided direct evidence that dendritic cells are involved in 
vitiligo pathogenesis (Wang et al., 2011, Sanchez-Sosa et al., 2013, Yang et al., 2017a). 
Immunohistochemical studies showed that early vitiligo patches are infiltrated mostly 
by dendritic cells, whereas later lesions show lower numbers of these cells, but 
increased proportions of T cells (Sanchez-Sosa et al., 2013). The data imply that the 
antigen-presentation process occurs at an early stage of vitiligo development (Sanchez-
Sosa et al., 2013). Additionally, in vivo and in vitro studies have shown that melanocyte 
destruction is mediated by dendritic cells (Kroll et al., 2005). Though the role of dendritic 
cells in vitiligo is still unclear, they themselves might be cytotoxic or carry and present 
melanocyte associated antigens to T cells contributing to melanocyte destruction 
(Rashighi and Harris, 2017). 
1.3.9.7.3 Natural killer cells 
Natural killer cells are a vital component of the innate immune system. Although they 
are most noticeably involved in defending against bacterial, viral and parasitic infections, 
several lines of evidence suggest that natural killer cells play a key role in the initiation 
of vitiligo. For example, a number of studies have reported an aberrant activation of 
natural killer cells in vitiligo patients (Basak et al., 2008, Yu et al., 2012a, van den Boorn 
et al., 2016). In addition, an increase in the number of circulating natural killer cells in 
the blood of vitiligo patients has been demonstrated by several studies (Ghoneum et al., 
1987, Mozzanica et al., 1989, Mozzanica et al., 1992, Hann et al., 1993b, Durham-Pierre 
et al., 1995, Basak et al., 2008). 
More recently, infiltration of GZMB-expressing natural killer cells has been demonstrated 




expression is a characteristic of activated natural killer cells (Afonina et al., 2010, Yu et 
al., 2012a) and its role is promoting the destruction of target cells through activation of 
the caspase pathway as well as generating and presenting autoantigens (Darrah and 
Rosen, 2010, Yu et al., 2012a). 
The upregulation of C-type lectin domain family 2 member B (CLEC2B) gene has been 
observed in vitiliginous skin (Yu et al., 2012a). This gene is mostly expressed by 
monocytes and macrophages and encodes an activating ligand of natural killer cells 
which binds to NKp80 receptors (Welte et al., 2006, Yu et al., 2012a). Furthermore, 
elevated natural killer cell activating receptors (CD16+CD56+ and CD3+CD16+CD56+) 
and reduced natural killer cell inhibitory receptors (CD16+CD158a+) have been shown 
in vitiligo patients (Basak et al., 2008). Therefore, such abnormalities in natural killer 
cells of vitiligo patients, all imply a possible role for natural killer cells in the development 
of vitiligo. 
1.3.9.7.4 CD4+ helper T lymphocytes 
The CD4+ helper T cells are crucial components in regulating the immune response. The 
main function of CD4+ T lymphocytes is the secretion of cytokines that provide signals 
to other immune cell populations such as B lymphocytes to mature and secrete 
antibodies, and macrophages to induce phagocytosis of microorganisms. They also play 
a vital role in suppressing immune responses (Luckheeram et al., 2012). Naïve CD4+ 
lymphocytes become activated upon the recognition of antigen-MHC class II complexes 
presented by specific antigen-presenting cells (Luckheeram et al., 2012). Activated CD4+ 
T lymphocytes can be differentiated into several distinct effector subtypes of T helper 
cells including Th1, Th2, Th17 and Treg cells, (Muranski et al., 2008), which can 
contribute to amplifying immune reactions and potentiating the destruction of 
melanocytes in vitiligo (Lukinovic-Skudar, 2015). With respect to CD4+ T cell-mediated 
melanocyte destruction, CD4+ T cells are shown to be capable of destroying MHC class 
II antigen-expressing cells (Rathmell et al., 1995, Lambe et al., 2006) and melanocytes 
can express MHC class II antigens (al Badri et al., 1993, Lambe et al., 2006). It has been 
shown that the number of CD4+ T cells is significantly increased in lesional and peri-




The subset of Th1 CD4+ T cells and their cytokines IFN-γ, TNF-α, chemokine C-X-C motif 
ligand 9 (CXCL9), CXCL10, and CXCL11 seem to play a dominant role in vitiligo 
development (Harris et al., 2012, Antonelli et al., 2015, Lukinovic-Skudar, 2015, Wang et 
al., 2016), since they can recruit and activate immune cells e.g., macrophages, natural 
killer cells and CD8+ T cells, stimulating a cellular immune response that results in 
cytotoxicity to melanocytes (Lukinovic-Skudar, 2015). A predominantly Th1-mediated 
pattern with a dominant role of CXCL10 in skin depigmentation was revealed in both a 
vitiligo mouse model and in lesional skin and serum of human patients with vitiligo 
(Rashighi et al., 2014, Lukinovic-Skudar, 2015, Wang et al., 2016), suggesting the Th1 
immune response in vitiligo pathogenesis is significant (Antonelli et al., 2015). 
Another subset of CD4+ T lymphocytes, the Th17 cells, has been recently identified as 
an active participant in the destruction of melanocytes (Lukinovic-Skudar, 2015, Zhou et 
al., 2015). The Th17 cells play a central role in potentiation of the innate inflammatory 
response via the production of cytokines e.g., IL-17, IL-21, and IL-22, which in turn recruit 
neutrophils and macrophages to the antigen site (Lukinovic-Skudar, 2015). Several 
studies have suggested that Th17 cells and their effector molecule, IL-17, are active 
participants in the destruction of melanocytes observed in vitiligo (Singh et al., 2016). 
Studies have shown infiltration of Th17 cells, elevated levels of IL-17 mRNA  in vitiligo 
skin samples, and upregulated levels of IL-17 in vitiligo patient blood (Basak et al., 2009, 
Wang et al., 2011, Kotobuki et al., 2012, Elela et al., 2013, Zhou et al., 2015), thus 
implying a potential role for Th17 cells in vitiligo pathogenesis (Zhou et al., 2015). 
The predominance of the Th1 or Th17 phenotype in vitiligo may be attributed to a 
disturbed balance between inflammatory cells and Tregs (Lukinovic-Skudar, 2015). 
Regulatory T cells are also a subgroup of CD4+ T cells that primarily represent a 
phenotype of CD4+, CD25+ and forkhead box P3 (Foxp3). These cells have a vital role in 
controlling autoimmunity by maintaining immunological unresponsiveness to self-
antigens, playing a key role in the clearance of self-reactive T cells that have escaped 
clonal deletion (Jonuleit et al., 2001, Sakaguchi et al., 2001, Kidir et al., 2017). Alterations 
in Treg number and function can result in autoimmunity (Lukinovic-Skudar, 2015). Both 
Treg number and function have been shown to be impaired in patients with vitiligo 




that the density and the suppressive effects of peripheral Tregs in vitiligo patients are 
significantly decreased, suggesting a possible failure of Tregs to suppress cytotoxic T 
cells which target melanocytes (Ben Ahmed et al., 2012, Lili et al., 2012, Dwivedi et al., 
2013a). 
Notably, the serum concentration of transforming growth factor-β (TGF-β), an 
immunosuppressive cytokine expressed by Tregs (Bettini and Vignali, 2009) is lower in 
patients with vitiligo than in controls (Basak et al., 2009, Tu et al., 2011, Khan et al., 
2012). In addition, a lower level of TGF-β expression in the skin of patients with vitiligo 
than in healthy controls has been reported (Moretti et al., 2002b, Klarquist et al., 2010). 
The reduced TGF-β concentration is also correlated with an increase in the area of skin 
involvement (Tu et al., 2011). Another suppressor cytokine produced by Tregs, IL-10, has 
also been found to be decreased in lesional skin of vitiligo patients, suggesting that the 
IL-10 reduction may be due to Treg-cell insufficiency (Kidir et al., 2017). Furthermore, in 
a mouse model of vitiligo, repigmentation was accompanied by an elevated infiltration 
of Tregs into the skin, possibly resulting in the prevention of immune responses against 
melanocytes (Eby et al., 2014). Interestingly, a previous study found a dramatic increase 
in Tregs in the peri-lesional skin of vitiligo patients (Ben Ahmed et al., 2012, Lili et al., 
2012). However, these Tregs were diminished in their ability to suppress the 
proliferation and cytotoxic capacity of the elevated levels of peri-lesional CD8+ T cells, 
suggesting that defective functioning of Tregs and an increase in CD8+ T cells may 
contribute to melanocyte destruction (Ben Ahmed et al., 2012, Lili et al., 2012). 
1.3.9.7.5 CD8+ cytotoxic T lymphocytes 
Besides CD4+ T cells, the peri-lesional skin of vitiligo patients can be infiltrated with CD8+ 
cells, often with an elevated ratio of CD8+/CD4+ lymphocytes (Le Poole et al., 1996, Lili 
et al., 2012, Abdallah et al., 2014, Furue and Kadono, 2016, Speeckaert et al., 2017, Yang 
et al., 2017b, Boniface et al., 2018). In vitro culture of T cells from peri-lesional skin of 
vitiligo patients has shown that both CD8+ and CD4+ T cells secrete high levels of the 
pro-inflammatory cytokines TNF-α and IFN-γ (Wankowicz-Kalinska et al., 2003, van den 
Boorn et al., 2009, Boniface et al., 2018). In particular, IFN-γ is required for melanocyte-




Rodrigues et al., 2017b). Another important observation is that CD8+ T cells in vitiligo 
patients were demonstrated to express the skin-homing receptor, cutaneous 
lymphocyte-association antigen, which can recruit T cells from the peripheral circulation 
to the area of affected skin (Ogg et al., 1998, Sandoval-Cruz et al., 2011). 
Analysis of the specificity of skin-infiltrating CD8+ T cells in vitiligo patients has shown 
that they recognise specific antigens primarily involved in the melanogenic pathway and 
these include Melan-A/MART, tyrosinase and PMEL (Palermo et al., 2001, van den Boorn 
et al., 2009, Rodrigues et al., 2017b). These cytotoxic CD8+ T lymphocytes exhibit in vitro 
anti-melanocyte cytotoxic activity and show skin-homing capacity, which appears to 
associate with vitiligo extension and severity (Palermo et al., 2001, Sandoval-Cruz et al., 
2011, Rashighi et al., 2014, Agarwal et al., 2015). Furthermore, van den Boorn et al. 
(2009) observed that isolated peri-lesional cytotoxic T lymphocytes could infiltrate 
explants of autologous healthy pigmented skin and eliminate melanocytes. Further 
evidence for CD8+ T cells in destroying melanocytes in vitiligo patients is suggested by 
their expression of the inflammatory cytotoxic markers granzyme B, perforin and 
cutaneous lymphocyte-association antigen in the lesional and peri-lesional areas of 
vitiligo patient skin (van den Wijngaard et al., 2000, Oyarbide-Valencia et al., 2006, van 
den Boorn et al., 2009, Bertolotti et al., 2014, Lukinovic-Skudar, 2015, Yang et al., 
2017b). 
1.3.9.7.6 Cytokines  
Cytokines are small peptides that regulate inflammation and the immune responses and 
thus can cause an inappropriate immune reaction when imbalanced (Feldmann et al., 
1998, Zhang and An, 2007, Yang et al., 2015).  Several studies have shown cytokine 
imbalance in the skin of patients with vitiligo, indicating a role for cytokines in 
autoimmunity (Yang et al., 2015). A decreased level of GM-CSF has been found in vitiligo 
patients compared of healthy subjects (Moretti et al., 2002b, Moretti et al., 2009). The 
cytokine GM-CSF is suggested to serve as melanocyte growth factor, and a lower 
expression of this molecule might diminish the proliferation of surviving melanocytes in 




Elevated levels of soluble IL-2 receptor have been revealed in the vitiligo patient skin. 
Soluble IL-2 receptor is expressed on activated T cells and induces T cell proliferation via 
binding to its ligand, IL-2 (Grutters et al., 2003) and thus its high expression implies 
involvement of T cell in vitiligo pathogenesis (Yeo et al., 1999, Vaccaro et al., 2015). 
Additionally, increased production of IL-6 in vitiligo patients has been identified (Yu et 
al., 1997, Singh et al., 2012b). This cytokine induces ICAM-1 expression on melanocytes 
(Kirnbauer et al., 1992), which could facilitate leukocyte–melanocyte interactions and 
cause melanocyte damage (Kirnbauer et al., 1992, Yu et al., 1997, Sandoval-Cruz et al., 
2011). Furthermore, Yu et al. (1997) and Miniati et al. (2014) have reported increased 
levels of IL-8 in vitiligo patients. This cytokine may recruit neutrophils, T lymphocytes, 
and basophils to the lesional skin of vitiligo patients, so amplifying inflammation (Luger 
and Schwarz, 1990, Miniati et al., 2014).  
It has also been demonstrated that the expression of pro-inflammatory cytokine TNF-α 
is significantly elevated in lesional and peri-lesional vitiligo patient skin (Moretti et al., 
2002b, Moretti et al., 2009, Wu et al., 2013). This cytokine is secreted by the peri-lesional 
T cells of the CD4+ and CD8+ subsets in vitiliginous skin and it has an inhibitory influence 
on melanocyte proliferation and can cause apoptosis (Webb et al., 2015). In addition, 
TNF-α is implicated in cytotoxic T lymphocyte development and it can induce 
lymphocytic expression of IFN-γ, a cytokine involved in vitiligo development (Martinez-
Esparza et al., 1998, Kim et al., 2007, Chatterjee et al., 2014, Webb et al., 2015).  
High levels of IFN-γ, the cytokine required for the recruitment of melanocyte-specific 
autoreactive CD8+ T lymphocytes to the affected skin, are expressed both in serum and 
skin of vitiligo patients as well as in a vitiligo mouse model (Harris et al., 2012, Rashighi 
et al., 2014). The IFN-γ-induced cytokines CXCL9, CXCL10, and their receptor C-X-C 
chemokine receptor type 3 (CXCR3), which is expressed on autoreactive CD8+ T cells, 
are also increased in the serum and skin of vitiligo patients as well as in a vitiligo mouse 
model (Rashighi et al., 2014, Wang et al., 2016). More interestingly, knocking out CXCR3 
or blocking CXCL10 action prevents and reverses depigmentation in vitiligo (Harris et al., 
2012, Rashighi et al., 2014). These results indicate that CXCL9, CXCL10, and their 
receptor CXCR3 are required for the accumulation of autoreactive T cells in the skin of 




together, these data suggest that cytokines are likely to be involved in vitiligo 
pathogenesis.  
1.3.9.8 Humoral immunity in vitiligo 
1.3.9.8.1 Antibodies against melanocytes 
Besides cell-mediated and cytokine-mediated mechanisms, humoral (antibody-
mediated) immunity adds more supportive evidence for the pathological role of 
autoimmunity in vitiligo (Mohammed et al., 2015, Singh et al., 2016). Antibodies to 
melanocytes have been found at significantly elevated levels in the sera of vitiligo 
patients as opposed to healthy controls (Naughton et al., 1983a, Cui et al., 1992, Hann 
et al., 1996, Rocha et al., 2000, Farrokhi et al., 2005, Laddha et al., 2014a, Zhu et al., 
2015). Initially, immunoprecipitation experiments with melanocyte extracts revealed 
that 12/12 of vitiligo patient had anti-melanocyte antibodies in their sera versus 0/12 of 
healthy subjects (Naughton et al., 1983b). Another study observed that 24 (83%) of 29 
of patients with vitiligo, and 2 (7%) of 28 control subjects were positive for anti-pigment 
cell antibodies (Cui et al., 1995). 
A direct association has been shown between anti-melanocyte antibody levels and the 
extent and activity of vitiligo (Naughton et al., 1983b, Uda et al., 1984, Cui et al., 1995, 
Rocha et al., 2000, Farrokhi et al., 2005, Laddha et al., 2014a, Jimenez-Brito et al., 2016). 
93% of patients with greater extent of depigmentation (5-10% of skin area involved) and 
only 50% of patients with minimal vitiligo lesions (<2% of skin area involved) have anti-
melanocyte antibodies (Allam and Riad, 2013), suggesting that antibodies against 
melanocytes can be markers of disease severity. These anti-melanocyte antibodies 
belong to the Immunoglobulin G (IgG) class, including subclasses IgG1, IgG2, IgG3 and 
IgG4 (Rahoma et al., 2012, Colucci et al., 2015b, Li et al., 2016). 
Immunoprecipitation studies using melanocyte protein extracts have shown that 
antibodies in vitiligo patients are most frequently directed to antigens with molecular 
weights of 35, 40 to 45, 75, 90 and 150-kDa, these being found on the cell surface (Cui 
et al., 1992, Cui et al., 1995, Zhu et al., 2015). Some of these proteins, including those of 




kDa proteins are preferentially expressed on melanocytes (Cui et al., 1995). Additionally, 
other reports have identified vitiligo patient antibody targets of 45, 65, 70, 88, and 110-
kDa, which are specifically expressed in melanocytes (Park et al., 1996). 
Various melanocyte-associated autoantigens have been reported (Table 1.7). One of 
interest is tyrosinase and antibodies against this melanocyte-specific protein have been 
extensively reported in several independent studies of vitiligo patients (Song et al., 1994, 
Baharav et al., 1996, Kemp et al., 1997a, Kemp et al., 1997b, Merimsky et al., 1998, 
Pradhan et al., 2013, Speeckaert et al., 2015, Furue and Kadono, 2016). Moreover, 
antibodies against other proteins of the melanogenic pathway such as DCT, TYRP1, 
PMEL, and GTP-binding protein Rab38 have been detected in vitiligo patients, albeit at 
a low prevalence (Kemp et al., 1997b, Kemp et al., 1998a, Kemp et al., 1998b, Okamoto 
et al., 1998, Ram and Shoenfeld, 2007, Waterman et al., 2010, Pradhan et al., 2013, Zhu 
et al., 2015). 
1.3.9.8.2 Other antibody specificities  
In addition to the association of vitiligo with autoimmune diseases previously discussed 
in Section 1.2.5, a variety of organ-specific antibodies, mostly against gastric parietal 
cells, pancreatic islet cells, thyroid and adrenal glands, are commonly identified in vitiligo 
patients sera (Table 1.8) (Brostoff, 1969, Betterle et al., 1976, Zauli et al., 1986, Mandry 
et al., 1996, Rodríguez-Martín et al., 2012, Kasumagic-Halilovic et al., 2013, Hamid et al., 
2015). Furthermore, anti-nuclear antibodies and IgM-rheumatoid factor (IgM-RF) have 
been identified at significantly high levels in vitiligo patients (Farrokhi et al., 2005, 
Rodríguez-Martín et al., 2012, Hamid et al., 2015). Rheumatoid factor is involved in 
regulating immunoglobulin secretion by controlling the activation of B cells (Ingegnoli et 
al., 2013), whereas anti-nuclear antibodies are capable of penetrating cells leading to 
apoptotic cell death (Farrokhi et al., 2005, Kasumagic-Halilovic et al., 2013). 
Anti-keratinocyte antibodies that are associated with the activity and extent of disease 
have been observed in vitiligo patients (Yu et al., 1993, Pradhan et al., 2013, Hamid et 
al., 2015). Phage-display of peptides expressed by melanocyte cDNAs has identified, 
amongst others (Table 1.8), the melanin-concentrating hormone receptor 1 (MCHR1) 




Waterman et al., 2010, Kemp et al., 2011, Rahoma et al., 2012). The MCHR1 is the 
receptor for melanin concentrating hormone, and the signalling pathway of 
MCH/MCHR1 is involved in regulating function of melanocyte along with α-MSH and 
thus antibodies to MCHR1 may interfere with the normal function of this receptor 
leading to a change in melanocyte behaviour (Hamid et al., 2015). TH plays a critical role 
in melanogenesis by catalysing L-tyrosine conversion to L-dopa, a precursor molecule of 
melanin (Hamid et al., 2015). Taken together, there is obviously strong indication that 
antibodies are significantly implicated in melanocyte destruction in vitiligo. 
1.3.9.8.3 Pathogenic mechanisms of antibodies in vitiligo 
The ability of vitiligo-associated antibodies to destroy melanocytes has been 
demonstrated in vitro by both complement-mediated cytotoxicity and antibody-
dependent cellular cytotoxicity (Norris et al., 1988, Fishman et al., 1993, Gottumukkala 
et al., 2006, Ruiz-Arguelles et al., 2007, Ruiz-Argüelles et al., 2013, Speeckaert et al., 
2015). In vivo, the administration of IgG from vitiligo patients into human skin grafted 
onto nude mice has been shown to induce melanocyte destruction (Gilhar et al., 1995). 
In a reconstructed epidermis model, sera from 9/13 (69%) vitiligo patients induced the 
detachment of melanocytes, although this was not related to disease extent or activity 
(Cario-Andre et al., 2007). Vitiligo patient antibodies against MCHR1 were demonstrated 
to block the function of the receptor (Gottumukkala et al., 2006). However, it is not 
known if or how this activity could affect the melanocyte function. Moreover, IgG anti-
melanocyte antibodies are able to induce the expression of HLA-DR and ICAM-1 on 
melanocytes and the release of IL-8 from melanocytes (Yohn et al., 1993, Sandoval-Cruz 
et al., 2011). By enhancing the antigen-presenting activity of melanocytes in this way, 





Table 1.7: Melanocyte-specific antibodies in vitiligo patients 
 
Antibody target 
Number of vitiligo 
patients with antibodies 
Reference 
Tyrosinase 16/26 (61%) 
5/46 (11%) 
(Song et al., 1994) 
(Kemp et al., 1997a, 
Pradhan et al., 2013) 
TYRP1  3/53 (5.7%) 
2/46 (4%) 
(Kemp et al., 1998b) 
(Pradhan et al., 2013) 
DCT 3/53 (5.7%) 
20/30 (67%) 
2/46 (4%) 
(Kemp et al., 1997b) 
(Okamoto et al., 1998) 
(Pradhan et al., 2013) 
PMEL 3/53 (5.7%) (Kemp et al., 1998a) 
SOX10 transcription factor 3/93 (3.2%) (Hedstrand et al., 2001) 
SOX9 transcription factor 1/93 (1.1%) (Hedstrand et al., 2001) 






Table 1.8: Other antibody specificities identified in vitiligo patients 
 
 
Antibody target  
 










(Mandry et al., 1996) 
(Rodríguez-Martín et al., 2012) 
Thyroid peroxidase 10/20 (50%) 
30/196 (15%) 
12/51 (24%) 
(Mandry et al., 1996) 
(Rodríguez-Martín et al., 2012) 
(Pradhan et al., 2013) 
Thyroid cytoplasm 22/80 (28%) (Brostoff, 1969) 
Thyroglobulin 8/20 (40%) 
9/51(18%) 
14/197(7%) 
(Mandry et al., 1996) 
(Pradhan et al., 2013) 
(Rodríguez-Martín et al., 2012) 
Adrenal gland 3/80 (4%) (Brostoff, 1969) 
Pancreatic islet cells 7/96 (7%) (Betterle et al., 1976) 
IgM-rheumatoid factor 6/55(11%) (Farrokhi et al., 2005) 
Lamin A 24/84 (29%) 
29/50 (58%) 
(Li et al., 2011) 
(Zhu et al., 2015) 
Melanin-concentrating 




(Kemp et al., 2002b) 
(Zhou et al., 2011)  
(Pradhan et al., 2013) 
γ-enolase 4/53 (8%) (Waterman et al., 2010) 
α-enolase 5/53 (9%) (Waterman et al., 2010) 
Heat-shock protein 90 7/53 (13%) (Waterman et al., 2010) 
Heat-shock protein 70 16/60 (26%) (Kim et al., 2011) 
Osteopontin 5/53 (9%) (Waterman et al., 2010) 
Ubiquitin-conjugating 
enzyme 
8/53 (15%) (Waterman et al., 2010) 








Presently, it has not been determined if melanocytes are a primary or secondary target 
of the humoral immune response in vitiligo (Tarle et al., 2014). They might arise from a 
genetic susceptibility to immune dysregulation at the T or B lymphocyte level, leading 
to lack of tolerance to pigment cell antigens (Kemp et al., 2001c, Ongenae et al., 2003, 
Rezaei et al., 2007). Alternatively, vitiligo antibodies might originate from an immune 
response against melanocytes damaged by some other mechanism (Kemp et al., 2001c, 
Passeron and Ortonne, 2005b, Rezaei et al., 2007). Interestingly, the normally 
intracellular melanocyte antigens TYRP1 and PMEL can be expressed on the cell surface 
and so can be accessible by antibodies (Takechi et al., 1996, Leonhardt et al., 2011). In 
addition, pigment cell antibodies in vitiligo might be secondary to destruction of the 
melanocyte from another immune cause such as T-cells, but that once triggered the 
antibodies are themselves destructive to melanocytes. 
 The convergence theory 
The convergence theory of vitiligo aetiology suggests that several interacting factors 
contribute to the clinical manifestation of vitiligo (Figure 1.8) (Le Poole et al., 1993a, Le 
Poole and Luiten, 2008, Dwivedi et al., 2015, Ezzedine et al., 2015). The theory states 
that the elicitation stage of vitiligo can be due to physical trauma to the skin (van Geel 
et al., 2011b, Dwivedi et al., 2015), emotional stresses (Papadopoulos et al., 1998, 
Dwivedi et al., 2015) or imbalances in endogenous neural factors, metabolites, cytokines 
or hormones (Schallreuter et al., 1996, Yu et al., 1997, Alikhan et al., 2011, Dwivedi et 
al., 2015). Such factors can result in oxidative stress within melanocytes which 
subsequently respond by expressing HSP70 and chaperoned melanocyte antigens (Kroll 
et al., 2005, Hariharan et al., 2010, Mosenson et al., 2012, Dwivedi et al., 2015). 
In the stage of immune activation, ‘danger signals’ activate dendritic cells which in turn 
activate anti-melanocyte autoreactive cytotoxic T cells (van den Boorn et al., 2009, 
Dwivedi et al., 2015). An absence of functional skin-infiltrating Tregs may also contribute 
to the on-going immune response (Ben Ahmed et al., 2012, Dwivedi et al., 2015). 
Antibodies against melanocyte-specific proteins such as tyrosinase (Song et al., 1994, 
Baharav et al., 1996, Kemp et al., 1997a, Pradhan et al., 2013, Zhu et al., 2015) are likely 




melanocyte antibodies can damage pigment cells by activating complement or by 
antibody-dependent cellular cytotoxicity (Norris et al., 1988, Fishman et al., 1993, 
Gottumukkala et al., 2006, Hamid et al., 2015). Genetic susceptibility can also influence 
the development of vitiligo, particularly in regard to the immune activation phase 







Figure 1.8: A schematic representation of the convergence theory of vitiligo aetiology 
and pathogenesis. 
The convergence theory of vitiligo aetiology suggests that several interacting factors contribute 
to the clinical manifestation of vitiligo. HLA, human leuckocyte antigen; PTPN22, protein tyrosine 
phosphatase non-receptor type 22; NLRP1, NACHT leucine-rich-repeat protein 1; FOXP3, 
forkhead box P3; AIRE, autoimmune regulator; CTLA4,  cytotoxic T lymphocyte antigen 4; MHC, 





 The current project  
As discussed earlier in this chapter, there is much evidence to support a role for 
autoimmune responses in vitiligo pathogenesis (Kemp et al., 2001c, Hamid et al., 2015) 
and, indeed, antibodies and autoreactive T cells have been reported to be present in 
vitiligo patients (van den Boorn et al., 2009, Waterman et al., 2010, Hamid et al., 2015, 
Zhu et al., 2015). As with other autoimmune diseases, identifying and characterising 
antibodies in vitiligo in terms of their target autoantigen would help in (a) developing 
tests for vitiligo diagnosis and treatment monitoring, and in (b) uncovering the 
pathogenic mechanisms involved in the disease, as antibodies may act as markers of 
destructive T cell responses against melanocytes. Such knowledge would help define 
distinct immunological characteristics of the clinical subsets and would help in 
understanding the aetiological mechanisms of the disease, which is essential for the 
development of better therapies.  
 
The aims of the current project were: 
1. To describe the vitiligo patient group included in this study in relation to their 
demographic, clinical, and antibody profiles. 
2. To identify novel targets of antibodies in vitiligo patients by using phage-display 
technology (Waterman et al., 2010). 
3. To confirm the immunoreactivity of individual vitiligo patient sera to any novel 
autoantigens identified. 
4. To determine if antibodies to any novel autoantigens were related to any clinical 




















2 General Materials and Methods 
 Participant vitiligo patients and healthy controls 
Blood samples from 246 patients with vitiligo were obtained from dermatology 
(Professor David J. Gawkrodger) and endocrinology (Professor Anthony P. Weetman) 
clinics at the Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. Specific 
details of the patients used in this study are given in the relevant chapters. In addition, 
control blood samples were also collected from 100 healthy volunteers (42 male; 58 
female; mean age 34 years; age range 21-59 years) who had no current autoimmune 
disease, no personal history of autoimmune disease, and no family history of vitiligo or 
of autoimmune disease. Serum was separated from whole blood samples (10-20 ml) by 
centrifugation at 3,000 revolutions per minute (rpm) for 10 min in a Sorval® RT6000-D 
centrifuge. Sera were kept frozen at -80°C until use. The research was approved by the 
National Research Ethics Service – Sheffield Research Ethics Committee (REC Reference 
Number 09/H1308/91), and informed consent was gained from all participants. The 
project STH15257 was under the research governance of the Clinical Research Office, 
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. 
 Chemicals and reagents 
The majority of chemicals and reagents including buffers, solvents, acids, and media 
constituents were obtained from either Sigma-Aldrich (Poole, UK), Melford Laboratories 
(Ipswich, UK) or Fisher Scientific UK Ltd. (Loughborough, UK). The source of some 
chemicals and reagents is indicated in the text where appropriate.  
 Plasticware 
Plasticware including petri-dishes, 0.5-ml and 1.5-ml Eppendorf tubes, 30-ml universal 
container tubes, Gilson pipette tips, pipettes, and 50-ml container tubes were from 
either Sarstedt Ltd. (Numbrecht, Germany), Starlab (UK) Ltd. (Milton Keynes, UK), 
Corning Incorporated (Corning, NY, USA), Nalgene Nunc International (Rochester, NY, 




 Antibiotics  
Antibiotics were prepared as 1000x concentrated stocks. Ampicillin (sodium salt) and 
kanamycin sulphate was made in deionised water and tetracycline (hydrochloride) in 
50% (v/v) ethanol. Antibiotics were sterilised by filtration with a 0.22-micron Millex® 
Filter Unit (Millipore Corp., Bedford, MA, USA) and stored at -20°C. When required, 
culture medium and agar plates were supplemented with ampicillin at 100 µg/ml, 
kanamycin at 10 μg/ml and tetracycline at 10 µg/ml.  
 Luria Bertani medium and agar 
Luria Bertani (LB) medium was prepared in deionised water and consisted of 1% (w/v) 
tryptone, 0.5% (w/v) yeast extract and 1% (w/v) sodium chloride. To sterilise, LB medium 
was autoclaved at 121°C for 15 min. LB agar was made by adding 2% (w/v) agar to LB 
medium. Following autoclaving, the agar was left to cool to 40-45°C before the addition 
of appropriate antibiotics. Subsequently, the agar was poured into 90-mm petri-dishes 
and allowed to set. Plates were then stored at 4°C until use. 
 Bacterial strains 
The bacterial strains utilised in this study are derivatives of Escherichia coli (E. coli) K-12 
and are listed in Table 2.1. Bacterial strains harbouring plasmid vectors or recombinant 
plasmids were constructed by transformation (Section 2.16). 
 Growth and storage of bacterial strains 
All strains of E. coli were grown routinely from frozen stock by streaking onto LB agar 
plates with the appropriate selective antibiotic(s) (Section 2.4), and incubated at 37ᵒC 
overnight. A single bacterial colony of the desired E. coli strain was then inoculated into 
LB medium containing the appropriate antibiotics and placed in a rotary incubator 
shaking at 250 rpm at 37°C overnight. Additionally, 0.7-ml aliquots of an overnight-
grown bacterial culture were mixed with 0.3-ml aliquots of 50% (v/v) sterile glycerol, for 




Table 2.1: Bacterial strains 
 
Strain1 Details Supplier 
JM109 A bacterial strain used in the preparation 
of plasmid vectors and recombinant 
plasmids.  
Promega 
(Southampton, UK)  
JM109 pcDNA3-
LaminA 
Carries recombinant plasmid pcDNA3-
LaminA (Table 2.2). 
This study (Chapter 7) 
XL1-Blue MRF’ A bacterial strain grown to be infected by 










 Plasmids  
The plasmids used in this study are given in Table 2.2. They were stored at –20°C in 
sterile TE buffer (10 mM Tris-hydrochloride; 1 mM ethylenediaminetetraacetic acid 
(EDTA); pH 8.0) (Promega, Southampton, UK). Diagrams of maps of plasmid expression 
vectors employed in the experiments of DNA cloning are shown in the relevant chapters. 
 Small-scale plasmid preparations 
The Wizard® Plus SV Minipreps DNA Purification System (Promega) was used to purify 
plasmid DNA from a 5-ml or 10-ml overnight culture of the desired bacterial strain, 
according to the manufacturer’s protocol. In brief, a single colony of the required 
bacterial strain was isolated by streaking out 20 μl of frozen bacterial stock on to LB agar 
containing the appropriate antibiotic(s). A single colony from the selective plate was 
subsequently inoculated into 10 ml of LB medium containing the relevant antibiotic(s) 
and placed in a rotary incubator shaking at 250 rpm at 37°C overnight. 
A bacterial cell pellets was obtained by centrifugation at 10,000 g for 10 min. The pellet 
was re-suspended in 250 μl of Cell Resuspension Solution (50 mM Tris-hydrochloride, 
pH 7.5; 10 mM EDTA; 100 μg/ml RNase A) and the cells were then lysed by adding 250 
μl of Cell Lysis Solution (0.2 M sodium hydroxide; 1% (w/v) sodium dodecyl sulphate 
(SDS)). The cell lysate was subsequently neutralised by adding 350 μl of Neutralisation 
Solution (0.759 M potassium acetate; 4.09 M guanidine hydrochloride; 2.12 M glacial 
acetic acid; pH 4.2) and mixed gently before centrifugation at 10,000 g for 10 min at 
room temperature. The cleared cell lysate was loaded on to a Wizard® SV Minicolumn 
which was then centrifuged at 10,000 g for 1 min at room temperature. The Minicolumn 
was washed with 750 μl of Column Wash Solution (60% (v/v) ethanol; 60 mM potassium 
acetate; 8.3 mM Tris-hydrochloride; 0.04 mM EDTA) and subsequently with 250 μl of 






Table 2.2: Plasmids  
 
Plasmid Details Source 
pcDNA3 A 5.4-kb plasmid vector with a selectable 
resistance marker for ampicillin. Comprises 
promoters for T7 and SP6 polymerases flanking 





pDEST15 plasmid vector (7.0-kb) carrying 
LaminA cDNA (2.0-kb) (Figure 7.2). Contains a 





pcDNA3 plasmid vector carrying LaminA cDNA 
(2.0-kb) cloned between the KpnI and XbaI 
restriction sites (Figure 7.5). 




pcDNA3 vector containing tyrosinase cDNA  
cloned into the KpnI and XbaI restriction sites. 
Dr Helen Kemp 
pcMCHR1 pcDNA3 vector containing melanin-
concentrating hormone receptor-1 cDNA cloned 
into the EcoRI and XbaI restriction sites. 
Dr Helen Kemp 
pcDNA3-
TH 
pcDNA3 vector containing tyrosine hydroxylase 
cDNA cloned into the HindIII and BamHI 
restriction sites. 
Dr Helen Kemp 










pcDNA3.1 vector containing glycoprotein non-
metastatic melanoma protein b (GPNMB) cDNA 






pcDNA3.1 vector containing OCA2-encoded P 
protein (OCA2 protein) cDNA cloned into the 




pJuFo A 4.28 bp phage-display vector containing the 
leucine zippers Jun and Fos, and the viral coat 
protein, pill, of the filamentous phage. 
  
R. Crameri (Swiss 
Institute of Allergy 






In order to recover the plasmid DNA, 100 μl of nuclease-free water were added to the 
column which was then centrifuged at 10,000 g for 1 min at room temperature. The 
concentration of the plasmid DNA was determined by spectrophotometry at 260 nm 
using a NanoDrop ND-1000 Spectrometer (Labtech, Wilmington, DE, USA) and 
NanoDrop Software (Labtech). Plasmids were stored at -20°C until required. Plasmid 
DNA was checked qualitatively using agarose gel electrophoresis (Section 2.11). 
 Large-scale plasmid preparations  
A large-scale culture of the bacterial strain harbouring the required plasmid was 
prepared by inoculating of 0.5-1 litre of LB medium containing the relevant antibiotic(s), 
with a 10-ml starter culture and grown overnight, with shaking at 37°C. The culture was 
subsequently centrifuged at 4,000 g for 30 min in a 50-ml container tube and plasmid 
extracted from the cell pellet with the use of a Qiagen Plasmid DNA Maxiprep Kit (Qiagen 
Ltd., Crawley, UK) according to the kit instructions. The bacterial cell pellet was first re-
suspended in 10 ml of P1 Buffer (50 mM Tris-hydrochloride, pH 8.0; 10 mM EDTA; 100 
μg/ml RNaseA). Subsequently, 10 ml of P2 Buffer (0.2 M sodium hydroxide; 1% (w/v) 
SDS) was added to the re-suspended cells and mixed by gentle inversion before 
incubation at room temperature for 5 min. A volume of 10ml of P3 Buffer (1.32 M 
potassium acetate, pH 5.5) was added to the lysed cells and incubated on ice for 20 min. 
The cell lysate was then centrifuged at 20,000 g for 30 min at 4°C and the supernatant 
collected. 
A Qiagen column was equilibrated by the addition of 10 ml of QBT Buffer (750 mM 
sodium chloride; 50 mM 3-[N-morpholino]propanesulphonic acid (MOPS), pH 7.0; 15% 
(v/v) isopropanol; 0.15% (v/v) Triton X-100) and was left to empty by gravity flow. The 
supernatant was loaded onto the equilibrated column and allowed to flow through. The 
column was then washed twice with 30 ml of QC Buffer (1 M sodium chloride; 50 mM 
MOPS, pH 7.0; 15% (v/v) isopropanol). Plasmid DNA was subsequently eluted with 15 ml 
of QF Buffer (1.25 M sodium chloride; 50 mM Tris-hydrochloride, pH 8.5; 15% (v/v) 
isopropanol) into a clean tube and then precipitated by adding 10.5 ml of 100% 
isopropanol and centrifuged at 15,000 g for 30 min at 4°C. The resulting plasmid DNA 




buffer. DNA concentration was ascertained using spectrophotometry (Section 2.9). 
Plasmid DNA was checked qualitatively using agarose gel electrophoresis (Section 2.11). 
 Agarose gel electrophoresis 
For DNA analysis, agarose gels, 0.8-1% (w/v), were made by boiling molecular biology 
grade agarose (Sigma-Aldrich) in Tris-acetate-EDTA (TAE) buffer (40 mM Tris-acetate; 1 
mM EDTA; pH 8.3) (Promega) for 1-2 min in a microwave oven. After it had cooled, 1-2 
µl of ethidium bromide solution (10 mg/ml) (Promega) were added for every 50 ml of 
gel. The molten agarose was then poured into the casting deck of a Sub-Cell® Horizontal 
Electrophoresis System (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). After it had 
set, the combs were removed from the gel which was subsequently placed into the 
electrophoresis tank. The electrophoresis tank was then filled with TAE buffer. 
In order to visualise the DNA samples running in agarose gels, Blue/Orange Loading Dye 
6x (0.4% (w/v) orange G; 0.03% (w/v) bromphenol blue; 0.03% (w/v) xylene cyanol FF; 
15% (w/v) Ficoll® 400; 10 mM Tris-hydrochloride, pH 7.5; 50 mM EDTA, pH 8.0) 
(Promega) was added to the sample of DNA at 1/6th of the volume, and this was then 
loaded into a gel slot. In order for DNA products to be sized after they had migrated 
through the gel, a `marker' lane was always included which contained a 0.5-1.0-μg 
sample of 1-kb DNA Ladder (500-10,000-bp DNA fragments) (New England Biolabs®, 
Hitchin, UK). The gels were run in a Sub-Cell® Horizontal Electrophoresis System (Bio-
Rad Laboratories Ltd.) at 85 volts using a PowerPac Basic Power Supply (Bio-Rad 
Laboratories Ltd.), and then viewed and recorded using a GBOX Gel Documentation 
System (Syngene, Cambridge, UK) and GeneSnap Image Acquisition Software (Syngene). 
  Restriction enzyme digests 
All restriction enzymes (Table 2.3) and restriction enzyme reaction buffers (Table 2.3) 
were supplied by Promega. Restriction enzyme digests of plasmids and polymerase 
chain reaction (PCR) amplification products were performed in 0.5-ml Eppendorf tubes 
in a volume not normally exceeding 25 μl and contained up to 1 μg of DNA, 10 units of 




reaction proceeded for 90 min at 37°C, unless otherwise stated. Restriction digests were 
then analysed by agarose gel electrophoresis (Section 2.11). 
 Polymerase chain reaction amplification 
Preceding the PCR amplification reaction, forward and reverse oligonucleotide primers 
were appropriately designed to amplify the desired DNA fragment. Primers were 
supplied by Eurofins Genetic Services Ltd. (London, UK) and were stored at -40°C in 
sterile, nuclease-free water at a concentration of 100 pmol/μl. The PCR primers used in 
this study are listed in Table 2.4, and the exact primers used for PCR amplification of a 
particular DNA are indicated in the text at the relevant point. 
Reactions were carried out in 0.5-ml Eppendorf tubes in 50-μl volumes consisting of, 
unless indicated, 50 ng of template DNA, 0.01-1 μM of each required (forward and 
reverse) primer, 1.25 units of GoTaq® Flexi DNA polymerase (Promega), 0.2 mM 
deoxynucleotides (dATP, dGTP, dCTP and dTTP) (Promega), 1.5 mM magnesium chloride 
(Promega) and 0.2 volumes of 5x GoTaq® Flexi Buffer (50 mM Tris-hydrochloride, pH 
8.5; 0.05% (w/v) gelatin; 250 mM potassium chloride; 0.5% (v/v) Tween 20; and 0.5% 
(v/v) Nonidet P-40) (Promega). Reactions without template DNA were included as 
controls. Each reaction was then subjected to PCR amplification in a Techne TC-312 DNA 
Thermal Cycler (Bibby Scientific Ltd., Stone, UK). The thermocycling conditions were 
denaturation at 95°C for 1 min, annealing at 55°C for 1 min and extension at 72°C for 2 
min for 35 cycles, unless stated otherwise. The reactions were completed by a final 
extension at 72°C for 10 min, followed by storage at 4°C. Products of amplification were 













Buffer (10x concentration)1 
 
Restriction site 
KpnI Multi-Core™ Buffer (25 mM Tris-acetate, pH 7.5; 100 
mM potassium acetate; 10 mM magnesium acetate; 
1mM dithiothreitol) 
5’-GGTACC-3’ 
XbaI Multi-Core™ Buffer (25 mM Tris-acetate, pH 7.5; 100 









Table 2.4: Oligonucleotide PCR amplification primers  
 
Primer Sequence1 Source 
LaminA-F 5’-ttggtaccatggagaccccgtcc-3’ Eurofins Genetic 
Services Ltd. 
(London, UK) 
LaminA-R 5’-aatctagacgcctatcacatgatgctgcagtt-3’ Eurofins Genetic 
Services Ltd. 
 
1The KpnI restriction site is in red in the forward (F) primer. The XbaI restriction site is in red in 
the reverse (R) primer. The ATG translation start codon in the forward primer and the translation 






 Extraction and purification of DNA fragments from agarose gels  
DNA produced either from a PCR amplification reaction or a restriction enzyme digest 
was purified for further use using a Wizard® PCR Preps DNA Purification System 
(Promega). DNA fragments were initially separated by agarose gel electrophoresis 
(Section 2.11). The area of the agarose gel containing the relevant band of DNA was then 
visualised using a Chromato-vue TM-20 transilluminator (UVP, San Gabriel, CA, USA), 
and then excised using a clean scalpel. Subsequently, the agarose gel slice was placed in 
a 1.5-ml Eppendorf tube and dissolved by adding 1 ml of Wizard® PCR Preps DNA 
Purification Resin. The resulting mixture was applied via a 2-ml syringe to a Wizard® 
Minicolumn, followed by 2 ml of 80% (v/v) isopropanol. The Wizard® Minicolumn was 
centrifuged at 10,000 g for 2 min, to eliminate excess isopropanol, prior to the elution 
of DNA with 30 μl of sterile TE buffer. The DNA was kept at -20°C until use. Purified DNA 
fragments were analysed by agarose gel electrophoresis and the concentration of the 
DNA measured by spectrophotometry (Section 2.9). 
 DNA ligations  
Ligation of vector and DNA fragments was carried out using T4 DNA ligase (Promega) in 
a reaction volume of 10-20 μl. Reactions usually contained 20-100 ng of plasmid vector. 
The amount of insert DNA was calculated as: ng of vector x size of insert (kb)/size of 
vector (kb) x molar ratio of insert to vector. Vector and insert DNA were usually at a 
molar ratio of between 1 and 3. The vector and insert DNAs were combined in a 0.5-ml 
Eppendorf tube, and the required amount of nuclease-free water added prior to the 
addition of 1-2 units of T4 DNA ligase (Promega) and 0.1 volumes of 10x DNA ligase 
buffer (300 mM Tris-hydrochloride, pH 7.8; 100 mM magnesium chloride; 100 mM 
dithiothreitol; 10 mM adenosine triphosphate) (Promega). The reaction was then 
incubated at 15°C overnight, prior to using to transform bacterial cells (Section 2.16). 
 Bacterial transformation  
When required, a 50-μl aliquot of chemically competent E. coli JM109 (Promega) cells 




ligation reaction) was gently mixed with the cells and then incubated on ice for 5-10 min. 
The cells were subsequently heat-shocked at exactly 42°C for 45 sec and returned to ice 
for 2 min. The cells were then transferred to a sterile plastic universal containing 950 μl 
of chilled SOC medium (2% (w/v) tryptone; 0.5% (w/v) yeast extract; 10 mM sodium 
chloride; 2.5 mM potassium chloride; 10 mM magnesium chloride; 10 mM magnesium 
sulphate; 20 mM glucose) (Life Technologies). The culture was incubated in a rotary 
shaking at 150 rpm for 1 h to enable expression of the antibiotic resistance genes 
harboured by the transforming plasmid DNA. A 100-μl aliquot of undiluted transformed 
cells, and of 1:10 and 1:100 dilutions, were then streaked out on agar plates containing 
the relevant antibiotic(s), and these plates were subsequently incubated at 37°C 
overnight. As a control in each transformation experiment, an aliquot of untransformed 
cells was also spread onto an agar plate. Individual colonies, which had selectively grown 
from successful transformation, were then purified by streaking onto fresh LB agar 
plates containing selective antibiotic(s) for growth overnight at 37°C. 
 DNA sequencing  
Automated DNA sequencing was performed by the Genetics Core Facility at the Medical 
School, University of Sheffield, Sheffield, UK. DNA templates (plasmids or products of 
PCR amplification) and oligonucleotide sequencing primers were provided to the service 
at 50-100 ng/μl and 1 pmol/μl, respectively. Sequencing primers are listed in Table 2.5. 
Sequencing reactions were carried out using a BigDye® Terminator Cycle Sequencing Kit 
Version 3.1 (Applied Biosystems, Foster City, CA, USA) and an ABI 3730 Capillary 
Sequencer (Applied Biosystems). 
 DNA and protein analyses  
Analyses of DNA and protein sequences were performed using Lasergene® Core Suite 
version 11.0 (DNASTAR, Inc., Madison, WI, USA), and the network facilities of the 
European Bioinformatics Institute-European Molecular Biology Laboratory (EBI-EMBL) 
(http://www.ebi.ac.uk/) (Cambridge, UK) and the ExPASy Bioformatics Resources Portal 




searches of DNA and proteins against the DNA and protein sequences found in the 
database of GenBank were carried out by employing the BLAST service of the National 







Table 2.5: Oligonucleotide sequencing primers 
 
Primer Sequence Source 
GPNMB-1-Forward 5’-TCCTGACCAGTGACTCACCA-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
GPNMB-2-Forward  5’-TGTCTACAGAAGACATGGA-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
GPNMB-3-Forward  5’-TCAATGGAACCTTCA-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
GPNMB-4-Forward 5’-TTAGAGGTTAACATCATCCA-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
GPNMB-5-Forward  5’-TATTTGTCACTGTGAT-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
OCA2-1-Forward 5’-TGACTGGGAGCGAAGATAC-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
OCA2-2-Forward  5’-ACGCTTTGGGCTCCAGGT-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
OCA2-3-Forward  5’-TAAAGGCATACCGGCTCT-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
OCA2-4-Forward 
 
5’-TCAGCCCGGCCAGCCGCGA-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
OCA2-5-Forward  5’-TAAAGATGGTCCCAGAGGA-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
T7 5’-TAATACGACTCACTATAGGG-3’ Promega (Southampton, 
UK) 




5’-TGAGATGCTGCGGCG-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
Lamin A-700-
Revesrse 
5’-GCTTCCCATTGTCAA-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
Lamin A-1751-
Forward 
5’-GCACCGTGCTGTGCG-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
Lamin A-1600-
Forward 
5’-AGCCGTACGCAGGCT-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
JUFO-1192  5'-CCGCTGGATTGTTATTACTCGCTG-
3' 
Eurofins Genetic Services 
Ltd. (London, UK) 
JUFO-1500  5’-TGCAAGGCGATTAAGTTGGGTAAC-
3' 
Eurofins Genetic Services 






 In vitro coupled transcription-translation of cDNA  
A TnT® T7-Coupled Reticulocyte Lysate System (Promega, Southampton, UK) was used 
to produce the protein of interest labelled with [35S]-methionine according to the 
manufacturer’s instructions. Reactions were carried out in 0.5-ml tubes in 50-μl volumes 
comprising 0.5 μg of plasmid DNA carrying the appropriate cDNA, 0.5 volumes of TnT® 
Rabbit Reticulocyte Lysate, 10 units of TnT® T7 RNA Polymerase, 0.02 mM amino acid 
mixture minus methionine, 0.04 volumes of 25x TnT® Reaction Buffer, 40 units of 
RNasin® Ribonuclease Inhibitor (Promega) and 0.04 volumes of 10 mCi/ml translation-
grade [35S]-methionine (1,000 Ci/mmol) (Perkin-Elmer LAS UK Ltd., Beaconsfield, UK). 
Reactions were incubated for 90 min at 30°C and then stored at -40°C until required. For 
qualitative analysis, radiolabelled protein products were analysed by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography (Section 2.20). 
The percentage incorporation of [35S]-methionine into the translated protein was 
determined by trichloroacetic acid-precipitation, as detailed by the manufacturer 
(Promega). In brief, 2 µl of the in vitro translation reaction were added to 98 µl of 1 M 
sodium hydroxide/2% (v/v) hydrogen peroxide and incubated at 37°C for 10 min. 
Subsequently, 900 µl of ice-cold 25% (w/v) trichloroacetic acid/2% (w/v) casamino acids 
(Difco, Detroit, MI, USA) were added and the reaction incubated on ice for 30 min. To 
collect the precipitated translation products, 250 µl of the trichloroacetic acid reaction 
mixture were vacuum filtered onto a Whatman GF/A glass fibre filter (Whatman 
International Ltd., Maidstone, UK) pre-wetted with cold 5% (w/v) trichloroacetic acid. 
The filter was rinsed three times with 1 ml of ice-cold 5% (w/v) trichloroacetic acid, once 
with 1 ml of acetone and then allowed to dry at room temperature before immersing in 
3 ml of Ultima-Gold® XR scintillation fluid (Packard Bioscience, Groningen, The 
Netherlands) and counting in a Beckman LS 6500 Multi-Purpose Scintillation Counter 
(Beckman Coulter, Inc., Fullerton, CA, USA). To determine total counts per min (cpm) 
present in the reaction, a 5-µl aliquot of the trichloroacetic acid reaction mixture was 
spotted directly on to a filter. This was dried for 10 min before counting as above. The 
percent incorporation of [35S]-methionine was determined as: 100 x (cpm of washed 




 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and 
autoradiography 
The protocol used was that of Dr Helen Kemp (Department of Oncology and Metabolism, 
University of Sheffield, Sheffield, UK). SDS-PAGE of proteins was carried out in 10% (w/v) 
polyacrylamide gels. Resolving gels consisted of 10% (v/v) ProtoGel (37.5:1 
acrylamide:bisacrylamide) (GeneFlow, Lichfield, UK), 375 mM Tris-hydrochloride (pH 
8.8), 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate and 0.1% (v/v) N, N, N, N’-
tetramethylethylenediamine (TEMED). Stacking gels contained 4% (v/v) ProtoGel, 125 
mM Tris-hydrochloride (pH 6.8), 0.1% (w/v) SDS, 0.05% (w/v) ammonium persulphate 
and 0.1% (v/v) TEMED. 
The gels were generated using a Bio-Rad Mini-Protean Tetra Cell apparatus (Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK). In brief, glass plates were assembled using 
the dedicated equipment as per the manufacturer’s instructions. The resolving gel 
solution was poured into the space between the plates and overlaid with 1 ml of butan-
1-ol. After the gel had polymerized, the butanol-1-ol was decanted and a gel comb was 
inserted prior to the solution of the stacking gel was poured in on top. The gel comb was 
subsequently removed and a full apparatus holding the glass plates with the gel in 
between was assembled into the gel tank. Running Buffer (25 mM Tris-base; 0.1% (w/v) 
SDS; 192 mM glycine; pH 8.3) (GeneFlow) was poured into the tank until the bottom of 
the plates was covered and the top buffer reservoir was full. 
Before loading, 5-µl samples of in vitro [35S]-labelled proteins were individually mixed 
with 20 µl of 2x Laemmli sample buffer (2% (w/v) SDS; 25% (v/v) glycerol; 0.01% (w/v) 
bromophenol blue; 2% (v/v) 2-mercaptoethanol; 62.5 mM Tris-hydrochloride, pH 6.8) 
(Bio-Rad Laboratories Ltd.) and heated at 100°C for 5 min. Approximately 10 µl of each 
sample was then loaded into a well. Protein molecular weight markers, either Prestained 
SDS-PAGE Standards, Low Range (21-103 kDa) (Bio-Rad Laboratories Ltd.) or Precision 
Plus Protein All Blue Standards (10-250 kDa) (Bio-Rad Laboratories Ltd.) were also run 
on each gel. Gels were run initially at 44 volts for 20 min up to the resolving gel, and 
then at 111 volts for 90 min. The apparatus was then disassembled and the gel 




and 10% (v/v) glacial acetic acid for 30 min at room temperature with slow shaking on a 
rocking platform.  
Subsequently, the gel was soaked in Amersham Amplify™ Fluorographic Reagent (GE 
Healthcare Life Sciences, Little Chalfont, UK), for 30 min without shaking. This was 
followed by soaking the gel in 7% (v/v) methanol/1% (v/v) glycerol for 5 min prior to 
being dried for 2 h at 60°C on to 3MM Whatman paper (Whatman International Ltd., 
Maidstone, UK) in a Bio-Rad Gel Dryer 583 (Bio-Rad Laboratories Ltd.). Dried gels were 
subjected to autoradiography by exposure to Fuji RX x-ray film (Genetic Research 
Instrumentation Ltd., Dunmow, UK) in a Hypercassette™ (GE Healthcare Life Sciences) 
at room temperature for 24 h. The film was then developed using Photosol CD18 x-ray 
developer (Photosol Ltd., Basildon, UK) for 3 min, rinsed with water and subsequently 
fixed for 3 min in Photosol CF40 fixer (Photosol Ltd.). 
 Radioligand binding assays 
Antibody-binding to [35S]-labelled antigens was detected in radioligand binding assays 
(RLBAs) (Figure 2.1). For each RLBA reaction, a 1-2-μl aliquot of the desired in vitro 
coupled transcription-translation reaction was suspended in 50 μl of 
immunoprecipitation buffer (20 mM Tris-hydrochloride, pH 8.0; 150 mM sodium 
chloride; 1% (v/v) Triton X-100; 10 mg/ml protease inhibitor aprotinin) in a 1.5-ml 
Eppendorf tube. Serum (e.g., patient serum, healthy control serum or animal antiserum) 
was then added to the required final dilution. Following incubation overnight with 
shaking in a cold room at 4°C, 50 μl of protein G Sepharose™ 4 Fast Flow (GE Healthcare 
Life Sciences), prepared according to the manufacturer, were added and incubated for 
a further 90 min at 4°C. The protein G Sepharose™-antibody-antigen complexes were 
subsequently collected by centrifugation at 5000 rpm for 30 sec and washed six times 
for 15 min in immunoprecipitation buffer. In each wash, the reaction tube was incubated 
with shaking for 15-20 min at 4°C. Following each wash, the tubes were spun for 30 sec 
at 5000 rpm and the supernatant was removed. Fifty microlitres of immunoprecipitation 
buffer was then added to the reaction tube and mixed gently. The protein G 
Sepharose™-antibody-antigen complexes were then transferred to a scintillation vial 




Immunoprecipitated radioactivity was measured in a Beckman LS 6500 Multi-Purpose 
Scintillation Counter (Beckman Coulter, Inc., Fullerton, CA, USA). Samples were always 
tested in duplicate in each experiment and the mean of the cpm was calculated from 
the two samples. 
The binding activity of antibodies to radiolabelled antigen was expressed as an antibody 
index. This was calculated for each serum tested as: cpm immunoprecipitated by tested 
serum/mean cpm immunoprecipitated by the group of healthy control sera. Each serum 
was tested in at least three experiments and the mean antibody index was calculated 
from these values. The upper limit of normal for RLBA was calculated using the mean 
antibody index + 3SD of the population of healthy control subjects. Any patient serum 
with an antibody index higher than the upper limit of normal was regarded as positive 
for antibody reactivity. 
To determine the titres of antibodies, serum samples from vitiligo patients were 
analysed in RLBAs at a series of dilutions ranging from 1:100 up to 1:10000. For each 
dilution of each serum sample, an antibody index was determined as explained above. 
SDS-PAGE and autoradiography were performed to qualitatively analyse the 
immunoprecipitated proteins. The protein G Sepharose-antibody complexes were firstly 
resuspended in 100 μl of 2x Laemmli sample buffer. Subsequently, they were boiled for 
5 min at 100°C. Following centrifugation, the recovered supernatants were subjected to 















 Antibody absorption experiments using cell extracts 
The protocol used was that of Dr Helen Kemp. Cell extracts were a gift from Dr Helen 
Kemp (Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK). 
These were made from untransfected human embryonic kidney 293 (HEK293) cells as 
well as HEK293 cells harbouring the expressed protein (antigen) of interest. To confirm 
that heterologous proteins were expressed in HEK293 cells, immunoblotting assays with 
antigen-specific animal antibody (Table 2.6) were carried out. Cell extract samples were 
kept in extract buffer (150 mM sodium chloride; 10 mM Tris-hydrochloride, pH 7.4; 1% 
(v/v) Triton X-100; Protease Cocktail Inhibitor) (Sigma-Aldrich) at a concentration of 1 
mg/ml total protein. Extract samples were kept at -80°C until use. 
In order to assess antibody specificity, absorption experiments were performed. Briefly, 
samples of sera (100 µl) were incubated with cell extract samples (400 µl) as prepared 
above. In addition, serum samples without adding any cell extract were incubated in cell 
extract buffer. Following incubation at 4°C for 16 h, absorbed serum (supernatant) was 
recovered by centrifugation at 45,000 g for 1 h at 4°C. Serum samples of unabsorbed 
and pre-absorbed were analysed in RLBAs as described earlier (Section 2.21), in order to 
assess their immunoreactivity against the specific antigen.  
 Antibodies 
All antibodies employed in this present work were kept as per the manufacturer’s 
instruction at either 4°C or -20°C. These are shown in Table 2.6. 
 Statistical analyses 
Statistical analyses performed in this study were: Fisher's exact tests for 2 x 2 
contingency tables or Chi-square tests to compare categorical data; unpaired t tests to 
compare two unpaired groups of continuous data; and one-way ANOVA for comparisons 
of multiple continuous data sets. The tests were carried out as appropriate using 
GraphPad Prism software (GraphPad Software, San Diego, CA, USA). In all tests, P values 









Antibody Details Source 
Polyclonal rabbit anti- 
GPNMB antiserum 
sc271435 
Raised against a synthetic 
peptide corresponding to 
the C-terminal of GPNMB. 
Santa Cruz 
Biotechnology, Inc. 
(Santa Cruz, CA, USA) 
Polyclonal rabbit anti-
OCA2 protein antiserum 
PA5-23708 
Raised against a synthetic 
peptide corresponding to 
the C-terminal of OCA2 
protein. 
Thermo Fisher Scientific, 




Raised against a synthetic 
peptide corresponding to 
the C-terminal of LaminA. 





Raised against a synthetic 
peptide corresponding to 




Institutes of Health, 
Bethesda, MD, USA) 
Polyclonal rabbit anti-DCT 
antiserum α-PEP8 
Raised against a synthetic 
peptide corresponding to 
the C-terminal of DCT. 
Professor Vincent 
Hearing (National 
Institutes of Health, 




Raised against a 16-amino 
acid peptide close to the 
C-terminal of MCHR1.  
Alpha Diagnostics 
International, Inc. (San 
Antonio, TX, USA) 
Polyclonal rabbit anti-TH 
antiserum  ab59276 
Raised against a synthetic 
peptide close to the N-
terminal of TH.  






















3 An analysis of the demographic and clinical profile of a Sheffield 
vitiligo patient cohort  
 Introduction 
As previously detailed (Section 1.2), vitiligo is the most common skin depigmenting 
condition (Ezzedine et al., 2015, Picardo et al., 2015). Worldwide, the estimated 
prevalence of vitiligo is 0.4% to 2%, although greater rates of up to 8.8% have been 
reported in India (Ezzedine et al., 2015, Picardo et al., 2015). The disease affects all races 
and both genders seem equally vulnerable to vitiligo, although women report to clinic 
more frequently, probably because of greater social burden (Ezzedine et al., 2015, 
Picardo et al., 2015). Although vitiligo can occur at any age, almost half of patients 
develop vitiligo by the age of 20 years, and in approximately 70-80% of cases, vitiligo 
begins before the age of 30 years (Ezzedine et al., 2015, Picardo et al., 2015). Non-
segmental vitiligo can appear at any age, while segmental vitiligo usually occurs at a 
young age (a median age at onset of 12-16 years) (Khaitan et al., 2012). 
The evidence for an autoimmune pathogenesis in vitiligo is supported by its strong 
association with other autoimmune diseases, with autoimmune thyroid disease being 
the highest vitiligo-associated disorder (Alkhateeb et al., 2003, Nejad et al., 2013, 
Lukinovic-Skudar, 2015). The association of vitiligo with other autoimmune disorders 
and their frequencies are listed in Table 1.3 and Table 1.4. An increased incidence of 
vitiligo is also observed in patients with vitiligo family records (Alkhateeb et al., 2003, 
Singh and Pandey, 2011, Nicolaidou et al., 2012, Nejad et al., 2013, Vora et al., 2014). 
Although this association exists, values vary depending on the population studied, and 
they range from 12% to 40% (Sehgal and Srivastava, 2007, Nejad et al., 2013, Pradhan 
et al., 2013). The clinical and demographic characteristics of vitiligo are previously 







The aim of the work in this chapter was to describe our Sheffield vitiligo patient cohort 






 Study participants 
The study included 246 vitiligo patients referred to the dermatology (Professor David 
Gawkrodger) and endocrinology (Professor Anthony Weetman) clinics at the Sheffield 
Teaching Hospitals NHS Foundation Trust, Sheffield, UK. Local ethics approval was in 
place for the study and all the participants had given written informed consent. 
 Skin examination and classification of disease status 
Clinical diagnosis of vitiligo by these two experienced clinicians was based on the 
presence of depigmented macules with special focus on lesion morphology, distribution, 
and comorbidities. The clinical types of vitiligo were categorised as segmental, non-
segmental and unclassified/undetermined according to the VGICC classification 
(Ezzedine et al., 2012b). 
Segmental vitiligo was defined as one or a few macules in one area, but in a non-
dermatomal pattern. Unclassifiable or undetermined vitiligo included focal vitiligo, and 
mucosal vitiligo when affecting one site.   
Non-segmental vitiligo, defined by a symmetrical distribution of the lesions, was sub-
divided into different types. Acral was characterised by several depigmented patches on 
the extremities of different regions, acrofacial by lesions over the face and acral parts of 
the extremities, symmetrical (generalised) by scattered lesions extensively distributed, 
and universal by depigmentation of over 90% to 100% of the body. Mixed vitiligo was 
considered when there was evidence of the coexistence of segmental and non-
segmental types. 
Vitiligo was considered active when existing and/or new lesions had spread over the 
past 12 months (Ezzedine et al., 2012b). Vitiligo was considered stable when there was 
no history that depigmentation had not progressed during the last 12 months (Ezzedine 




 Data collection 
A questionnaire was used for data collection. For this, each patient was interrogated and 
examined. The results of the history and of a detailed examination were recorded. 
Special attention was given to gender, age, age at onset, duration of disease, type of 
vitiligo, progression status, previous treatment, any precipitating factors, history of 
autoimmune disorders reported in association with vitiligo, family history of vitiligo 
and/or other autoimmune disease. Associated autoimmune disorders were confirmed 
by reviewing the medical history of each patient and carrying out a physical examination 
and, by carrying out relevant laboratory tests. 
 Statistical analysis 
The frequencies of demographic details and clinical features were analysed using 







 Age and sex of vitiligo patients 
Of the 246 British Caucasian vitiligo patients recruited to the study, 142 (58%) were 
female and 104 (42%) were male giving a male to female ratio of 1:1.37 (Table 3.1). As 
shown in Table 3.1, the age of the patients ranged from less than 1 to 88 years with a 
mean age of 44 ± 17 years. For male patients, the mean age was 43 ± 18 years (range 0-
78 years). For female, 45 ± 17 years (range 7-88 years). There was no significant 
difference in the age profile of the two gender groups (P = 0.38, Unpaired t test). 
 Age at onset of vitiligo 
The age of vitiligo onset varied notably, ranging from birth to 83 years with a mean age 
of onset of 31 ± 17 years (Table 3.1). Grouping patients by 10-year intervals, the most 
frequent vitiligo onset age was between 11-20 years of age accounting for 54 of the 246 
patients (22%) (Figure 3.1). The majority of patients, 53% (131/246), had their vitiligo 
develop before the age of 30 years, and 72% (178/246) before 40 years (Figure 3.1).  
 Duration of vitiligo 
The duration of vitiligo at the point of referral ranged from 0-71 years with a mean of 14 
± 13 years (Table 3.1). At the time of inclusion in the study, 55% (136/246) of cases had 
had vitiligo for 0-10 years, with the 74% (183/246) having a disease duration of less than 
20 years (Figure 3.2).  
 Vitiligo classification 
According to the VGICC classification (Ezzedine et al., 2012b), the type of vitiligo in the 
patient cohort was predominantly non-segmental with 94% (231/246) of patients 
diagnosed with this type (Table 3.1). Only 4 of 246 (1.6%) patients showed a pattern of 
segmental vitiligo (Table 3.1). An undetermined classification was attributed to 11/246 




 Non-segmental vitiligo subtypes 
Amongst 231 non-segmental vitiligo, symmetrical (generalised) was the most common 
subtype with 157 (68%) cases, followed by acrofacial, 42 (18.2%), acral, 4 (1.7%), peri-
orificial, 3 (1.3%), and universal, 1 (0.4%) (Figure 3.3). In addition, there were patients 
with a combination of symmetrical and peri-orificial, 10 (4.3%), symmetrical and 
acrofacial, 7 (3.0%), and symmetrical with peri-orificial and acrofacial, 1 (0.4%) (Figure 
3.3). One (0.4%) patient had occupational vitiligo (Figure 3.3). Only five (2.2%) patients 
exhibited mixed (segmental and non-segmental) vitiligo (Figure 3.3).  
 Vitiligo activity status 
Active vitiligo is defined as the spread of existing and/or new lesions within the previous 
12 months. Stable vitiligo is defined by depigmentation that had shown no progression 
for the previous 12 months (Ezzedine et al., 2012b). Of the 246 vitiligo patients included 
in the study, 226 (92%) were considered to have actively progressing vitiligo at the time 
of their recruitment (Table 3.1). Only 20 of 246 (8%) patients were classified as having 
stable vitiligo (Table 3.1). 
Of the 226 active vitiligo cases, 216 (95.6%) were non-segmental, 9 (4%) focal, and one 
(0.4%) segmental (Figure 3.4). In the 20 patients with stable vitiligo, 15 (75%) had non-
segmental, two (10%) had focal and three (15%) had segmental vitiligo (Figure 3.4). 
Comparing vitiligo activity status in the different disease classifications, the frequency 
of active vitiligo was significantly increased in the patient group (216/231 = 93.5%) with 
non-segmental vitiligo when compared with the segmental vitiligo patient cohort (1/4 = 






Table 3.1: The demographic and clinical characteristics of 246 vitiligo patients  
 
Characteristic 
Detail for vitiligo patients 
(n = 246) 
Sex 
Male  104 (42%) 
Female 142 (58%) 
Age at inclusion in study 
Age, mean ± SD  44 ± 17 years 
Age range 0-88 years 
Age at onset 
Age at onset, mean ± SD  31 ± 17 years 
Age at onset range 0-83 years 
Disease duration 
Disease duration, mean ± SD 14 ± 13 years 
Disease duration range 0-71 years 
Vitiligo clinical type 
Segmental   4 (1.6%) 
Non-segmental  231 (94%) 
Undetermined (all focal) 11 (4.5%) 
Vitiligo activity1 
Active  226 (92%) 
Stable   20 (8%) 
Autoimmune disease  
Absent   162 (66%)  
Present (at least one disease) 84 (34%) 
    One disease  70 (28%) 
    Two diseases  9 (3.7%) 
    Three diseases 5 (2.0%) 
Family history of vitiligo or autoimmune disease 
No 135 (55%) 
Yes (vitiligo and/or autoimmune disease) 111 (45%) 
          Vitiligo only 19 (7.7%)  
          Vitiligo with autoimmune disease 26 (10.6%) 
          Autoimmune disease only 66 (26.8%) 
 
1Active vitiligo is defined as the spread of existing and/or new lesions within the previous 12 
months. Stable vitiligo is defined by depigmentation that had shown no progression for the 
















Figure 3.1: Age distribution at vitiligo onset. 
The percentage of the 246 vitiligo patients, including segmental, non-segmental and focal types, 














Figure 3.2: Disease duration distribution  











Figure 3.3: Frequency of the non-segmental vitiligo subtypes 















Figure 3.4: The frequency of the three vitiligo subtypes in the active and stable vitiligo 
classifications. 
The frequency of non-segmental, segmental, and focal vitiligo in the active (n = 226) and stable 




















Figure 3.5: The proportion of active and stable vitiligo in the three vitiligo 
classifications. 
The distribution of active and stable vitiligo is shown for the three different vitiligo types. Non-






 Comorbid diseases 
3.4.7.1 Frequency and type of autoimmune diseases  
The frequency of different comorbid diseases in the vitiligo patient cohort is illustrated 
in Figure 3.6. Autoimmune hypothyroidism, including Hashimoto’s thyroiditis, was the 
most common autoimmune disease being present in 41/246 (16.7%) patients with 
vitiligo. Other associated autoimmune diseases included Graves’ disease 
(hyperthyroidism), 15 (6.1%), alopecia areata (4.1%), type 1 diabetes, 8 (3.3%), psoriasis, 
3 (1.2%), lichen sclerosus, 4 (1.6%), pernicious anaemia, 5 (2.0%), rheumatoid arthritis, 
4 (1.6%), systemic lupus erythematosus, 3 (1.2%), Sjögren's syndrome, 1 (0.4%), 
Addison’s disease (adrenal insufficiency), 3 (1.2%), chronic urticaria, 2 (0.8%), Crohn's 
disease, 1 (0.4%), hypopituitarism, 1 (0.4%), angioedema, 1 (0.4%), and 
hyperparathyroidism, 1 (0.4%). 
Overall, 84/246 (34%) of the vitiligo patients had at least one comorbid autoimmune or 
inflammatory disease (Table 3.1). Fourteen of the 246 (5.7%) vitiligo patients had more 
than one concomitant disease (Table 3.1). Nine of the 246 (3.7%) patients had two 
comorbid autoimmune diseases (Table 3.1). These included two patients each with 
autoimmune hypothyroidism and type 1 diabetes, two patients each with autoimmune 
hypothyroidism and Addison's disease, two patients each with autoimmune 
hypothyroidism and pernicious anaemia, one patient with hypopituitarism and alopecia 
areata, one patient with chronic idiopathic urticaria and angioedema, and one patient 
with hyperthyroidism and systemic lupus erythematosus.  
Five of the 246 (2.0%) patients were affected by three concomitant autoimmune 
disorders (Table 3.1). One patient suffered from autoimmune hypothyroidism, type 1 
diabetes, and alopecia areata, the second had type 1 diabetes, pernicious anaemia, and 
rheumatoid arthritis, and the third patient had Addison's disease, autoimmune 
hypothyroidism and type 1 diabetes. A fourth patient had hyperparathyroidism, 
autoimmune hypothyroidism, and lichen sclerosus, and a fifth suffered from alopecia 














Figure 3.6: Frequency of associated comorbid diseases in vitiligo patients. 
The figure shows the percentage of autoimmune and auto-inflammatory diseases observed in 





3.4.7.2 Comparison of frequency of autoimmune diseases with general population 
The frequency of the various autoimmune diseases are compared with those in the 
general population in Table 3.2. Amongst the vitiligo patients, there was a twelve -fold 
increase over the 1.9% population frequency of self-reported clinical autoimmune 
thyroid disease in Caucasians (Jacobson et al., 1997). The frequency of pernicious 
anaemia at 2% was elevated in the study population compared with the frequency in 
the general population of 0.15% (Jacobson et al., 1997), a fold increase of 13. The 
frequency of Addison’s disease in the general population is extremely low at 0.005% 
(Jacobson et al., 1997). In the current study, the frequency was 1.2%, a very large fold 
increase in our vitiligo group.  
3.4.7.3 Association with gender  
Of the 84 patients with an associated autoimmune disease, 21 (25%) were male and 63 
(75%) were female. In respect of the total of 142 female patients with vitiligo, 44% had 
an associated disorder, while 20% of the 104 male patients with vitiligo suffered from a 
comorbid disease. Comparing male with female patients, the frequency of an associated 
autoimmune disease was significantly increased in females (P < 0.0001, Fisher’s exact 
test).  
3.4.7.4 Association with vitiligo type 
With respect to vitiligo classification, 81 of the 84 (96%) patients with autoimmune 
disease had non-segmental vitiligo, three (4%) had focal, but none had segmental. With 
respect to patients with non-segmental, focal, and segmental vitiligo, 81/231 (35%), 
3/11 (27%), and 0/4 (0%), respectively, had at least one autoimmune disease. 
Comparisons indicated there was no significant statistical difference in the frequency of 






Table 3.2: Autoimmune disorders in our vitiligo patients compared with the general 
population 
 
Disease Frequency in 
vitiligo patients 





frequency in the 
general population  




22.8 1.9 (Jacobson et al., 
1997) 
Alopecia areata 4.1 0.2-2.0 (Safavi, 1992, Safavi 
et al., 1995) 
Psoriasis 1.2 0.5-1.6 (Farber and Nall, 
1998) 
Pernicious anaemia 2.0 0.15 (Jacobson et al., 
1997) 




1.2 0.024 (Jacobson et al., 
1997) 
Sjogren’s syndrome 0.4 0.014 (Jacobson et al., 
1997) 






 Family history of vitiligo and/or autoimmune disorders 
A positive family history of vitiligo and/or other autoimmune disorders was present in 
111/246 (45%) patients, whereas 135 (55%) cases had no family history of vitiligo and/or 
other autoimmune diseases (Table 3.1). Nineteen (7.7%) patients reported a positive 
family history of vitiligo alone, 26 (10.6%) reported a family history of vitiligo and 
autoimmune disease, and 66 (26.8%) reported a family history of autoimmune disease 
alone (Table 3.1). 
The frequency of autoimmune diseases reported in vitiligo patient familial histories is 
shown in Figure 3.7. Type 1 diabetes was the most common, at 19% (47/246). 
Autoimmune hypothyroidism was the second most common at 18.7% (46/246). Less 
common in the family history were pernicious anaemia at 3.3% (8/246), psoriasis and 
systemic lupus erythematosus each at 1.2% (3/246), Addison’s disease and Graves’ 
disease each at 0.8% (2/246), and alopecia areata at 0.4% (1/246). 
Of the 45 patients reporting a positive family history of vitiligo (Table 3.1), 26 also 
reported coexistence of autoimmune disorders in their family history. The autoimmune 
diseases reported as the only comorbid disorder were: autoimmune hypothyroidism, 9; 
type 1 diabetes, 7; systemic lupus erythematosus, 2; and pernicious anaemia, 1. In 
addition, multiple autoimmune diseases reported were: autoimmune hypothyroidism 
and type 1 diabetes, 3; autoimmune hypothyroidism and pernicious anaemia, 1; 
autoimmune hypothyroidism and alopecia areata, 1; type 1 diabetes and pernicious 
anaemia, 1; and type 1 diabetes and psoriasis, 1. 
The diseases, reported in the 66 vitiligo patients who had a family history of 
autoimmunity alone (Table 3.1) were: autoimmune hypothyroidism, 22; type 1 diabetes, 
24; pernicious anaemia, 2; psoriasis, 2; Graves’ disease, 1; hyperthyroidism, 1;  Addison's 
disease and autoimmune hypothyroidism, 2; Graves’ disease and pernicious anaemia, 1; 
type 1 diabetes and pernicious anaemia, 2; type 1 diabetes and systemic lupus 














Figure 3.7: Frequency of associated comorbid diseases in vitiligo patient family history. 
The frequency of autoimmune diseases reported in the family history of 246 patients with 






Vitiligo is the most prevalent disease of skin depigmentation. It affects 0.4-2% of the 
world population (Kruger and Schallreuter, 2012), not showing any difference between 
races. In spite of the high frequency of vitiligo, few studies have been made on its 
epidemiology, especially longitudinal studies. The aim of this part of the study was to 
describe our vitiligo patient cohort in terms of demographic details and clinical features. 
 Gender distribution 
Some previous studies have reported both genders are equally affected with vitiligo 
(Sarin and Ajit, 1977, Taieb and Picardo, 2009, Ezzedine et al., 2012b, Shankar et al., 
2012, Picardo et al., 2015). However, a slightly greater prevalence in females have been 
reported by most studies (Martis et al., 2002, Dogra et al., 2005, Singh and Pandey, 2011, 
Vora et al., 2014, Lee et al., 2015), although some have observed a substantially higher 
incidence of vitiligo in women (McBurney, 1979, Shah et al., 2008). In contrast, a higher 
frequency of vitiligo in men has also been recorded (McBurney, 1979, Wang et al., 2013). 
The female to male ratio in our sample of vitiligo patients was 1.37:1. The excess of 
females observed in our study and other studies could result from greater cosmetic 
awareness which prompts women to present themselves for treatment. Inconsistency 
in the ratio of male to female vitiligo patients may also be attributed to differences in 
sample sizes and ascertainment and referral patterns included in different studies.  
 Age of onset  
Though vitiligo can present at any age from birth to senescence, our study showed that 
the most common onset age of vitiligo was between 11-20 years, accounting for 22% of 
patients, and this is consistent with previous studies (Shajil et al., 2006). More than half 
(53%) of the cases in our study claimed onset occurred before 30 years of age, which 
agreed with studies reported by Shajil et al. (2006) and Karelson et al. (2009), but 
differed from another report which showed that the disease appeared before the age 




(Sehgal and Srivastava, 2007) also reported that around 70-80% of vitiligo patients had 
onset of the disease below 30 years of age. However, our study observed that a similar 
percentage of patients (72%) came within an onset age of under 40 years. Interestingly, 
an epidemiological study in Denmark reported that the age of onset of vitiligo most 
frequently ranged between 40 to 60 years (Howitz et al., 1977). 
Non-segmental vitiligo can occur at all ages, and this was apparent in our study with an 
onset age range of 0-83 years. In contrast, segmental vitiligo usually presents before 30 
years of age in 87% of cases and before 10 years of age in 41.3% (Hu et al., 2006, Picardo 
et al., 2015). However, the four patients with segmental vitiligo in this study had onset 
ages of 4, 31, 32, and 54 years. 
 Disease duration 
The mean disease duration we observed of approximately 14 years is a finding almost 
identical to those shown in some studies (Jarallah et al., 1993, Karelson et al., 2009), but 
different to most series, which most often report a mean duration of less than five years 
(George, 1989, Handa and Kaur, 1999, Dave et al., 2002, Martis et al., 2002, Shajil et al., 
2006, Khaitan et al., 2012).  
 Vitiligo classification 
Non-segmental vitiligo was the most common clinical type observed in our study at a 
frequency of 94%, which is consistent with other studies where this vitiligo pattern 
accounted for 39-83% of the subjects (Handa and Kaur, 1999, Dogra et al., 2005, Liu et 
al., 2005, Mason and Gawkrodger, 2005, Singh and Pandey, 2011, Vora et al., 2014). Of 
the non-segmental vitiligo subtypes, symmetrical (generalised) was the most frequent 
type (68%) followed by acrofacial 18.2%, which is consistent with other studies (Karelson 
et al., 2009, Esfandiarpour and Farajzadeh, 2012, Vora et al., 2014). Acrofacial has been 
reported to be seen in between 17-35% of cases in different clinical studies (Dave et al., 
2002, Martis et al., 2002, Nejad et al., 2013, Vora et al., 2014). Acral without facial 
involvement (1.7%), peri-orificial alone (1.3%), and universal (0.4%) were rare in our 




Farajzadeh, 2012). In one series, though, the universal subtype was been recorded in 
18% of patients (Dogra et al., 2005, Wang et al., 2013). The mixed subtype of non-
segmental vitiligo is a relatively recent description, made in a few studies only (Ezzedine 
et al., 2011, Ezzedine et al., 2012a). Its frequency in the current study was 2.2%. 
Segmental vitiligo reportedly accounts for approximately 5-16% of all vitiligo cases 
(Koranne and Sachdeva, 1988). Also documented is that a third of paediatric cases 
(Halder et al., 1987, Nicolaidou et al., 2012, Shankar et al., 2012) but only 0-4.5% of the 
adult population have this vitiligo type (Dogra et al., 2005, Mason and Gawkrodger, 
2005). In the present study, segmental vitiligo was seen in only 1.6% of our patients, 
perhaps because this pattern generally presents in children below 10 years of age (Palit 
and Inamadar, 2012), and only 10.6% of our patients belonged to this age group. Indeed, 
only one of our cases of segmental vitiligo had an onset age below 10 years. Late onset 
(median age at onset 41 years) of segmental vitiligo has been reported in Chinese (Wang 
et al., 2013). In this study, the disease started in three of the four segmental vitiligo 
patients later than 30 years of age. The frequency of segmental vitiligo might be 
abnormally low in this series since patients were recruited from adult clinics and not 
from paediatric clinics, in which the incidence of segmental vitiligo might be presumed 
to be higher. 
Focal and mucosal vitiligo are now assigned to the category of 
undetermined/unclassified vitiligo until a more definite classification can be made on 
clinical description (Ezzedine et al., 2012b). Focal vitiligo was present in 4.5% of patients. 
No cases of mucosal vitiligo were reported in our vitiligo patient cohort. Mucosal vitiligo 
has also been reported as a rarer clinical type at 2.2% (Dogra et al., 2005). 
 Vitiligo activity 
The vast majority (92%) of patients included in this study had active vitiligo at the time 
of presentation and this is in agreement with previous studies (Chun and Hann, 1997, 
Dave et al., 2002, Karelson et al., 2009). One study has shown that out of 318 patients 
with non-segmental vitiligo, 289 (91%) exhibited active vitiligo and the same study 
concluded that non-segmental vitiligo was significantly associated with disease 




segmental vitiligo patients had active disease and the frequency of active disease was 
significantly increased compared with patients with segmental vitiligo where only 1 of 4 
(25%) patients had active disease.  
 Associated autoimmune disease 
Based on autoimmunity as the leading hypothesis in the pathogenesis of vitiligo, studies 
on vitiligo-associated autoimmune conditions in vitiligo patients and in their families has 
also been a subject of great interest. Various authors have proposed that vitiligo patients 
have a higher risk of developing autoimmune disorders than the general population 
(Safavi, 1992, Safavi et al., 1995, Jacobson et al., 1997, Farber and Nall, 1998, Alkhateeb 
et al., 2003, Nejad et al., 2013, Lukinovic-Skudar, 2015, Gill et al., 2016), though the 
findings have been variable in different populations. From this study, we found that 
many of the associated autoimmune diseases were seen at a higher frequency than in 
the general population. 
In our study, 84 of 246 (34%) patients suffered from at least one other concomitant 
autoimmune disease. Thyroid disease (22.8%) was the most frequent autoimmune 
disease reported by our subjects, a finding similar to previous studies in which the 
association of vitiligo with thyroid disease varied between 12% (Narita et al., 2011, Singh 
and Pandey, 2011, Gill et al., 2016), 15.4% (Huang et al., 2013), 21% (Karelson et al., 
2009, Nejad et al., 2013) and 34% (Mason and Gawkrodger, 2005). Autoimmune 
hypothyroidism 16.7% was the most prevalent thyroid disease among our vitiligo 
patients, and this corresponds with previous studies (Nejad et al., 2013, Gill et al., 2016). 
This was followed by Graves’ disease (6.1%), a proportion that is in line with a previous 
study (Prindaville and Rivkees, 2011).  
Alopecia areata also was quite frequent occurring in 4.1% of our patients. This was 
similar to previous findings of 7.4% (Gopal et al., 2007) and 5.3% (Narita et al., 2011). 
Rheumatoid arthritis, type 1 diabetes and psoriasis were all rarer, each seen in only four 
(1.6%), eight (3.3%) and three (1.2%) of our patients, respectively. This observation was 
consistent with data for vitiligo patients in the Caucasian population (Alkhateeb et al., 
2003). In contrast, however, Karelson et al. (2009) reported high frequencies of type 1 




vitiligo reported in Estonia. The risk of the presence of coexisting autoimmune diseases 
in our vitiligo patient group was significantly greater in females compared with males, a 
finding that is similar to previous studies (Karelson et al., 2009, Amerio et al., 2010, 
Narita et al., 2011, Vijayalakshmi et al., 2017). 
With respect to vitiligo type, none of the four patients with segmental vitiligo, 35% of 
patients with non-segmental vitiligo, and 27% of patients with focal vitiligo had an 
associated autoimmune disease. This is in agreement with autoimmune diseases being 
more frequently associated with the non-segmental classification of the disease 
(Ezzedine et al., 2011), although our study only contained a small number of segmental 
vitiligo patients.  
Differences in the frequency of vitiligo-associated autoimmune diseases between 
different studies may be due to the sample sizes, genetic factors and demographic 
variations. However, altogether, our findings further verify the previous evidence of 
association between vitiligo and other autoimmune disorders (Majumder et al., 1993, 
Zelissen et al., 1995, Alkhateeb et al., 2003, Nejad et al., 2013, Gill et al., 2016) and 
highlight the magnitude of vitiligo-associated diseases in Caucasians.  
 Family history of vitiligo and autoimmune disease 
Our study showed a family history of vitiligo in 18.3% of subjects, a finding midway 
between 8% (Dave et al., 2002, Shankar et al., 2012) and 30% (Hann et al., 1997, Pajvani 
et al., 2006) previously noted. These results suggests a genetic component is likely to be 
involved in the manifestation of vitiligo (Gopal et al., 2007). Moreover, a positive family 
history of other autoimmune diseases was found in 37.4% of cases, which is in line with 
a previous study by Mason and Gawkrodger (2005). This finding further indicated that 
vitiligo aetiology involves susceptibility genes shared with other autoimmune disorders. 
At least 17 confirmed vitiligo susceptibility genes have been identified recently by 
genome wide association studies (Jin et al., 2007b, Birlea et al., 2011). Most of these 
genes have also been involved in other autoimmune disorders e.g., autoimmune thyroid 
disease, rheumatoid arthritis, and type 1 diabetes (Narita et al., 2011). Therefore, these 
shared autoimmune disorder susceptibility genes may underlie our detected 




 Limitations of the study 
The main limitation of our study was that it was based on adult clinics. Like any 
investigation based on selectively referred cases, some of the results may not be 
representative of the population at large. A population-based sample is desirable to 
understand the exact prevalence and the clinical characteristics of vitiligo in the general 
population. Additionally, in spite of having information on the family history of vitiligo 
patients, further definition of the exact relationship of family members, such as whether 
they were siblings, parents or extended relatives, and so forth would have been helpful. 
Thus, this is an area for further exploration. Furthermore, the lacking of consensus on 
disease classification may affect the results of disease classification.  Other limitations 
include the fact that most patients were seen in adult clinics, perhaps missing out 
presentations in children, the sample size, and possible recall errors by patients, 
particularly in those whose condition appeared many years prior to presentation to our 
clinic.  
 Conclusion 
In conclusion, the demography and comorbidities at presentation for patients with 
vitiligo in Sheffield were generally in accordance with results from elsewhere in the 
world. The results of the analysis support the autoimmune hypothesis of vitiligo 
aetiology since co-existing autoimmune diseases, particularly thyroid diseases, were 
common in our subjects. In addition, vitiligo and autoimmune diseases, principally again 
thyroid diseases, were prevalent in patient families indicating that genetic factors may 
predispose to the disease. Patients with vitiligo should be investigated for and followed 

















Investigation of phage-display to identify novel antibody targets 





4 Investigation of phage-display to identify novel antibody targets 
(autoantigens) in vitiligo 
 Introduction to phage-display technology 
Filamentous bacteriophages are thin, cylindrical particles. They infect strains of E. coli 
which bear the F conjugative episome expressing the primary receptor of the phage; the 
F pilus. Each phage particle contains a circular single-stranded DNA molecule packaged 
into a coat composing of several thousands of copies of major coat protein pVlll, which 
covers the length of the particle (Marvin, 1998, Wilson and Finlay, 1998, Rami et al., 
2017). Low copy numbers of the minor coat proteins (pIII, pVI, pVII, and pIX) are located 
at either extremity of the phage particle (Figure 4.1) (Marvin, 1998, Wilson and Finlay, 
1998, Appenzeller et al., 2000, Rami et al., 2017). 
The development of phage-display methodology arose from the breakthrough that 
insertion of DNA molecules into the phage gene gIII leads to the expression of encoded 
polypeptides as coat-protein fusions with pIII protein which are displayed on the phage 
particle surface (Figure 4.2) (Smith, 1985, Hairul Bahara et al., 2013). As such, large-scale 
libraries of fusion proteins that are displayed on the phage can be screened for binding 
peptides by panning against the ligand/s of choice. Since the selected peptides are 
“physically” linked to the genetic materials required for their expression, i.e., inside the 
phage particle, their identity can be determined by sequencing the DNA fragments that 
encode them. 
In order to express cDNA-encoded peptides on phage surfaces, a strategy based on the 
high affinity binding of Jun and Fos heterodimers combined with elements of phagemid 
pComb3 was developed (Barbas and Lerner, 1991, Pernelle et al., 1993, Crameri and 
Walter, 1999, Appenzeller et al., 2000, Waterman et al., 2010). The resulting construct, 
the pJuFo phagemid vector allows the expression of full-length cDNA products on the 
phage surface (Figure 4.2) (Crameri and Suter, 1993, Crameri and Walter, 1999). In this 
cloning system, the Jun protein is expressed as an N-terminal fusion to phage coat 
protein pIII. The Fos protein is also expressed as an N-terminal fusion with the cDNA-




the bacterial periplasmic space where Jun-Fos heterodimerisation occurs and the 
formation of disulphide bonds takes place. This provides the phage surface with a 
covalent link for cDNA products during phage morphogenesis. The physical phenotype-
genotype coupling makes the technology a feasible platform for isolating and identifying 
novel binding peptides based on the powerful panning procedures by which pJuFo 
phage-displayed proteins are selectively enriched by consecutive rounds of panning 
against an appropriate ligand (Figure 4.3). Subsequently, enriched proteins can be 
identified by sequencing the cDNA that encodes them. 
Phage-display has been very successfully used to isolate novel ligands for different 
targets including receptors (Bass et al., 1990) and transcription factors (Butteroni et al., 
2000, Lawson and Bleris, 2017). It has also been employed to study antibody-antigen 
interactions (Barbas, 1993, Burgoon et al., 2001, Kemp et al., 2002b, Rami et al., 2017), 
and enzyme-substrate interactions (Redl et al., 1999, Cheok and Jaworski, 2016). 
For the identification of autoantigens recognised by antibodies, the major advantage of 
phage-display lies in utilising the process of enrichment which enables efficient isolation 
of desired target peptides even if the titre of antibodies is relatively low in the patients 
under study. Moreover, the phage-display technique can identify conformational 
epitopes, unlike the classical phage lambda-based system which allows only the 
identification of linear binding domains; enrichment of phage in a fluid phase avoids the 
effects of denaturation due to protein adsorption to nitrocellulose membranes. In 
addition, panning enables large phage-displayed cDNA libraries to be screened and 
characterised more rapidly (Appenzeller et al., 2000, Hairul Bahara et al., 2013, Rami et 
al., 2017). Due to lower labour intensity and quantifiable analysis, the technique is a 












Figure 4.1: Schematic representation of the structure of a filamentous phage particle. 
A single-stranded circular DNA is covered by 2,700 copies of pVIII protein (the major coat 
protein), and 4-5 copies of each of four types of minor coat proteins, including pIII. The figure 








Figure 4.2: The pJuFo phage-display system. 
The Jun-coat protein pIII fusion protein and the Fos-cDNA fusion protein are expressed and exported to the periplasm. During assembly of the phage, 
there is heterodimerisation of Jun-pIII/Fos-cDNA fusion proteins and incorporation of the heterodimers into the surface of the phage particles along 








Figure 4.3: Enrichment of phage displaying melanocyte peptides that bind IgG 
molecules. 
1. Phage displaying melanocyte peptides from melanocyte cDNA. 2. Patient IgG. 3. Phage 
expressing immunoreactive melanocyte peptides bind to patient IgG. 4. Unbound phage are 
removed by washing. 5. Phage displaying IgG-binding peptides are eluted with glycine-
hydrochloride. 6. Phage eluted are enriched by the infection into E. coli XL1-Blue MRF’ 7. Phage 
eluted are grown to prepare a new library for further rounds of panning. 8. In the fifth round, 
phagemid DNA is extracted from infected cells. 9. Isolated phagemid DNA is sequenced to 
identify melanocyte cDNA inserts. The figure was adapted from a paper by Waterman et al. 






For this part of the project, the aim was to identify novel antibody targets (autoantigens) 
in patients suffering from vitiligo by utilising the benefits of phage-display methodology. 
Antibody targets in vitiligo are important to identify as the autoantigens themselves may 
also be T cell targets, as is the case with tyrosinase and PMEL (Ogg et al., 1998, Lang et 






 Materials and Methods 
 Vitiligo patient and healthy controls 
The details of the clinical and demographic characterstics of the 22 vitiligo patients 
included in this part of the study are given in Table 4.1. The two controls were one male 
(age at sample, 27 years) and one female (age at sample, 43 years). 
 Phage-displayed melanocyte cDNA-encoded peptide library 
The melanocyte peptide phage-display library was constructed in the vector pJuFo 
(Figure 4.2) and was constructed and verified by Dr Helen Kemp (Department of 
Oncology and Metabolism, University of Sheffield, Sheffield, UK). In brief, the phage-
display library contained melanocyte cDNAs cloned into the XbaI-KpnI site of the pJuFo 
vector (Figure 4.4). The phage-display library had a titre of 1011 colony-forming units 
(cfu)/ml and the frequency of recombinants (i.e. pJuFo carrying a cDNA insert) in the 
library had been estimated at 90%. The size of the cloned cDNA inserts ranged from 0.5-
2.5 kb with an average of 1.5 kb. In addition, DNA hybridisation experiments had shown 
that the frequency of β-actin and tyrosinase cDNA inserts were 0.04% and 0.1%, 
respectively.  
 Titre of the phage-display library 
The phage-display library was stored at -80°C until needed. The titre of the phage-display 
library was determined by infecting E. coli XL1-Blue MRF’ cells (Table 2.1). Briefly, E. coli 
XL1-Blue MRF’ cells were grown with shaking to log phase in LB medium (10 ml) (Section 
2.5) supplemented with 10 µg/ml tetracycline (Section 2.4) at 37°C. An aliquot of 0.5 ml 
of the culture was subsequently infected with an aliquot of 2 µl of a 10-4 phage dilution 
made in phosphate-buffered saline (PBS) (pH 7.4) and incubated for 15 min at room 
temperature. From the infected culture, 1, 10 and 100-µl samples were spread on LB 
agar plates (Section 2.5) supplemented with 100 μg/ml of ampicillin and 10 μg/ml of 
tetracycline (Section 2.4). A negative control of a 10-µl sample of uninfected culture was 




counted. Subsequently, the titre of the phage which was expressed as cfu/ml was 
calculated. 
 IgG purification 
Purification of IgG was performed by Dr Helen Kemp (Department of Oncology and 
Metabolism, University of Sheffield, Sheffield, UK). Briefly, IgG molecules were isolated 
from samples of serum using protein G Sepharose 4 Fast Flow affinity column 
chromatography (GE Healthcare, Little Chalfont, UK). To elute IgG molecules, 1-2 ml of 
each serum sample was passed through a protein G sepharose column with 0.01 M 
sodium phosphate buffer (pH 7.0).  UV absorption at 280 nm with a 2138 UVIcord (LKB 
Wallac, Turku, Finland) was employed to monitor the IgG eluate with 0.1 M glycine-
hydrochloride (pH 2.7). Eluted IgGs were subsequently neutralised with 1 M Tris-
hydrochloride (pH 9.0). The IgG fractions were then pooled. Following dialysis overnight 
against PBS at 4°C, samples of IgG were concentrated by an Amicon Concentrator 
(Amicon Inc., Beverley, MA, USA) and filter-sterilised with a Millex® Filter Unit (Millipore 
Corp., Bedford, MA, USA). The IgG concentration was determined by spectrophotometry 
at 280 nm using a NanoDrop ND-1000 Spectrophotometer (Labtech, Wilmington, DE, 
USA) and NanoDrop Software (Labtech). IgG samples were stored at -20°C with a 





















Autoimmune disease Family history of vitiligo or of 
autoimmune disease 
V6-1  Female 41 21 20 Non-segmental Active Absent Vitiligo  
V11-2  Female 36 31 5 Non-segmental Active Absent Absent  
V12-3  Male 76 72 4 Non-segmental Stable Absent  Absent  
V13-4  Male 70 20 50 Non-segmental Active Hypopituitarism and 
alopecia areata 
Vitiligo   
V15-5  Female 33 32 1 Segmental Stable Absent  Autoimmune hypothyroidism  
V20-6 Male 47 5 42 Non-segmental Active Psoriasis Absent  
V21-7 Male 46 32 14 Non-segmental Active Absent Type 1 diabetes 
V22-8 Female 31 31 1 Segmental Active Alopecia areata Vitiligo  
V23-9 Female 28 20 8 Non-segmental Active Absent Vitiligo and systemic lupus 
erythematosus 
V24-10 Female 55 50 5 Non-segmental Active Absent Absent 
V224-11 Male 29 15 14 Non-segmental Active Absent Type 1 diabetes 
V38-12 Male 21 20 1 Non-segmental Active Absent Psoriasis 
V56-13 Male 74 58 16 Non-segmental Active Absent Absent 
V73-14 Male 38 26 12 Non-segmental Active Alopecia areata  Type 1 diabetes 
V102-15 Female 41 0 41 Non-segmental Active Absent Vitiligo   
V169-16 Male 36 31 5 Non-segmental Active Absent  Type 1 diabetes  
V189-17 Female 16 13 3 Non-segmental Active Absent  Absent  
V216-18 Male 27 17 10 Non-segmental Active Absent Absent  
V219-19 Female 36 19 17 Non-segmental Active Graves’ disease Autoimmune hypothyroidism 
V234-20 Female 48 22 26 Non-segmental Active Absent Vitiligo   
V45-21 Male 43 40 3 Non-segmental Active Absent Type 1 diabetes 







Figure 4.4: Detail of the cloning site of pJuFo. 
The sequence shows the PelB and Fos sequences (DNA and amino acid) that form fusions with 
cDNAs cloned in the XbaI (TCTAGA)-KpnI (GGTACC) cloning site. The XbaI site starta at nucleotide 






 Enrichment of the melanocyte peptide phage-display library (panning) 
In panning experiments, a 10-μl aliquot of patient or control IgG was immobilised on the 
well of a 96-well microtitre plate in 50 µl of coating buffer composed of 3.5 mM sodium 
hydrogen carbonate and 1.5 mM sodium carbonate (pH 9.2). In addition, two specific 
antibodies α-PEP7 (anti-tyrosinase antibody) and α-PEP8 (anti-L-dopachrome 
tautomerase (DCT)) were used as positive controls. Prior to washing with PBS/0.05% 
(w/v) Tween 20 (PBS/Tween), plates were incubated for 2 h at room temperature to 
allow the binding of patient IgG to the well surface. The plate wells were then blocked 
using 400 μl of 2% (w/v) bovine serum albumin prepared in PBS in order to prevent non-
specific phage from binding later in the process, and plates were subsequently 
incubated for a further 2 h at room temperature. The wells were then rinsed once with 
PBS/Tween prior to adding a 100-μl sample of phage-display library containing an 
estimation of 1011 phage. To permit the interaction of immobilised patient IgG with 
proteins displayed on phage surfaces, plates were kept at 4°C overnight. Wells were 
washed 10 times with PBS/Tween in order to remove unbound phage. Following elution 
of bound phage with 100 μl of acidified glycine (pH 2.2), eluted phage were neutralised 
with 9 μl of 2 M Tris-base and then used to infect a 2 ml sample of E. coli XL1-Blue MRF’. 
After, the infected cultures were kept for 15 min at room temperature to allow the 
phage to infect the cells. To assess the total number of eluted phage, infected culture 
samples (10 µl and 100 µl) were spread onto LB agar supplemented with tetracycline (10 
µg/ml) and ampicillin (100 µg/ml), and plates were then incubated at 37°C overnight. 
To prepare a phage-display library to use in the subsequent round of panning, 8 ml of 
LB medium was added to the sample of infected E. coli XL1-Blue MRF’ cells with the 
eluted phage to make it up to 10 ml and then incubated shaking at 37°C for 1 h. The 
culture was subsequently superinfected with 1011 plaque-forming units (pfu) of VCS-
M13 helper phage (Agilent Technologies) and left to incubate for 15 min at room 
temperature. The culture was then inoculated into 100 ml of LB medium supplemented 
with 10 μg/ml tetracycline and 100 μg/ml ampicillin. After further incubation with 
shaking at 37°C for 1 h, kanamycin at 10 μg/ml (Section 2.4) was added and culture was 




The bacterial culture was centrifuged for 15 min at 2,000 g to pellet cell debris. For 
phage precipitation from the culture supernatant, 40% (w/v) polyethylene glycol 4000 
(15 ml) and 5 M sodium chloride (15 ml) were added and culture was then incubated 
overnight at 4°C. To harvest phage particles, the culture was centrifuged at 10,000 g for 
20 min and subsequently the pellet of phage was resuspended in PBS (1-2 ml) and stored 
at -20°C until use. This first round library was titrated and used subsequently in panning 
round 2 following the same way as the original library. For each sample of IgG, five 
panning rounds in total were carried out. 
 Analysis of the panned phage-display library 
Following the fifth panning round with patient IgG, randomly selected individual 
colonies of bacterial cells, isolated by plating out the infected E. coli XL1-Blue MRF’ 
culture with eluted phage particles, were streaked onto fresh LB agar supplemented 
with ampicillin at 100 µg/ml and tetracycline at 10 μg/ml. The bacterial clones were then 
grown shaking overnight at 37°C in 10 ml of LB medium to which 100 μg/ml ampicillin 
and 10 μg/ml tetracycline were added. Subsequently, phagemid DNA preparation was 
made from each culture employing a Wizard® Plus SV Minipreps DNA Purification 
System (Section 2.14). 
To identify melanocyte peptides enriched during the panning process, 30 phagemid 
DNAs carrying peptide-encoding cDNAs were sequenced. Sequencing primers used were 
JUFO-1192 (5'-CCGCTGGATTGTTATTACTCGCTG-3') and JUFO-1500 (5’-
TGCAAGGCGATTAAGTTGGGTAAC-3'), which bind to the pJuFo cloning vector upstream 
of the cDNA cloning site and downstream of the cDNA cloning site, respectively (Figure 
4.2). The cDNAs were identified by comparison with the international genetic sequence 








 Screening of the melanocyte peptide phage-display library with vitiligo 
patient IgG, IgG from healthy controls, and positive control antibodies  
The melanocyte peptide phage-display library in the vector pJuFo (Figure 4.2) was 
screened in panning experiments with IgG prepared from 22 vitiligo patients and two 
healthy controls. In addition, two specific antibodies α-PEP7 (anti-tyrosinase antibody) 
and α-PEP8 (anti-DCT antibody) were used as positive controls in panning experiments. 
Five rounds of panning were performed for each individual IgG and postive control 
antibody. In each round, the number of phage applied to the microtitre plate well and 
the number of phage eluted were calculated and the ratio of eluted to applied phage 
determined. The ratio at each round was normalised against the ratio in round one of 
panning. 
The results for the two positive control antibodies α-PEP7 and α-PEP8 are given in Figure 
4.5. An increase in the normalised ratio was seen through the panning rounds, indicating 
the enrichment of phage expressing specific IgG-binding proteins on their surfaces. The 
results for each of the 22 vitiligo patients and two healthy controls are shown in Figure 
4.6. In experiments with 13 of the vitiligo patient IgGs, the normalised ratio was higher 
by the fifth round of panning, indicating enrichment of the phage-display library. 
However, in the remaining cases, including both healthy control IgGs, there was either 













Figure 4.5: Enrichment of the melanocyte peptide phage-display library with anti-
tyrosinase  and anti-DCT antibodies. 
The melanocyte cDNA-encoded peptide phage-display library was used in five rounds of 
enrichment with anti-tyrosinase antibody α-PEP7 and anti-DCT antibody α-PEP8. The results are 
given as a fold increase in the ratio of eluted to applied phage in each subsequent panning round 
























Figure 4.6: Enrichment of the melanocyte peptide phage-display library with vitiligo 
patient and healthy control IgG samples. 
The melanocyte cDNA-encoded peptide phage-display library was used in five rounds of 
enrichment with IgG from 22 vitiligo patients and from two controls individually. The results are 
given as a fold increase in the ratio of eluted to applied phage in each subsequent panning round 





 Identification of IgG-binding peptides enriched by screening of the 
melanocyte peptide phage-display library 
Following five rounds of panning with each of the 22 vitiligo patient IgG, two healthy 
control IgG, and two positive control antibodies α-PEP7 (anti-tyrosinase antibody) and 
α-PEP8 (anti-DCT antibody), 64 randomly selected bacterial clones were grown on LB 
agar supplemented with antibiotics. Subsequently, 30-50 of the bacterial clones were 
inoculated into 10 ml of fresh LB media containing 100 μg/ml of ampicillin and 
tetracycline at 10 μg/ml, and grown overnight in the shaking incubator at 37°C. pJuFo 
phagemid DNA was prepared from the 30-50 clones and each phagemid subjected to 
DNA sequencing. 
Using BLAST searches of the acquired DNA sequences against the GenBank database, 
the results of panning experiments with the two positive control antibodies indicated 
that α-PEP7 (anti-tyrosinase antibody) and α-PEP8 (anti-DCT antibody) enriched 
tyrosinase and DCT peptides, respectively. In-frame, tyrosinase peptides represented 
48/50 sequences (96%) after panning the phage-display library with antibody α-PEP7. 
In-frame, DCT peptides represented 49/50 sequences (98%) after enrichment of the 
phage-display library using α-PEP8 as the antibody. The sequences enriched by the two 
healthy control IgGs were in for the most part out of frame or no significant matches. 
For one healthy control IgG, none of the peptide sequences in the final panning round 
were in-frame peptides and 28/30 (93%) had no significant matches to sequences in the 
GenBank database. For the second healthy control IgG, only one of the peptide 
sequences was in-frame and identifiable as HSP70. 
In the case of the vitiligo patient IgG samples, the results showed that cDNAs encoding 
several different peptides had been isolated from the panning experiments. These are 
detailed in the next sections, and in Figure 4.7 and Tables 4.2 to 4.23. 
4.4.2.1 Vitiligo patient V6-1 
The BLAST analysis of the 30 cDNAs encoded by the enriched phage revealed that 24 of 
them (80%) showed homology with peptides present in the database and these were all 




expressed and displayed on the phage surface (Table 4.2). Of the 24, eight were found 
to encode tyrosinase and seven were identified as PMEL. The other detected IgG-binding 
peptides were GTP-binding protein Rab27A (Rab27A), heat-shock protein 90 (HSP90), 
and 39s ribosomal protein L24 (RPL24) which were represented five, two, and two times, 
respectively (Figure 4.7a). Of the remainder, four cDNAs encoded Rab27A, but these 
were not in-frame for display on the phage surface, and two of the encoded sequences 
showed no significant matches with DNA sequences in the database (Figure 4.7a). 
4.4.2.2 Vitiligo patient V11-2 
For vitiligo patient V11-2, the DNA sequences of 87% (26/30) of the analysed clones 
encoded identifiable peptides (Table 4.3). These included tyrosinase (4/30), TYRP1 
(16/30), PMEL (2/30), HSP90 (3/30), and RPL24 (1/30) (Figure 4.7b). The remaining four 
cDNA sequences matched Rab27A, but each of these was in an alternative reading frame 
with respect to the Fos peptide in the pJuFo vector (Figure 4.7b).  
4.4.2.3 Vitiligo patient V12-3 
For vitiligo patient V12-3, 26/30 (87%) of the peptide sequences analysed were 
homologous with DNA sequences in the Genbank database and were in-frame with the 
pJuFo encoded Fos protein required for peptide expression on the phage surface (Table 
4.4). These were glycoprotein non-metastatic melanoma protein b (GPNMB) (13/30), 
MC1R (4/30), tyrosinase (5/30), HSP90 (3/30), and Rab27A (1/30) (Figure 4.7c). One of 
the remaining four DNAs encoded Rab27A but this could not be expressed and displayed 
as fusion proteins on the phage particles due to an incorrect reading frame with the Fos 
protein encoded by the vector (Figure 4.7c). A further three had sequences without 
significant similarity to database sequences (Figure 4.7c). 
4.4.2.4 Vitiligo patient V13-4 
For vitiligo patient V13-4, 26 of 30 (87%) of the phage clones encoded identifiable 
peptides (Table 4.5). These were tyrosinase (11/30), TYRP1 (2/30), PMEL (1/30), HSP90 




sequences were in-frame with the Fos protein expressed by the pJuFo vector. The 
remaining four phagemid carried DNA insert which did not show significant matches to 
any sequence in the database. 
4.4.2.5 Vitiligo patient V15-5 
For vitiligo patient V15-5, of the 30 clones sequenced, 26 (87%) cDNAs encoded peptides 
that matched to human sequences present in the database (Table 4.6).These were  
containing OCA2-encoded P protein (OCA2 protein) (12/30), tyrosinase (7/30), HSP90 
(3/30), PMEL (2/30), Rab27A (1/30), and RPL24 (1/30) (Figure 4.7e). All 26 identified 
proteins were in-frame with Fos protein encoded by pJuFo that it is essential for 
expression of the proteins on the phage surface. The remaining 4 phagemid carried 
cDNA fragments that had no significant matches to sequences in the database. 
4.4.2.6 Vitiligo patient V20-6 
For vitiligo patient V20-6, 29/30 (97%) phage clones selected had identifiable peptide 
inserts except for one clone which did not have significant match to sequences in the 
database (Table 4.7). Peptide inserts of 15 phage clones matched tyrosinase, six 
contained HSP90 cDNA, four TYRP1, three Rab27A, and one RPL24 (Figure 4.7f). All 29 
identified proteins were in correct frame with the Fos protein encoded by pJuFo vector. 
4.4.2.7 Vitiligo patient V21-7 
For vitiligo patient V21-7, all 30 (100%) clones selected for sequence analysis had a 
cloned cDNA insert in-frame with the pJuFo-encoded Fos protein (Table 4.8). These 
included TYRP1 (16/30), tyrosinase (4/30), HSP90 (5/30), and PMEL (5/ 30) (Figure 4.7g). 
4.4.2.8 Vitiligo patient V22-8 
For vitiligo patient V22-8, all 30 (100%) clones sequenced encoded identifiable peptides 




(10/30), and GPNMB (8/30) (Figure 4.7h). All these identified DNA inserts were in-frame 
with Fos protein encoded by the vector pJuFo. 
4.4.2.9 Vitiligo patient V23-9 
For vitiligo patient V23-9, analysis of the 30 cDNA inserts showed that 24 (80%) encoded 
proteins of known function (Table 4.10). These included DCT (9/30), HSP90 (4/30), RPL24 
(4/30), tyrosinase (2/30), MC1R (5/30) (Figure 4.7i). These proteins were all in-frame 
with the Fos protein encoded by the pJuFo. The remaining six phage clones had no 
significant matches to DNA sequences present in the database.  
4.4.2.10 Vitiligo patient V24-10 
For vitiligo patient V24-10, database matches were present for all 30 (100%) sequenced 
clones (Table 4.11). Eighteen clones showed homology with tyrosinase and the 
remaining 12 clones had homology with TYRP1 (Figure 4.7j). All 30 peptide sequences 
were in-frame with the Fos peptide encoded by the pJuFo. 
4.4.2.11 Vitiligo patient V224-11 
For vitiligo patient V224-11, of the 30 cloned sequences, 26 (87%) encoded proteins of 
known function that were all in-frame with the pJuFo-encoded Fos protein (Table 4.12). 
These proteins were PMEL (7/30), tyrosinase (4/30), HSP90 (4/30), Rab27A (2/30), and 
GPNMB (9/30) (Figure 4.7k). Four phagemid clones carried cDNA inserts that had no 
significant matches to sequences in the database.  
4.4.2.12 Vitiligo patient V38-12 
For vitiligo patient V38-12, 24 of 30 (80%) of the clones sequenced showed homology 
with cDNA sequences in the Genbank database (Table 4.13). Of these homologies, 7/30 
corresponded to TYRP1, 5/30 to tyrosinase, 5/30 to HSP90, 3/30 to Rab27A, 2/30 to 
RPL24, and 2/30 to OCA2 protein (Figure 4.7l). All these 24 identified peptides were in-




harboured cloned DNA which did not show any significant matches to sequences in the 
database.  
4.4.2.13 Vitiligo patient V56-13 
For vitligo patient V56-13, database homologies were found for all clones sequenced 
except for three (Table 4.14). Fourteen clones matched the coding sequence of PMEL, 
6/30 the coding sequence of DCT, 4/30 HSP90, and 3/30 RPL24 (Figure 4.7m). All these 
peptides were in-frame with pJuFo encoded Fos peptide for expression on the phage 
surface. 
4.4.2.14 Vitiligo patient V73-14 
For vitiligo patient V73-14, of the 30 clones sequenced, 25 (83%) had homology with 
known proteins (Table 4.15). These were TYRP1 (10/30), tyrosinase (7/30), Rab27A 
(5/30), and HSP90 (3/30) (Figure 4.7n). All these were in the correct frame with the Fos 
peptide encoded by the pJuFo. The remaining five clones did not have significant 
matches with sequences in the database. 
4.4.2.15 Vitiligo patient V102-15 
For vitiligo patient V102-15, of the 30 phage clones sequenced, 25 (83%) carried DNA 
fragments which matched known sequences in the database (Table 4.16). The remaining 
five plasmid had cloned DNA which did not show significant homology with sequences 
in the database. Seven of the IgG-binding proteins were identified as TYRP1 (Figure 
4.7o). Other proteins represented more than one time in the analysed sequences 
included tyrosinase (4/30), HSP90 (4/30), RPL24 (4/30), Rab27A (3/30), and OCA2 
protein (3/30) (Figure 4.7o). 
4.4.2.16 Vitiligo patient V169-16 
For vitiligo patient V169-16, 24/30 (80%) of the sequenced insert cDNAs showed 




encoded several different proteins and each identified protein was represented more 
than once. IgG-binding peptides identified here were GPNMB (4/30), HSP90 (4/30), 
MC1R (4/30), Rab27A (4/30), RPL24 (3/30), tyrosinase (3/30), and DCT (2/30) (Figure 
4.7p). All these proteins were in-frame with the Fos protein encoded by the vector. The 
remaining six phagemid clones contained DNA that had no significant matches to 
sequences in the database. 
4.4.2.17 Vitiligo patient V189-17 
For vitiligo patient V189-17, 27 of the 30 (90%) clones sequenced carried DNA fragments 
which had homology with known peptides (Table 4.18). These homologies corresponded 
to PMEL (10/30), HSP90 (6/30), tyrosinase (4/30), RPL24 (4/27), and OCA2 protein (3/30) 
(Figure 4.7q). Again, all these peptides were in frame with the Fos protein encoded by 
the pJuFo. Three of the 30 clones analysed showed no matches with sequences in the 
Genbank database. 
4.4.2.18 Vitiligo patient V216-18 
For vitiligo patient V216-18, 27/30 (90%) sequenced clones encoded identifiable 
proteins (Table 4.19). These included TYRP1 (8/30), Rab27A (6/30), HSP90 (5/30), 
tyrosinase (3/30), GPNMB (3/30) and MC1R (2/30) (Figure 4.7r). All 27 peptides were in-
frame with the Fos protein encoded by the vector. The remaining three clones did not 
show any significant matches in the sequence analysis. 
4.4.2.19 Vitiligo patient V219-19 
For vitiligo patient V219-19, 25 of 30 (83%) clones identified as IgG-binding peptides 
(Table 4.20) were tyrosinase (12/30), DCT (5/30), Rab27A (3/30), RPL24 (2/30), HSP90 
(2/30), and TYRP1 (1/30) (Figure 4.7s). All 25 proteins were in-frame with the Fos protein 
encoded by the pJuFo. The remaining five phagemid contained DNA which did not 




4.4.2.20 Vitiligo patient V234-20 
For vitiligo patient V234-20, of the 30 phage clones sequenced, 27/30 (90%) contained 
cloned DNA which matched identifiable proteins in the database (Table 4.21). These 
included GPNMB (10/30), OCA2 protein (8/30), MC1R (2/30), Rab27A (4/30), and HSP90 
(3/30) (Figure 4.7t). All the 27 peptides were in-frame with the Fos protein encoded by 
the vector pJuFo. The remaining three clones contained DNA inserts with no homology 
to sequences in the database.  
4.4.2.21 Vitiligo patient V45-21 
For vitiligo patient V45-21, 26 of the 30 (87%) clones sequenced demonstrated 
homology with DNA sequences present in the database (Table 4.22). These were HSP90 
(4/30), LaminA (10/30), OCA2 protein (8/30), and GPNMB (4/30) (Figure 4.7u). All these 
proteins were in-frame with the Fos protein encoded by the vector. Four clones 
harboured cDNA which had no significant matches with sequences in the Genbank 
database. 
4.4.2.22 Vitiligo patient V46-22 
For vitiligo patient V46-22, several different proteins were encoded by 27 out of the 30 
(90%) clones (Table 4.23). These peptides included tyrosinase (9/30), TYRP1 (8/30), 
LaminA (4/30), HSP90 (3/30), and OCA2 protein (3/30) (Figure 4.7v).  All these were in-
frame with the Fos protein encoded by the pJuFo vector. The remaining three clones did 































Figure 4.7: Enriched cDNA-encoded proteins isolated from panning of the melanoctye 
cDNA phage-display library with vitiligo patient IgG. 
Phagemid DNA from 30 randomly selected bacterial clones were isolated from the fifth panning 
round with 22 vitiligo patient IgG individually. To identify if particular proteins had been enriched 
during the panning process, the DNA samples were subjected to DNA sequencing. GPNMB, 
glycoprotein non-metastatic melanoma protein b; HSP90, heat-shock protein 90; MC1R, 
melanocortin 1 receptor; PMEL, melanocyte-specific protein PMEL; OCA2, OCA2-encoded P 
protein; Rab27A, GTP-binding protein Rab27A; RPL24, 39s ribosomal protein L24; TYRP1, 




Table 4.2: Identification of cDNA-encoded peptides enriched in the panning 






















V6-1.R5.1 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V6-1.R5.2 Tyrosinase NM_000372.4 19-1587 7-529 Yes 




NM_001200054.1 13-2004 5-668 Yes 
V6-1.R5.5 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V6-1.R5.6 Heat-shock protein 90 NM_001017963.2 2260-2562 754-854 Yes 
V6-1.R5.7 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 




NM_001200054.1 13-2004 5-668 Yes 
V6-1.R5.10 No significant similarity found - - - - 




NM_001200054.1 13-2004 5-668 Yes 
V6-1.R5.13 Heat-shock protein 90 NM_001017963.2 2260-2562 754-854 Yes 
V6-1.R5.14 GTP-binding protein Rab27A NM_004580.4 104-221 104-221 No 
V6-1.R5.15 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V6-1.R5.16 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 








NM_001200054.1 28-2004 10-668 Yes 
V6-1.R5.20 Tyrosinase NM_000372.4 37-1587 13-529 Yes 
V6-1.R5.21 Tyrosinase NM_000372.4 46-1587 16-529 Yes 
V6-1.R5.22 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V6-1.R5.23 GTP-binding protein Rab27A NM_004580.4 10-663 4-221 Yes 
V6-1.R5.24 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 








NM_001200054.1 13-2004 5-668 Yes 
V6-1.R5.28 GTP-binding protein Rab27A NM_004580.4 104-221 104-221 No 
V6-1.R5.29 Tyrosinase NM_000372.4 55-1587 19-529 Yes 




Table 4.3 Identification of cDNA-encoded peptides enriched in the panning 



















V11-2.R5.1 Tyrosinase-related protein 1 NM_000550.2 1-1611 1-537 Yes 
V11-2.R5.2 Tyrosinase-related protein 1 NM_000550.2 1-1611 1-537 Yes 
V11-2.R5.3 Tyrosinase-related protein 1 NM_000550.2 19-1611 7-537 Yes 
V11-2.R5.4 Tyrosinase-related protein 1 NM_000550.2 43-1611 15-537 Yes 
V11-2.R5.5 Heat-shock protein 90 NM_005348.3 2260-2562 754-854 Yes 
V11-2.R5.6 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V11-2.R5.7 Tyrosinase-related protein 1 NM_000550.2 28-1611 10-537 Yes 
V11-2.R5.8 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V11-2.R5.9 Tyrosinase-related protein 1 NM_000550.2 1-1611 1-537 Yes 




NM_001200054.1 31-2004 11-668 Yes 
V11-2.R5.12 Tyrosinase-related protein 1 NM_000550.2 31-1611 11-537 Yes 
V11-2.R5.13 Tyrosinase NM_000372.4 37-1587 13-529 Yes 




NM_001200054.1 25-2004 9-668 Yes 
V11-2.R5.16 Tyrosinase-related protein 1 NM_000550.2 37-1611 13-537 Yes 
V11-2.R5.17 Tyrosinase-related protein 1 NM_000550.2 37-1611 13-537 Yes 
V11-2.R5.18 GTP-binding protein Rab27A NM_004580.4 322-663 108-221 No 
V11-2.R5.19 Heat-shock protein 90 NM_005348.3 2260-2562 754-854 Yes 
V11-2.R5.20 Tyrosinase-related protein 1 NM_000550.2 1-1611 1-537 Yes 
V11-2.R5.21 Tyrosinase-related protein 1 NM_000550.2 1-1611 1-537 Yes 
V11-2.R5.22 Tyrosinase-related protein 1 NM_000550.2 34-1611 12-537 Yes 
V11-2.R5.23 Tyrosinase-related protein 1 NM_000550.2 49-1611 17-537 Yes 
V11-2.R5.24 Tyrosinase NM_000372.4 76-1587 26-529 Yes 
V11-2.R5.25 Tyrosinase-related protein 1 NM_000550.2 64-1611 22-537 Yes 
V11-2.R5.26 GTP-binding protein Rab27A NM_005348.3 2272-2562 758-854 No 
V11-2.R5.27 Tyrosinase-related protein 1 NM_000550.2 7-1611 3-537 Yes 
V11-2.R5.28 Tyrosinase-related protein 1 NM_000550.2 31-1611 11-537 Yes 
V11-2.R5.29 GTP-binding protein Rab27A NM_004580.4 331-663 111-221 No 




Table 4.4:  Identification of cDNA-encoded peptides enriched in the panning 
experiments of the melanocyte cDNA phage-display library with IgG from vitiligo 
patient V12-3 



















melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V12-3.R5.2 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V12-3.R5.3 Tyrosinase NM_000372.4 19-1587 7-529 Yes  
V12-3.R5.4 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V12-3.R5.5 Melanocortin 1 receptor NM_002386.3 34-951 12-317 Yes 
V12-3.R5.6 Melanocortin 1 receptor NM_002386.3 37-951 13-317 Yes 
V12-3.R5.7 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 37-1716 13-527 Yes 
V12-3.R5.8 Melanocortin 1 receptor NM_002386.3 1-951 1-317 Yes 
V12-3.R5.9 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 64-1716 22-572 Yes 
V12-3.R5.10 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 16-1716 6-572 Yes 
V12-3.R5.11 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V12-3.R5.12 No significant similarity found - - - - 
V12-3.R5.13 GTP-binding protein  Rab27A  NM_004580.4 1-663 1-221 Yes 
V12-3.R5.14 Tyrosinase NM_000372.4 13-1587 7-529 Yes 
V12-3.R5.15 
Glycoprotein non-metastatic 
melanoma protein b  
NM_001005340.1 1-1716 1-572 Yes 
V12-3.R5.16 No significant similarity found - - - - 
V12-3.R5.17 Heat-shock protein 90 NM_005348.3 1895-2196 632-732 Yes 
V12-3.R5.18 Tyrosinase NM_000372.4 37-1587 13-529 Yes 
V12-3.R5.19 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 46-1716 16-572 Yes 
V12-3.R5.20 No significant similarity found - - - - 
V12-3.R5.21 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V12-3.R5.22 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V12-3.R5.23 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 28-1719 10-572 Yes 
V12-3.R5.24 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V12-3.R5.25 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V12-3.R5.26 Melanocortin 1 receptor NM_002386.3 1-951 1-317 Yes 
V12-3.R5.27 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 37-1716 13-572 Yes 
V12-3.R5.28 GTP-binding protein Rab27A NM_004580.4 310-663 104-221 No  
V12-3.R5.29 
Glycoprotein non-metastatic 
melanoma protein b 
NP_001005340.1 124-1719 42-572 Yes 




Table 4.5: Identification of cDNA-encoded peptides enriched in the panning 






















V13-4.R5.1 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V13-4.R5.2 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V13-4.R5.3 No significant similarity found - - - - 
V13-4.R5.4 Tyrosinase-related protein 1 NM_000550.2 7-1611 3-537 Yes 




V13-4.R5.6 Tyrosinase-related protein 1 NM_000550.2 1-1611 1-537 Yes 
V13-4.R5.7 Tyrosinase NM_000372.4 49-1587  Yes 
V13-4.R5.8 L-dopachrome tautomerase NM_001129889.2 1-1656 1-552 Yes 
V13-4.R5.9 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V13-4.R5.10 No significant similarity found - - - - 
V13-4.R5.11 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V13-4.R5.12 Tyrosinase NM_000372.4 28-1587 10-529 Yes 
V13-4.R5.13 Tyrosinase NM_000372.4 82-1590 28-529 Yes 
V13-4.R5.14 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V13-4.R5.15 Tyrosinase NM_000372.4 49-1587 17-529 Yes 
V13-4.R5.16 Tyrosinase NM_000372.4 49-1587 17-529 Yes 
V13-4.R5.17 L-dopachrome tautomerase NM_001129889.2 10-1656 4-552 Yes 
V13-4.R5.18 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V13-4.R5.19 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V13-4.R5.20 L-dopachrome tautomerase NM_001129889.2 22-1659 8-552 Yes 




NM_001200054.1 31-2004 11-668 Yes 
V13-4.R5.23 Ras-related protein Rab27A NM_004580.4 1-663 1-221 Yes 
V13-4.R5.24 No significant similarity found - - - - 
V13-4.R5.25 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V13-4.R5.26 No significant similarity found - - - - 
V13-4.R5.27 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V13-4.R5.28 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V13-4.R5.29 Tyrosinase NM_000372.4 25-1587 9-529 Yes 




Table 4.6: Identification of cDNA-encoded peptides enriched in the panning 





















V15-5.R5.1 Heat-shock protein 90 NM_005348.3 1906-2196 636-732 Yes  
V15-5.R5.2 OCA2-encoded P protein  NM_001300984.1 1-2442 1-814 Yes 
V15-5.R5.3 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V15-5.R5.4 Tyrosinase NM_000372.4 46-1587 16-529 Yes 
V15-5.R5.5 
No significant similarity 
found 
- - - - 
V15-5.R5.6 OCA2-encoded P protein NM_001300984.1 22-2442 8-814 Yes 
V15-5.R5.7 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V15-5.R5.8 OCA2-encoded P protein NM_001300984.1 28-2442 10-814 Yes 
V15-5.R5.9 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V15-5.R5.10 
No significant similarity 
found 
- - - - 
V15-5.R5.11 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V15-5.R5.12 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V15-5.R5.13 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V15-5.R5.14 
No significant similarity 
found 




NM_004580.4 277-663 93-221 Yes 
V15-5.R5.16 
Melanocyte- specific 
protein PMEL  
NM_001200054.1 22-2004 8-668 Yes 
V15-5.R5.17 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V15-5.R5.18 OCA2-encoded P protein NM_001300984.1 10-2442 4-814 Yes 
V15-5.R5.19 
No significant similarity 
found 
- - - - 
V15-5.R5.20 OCA2-encoded P protein NM_001300984.1 13-2442 5-814 Yes 
V15-5.R5.21 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V15-5.R5.22 OCA2-encoded P protein NM_001300984.1 22-2442 8-814 Yes 




NM_001200054.1 22-2004 8-668 Yes 
V15-5.R5.25 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V15-5.R5.26 Tyrosinase NM_000372.4 58-1587 20-529 Yes 
V15-5.R5.27 Tyrosinase NM_000372.4 31-1587 11-529 Yes 
V15-5.R5.28 OCA2-encoded P protein NM_001300984.1 10-2443 4-814 Yes 
V15-5.R5.29 OCA2-encoded P protein NM_001300984.1 16-2442 6-814 Yes 




Table 4.7: Identification of cDNA-encoded peptides enriched in the panning 



























V20-6.R5.1 Tyrosinase-related protein 1 NM_000550.2 13-1611 5-537 Yes  
V20-6.R5.2 Tyrosinase-related protein 1 NM_000550.2 1-1611 1-537 Yes 
V20-6.R5.3 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V20-6.R5.4 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V20-6.R5.5 Tyrosinase NM_000372.4 43-1587 15-529 Yes 
V20-6.R5.6 No significant similarity found - - - - 
V20-6.R5.7 Tyrosinase NM_000372.4 28-1587 10-529 Yes 
V20-6.R5.8 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V20-6.R5.9 Tyrosinase NM_000372.4 37-1587 13-529 Yes 
V20-6.R5.10 Heat-shock protein 90 NM_005348.3 1894-1196 632-732 Yes 
V20-6.R5.11 Tyrosinase NM_000372.4 37-1587 13-529 Yes 
V20-6.R5.12 Heat-shock protein 90 NM_005348.3 1894-1196 632-732 Yes 
V20-6.R5.13 Tyrosinase-related protein 1 NM_000550.2 1-1611 1-537 Yes 
V20-6.R5.14 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V20-6.R5.15 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V20-6.R5.16 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V20-6.R5.17 Tyrosinase-related protein 1  NM_000550.2 1-1611 1-537 Yes 
V20-6.R5.18 Tyrosinase NM_000372.4 28-1587 10-529 Yes 
V20-6.R5.19 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V20-6.R5.20 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V20-6.R5.21 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V20-6.R5.22 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V20-6.R5.23 Tyrosinase NM_000372.4 37-1587 13-529 Yes 
V20-6.R5.24 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V20-6.R5.25 Tyrosinase NM_000372.4 42-1587 15-529 Yes 
V20-6.R5.26 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V20-6.R5.27 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V20-6.R5.28 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V20-6.R5.29 Tyrosinase NM_000372.4 19-1587 7-529 Yes 




Table 4.8: Identification of cDNA-encoded peptides enriched in the panning 
experiments of the melanocyte cDNA phage-display library with IgG from vitiligo 
patient V21-7 
 



















V21-7.R5.1 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V21-7.R5.2 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V21-7.R5.3 Tyrosinase NM_000372.4 19-1586 7-529 Yes 




NM_001200054.1 21-2004 8-668 Yes 
V21-7.R5.6 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V21-7.R5.7 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V21-7.R5.8 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V21-7.R5.9 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V21-7.R5.10 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 




NM_001200054.1 21-2004 8-668 Yes 
V21-7.R5.13 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 




NM_001200054.1 21-2004 8-668 Yes 
V21-7.R5.16 Heat-shock protein 90 NM_005348.3 1894-2197 632-732 Yes 
V21-7.R5.17 Heat-shock protein 90 NM_005348.3 1894-2197 632-732 Yes 




NM_001200054.1 21-2004 8-668 Yes 
V21-7.R5.20 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V21-7.R5.21 Heat-shock protein NM_005348.3 1894-2196 632-732 Yes 
V21-7.R5.22 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V21-7.R5.23 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V21-7.R5.24 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 




NM_001200054.1 21-2004 8-668 Yes 
V21-7.R5.27 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V21-7.R5.28 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V21-7.R5.29 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 




Table 4.9: Identification of cDNA-encoded peptides enriched in the panning 
experiments of the melanocyte cDNA phage-display library with IgG from vitiligo 
patient V22-8 
 

















V22-8.R5.1 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V22-8.R5.2 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 y 
V22-8.R5.3 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V22-8.R5.4 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V22-8.R5.5 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V22-8.R5.6 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V22-8.R5.7 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V22-8.R5.8 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V22-8.R5.9 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V22-8.R5.10 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V22-8.R5.11 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V22-8.R5.12 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V22-8.R5.13 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V22-8.R5.14 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V22-8.R5.15 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V22-8.R5.16 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V22-8.R5.17 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V22-8.R5.18 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V22-8.R5.19 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V22-8.R5.20 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V22-8.R5.21 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V22-8.R5.22 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V22-8.R5.23 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V22-8.R5.24 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V22-8.R5.25 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V22-8.R5.26 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V22-8.R5.27 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V22-8.R5.28 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V22-8.R5.29 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 




Table 4.10: Identification of cDNA-encoded peptides enriched in the panning 





















V23-9.R5.1 Melanocortin 1 receptor NM_002386.3 13-951 5-317 Yes 
V23-9.R5.2 L-dopachrome tautomerase NM_001129889.2 22-1657 8-552 Yes 
V23-9.R5.3 L-dopachrome tautomerase NM_001129889.2 22-1657 8-552 Yes 
V23-9.R5.4 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V23-9.R5.5 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V23-9.R5.6 No significant similarity found - - - - 
V23-9.R5.7 L-dopachrome tautomerase NM_001129889.2 1-1651 1-552 Yes 
V23-9.R5.8 No significant similarity found - - - - 
V23-9.R5.9 L-dopachrome tautomerase NM_001129889.2 1-1651 1-552 Yes 
V23-9.R5.10 No significant similarity found - - - - 
V23-9.R5.11 No significant similarity found - - - - 
V23-9.R5.12 L-dopachrome tautomerase NM_001129889.2 22-1657 8-552 Yes 
V23-9.R5.13 L-dopachrome tautomerase NM_001129889.2 22-1657 8-552 Yes 
V23-9.R5.14 Melanocortin 1 receptor NM_002386.3 13-951 5-317 Yes 
V23-9.R5.15 No significant similarity found - - - - 
V23-9.R5.16 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V23-9.R5.17 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V23-9.R5.18 Melanocortin 1 receptor NM_002386.3 13-951 5-317 Yes 
V23-9.R5.19 No significant similarity found - - - - 
V23-9.R5.20 Melanocortin 1 receptor NM_002386.3 13-951 5-317 Yes 
V23-9.R5.21 L-dopachrome tautomerase NM_001129889.2 22-1657 8-552 Yes 
V23-9.R5.22 L-dopachrome tautomerase NM_001129889.2 22-1657 8-552 Yes 
V23-9.R5.23 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V23-9.R5.24 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V23-9.R5.25 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V23-9.R5.26 L-dopachrome tautomerase NM_001129889.2 22-1657 8-552 Yes 
V23-9.R5.27 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V23-9.R5.28 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V23-9.R5.29 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 




Table 4.11: Identification of cDNA-encoded peptides enriched in the panning 























V24-10.R5.1 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V24-10.R5.2 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V24-10.R5.3 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.4 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.5 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.6 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V24-10.R5.7 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V24-10.R5.8 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V24-10.R5.9 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.10 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V24-10.R5.11 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V24-10.R5.12 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V24-10.R5.13 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.14 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V24-10.R5.15 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.16 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V24-10.R5.17 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.18 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V24-10.R5.19 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V24-10.R5.20 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.21 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V24-10.R5.22 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.23 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V24-10.R5.24 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.25 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V24-10.R5.26 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V24-10.R5.27 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.28 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V24-10.R5.29 Tyrosinase NM_000372.4 40-1587 14-529 Yes 




Table 4.12: Identification of cDNA-encoded peptides enriched in the panning 
experiments of the melanocyte cDNA phage-display library with IgG from vitiligo 
patient V224-11 
 
1Patient number.panning round.clone number. 













V224-11.R5.1 No significant similarity found - - - - 
V224-11.R5.2 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 64-1716 22-572 Yes 
V224-11.R5.3 No significant similarity found - - - - 
V224-11.R5.4 Melanocyte-specific protein PMEL NM_001200054.1 22-2004 8-668 Yes 
V224-11.R5.5 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 64-1716 22-572 Yes 
V224-11.R5.6 Melanocyte-specific protein PMEL NM_001200054.1 22-2004 8-668 Yes 
V224-11.R5.7 Melanocyte-specific protein PMEL NM_001200054.1 22-2004 8-668 Yes 
V224-11.R5.8 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 64-1716 22-572 Yes 
V224-11.R5.9 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V224-11.R5.10 Melanocyte-specific protein PMEL NM_001200054.1 22-2004 8-668 Yes 
V224-11.R5.11 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 64-1716 22-572 Yes 
V224-11.R5.12 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 64-1716 22-572 Yes 
V224-11.R5.13 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 64-1716 22-572 Yes 
V224-11.R5.14 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 






melanoma protein b 
NM_001005340.1 64-1716 22-572 Yes 
V224-11.R5.17 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V224-11.R5.18 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V224-11.R5.19 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 64-1716 22-572 Yes 
V224-11.R5.20 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V224-11.R5.21 Melanocyte-specific protein PMEL NM_001200054.1 22-2004 8-668 Yes 




V224-11.R5.23 No significant similarity found - - - - 
V224-11.R5.24 No significant similarity found - - - - 
V224-11.R5.25 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 64-1716 22-572 Yes 
V224-11.R5.26 Melanocyte-specific protein PMEL NM_001200054.1 22-2004 8-668 Yes 
V224-11.R5.27 Melanocyte-specific protein PMEL NM_001200054.1 22-2004 8-668 Yes 
V224-11.R5.28 Tyrosinase NM_000372.4 37-1987 13-529 Yes 











Table 4.13: Identification of cDNA-encoded peptides enriched in the panning 






















V38-12.R5.1 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V38-12.R5.2 
No significant similarity 
found 
- - - - 
V38-12.R5.3 
No significant similarity 
found 
- - - - 
V38-12.R5.4 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V38-12.R5.5 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V38-12.R5.6 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V38-12.R5.7 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V38-12.R5.8 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V38-12.R5.9 
No significant similarity 
found 
- - - - 
V38-12.R5.10 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V38-12.R5.11 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V38-12.R5.12 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V38-12.R5.13 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V38-12.R5.14 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V38-12.R5.15 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V38-12.R5.16 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V38-12.R5.17 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V38-12.R5.18 
No  significant similarity 
found 
- - - - 
V38-12.R5.19 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V38-12.R5.20 OCA2-encoded P protein NM_001300984.1 1-2442 1-814 Yes 
V38-12.R5.21 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V38-12.R5.22 
No  significant similarity 
found 
- - - - 
V38-12.R5.23 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V38-12.R5.24 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V38-12.R5.25 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V38-12.R5.26 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V38-12.R5.27 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V38-12.R5.28 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V38-12.R5.29 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V38-12.R5.30 
No  significant similarity 
found 




Table 4.14: Identification of cDNA-encoded peptides enriched in the panning 
experiments of the melanocyte cDNA phage-display library with IgG from vitiligo 
patient V56-13 
 
1Patient number.panning round.clone number. 
  












V56-13.R5.1 L-dopachrome tautomerase NM_001129889.2 1-1651 1-552 Yes 
V56-13.R5.2 No significant similarity found - - - - 
V56-13.R5.3 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V56-13.R5.4 No significant similarity found - - - - 




NM_001200054.1 13-2004 5-668 Yes 
V56-13.R5.7 L-dopachrome tautomerase NM_001129889.2 1-1651 1-552 Yes 












NM_001200054.1 13-2004 5-668 Yes 








NM_001200054.1 13-2004 5-668 Yes 




NM_001200054.1 13-2004 5-668 Yes 




NM_001200054.1 13-2004 5-668 Yes 
V56-13.R5.19 L-dopachrome tautomerase NM_001129889.2 1-1651 1-552 Yes 




NM_001200054.1 13-2004 5-668 Yes 












NM_001200054.1 13-2004 5-668 Yes 




NM_001200054.1 13-2004 5-668 Yes 
V56-13.R5.28 
Melanocyte-specific  protein 
PMEL 
NM_001200054.1 13-2004 5-668 Yes 
V56-13.R5.29 L-dopachrome tautomerase NM_001129889.2 1-1651 1-552 Yes 




Table 4.15: Identification of cDNA-encoded peptides enriched in the panning 






















V73-14.R5.1 Heat-shock protein 90 
NM_001017963
.2 
2260-2562 754-854 Yes 
V73-14.R5.2 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V73-14.R5.3 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V73-14.R5.4 
No significant similarity 
found 
- - - - 
V73-14.R5.5 
No significant similarity 
found 
- - - - 
V73-14.R5.6 
No significant similarity 
found 
- - - - 
V73-14.R5.7 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V73-14.R5.8 Heat-shock protein 90 
NM_001017963
.2 
2260-2562 754-854 Yes 
V73-14.R5.9 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V73-14.R5.10 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V73-14.R5.11 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V73-14.R5.12 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V73-14.R5.13 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V73-14.R5.14 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V73-14.R5.15 GTP-binding proteinRab27A NM_004580.4 1-663 1-221 Yes 
V73-14.R5.16 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V73-14.R5.17 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V73-14.R5.18 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V73-14.R5.19 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V73-14.R5.20 
No significant similarity 
found 
- - - - 
V73-14.R5.21 
No significant similarity 
found 
- - - - 
V73-14.R5.22 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V73-14.R5.23 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V73-14.R5.24 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V73-14.R5.25 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V73-14.R5.26 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V73-14.R5.27 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V73-14.R5.28 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V73-14.R5.29 Tyrosinase NM_000372.4 37-1987 13-529 Yes 
V73-14.R5.30 Heat-shock protein 90 
NM_001017963
.2 




Table 4.16: Identification of cDNA-encoded peptides enriched in the panning 























No significant similarity 
found 
- - - - 
V102-15.R5.2 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V102-15.R5.3 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V102-15.R5.4 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V102-15.R5.5 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V102-15.R5.6 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V102-15.R5.7 
No significant similarity 
found 
- - - - 
V102-15.R5.8 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V102-15.R5.9 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V102-15.R5.10 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V102-15.R5.11 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V102-15.R5.12 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V102-15.R5.13 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V102-15.R5.14 
No significant similarity 
found 
- - - - 
V102-15.R5.15 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V102-15.R5.16 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V102-15.R5.17 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V102-15.R5.18 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V102-15.R5.19 OCA2-encoded P protein 
NM_001300984
.1 
1-2442 1-814 Yes 
V102-15.R5.20 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V102-15.R5.21 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V102-15.R5.22 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V102-15.R5.23 
No significant similarity 
found 
- - - - 
V102-15.R5.24 OCA2-encoded P protein 
NM_001300984
.1 
1-2442 1-814 Yes 
V102-15.R5.25 OCA2-encoded P protein 
NM_001300984
.1 
1-2442 1-814 Yes 
V102-15.R5.26 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V102-15.R5.27 
No significant similarity 
found 
- - - - 
V102-15.R5.28 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V102-15.R5.29 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 




Table 4.17: Identification of cDNA-encoded peptides enriched in the panning 




1Patient number.panning round.clone number.  














V169-16.R5.1 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V169-16.R5.2 
Glycoprotein non-metastatic 
melanoma protein b 
NM_0010053
40.1 
13-1716 5-572 Yes 
V169-16.R5.3 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V169-16.R5.4 
Glycoprotein non-metastatic 
melanoma protein b 
NM_0010053
40.1 
13-1716 5-572 Yes 
V169-16.R5.5 
No significant similarity 
found 
- - - - 
V169-16.R5.6 
No significant similarity 
found 
- - - - 
V169-16.R5.7 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V169-16.R5.8 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V169-16.R5.9 Melanocortin 1 receptor NM_002386.3 13-951 5-317 Yes 
V169-16.R5.10 Melanocortin 1 receptor NM_002386.3 13-951 5-317 Yes 
V169-16.R5.11 
No significant similarity 
found 
- - - - 
V169-16.R5.12 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V169-16.R5.13 
Glycoprotein non-metastatic 
melanoma protein b 
NM_0010053
40.1 
13-1716 5-572 Yes 
V169-16.R5.14 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V169-16.R5.15 Heat-shock protein 90 NM_005348.3 1894-2196 632-732 Yes 
V169-16.R5.16 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V169-16.R5.17 
Glycoprotein non-metastatic 
melanoma protein b 
NM_0010053
40.1 
13-1716 5-572 Yes 
V169-16.R5.18 
No significant similarity 
found 
- - - - 
V169-16.R5.19 L-dopachrome tautomerase 
NM_0011298
89.2 
22-1657 8-552 Yes 
V169-16.R5.20 L-dopachrome tautomerase 
NM_0011298
89.2 
22-1657 8-552 Yes 
V169-16.R5.21 Tyrosinase NM_000372.4 19-1587 7-529 Yes 
V169-16.R5.22 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V169-16.R5.23 Melanocortin 1 receptor NM_002386.3 13-951 5-317 Yes 
V169-16.R5.24 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V169-16.R5.25 
No significant similarity 
found 
- - - - 
V169-16.R5.26 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V169-16.R5.27 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V169-16.R5.28 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V169-16.R5.29 
No significant similarity 
found 
- - - - 




Table 4.18: Identification of cDNA-encoded peptides enriched in the panning 




1Patient number.panning round.clone number. 














V189-17.R5.1 Heat-shock protein 90 NM_005348.3 1906-2196 616-732 Yes 






22-2004 8-668 Yes 
V189-17.R5.4 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V189-17.R5.5 No significant similarity found - - - - 
V189-17.R5.6 OCA2-encoded P protein 
NM_0013009
84.1 






22-2004 8-668 Yes 






22-2004 22-668 Yes 






22-2004 8-668 Yes 
V189-17.R5.12 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V189-17.R5.13 Heat-shock protein 90 NM_005348.3 1906-2196 624-732 Yes 
V189-17.R5.14 Heat-shock protein 90 NM_005348.3 1906-2196 636-732 Yes 






22-2004 8-668 Yes 






22-2004 22-668 Yes 
V189-17.R5.19 OCA2-encoded P protein 
NM_0013009
84.1 
22-2442 8-814 Yes 
V189-17.R5.20 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V189-17.R5.21 No significant similarity found - - - - 
V189-17.R5.22 Tyrosinase NM_000372.4 46-1587 36-529 Yes 






22-2004 8-668 Yes 






22-2004 22-668 Yes 












22-2004 8-668 Yes 
V189-17.R5.30 OCA2-encoded P protein 
NM_0013009
84.1 




Table 4.19: Identification of cDNA-encoded peptides enriched in the panning 




1Patient number.panning round.clone number. 
  














V216-18.R5.1 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V216-18.R5.2 
No significant similarity 
found 
- - - - 
V216-18.R5.3 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V216-18.R5.4 Heat-shock protein 90 NM_005348.3 1894-2197 632-732 Yes 
V216-18.R5.5 Heat-shock protein 90 NM_005348.3 1894-2197 632-732 Yes 
V216-18.R5.6 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 







13-1716 5-572 Yes 







13-1716 5-572 Yes 
V216-18.R5.11 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V216-18.R5.12 
No significant similarity 
found 
- - - - 
V216-18.R5.13 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V216-18.R5.14 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V216-18.R5.15 Heat-shock protein 90 NM_005348.3 1894-2197 632-732 Yes 
V216-18.R5.16 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V216-18.R5.17 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V216-18.R5.18 
No significant similarity 
found 
- - - - 
V216-18.R5.19 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V216-18.R5.20 Tyrosinase NM_000372.4 19-1586 7-529 Yes 







13-1716 5-572 Yes 
V216-18.R5.23 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V216-18.R5.24 Heat-shock protein 90 NM_005348.3 1894-2197 632-732 Yes 
V216-18.R5.25 Melanocortin 1 receptor NM_002386.3 16-951 6-317 Yes 
V216-18.R5.26 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V216-18.R5.27 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V216-18.R5.28 GTP-binding protein Rab27A NM_004580.4 1-663 1-221 Yes 
V216-18.R5.29 Melanocortin 1 receptor NM_002386.3 16-951 6-317 Yes 




Table 4.20: Identification of cDNA-encoded peptides enriched in the panning 




1Patient number.panning round.clone number. 
  














V219-19.R5.1 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V219-19.R5.2 
No significant similarity 
found 
- - - - 
V219-19.R5.3 L-dopachrome tautomerase 
NM_0011298
89.2 
22-1656 8-552 Yes 
V219-19.R5.4 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V219-19.R5.5 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V219-19.R5.6 
No significant similarity 
found 
- - - - 
V219-19.R5.7 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V219-19.R5.8 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V219-19.R5.9 L-dopachrome tautomerase 
NM_0011298
89.2 
22-1656 8-552 Yes 
V219-19.R5.10 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V219-19.R5.11 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V219-19.R5.12 
No significant similarity 
found 
- - - - 
V219-19.R5.13 Heat-shock protein 90 NM_005348.3 1900-2196 633-732 Yes 
V219-19.R5.14 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V219-19.R5.15 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V219-19.R5.16 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V219-19.R5.17 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V219-19.R5.18 L-dopachrome tautomerase 
NM_0011298
89.2 
22-1656 8-552 Yes 
V219-19.R5.19 L-dopachrome tautomerase 
NM_0011298
89.2 
22-1656 8-552 Yes 
V219-19.R5.20 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V219-19.R5.21 
No significant similarity 
found 
- - - - 
V219-19.R5.22 
No significant similarity 
found 
- - - - 
V219-19.R5.23 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V219-19.R5.24 39S ribosomal protein L24 NM_024540.3 1-648 1-216 Yes 
V219-19.R5.25 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V219-19.R5.26 L-dopachrome tautomerase 
NM_0011298
89.2 
22-1656 8-552 Yes 
V219-19.R5.27 Tyrosinase NM_000372.4 40-1587 14-529 Yes 
V219-19.R5.28 Heat-shock protein 90 NM_005348.3 1900-2196 633-732 Yes 
V219-19.R5.29 Tyrosinase NM_000372.4 40-1587 14-529 Yes 




Table 4.21: Identification of cDNA-encoded peptides enriched in the panning 




1Patient number.panning round.clone number. 
 
 














V234-20.R5.1 GTP-binding protein Rab27A NM_004580.4 278-663 96-221 Yes 
V234-20.R5.2 No significant similarity found - - - - 
V234-20.R5.3 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V234-20.R5.4 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V234-20.R5.5 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 






melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V234-20.R5.8 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V234-20.R5.9 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 






melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V234-20.R5.12 GTP-binding protein Rab27A NM_004580.4 278-663 96-221 Yes 
V234-20.R5.13 OCA2-encoded P protein NM_001300984.1 60-2442 20-814 Yes 
V234-20.R5.14 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V234-20.R5.15 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V234-20.R5.16 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 




V234-20.R5.18 GTP-binding protein Rab27A NM_004580.4 277-663 93-221 Yes 
V234-20.R5.19 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V234-20.R5.20 No significant similarity found - - - - 
V234-20.R5.21 OCA2-encoded P protein NM_001300984.1 60-2442 20-814 Yes 
V234-20.R5.22 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 
V234-20.R5.23 OCA2-encoded P protein NM_001300984.1 60-2442 20-814 Yes 
V234-20.R5.24 OCA2-encoded P protein NM_001300984.1 60-2442 20-814 Yes 
V234-20.R5.25 Melanocortin 1 receptor NM_002386.3 34-951 12-317 Yes 
V234-20.R5.26 No significant similarity found - - - - 
V234-20.R5.27 OCA2-encoded P protein NM_001300984.1 60-2442 20-814 Yes 
V234-20.R5.28 OCA2-encoded P protein NM_001300984.1 60-2442 20-814 Yes 
V234-20.R5.29 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 1-1716 1-572 Yes 




Table 4.22: Identification of cDNA-encoded peptides enriched in the panning 























V45-21.R5.1 Lamin A NM_170707 1-1992 1-664 Yes  
V45-21.R5.2 Heat-shock protein 90 NM_005348.3 1894-2197 632-732 Yes 
V45-21.R5.3 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V45-21.R5.4 Lamin A NM_170707 1-1992 1-664 Yes 
V45-21.R5.5 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V45-21.R5.6 Lamin A NM_170707 1-1992 1-664 Yes 
V45-21.R5.7 
No significant similarity 
found 
- - - - 
V45-21.R5.8 Lamin A NM_170707 1-1992 1-664 Yes 
V45-21.R5.9 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V45-21.R5.10 Lamin A NM_170707 1-1992 1-664 Yes 
V45-21.R5.11 
No significant similarity 
found 
- - - - 
V45-21.R5.12 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V45-21.R5.13 Heat-shock protein 90 NM_005348.3 1894-2197 632-732 Yes 
V45-21.R5.14 Heat-shock protein 90 NM_005348.3 1894-2197 632-732 Yes 
V45-21.R5.15 Lamin A NM_170707 1-1992 1-664 Yes 
V45-21.R5.16 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V45-21.R5.17 Lamin A NM_170707 1-1992 1-664 Yes 
V45-21.R5.18 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V45-21.R5.19 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V45-21.R5.20 
No significant similarity 
found 
- - - - 
V45-21.R5.21 Lamin A NM_170707 1-1992 1-664 Yes 
V45-21.R5.22 Heat-shock protein 90 NM_005348.3 1894-2197 632-732 Yes 
V45-21.R5.23 
Glycoprotein non-metastatic 
melanoma protein b 
NM_001005340.1 13-1716 5-572 Yes 
V45-21.R5.24 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V45-21.R5.25 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V45-21.R5.26 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V45-21.R5.27 Lamin A NM_170707 1-1992 1-664 Yes 
V45-21.R5.28 Lamin A NM_170707 1-1992 1-664 Yes 
V45-21.R5.29 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V45-21.R5.30 
No significant similarity 
found 




Table 4.23: Identification of cDNA-encoded peptides enriched in the panning 


























No significant similarity 
found 
- - - - 
V46-22.R5.2 Lamin A NM_170707 1-1992 1-664 Yes 
V46-22.R5.3 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V46-22.R5.4 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V46-22.R5.5 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 





No significant similarity 
found 
- - - - 
V46-22.R5.8 Lamin A NM_170707 1-1992 1-664 Yes 
V46-22.R5.9 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 




V46-22.R5.11 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V46-22.R5.12 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V46-22.R5.13 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V46-22.R5.14 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V46-22.R5.15 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V46-22.R5.16 OCA2-encoded P protein NM_001300984.1 36-2442 12-814 Yes 
V46-22.R5.17 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V46-22.R5.18 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V46-22.R5.19 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V46-22.R5.20 Lamin A NM_170707 1-1992 1-664 Yes 
V46-22.R5.21 Lamin A NM_170707 1-1992 1-664 Yes 
V46-22.R5.22 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V46-22.R5.23 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V46-22.R5.24 Tyrosinase NM_000372.4 19-1586 7-529 Yes 
V46-22.R5.25 Tyrosinase NM_000372.4 19-1586 7-529 Yes 





No significant similarity 
found 
- - - - 
V46-22.R5.28 Tyrosinase-related protein 1 NM_000550.2 1-1601 1-537 Yes 
V46-22.R5.29 Tyrosinase NM_000372.4 19-1586 7-529 Yes 




 Summary of autoantigens from the panning experiments with vitiligo patient 
IgG  
The results for the panning of 22 vitiligo patient IgG against the melanocyte peptide 
phage-display library revealed that several different proteins were enriched during the 
process (Table 4.24). These included peptides already described as autoantigens in 
vitiligo, including, HSP90 (Waterman et al., 2010), tyrosinase (Song et al., 1994, Baharav 
et al., 1996, Kemp et al., 1997a, Pradhan et al., 2013), RPL24 (Waterman et al., 2010), 
TYRP1 (Kemp et al., 1998b, Li et al., 2011, Pradhan et al., 2013), PMEL (Kemp et al., 
1998a, Pradhan et al., 2013), DCT (Kemp et al., 1997b, Okamoto et al., 1998, Pradhan et 
al., 2013), and LaminA (Li et al., 2011). In addition, previously unreported putative 
autoantigens were recognised by some vitiligo patient IgGs and these included GPNMB, 





Table 4.24: Summary of cDNA-encoded peptides isolated from selective enrichment 
of the melanocyte cDNA phage-display library with vitiligo patient IgG 
 
cDNA-encoded peptide1 
Number of patients with 
the identified antigen (%) 
(n = 22) 
Previously identified as 
an autoantigen 
HSP90 21 (95.5) (Waterman et al., 2010) 
Tyrosinase 19 (86.4) 
 (Song et al., 1994, 
Baharav et al., 1996, Kemp 
et al., 1997a, Pradhan et 
al., 2013) 
Rab27A 13 (59.1) Not previously identified 
RPL24 12 (54.6) (Waterman et al., 2010) 
TYRP1 11 (50) 
(Kemp et al., 1998b, Li et 
al., 2011, Pradhan et al., 
2013) 
PMEL 8 (36.4) 
(Kemp et al., 1998a, 
Pradhan et al., 2013) 
GPNMB 8 (36.4) Not previously identified 
OCA2 protein 8 (36.4) Not previously identified 
MC1R 5 (22.7) Not previously identified 
DCT 5 (22.7) 
(Kemp et al., 1997b, 
Okamoto et al., 1998, 
Pradhan et al., 2013) 
LaminA 2 (9.1) (Li et al., 2011) 
 
1GPNMB, glycoprotein non-metastatic melanoma protein b; HSP90, heat-shock protein 90; 
MC1R, melanocortin 1 receptor; OCA2, OCA2-encoded P protein; PMEL, melanocyte-specific 
protein PMEL; Rab27A, GTP-binding protein Rab27A; RPL24, 39s ribosomal protein L24; TYRP1, 





 Discussion  
The identification of autoantigens is key to a full understanding of the role of 
autoimmunity in the pathogenesis of vitiligo. Autoantigens can be the targets of 
antibodies and/or T cells. Of course, antibodies might just be passive markers of disease 
without being involved in the depigmentation process (Zhang et al., 2005), but they can 
suggest the presence of autoreactive anti-melanocyte T lymphocytes (Norris et al., 1988, 
Oyarbide-Valencia et al., 2006, van den Boorn et al., 2009). Indeed, the autoantigens 
tyrosinase and PMEL were initially identified as antibody targets in vitiligo (Song et al., 
1994, Baharav et al., 1996, Kemp et al., 1997a, Kemp et al., 1998a, Pradhan et al., 2013) 
and were then studied further as cytotoxic T lymphocyte targets; the T cells were able 
to destroy melanocytes in vitro leading to depigmentation (Lang et al., 2001, Palermo et 
al., 2001, Mandelcorn-Monson et al., 2003). 
Phage-display technology is a powerful tool that offers a sensitive and effective 
approach to identify novel antibody targets in an unbiased fashion by combining high-
affinity selection with biological amplification. Large numbers of phage (1011) can be 
screened in a one experiment, thus increasing the possibility of recovering autoantigens 
(Kemp et al., 2002a). Even if expressed rarely in the original library, IgG-binding proteins 
can become highly enriched through repeated rounds of panning. This can increase the 
chance of detection and identification of autoantigens. In addition, peptides displayed 
on the phage surface are assumed to retain native structure (Skerra and Pluckthun, 
1988) as they are screened in a fluid-phase which avoids polypeptides denaturation. This 
could be important to detect antibody binding to conformational epitopes 
(Morgenthaler et al., 1999). 
Previously, a phage-display strategy has been utilised widely to identify antigen-
antibody interactions (Germaschewski and Murray, 1995, Grihalde et al., 1995). 
Employing phage-display, novel autoantigens have been identified in chronic 
inflammatory central nervous system disease (Burgoon et al., 2001), systemic lupus 
erythematosus (Kemp et al., 2002a), type 1 diabetes (Fierabracci et al., 1999), 
rheumatoid arthritis (Mewar et al., 2005) and vitiligo (Kemp et al., 2002b, Waterman et 




display technology including TH, MCHR1, γ-enolase, α-enolase, ubiquitin-conjugating 
enzyme, and osteopontin (Kemp et al., 2002b, Waterman et al., 2010). However, the IgG 
sample used in enrichment experiments by Kemp et al (2002b) and Waterman et al 
(2010) was a pool from 10 vitiligo patients so using the panning of individual patient IgG 
samples might have the advantage of antibody titres being less dilute.  
In the current project, phage-display based on the pJuFo cDNA expression system 
(Crameri and Suter, 1993) was utilised to identify novel autoantigens in vitiligo. The 
results showed that during the panning procedure with vitiligo patient IgG samples, 
there was a demonstrable increase in the normalised ratio of phage eluted to phage 
applied, indicating that IgG-binding phage were being enriched through each panning 
round. However, it was notable that in some panning experiments there was a decrease 
in this normalised ratio indicating that enrichment might not have occurred. Despite 
this, sequencing of clones from the final panning rounds in these experiments did show 
enrichment of autoantigens. Although the reason for this is not clear, it may have been 
due to low antibody titres in some of the patients. 
Sequence analysis revealed that several putative vitiligo-associated autoantigens had 
been enriched from the melanocyte cDNA phage-display library. Several of the 
autoantigens identified here had already been characterised as autoantigens in vitiligo 
including HSP90 (Waterman et al., 2010), tyrosinase (Song et al., 1994, Baharav et al., 
1996, Kemp et al., 1997a, Pradhan et al., 2013), RPL24 (Waterman et al., 2010), TYRP1 
(Kemp et al., 1998b, Li et al., 2011, Pradhan et al., 2013), PMEL (Kemp et al., 1998a, 
Pradhan et al., 2013), DCT (Kemp et al., 1997b, Okamoto et al., 1998, Pradhan et al., 
2013) and LaminA (Li et al., 2011), or had previously been described as autoantigens in 
other disorders (Conroy et al., 1994, Kiniwa et al., 2001, Zippelius et al., 2007). However, 





 Previously identified autoantigens 
4.5.1.1 Melanocyte-specific enzymes and PMEL 
The melanocyte-specific proteins tyrosinase, TYRP1, DCT, and PMEL were enriched by 
19, 11, five, and eight vitiligo patient IgGs, respectively. Tyrosinase, TYRP1 and DCT are 
key enzymes involved in melanin biosynthesis, and PMEL plays an important role in the 
structural organisation of premelanosomes (Yamaguchi et al., 2007, Tang et al., 2013, 
D'Mello et al., 2016). These melanocyte-specific proteins are localised to the 
melanosomes and so are considered as cytoplasmic proteins. However, different studies 
have shown that tyrosinase, TYRP1 and PMEL can be expressed transiently on the 
surface of the cell (Takechi et al., 1996, Calvo et al., 1999, Le Borgne et al., 2001, Lepage 
and Lapointe, 2006, Theos et al., 2006), which would make them available as targets for 
the immune system. Antibodies against these four melanogenic proteins have also been 
detected in earlier studies (Song et al., 1994, Baharav et al., 1996, Kemp et al., 1997a, 
Kemp et al., 1997b, Kemp et al., 1998a, Kemp et al., 1998b, Okamoto et al., 1998, Li et 
al., 2011, Pradhan et al., 2013). 
4.5.1.2 LaminA 
IgG from two individual vitiligo patients enriched the antibody target, Lamin A. In 2011, 
Li and colleagues (Li et al., 2011) demonstrated that a previously undefined melanocyte 
protein with a molecular weight of 75-kD, and that was defined as a vitiligo-associated 
autoantigen (Cui et al., 1995), was LaminA. LaminA exists in the cell nucleus and can be 
expressed also on the surface of melanocytes since it can be detected using 
lactoperoxidase-labelling (Cui et al., 1995). LaminA plays a significant role in maintaining 
cellular morphological structure along with other nuclear laminar proteins B and C (Zhu 
et al., 2015). Antibodies to nuclear laminar proteins have been previously detected in 
patients suffering from other autoimmune disorders such as autoimmune liver disease 
(Wesierska-Gadek et al., 1988) and systemic lupus erythematosus (Senecal et al., 1999), 




4.5.1.3 Heat-shock protein 90 
Our experiments revealed an enrichment of HSP90 by IgG from 95.5% (21/22) of the 
vitiligo patients. This protein has been previously described as an autoantigen in vitiligo 
by Waterman et al. (2010) as well as in systemic lupus erythematosus (Conroy et al., 
1994, Stephanou et al., 1998). Interestingly, antibody reactivity to HSP70 and HSP90 has 
been identified also in a single patient with melanoma-associated hypopigmentation 
(Kiniwa et al., 2001). HSP90 has been found to play a vital role in antigen presentation, 
activation of lymphocytes and macrophages, maturation and activation of dendritic 
cells, and in inflammation induction (Srivastava, 2002). The high levels of HSP90 in the 
serum of patients suffering from systemic lupus erythematosus have been correlated 
with elevated levels of IL-6 and the existence of antibodies against HSP90 (Shukla and 
Pitha, 2012). Albeit not normally expressed on the surface of the cell, HSP90 has been 
observed on the surface of peripheral blood monocytes in all patients with moderate or 
severe systemic lupus erythematosus (Conroy et al., 1994) where it could be targeted 
by the immune system (Conroy et al., 1994). In addition, more recent studies have 
shown the secretion of HSP70 from stressed melanocytes (Denman et al., 2008).  
 Novel putative antibody targets in vitiligo  
Four novel putative antibody targets associated with epidermal and melanocyte 
function were enriched by vitiligo patient IgG. 
4.5.2.1 Melanocortin 1 receptor 
The MC1R which is expressed specifically on the integumental melanocyte membrane 
(Hadley et al., 1981, Suzuki et al., 1996) was identified from the panning of the phage-
display library with IgG from five different vitiligo patients. The receptor’s ligand α-MSH 
regulates melanin production by acting through MC1R to increase melanin synthesis 
(Valverde et al., 1995). It could be argued that the function of MC1R might be adversely 





4.5.2.2 Glycoprotein non-metastatic melanoma protein b 
The GPNMB, a membrane-bound glycoprotein expressed in numerous types of cells 
including melanocytes, antigen presenting cells, macrophages, and retinal pigment 
epithelial cells (Owen et al., 2003, Kumagai et al., 2015), was a putative autoantigen in 
eight patients. In melanocytes, GPNMB is specifically expressed in late stage 
melanosomes, and thus it is speculated to play a role in late melanogenesis, possibly 
trafficking of melanosomes to keratinocytes (Hoashi et al., 2010). It has also been 
demonstrated that GPNMB promotes melanocyte adhesion to keratinocytes (Tomihari 
et al., 2009). The same study revealed the expression of GPNMB on the surface of 
pigment cells, albeit to a lesser degree than intracellularly where it is preferentially 
localised within melanosomes. In addition, the melanocyte surface-expression of 
GPNMB was noted to be upregulated by the pro-inflammatory cytokines IFN-γ and TNF-
α, suggesting that GPNMB-mediated adhesion between melanocyte and keratinocyte 
maybe modulated by these cytokines (Tomihari et al., 2009). 
4.5.2.3 OCA2-encoded P protein 
The third previously unreported antigen detected in this study was OCA2 protein, a 
melanosome-specific membrane protein which regulates pH providing an optimal 
environment to facilitate tyrosine transportation and folding and consequent melanin 
production (Puri et al., 2000, Sitaram et al., 2009, Bellono et al., 2014). Additionally, 
OCA2 protein is suggested to play a critical role in determining the colour of skin, hair 
and eyes (Jin et al., 2012a). Cheng et al. (2013) found that polymorphisms in the OCA2 
gene were correlated with a high risk of developing vitiligo and melanoma. Moreover, 
previous studies showed that mutations in OCA2 result in its mislocalisation to the cell 
surface and this impairs OCA2 protein function in melanin synthesis (Sitaram et al., 
2009).  
4.5.2.4 GTP-binding protein Rab27A 
A further novel candidate was Rab27A, a small GTP-binding protein which belongs to 




correlation between the levels of Rab27A expression and the melanin content of 
melanocytes (Yoshida-Amano et al., 2012). Melanosome transfer to keratinocytes was 
decreased with lower levels of Rab27A expression and the intensity of skin colour was 
less when Rab27A expression was driven down by Rab27A-specific small interfering RNA 
(siRNA) (Yoshida-Amano et al., 2012). These data indicate consistently that Rab27A plays 
a vital role in trafficking melanosomes to the melanocyte outer edges and in consequent 
cutaneous pigmentation in humans. In terms of its cellular location, Rab27A localises 
with melanosomes but not with the cell membrane (Bahadoran et al., 2001). 
Interestingly, antibodies to the melanocyte-expressed GTP-binding protein Rab38, 
which is involved in the transport of melanogenic enzymes from the Golgi apparatus to 
melanosomes (Wasmeier et al., 2006), have been revealed in vitiligo patients 
(Waterman et al., 2010). 
 Limitations of phage-display in autoantigen discovery 
Despite the encouraging results, it is important to be aware that phage-display does 
have disadvantages in its application related to antigen discovery. Expression of proteins 
on the phage surface may be prevented by different factors, hence limiting the available 
target autoantigens. The proteins displayed on the phage must be effectively secreted 
through E. coli inner membrane, fold into the correct structure in the periplasm, and 
retain their native configuration on the phage surface following exposure to an oxidising 
environment (Sambrook and Russell, 2001). Additionally, proteins normally associated 
with membranes may not have the ability to be transferred to the periplasm, and 
proteins with charged residues may not be expressed (Wilson and Finlay, 1998). 
However, phage-display has identified the MCHR1 as an autoantigen (Kemp et al., 
2002b) and, in this study, the receptor MC1R was panned from the phage-display library. 
A further issue is that the diversity of the library is limited by its source mRNA and the 





Overall, our results illustrate that phage-display technology is applicable to the 
identification of novel autoantigens in vitiligo. However, further experiments are 
required to prove the immunoreactivity of the potential autoantigens against a panel of 
vitiligo patient sera. This can be accomplished by testing the binding activity of patient 
IgG to [35S]-labelled autoantigen, produced in an in vitro transcription-translation system 
(Section 2.19), in RLBAs (Section 2.21). Due to their reported effects on melanogenesis, 
the putative novel autoantigens GPNMB and OCA2 protein as well as the previously 

















Analysis of antibody reactivity against glycoprotein non-metastatic 





5 Analysis of antibody reactivity against glycoprotein non-metastatic 
melanoma protein b in vitiligo patients 
 Introduction  
Glycoprotein non-metastatic melanoma protein b (GPNMB) is a type I transmembrane 
protein, secreted by different phagocytic cell types such as macrophages, dendritic cells, 
and osteoclasts as well as melanocytes and keratinocytes (Tomihari et al., 2009, Kramer 
et al., 2016). In melanocytes, GPNMB is a vital structural protein of melanosomes, which 
mostly resides intracellularly within melanosomes, but with a small fraction on the 
pigment cell surface (Tomihari et al., 2009). GPNMB is enriched in late-stage (III and IV) 
melanosomes in contrast to its close homologue, PMEL, which is abundant in early-stage 
(I and II) melanosomes (Yamaguchi and Hearing, 2014). PMEL protein is a key element 
in early-melanosome maturation; thus, GPNMB was speculated to likely play an 
important role in the function of late-stage melanosomes, perhaps their transport to 
keratinocytes (Yamaguchi and Hearing, 2014). Indeed, pigment dispersion in the iris in 
mouse pigmentary glaucoma was shown to result from mutations in the gene GPNMB 
(Anderson et al., 2001, Tomihari et al., 2010). In addition, GPNMB expression on 
melanocytes has been shown to contribute to melanocyte/keratinocyte adhesion by 
binding to integrins (Hoashi et al., 2010, Maric et al., 2013), indicating it may be involved 
in melanin transfer (Tomihari et al., 2009, Zhang et al., 2013).  
Of particular note, GPNMB expressed on antigen presenting cells has been shown to 
serve as an inhibitor of T cell activation through binding to syndecan-4 on the surface of 
activated T cells (Tomihari et al., 2009). Therefore, it has been suggested that the 
GPNMB/syndecan-4 pathway is involved in the regulation of autoimmune responses 
(Kramer et al., 2016). The ability of GPNMB to modulate immune responses has also 
been documented in graft-versus-host disease, where GPNMB engaged with its 
respective T cell ligand suppressed the activity of T lymphocytes, diminished IL-2 
secretion, and T cell proliferation (Chung et al., 2007). Furthermore, expression of the 
GPNMB gene associated inversely with the metastatic capacity of human melanoma 




This would indicate that GPNMB may play a role in the spread of cancerous melanocytes. 
In this project, GPNMB was identified as a potential antibody target following rounds of 







The main objectives of this part of the project were: 
a) To develop a radioligand binding assay (RLBA) to confirm antibody reactivity 
against GPNMB. 
b) To investigate GPNMB antibody frequencies in 246 vitiligo patients and 100 
healthy controls using the RLBA. 
c) To determine if antibodies to GPNMB were related to any clinical, demographic 





 Experiments and Results 
 Development of an GPNMB RLBA  
In order to study the prevalence of antibodies against GPNMB in vitiligo patient sera, it 
was first necessary to have GPNMB cDNA in a suitable plasmid vector for expression of 
the GPNMB, which could then be used as the target antigen to test antibody binding in 
RLBAs. Plasmid pcDNA3.1 (Figure 5.1) was chosen as it contains a T7 polymerase 
promoter binding site from which cloned cDNA can be transcribed and translated in vitro 
with concomitant incorporation of radiolabelled [35S]-methionine. The [35S]-GPNMB 
produced in this way can then be used in RLBAs to detect GPNMB antibodies in vitiligo 
patient and healthy control serum samples. 
5.3.1.1 GPNMB cDNA clone confirmation 
The GPNMB cDNA cloned into the KpnI-HindIII sites of pcDNA3.1 was obtained from 
GeneScript (Piscataway, NJ, USA). As a check that the recombinant plasmid pcDNA3.1-
GPNMB was correct, the plasmid was subjected to DNA sequencing (Section 2.17) using 
primers T7, SP6, GPNMB-1-Forward, GPNMB-2-Forward, GPNMB-3-Forward, GPNMB-4-
Forward, and GPNMB-5-Forward (Table 2.5). The results verified that the cloned GPNMB 
cDNA was correct when searched against the GenBank database using the network 
facilities of the NCBI (Bethesda, MD, USA) (Figure 5.2). The amino acid sequence of 











Figure 5.1: A map of the pcDNA3.1 plasmid vector. 
The map shows restriction enzyme sites and the direction of T7 promoter in the pcDNA3.1 













Figure 5.2: The cDNA sequence encoding the GPNMB. 
The cDNA sequence matched that of GPNMB cDNA Accession Number BC032783 when searched 
against the GenBank database using the network facilities of the NCBI (Bethesda, MD, USA). The 
ATG translation start codon and the TAA translation termination codon are underlined and given 


















Figure 5.3: GPNMB amino acid sequence. 








5.3.1.2 In vitro transcription-translation of GPNMB cDNA  
Plasmid pcDNA3.1-GPNMB was transcribed and translated in a TnT® T7-Coupled 
Reticulocyte Lysate System, as described in Section 2.19. In order to analyse the 
radiolabelled product qualitatively, a 5-μl aliquot of the in vitro transcription-translation 
reaction was added to 20 μl of 2x Laemmli sample buffer (Section 2.20) and heated to 
100°C for 5 min. A 10-μl sample was then applied to a 10% (w/v) SDS-polyacrylamide gel 
and subjected to electrophoresis (Section 2.20). After drying, the gel was exposed to x-
ray film, which was developed after 24 h (Section 2.20).  
The result showed a protein product with an estimated molecular weight of 64 kDa 
(Figure 5.4). This agrees well with the molecular weight of 63 kDa calculated from the 
amino acid sequence of the protein with 572 residues (Figure 5.3). 
5.3.1.3 Analysis of the immunoreactivity of [35S]-GPNMB  
The immunoreactivity of in vitro translated [35S]-GPNMB was analysed in a RLBA (Section 
2.21) with an anti-GPNMB antibody and a panel of antibodies raised against proteins 
unrelated to GPNMB (Table 2.6). The antibodies used were sc271435 (anti-GPNMB), α-
PEP7 (anti-tyrosinase), MCHR11-S (anti-MCHR1), ab59276 (anti-TH)), and α-PEP8 (anti-
DCT). They were all used at a 1:100 dilution. An immunoprecipitation reaction without 
any antibodies was also included in each assay set, as a background control. From each 
RLBA, a GPNMB antibody index was calculated for each of the antibodies tested as: cpm 
immunoprecipitated by tested antibody/cpm immunoprecipitated by the background 
control. Each antibody was tested in four experiments and the mean GPNMB antibody 
index was calculated from these values. The GPNMB antibody indices of the different 
antibodies were compared using one-way ANOVA, with P values < 0.05 considered 
significant. 
The results are shown in Figure 5.5, and indicated that the mean GPNMB antibody index 
± SD for each antibody was 19.6 ± 3.44 for sc271435, 1.02 ± 0.15 for α-PEP7, 1.12 ± 0.13 
for MCHR11-S, 1.07 ± 0.11 for ab59276, and 1.01 ± 0.10 for α-PEP8. In one-way ANOVA, 
the GPNMB antibody index of GPNMB antibody sc271435 was statistically significantly 




P < 0.0001. The result demonstrated a specific immunoprecipitation of [35S]-GPNMB by 
anti-GPNMB antibody, and indicated that [35S]-GPNMB could be used as a ligand in a 
RLBAs to detect antibodies against GPNMB. 
The GPNMB immunoprecipitated in the RLBA by antibody sc271435 was also analysed 
quantitatively. Following the RLBA using [35S]-GPNMB and antibody sc271435, the 
protein G Sepharose-GPNMB-antigen complexes were suspended in 50 μl of Laemmli 
sample buffer, heated at 100°C for 5 min, centrifuged, and the supernatant analysed by 
SDS-PAGE in a 10% (w/v) SDS-polyacrylamide gel (Section 2.20). The gel was then 
subjected to autoradiography (Section 2.20). The results indicated that the antibody 
sc271435 immunoprecipitated a protein band equivalent in size (64 kDa) to that of in 












               
 
Figure 5.4: SDS-PAGE and autoradiography of [35S]-GPNMB. 
[35S]-GPNMB was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate System using 
plasmid pcDNA3.1-GPNMB as a template for transcription and translation of GPNMB cDNA. For 
analysis, the radiolabelled protein was run in a 10% (w/v) SDS-polyacrylamide gel and 
autoradiographed. The protein molecular weight markers on the gel are Prestained SDS-PAGE 










Figure 5.5: GPNMB RLBA using different antibodies.  
The immunoreactivity of in vitro translated [35S]-GPNMB was tested in a RLBA with antibodies 
anti-GPNMB (sc271435), anti-tyrosinase (α-PEP7), anti-MCHR1 (MCHR11-S), anti-TH (ab59276) 
and anti-DCT (α-PEP8). An immunoprecipitation reaction without serum was included as a 
background control. The mean GPNMB antibody index ± SD of four experiments is given for each 
antibody: sc271435, 19.6 ± 3.44; α-PEP7, 1.02 ± 0.15; MCHR11-S, 1.12 ± 0.13; ab59276, 1.07 ± 












Figure 5.6: SDS-PAGE and autoradiography of [35S]-GPNMB and [35S]-GPNMB 
immunoprecipitated by anti-GPNMB antibody sc271435 
[35S]-GPNMB was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate System using 
plasmid pcDNA3.1-GPNMB. Subsequently, radiolabelled GPNMB was immunoprecipitated in a 
RLBA with anti-GPNMB antibody sc271435. For analysis, immunoprecipitated proteins were run 
in a 10% (w/v) SDS-polyacrylamide gel and autoradiographed. The results show: In vitro 
translated, non-immunoprecitated [35S]-GPNMB (lane 1); [35S]-GPNMB immunoprecipitated 
with anti-GPNMB antibody sc271435 (lane 2). The protein molecular weight markers on the gel 
are Prestained SDS-PAGE Standards, Low Range (Bio-Rad Laboratories Ltd.). The GPNMB protein 









5.3.1.4 Analysis of the specificity of anti-GPNMB antibody 
In order to determine the anti-GPNMB antibody sc271435s specificity, sc271435s was 
used in RLBAs with other radiolabelled antigens and these included tyrosinase, MCHR1, 
TH and DCT. 
Radiolabelled [35S]-tyrosinase, [35S]-MCHR1, [35S]-TH, and [35S]-DCT were produced in a 
TnT® T7-Coupled Reticulocyte Lysate System (Section 2.19) from plasmids pcDNA3-TYR, 
pcMCHR1, pcDNA3-TH and pCMVDTS (Table 2.2), respectively. RLBAs were carried out 
as detailed in (Section 2.21), using these labelled antigens with antibody sc271435 at a 
1:100 dilution. Appropriate positive control antibodies were included at a 1:100 dilution 
in each RLBA: α-PEP7 for tyrosinase, MCHR11-S for MCHR1, ab59276 for TH, and α-PEP8 
for DCT (Table 2.6). An immunoprecipitation reaction without antibody was also 
included in each RLBA, as a background control. In each RLBA, an antibody index was 
calculated for each antibody as: cpm immunoprecipitated by tested antibody/cpm 
immunoprecipitated by the background control. Each antibody was tested in four 
experiments and the mean antibody index was calculated from these values. Antibody 
indices were compared using one-way ANOVA with P values < 0.05 considered 
significant. 
The mean antibody index ± SD for anti-GPNMB antibody in RLBAs against different 
antigens was 19.5 ± 4.14 against GPNMB, 0.99 ± 0.17 against tyrosinase, 1.09± 0.19 
against MCHR1, 1.12 ± 0.15 against TH, and 1.09 ± 0.11 against DCT (Figure 5.7). In one-
way ANOVA, the antibody index of the anti-GPNMB antibody in the different RLBAs was 
compared; P < 0.0001, indicating there was no significant immunoprecipitation of other 
unrelated proteins. Anti-GPNMB antibody sc271435 could be used therefore as a 
positive control antibody in GPNMB RLBAs. 
Additionally, the mean antibody index ± SD for the antibodies α-PEP7 (anti-tyrosinase), 
MCHR11-S (anti-MCHR1), ab59276 (anti-TH), and α-PEP8 (anti-DCT) in RLBAs against 
their cognate antigens was 12.5 ± 1.83, 10.1 ± 1.42, 16.2 ± 1.86 and 15.1 ± 1.36, 









Figure 5.7: RLBAs with anti-GPNMB antibody sc271435 and different antigens. 
The immunoreactivity of the anti-GPNMB antibody sc271435 was tested against in vitro 
translated [35S]-GPNMB, [35S]-tyrosinase, [35S]-MCHR1, [35S]-TH, and [35S]-DCT in RLBAs. 
Antibodies anti-tyrosinase (α-PEP7), anti-MCHR1 (MCHR11-S), anti-TH (ab59276), and anti-DCT 
(α-PEP8) were included in the relevant RLBA as positive controls for immunoprecipitation of 
their respective antigens. An immunoprecipitation reaction without any serum was included as 
a background control in each RLBA. The mean antibody index ± SD of four experiments is shown 
for the antibody sc271435 in RLBAs against the different antigens; 19.5 ± 4.14 against GPNMB, 
0.99 ± 0.17 against tyrosinase, 1.09 ± 0.19 against MCHR1, 1.12 ± 0.15 against TH, and 1.09 ± 
0.11 against DCT. P < 0.0001 (One-way ANOVA). The mean antibody index ± SD of four 
experiments is also shown for the antibodies anti-tyrosinase (α-PEP7), anti-MCHR1 (MCHR11-
S), anti-TH (ab59276), and anti-DCT (α-PEP8) in RLBAs against their cognate antigens; 12.5 ± 






 Use of the GPNMB RLBA to analysis vitiligo patients and control sera for 
GPNMB antibodies 
To analyse vitiligo patient and control sera for the presence of GPNMB antibodies, 
GPNMB RLBAs were carried out using [35S]-GPNMB as the radiolabelled antigen. The 
sera analysed were from patients with vitiligo (n = 246) and from healthy controls (n = 
100). All sera were assayed in duplicate at a final dilution of 1:100. The positive control 
anti-GPNMB antibody sc271435 was also included in each set of the RLBAs at a 1:100 
dilution. GPNMB antibody index that express antibody levels was assigned to each 
serum sample, and this was the mean GPNMB antibody index of three experiments at 
least. The GPNMB antibody index was determined for each serum tested as: cpm 
immunoprecipitated by tested serum/mean cpm immunoprecipitated by 100 healthy 
control sera. The upper limit of normal for the RLBA with GPNMB was determined using 
the mean GPNMB antibody index + 3SD of the population of 100 healthy controls. Serum 
samples with a GPNMB antibody index higher than the upper limit of normal were 
considered as positive for GPNMB antibodies.  
The results of the GPNMB RLBAs are given in Figure 5.8. The mean GPNMB antibody 
index ± SD for the control group (n = 100) was 1.03 ± 0.12 with a range of 0.71 to 1.31. 
The mean GPNMB antibody index ± SD for patients with non-segmental vitiligo (n = 231), 
segmental vitiligo (n = 4), and undetermined vitiligo (n = 11) was 2.46 ± 2.42 (range of 
0.56 to 11.09), 0.99 ± 0.04 (range of 0.96 to 1.05), and 1.04 ± 0.16 (range of 0.78 to 1.42), 
respectively. The upper limit of normal for the GPNMB RLBA was a GPNMB antibody 
index of 1.38. 
Healthy controls were all GPNMB antibody-negative with GPNMB antibody indices 
below 1.38. Of the 231 non-segmental vitiligo patients, 91 (39%) were considered 
GPNMB antibody-positive (Table 5.1), as their GPNMB antibody index was above the 
upper limit of normal value of 1.38. GPNMB antibodies were not detected in any patient 
with segmental vitiligo and only one patient with undetermined vitiligo sub-type was 
GPNMB antibody-positive (Table 5.1), as their GPNMB antibody index was above the 




The prevalence of GPNMB antibodies was compared between vitiligo patients and 
controls in Fisher's exact test for 2 x 2 contingency tables (Section 2.24). P values < 0.05 
were regarded as significant. The results are given in Table 5.1. In comparison with 
controls, a statistically significant increase in the prevalence of GPNMB antibodies was 
found in the patient group with non-segmental vitiligo; the P value was < 0.0001. In 
addition, there was a statistically significant increase in the frequency of GPNMB 
antibodies in patients with symmetrical or acrofacial vitiligo (Table 5.1). However, in 
most vitiligo sub-type groups, there were too few patients to make statistical analysis 
robust (Table 5.1). A statistically significant increase in GPNMB antibody frequency was 
also noted in the active vitiligo patient cohort in comparison to the stable disease patient 
group: P was 0.001 (Table 5.1). However, there was no difference in GPNMB antibody 
prevalence in patients with autoimmune diseases compared to those without (Table 
5.1). 
To analyse qualitatively, the proteins immunoprecipitated in the GPNMB RLBA by vitiligo 
patient and control sera, protein G Sepharose-GPNMB-antigen complexes were 
suspended in 50 μl of Laemmli sample buffer, heated at 100°C for 5 min, centrifuged 
and the supernatant recovered for SDS-PAGE in 10% (w/v) SDS-polyacrylamide gels and 
subsequent autoradiography (Section 2.20). 
The results indicated that all 92 of the GPNMB antibody-positive vitiligo patient sera 
analysed immunoprecipitated a protein band of 64 kDa, comparable to the size of 
GPNMB in SDS-polyacrylamide gels. The results for six GPNMB antibody-positive vitiligo 












Figure 5.8: GPNMB RLBA results for vitiligo patient and healthy control sera. 
Vitiligo patient and healthy control sera were evaluated for GPNMB antibodies in the GPNMB 
RLBA. The GPNMB antibody indices are shown for sera from vitiligo patients (n = 246) and 
healthy controls (n = 100). The GPNMB antibody index shown for each serum is the mean of 
three experiments. The mean GPNMB antibody index ± SD for the control group was 1.03 ± 0.12 
with a range of 0.71 to 1.31. The mean GPNMB antibody index ± SD for patients with non-
segmental vitiligo (n = 231), segmental vitiligo (n = 4), and undetermined vitiligo (n = 11) was 
2.46 ± 2.42 (range of 0.56 to 11.09), 0.99 ± 0.04 (range of 0.96 to 1.05), and 1.04 ± 0.16 (range 
of 0.78 to 1.42), respectively.  The upper limit of normal (mean GPNMB antibody index + 3SD of 
100 healthy controls) for the GPNMB RLBA was a GPNMB antibody index of 1.38, and this is 





Table 5.1: GPNMB antibody prevalence in vitiligo patients and healthy controls 
 
 





P value1 P value2 
Vitiligo patient or control group  
Non-segmental vitiligo 91/231 (39%) < 0.0001 - 
Segmental vitiligo 0/4 (0%) ND - 
Undetermined vitiligo (all focal) 1/11 (9%) ND - 
Healthy controls 0/100 (0%) ND - 
Non-segmental vitiligo sub-type  
Symmetrical (generalised) 82/157 (52%) < 0.0001 - 
Acrofacial 7/42 (17%) 0.0001 - 
Acral 0/4 (0%) ND - 
Peri-orificial 0/3 (0%) ND - 
Universal 0/1 (0%) ND - 
Symmetrical and peri-orificial 1/10 (10%) ND - 
Symmetrical and acrofacial 1/7 (14.3%) ND - 
Symmetrical with peri-orificial and 
acrofacial 
0/1 (0%) ND - 
Occupational  0/1 (%) ND - 
Mixed  0/5 (0%) ND - 
Vitiligo activity   
Active 91/226 (40%) < 0.0001 
0.001 
Stable 1/20 (5%) 0.17 
Autoimmune disease 
Present 37/84 (44%) < 0.0001 
0.13 
Absent 55/162 (34%) < 0.0001 
 
1P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.24) for 
comparing the prevalence of GPNMB antibodies in vitiligo patients and controls. P < 0.05 was 
considered statistically significant. 
2P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.24) for 
comparing the prevalence of GPNMB antibodies in vitiligo patient groups. P < 0.05 was 
considered statistically significant. 











Figure 5.9: SDS-PAGE and autoradiography of [35S]-GPNMB following 
immunoprecipitation in GPNMB RLBAs with vitiligo patient and healthy control sera. 
Radiolabelled GPNMB was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate System 
and then immunoprecipitated in GPNMB RLBAs with either vitiligo or healthy control sera. For 
analysis, immunoprecipitated proteins were run in a 10% (w/v) SDS-polyacrylamide gel and 
autoradiographed. The results are shown for six vitiligo patient and two healthy control sera: 
[35S]-GPNMB immunoprecipitated with sera from GPNMB antibody-positive vitiligo patients 












 Determination of GPNMB antibody titres in vitiligo patients  
To determine the titres of GPNMB antibodies, sera from all GPNMB antibody-positive 
vitiligo patients (n = 92) and healthy controls (n = 10) were analysed in the GPNMB 
antibody RLBA at different dilutions including 1:100, 1:200, 1:500, 1:1000, 1:2000, 
1:5000 and 1:10000. For each serum sample tested, a GPNMB antibody index (cpm 
immunoprecipitated by tested serum at each dilution/the cpm immunoprecipitated by 
10 healthy control sera at each dilution) was calculated and this was the mean GPNMB 
antibody index of three experiments.  
The results of the antibody titration experiments are given in Figure 5.10. The titration 
results are also summarised in Table 5.2, and show the serum dilution at which GPNMB 
antibodies were still detectable at levels above the upper limit of normal for the GPNMB 
antibody RLBA. Although the titres of GPNMB antibodies varied between the different 
vitiligo patients, the majority, 72/92 (78%), had a titre at 1:1000 or above, and 28/92 














Figure 5.10: GPNMB antibody titres.  
The 92 GPNMB antibody-positive vitiligo patient sera were analysed in the GPNMB antibody 
RLBA at a range of dilutions (1:100, 1:200, 1:500, 1:1000, 1:2000, and 1:5000). The GPNMB 
antibody index (mean ± SD of three exepriments) of each serum at each dilution is given. (a) The 
results are shown for 12 vitiligo patients. (b) The results are shown for 12 vitiligo patients. (c) 
The results are shown for 12 vitiligo patients. (d) The results are shown for 12 vitiligo patients. 
(e) The results are shown for 12 vitiligo patients. (f) The results are shown for 12 vitiligo patients. 
























1The titre of GPNMB antibody is shown as the dilution at which antibody reactivity in the sample 






V130, V166, V22-8, V123, V41, V120, V232 1:200 
V167, V43, V239, V148, V36, V228, V76, V93, 
V29, V107, V78, V183 
1:500 
V3, V68, V66, V195, V1, V63, V213, V140, 
V71, V154, V12-3, V206, V134, V39, V82 
1:1000 
V133, V90, V40, V32, V89, V75, V4, V235, V9, 
V216-18, V199, V244, V135, V60, V226, V188, 
V204, V74, V30, V198, V58, V108, V85, V115, 
V111, V45-21, V101, V96, V44 
1:2000 
V225, V87, V113, V212, V26, V201, V13-4, 
V172, V42, V112, V55, V31, V20-6, V234-20, 
V245, V238 
1:5000 
V182, V50, V227, V25, V57, V33 >1:5000 






 Assessment of the specificity of GPNMB antibodies  
In order to determine that GPNMB antibodies in vitiligo patient sera reacted specifically 
against the protein GPNMB, absorption experiments were performed as detailed in 
Section 2.22. Briefly, serum samples from GPNMB antibody-positive vitiligo patients (n 
= 92) and healthy individuals (n = 10) were absorbed with extracts prepared from 
untransfected HEK293 cells or from HEK293 cells transfected with GPNMB, MCHR1 or 
tyrosinase. Subsequently, duplicate samples of pre-absorbed sera at a 1:100 dilution 
(equivalent to the original sera dilution) were evaluated in the GPNMB RLBA. For each 
serum sample, a GPNMB antibody index (cpm immunoprecipitated by tested serum/the 
cpm immunoprecipitated by 10 healthy control sera) was calculated. Serum samples 
were all tested in triplicate. To compare the GPNMB antibody index of absorbed against 
unabsorbed vitiligo patient sera, one-way ANOVA was used (Section 2.24). P values < 
0.05 were considered as significant in all tests. 
The absorption experiment results are given in Figure 5.11. There was a significant 
reduction in the GPNMB antibody indices by pre-absorption of GPNMB antibody-
positive vitiligo patient sera with the GPNMB protein expressed in the extracts prepared 
from HEK293 cells: all P values were < 0.05. In contrast, GPNMB antibody indices were 
not significantly decreased after pre-absorption of GPNMB antibody-positive vitiligo 
patient sera with extracts made from untransfected HEK293 cells or HEK293 cells 
harbouring expressed MCHR1 or tyrosinase: P values were > 0.05.  
Overall, these findings indicated that GPNMB antibodies in all GPNMB antibody-positive 
patient sera specifically recognised their target autoantigen without cross-reactivity 


















Figure 5.11: GPNMB antibody absorption experiments.  
The 92 GPNMB antibody-positive vitiligo patient sera were preabsorbed with extract prepared 
from either untransfected HEK293 cells or from HEK293 cells expressing glycoprotein non-
metastatic melanoma protein b (GPNMB), tyrosinase or melanin-concentrating hormone 
receptor 1 (MCHR1). Unabsorbed and preabsorbed sera were subsequently analysed in the 
GPNMB RLBA. The results demonstrate the mean GPNMB antibody index (± SD) of three 
experiments for unabsorbed and preabsorbed sera. The results are given for the 92 vitiligo 
patients. Comparing the antibody indices of GPNMB-absorbed sera with those without 






 Analysis of vitiligo patient sera for other vitiligo-associated antibodies 
To determine if antibodies to GPNMB are related to the presence of any antibodies 
directed against other vitiligo-associated autoantigens, RLBAs for tyrosinase, DCT, 
TYRP1, PMEL, TH, and MCHR1 antibodies (Kemp et al., 1997a, Kemp et al., 1997b, Kemp 
et al., 1998a, Kemp et al., 1998b, Kemp et al., 2002b, Kemp et al., 2011) were performed 
on all the 246 vitiligo patient sera.  
In order to produce radiolabelled ligands for use in RLBAs, transcription and translation 
of plasmids carrying the relevant cDNA (Table 2.2), were carried out using a TnT® T7-
Coupled Reticulocyte Lysate System as described in Section 2.19. Sera from either 
patients (n = 246) or healthy controls (n = 100) were tested for the presence of 
antibodies to the radiolabelled antigens in RLBAs (Section 2.21). Serum samples were all 
tested in duplicate at 1:100 dilutions. As a positive control, each assay set included an 
appropriate antigen-specific antibody (Table 2.6). In each assay set, antibody levels were 
expressed as an antibody index (Section 5.3.2). 
The results of the RLBAs are given in Table 5.3. All healthy controls were negative for all 
the antibodies tested. Of the 231 of the non-segmental vitiligo patient sera, 42 (18%), 
51 (22%), 35 (15%), 44 (19%), 43 (19%), and 53 (23%) were regarded as tyrosinase, 
MCHR1, PMEL, TYRP1, DCT, and TH antibody-positive, respectively, since their antibody 
indices were above the upper limit of normal for the specific antibody RLBA (Table 5.3). 
In the group of four segmental vitiligo patients, 1 (25%), 0 (0%), 1 (25%), 0 (0%), 0 (0%) 
and 2 (50%) were regarded as tyrosinase, MCHR1, PMEL, TYRP1, DCT, and TH antibody-
positive, respectively, as they had antibody indices above the upper limit of normal for 
the specific antibody RLBA (Table 5.3). In the group of 11 undetermined vitiligo patients, 
1 (9%), 0 (0%), 0 (0%), 0 (0%), 0 (0%) and 2 (18%) were regarded as tyrosinase, MCHR1, 





Table 5.3: Results of RLBAs for antibodies in vitiligo patients  
 
 
1Patient sera with an antibody index greater than the upper limit of normal (mean antibody 
index + 3SD of 100 healthy controls), were regarded as positive for antibodies. The upper limits 
of normal were: 1.72, 1.49, 1.29, 1.57, 1.36, and 1.24 for the tyrosinase, MCHR1, PMEL, TYRP1, 
DCT, and TH antibody RLBAs, respectively. 
 
 













(n = 11) 
Healthy 
controls 
(n = 100) Antibody RLBA 
↓ 
Tyrosinase  
Tyrosinase antibody index: 
mean ± SD 
1.61 ± 1.60 
(0.61-9.76) 
1.25 ± 0.52 
(0.96-2.03) 
1.06 ± 0.30 
(0.67-1.85) 
0.92 ± 0.27 
(0.23-1.40) 
Number positive for 
tyrosinase antibodies1 
42 (18%) 1 (25%) 1 (9%) 0 (0%) 
MCHR1  
MCHR1 antibody index: 
mean ± SD  
1.96 ± 2.21 
(0.12-11.2) 
0.94 ± 0.08 
(0.84-1.01) 
0.91 ± 0.16 
(0.67-1.11) 
1.02 ± 0.15 
(0.64-1.37) 
Number positive for MCHR1 
antibodies1 
51 (22%) 0 (0%) 0 (0%) 0 (0%) 
PMEL 
PMEL antibody index: mean 
± SD  
1.33 ± 1.41 
(0.01-11.36) 
0.83 ± 0.76 
(0.07-1.88) 
0.90 ± 0.14 
(0.76-1.2) 
0.99 ± 0.10 
(0.79-1.25) 
Number positive for PMEL 
antibodies1 
35 (15%) 1 (25%) 0 (0%) 0 (0%) 
TYRP1 
TYRP1 antibody index: mean 
± SD  
1.43 ± 1.28 
(0.44-10.52) 
1.07 ± 0.06 
(0.98-1.11) 
1.01 ± 0.09 
(0.81-1.12) 
1.00 ± 0.19 
(0.51-1.50) 
Number positive for TYRP1 
antibodies1 
44 (19%) 0 (0%) 0 (0%) 0 (0%) 
DCT 
DCT antibody index: mean ± 
SD  
1.39 ± 1.34 
(0.2-11.72) 
1.02 ± 0.04 
(0.97-1.05) 
0.98 ± 0.10 
(0.78-1.12) 
0.99 ± 0.12 
(0.44-1.40) 
Number positive for DCT 
antibodies1 
43 (19%) 0 (0%) 0 (0%) 0 (0%) 
TH 
TH antibody index: mean ± 
SD 
1.58 ± 1.63 
(0.26-10.77) 
2.51 ± 2.86 
(0.76-6.78) 
1.69 ± 2.33 
(0.65-8.65) 
1.01 ± 0.08 
(0.87-1.29) 
Number positive for TH 
antibodies1 




 Comparison of the demographic, clinical and serological details of the GPNMB 
antibody-positive and GPNMB antibody-negative non-segmental vitiligo 
patients  
In order to compare the details of the demographic, clinical and serological features of 
the GPNMB antibody-positive (n = 91) and antibody-negative (n = 140) non-segmental 
vitiligo patient groups, Fisher’s exact tests for 2 x 2 contingency tables or unpaired t tests 
were used as appropriate (Section 2.24). P values < 0.05 were considered as significant. 
The results are shown in Table 5.4. A statistically significant difference was not evident 
between the two cohorts in terms of sex, patient age, duration of disease, vitiligo onset 
age, the occurrence of other autoimmune disorders or the prevalence of tyrosinase, 
PMEL, TYRP1, DCT, and TH antibodies; P values were all > 0.05, indicating that GPNMB 
antibodies were not associated with any of these analysed parameters. 
A significantly increased incidence of patients with the symmetrical vitiligo sub-type was 
obvious in the group of GPNMB antibody-positive patients: P value was < 0.0001, 
whereas an elevated prevalence of patients with the acrofacial sub-type was 
demonstrated in the cohort of GPNMB antibody-negative patients: P value was 0.001. 
In addition, there was an increased prevalence of patients who had active disease in the 
cohort of GPNMB antibody-positive patients; P value was 0.006. Also, a statistically 
significant difference was observed in the patient group who were positive for GPNMB 
antibodies compared to patients in the GPNMB antibody-negative cohort in terms of the 




Table 5.4: Comparison of the demographic, clinical, and serological details in non-












(n = 140) 
P value 
Demographic details 
Male 40 (44%) 57 (41%) 
0.681 
Female 51 (56%) 83 (59%) 
Mean age ± SD (years) 46 ± 17 (13 - 77) 45 ± 18 (0 - 88) 0.882 
Mean onset age ± SD (years) 32 ± 18 (0 - 73) 30 ± 17 (0 - 83) 0.332 
Mean disease duration ± SD 
(years) 
13 ± 13 (0.5 - 51) 15 ± 14 (0 - 71) 0.292 
Non-segmental vitiligo sub-type 
Symmetrical  82 (90%) 75 (54%) < 0.00011 
Acrofacial 7 (8%) 35 (25%) 0.0011 
Vitiligo activity 
Active vitiligo 90 (99%)  126 (90%) 
0.0061 
Stable vitiligo 1 (1%) 14 (10%) 
Autoimmune disease 
Present 36 (40%) 45 (32%) 
0.261 
Absent 55 (60%) 95 (68%) 
Serology tests 
Tyrosinase antibody-positive 19 (21%) 23 (16%) 0.391 
MCHR1 antibody-positive 27 (30%) 24 (17%) 0.031 
PMEL antibody-positive 12 (13%) 23 (16%) 0.581 
TYRP1 antibody-positive 21 (23%) 23 (16%) 0.231 
DCT antibody-positive 19 (21%) 24 (17%) 0.491 
TH antibody-positive 25 (27%) 28 (20%) 0.201 
 
1P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.24) for 
comparing the prevalence of demographic, clinical, and serological details in the GPNMB 
antibody-positive and the GPNMB antibody-negative non-segmental vitiligo patient groups. P 
values < 0.05 were considered significant. 
2P value calculated using unpaired t tests (Section 2.24) for comparing the age, onset age, and 
disease duration in the GPNMB antibody-positive and GPNMB antibody-negative non-segmental 






 Discussion  
Expression of GPNMB in the epidermis, particularly within melanocyte, has been well-
documented (Loftus et al., 2009, Hoashi et al., 2010, Zhang et al., 2012, Maric et al., 
2013). It preferentially localises to mature (stage III and IV) melanosomes, which are 
characterised by the build-up of the melanin pigment, signifying a critical role for 
GPNMB in melanosome maturation (Tomihari et al., 2009, Hoashi et al., 2010, Maric et 
al., 2013). GPNMB has been confirmed to mediate melanocyte adhesion to 
keratinocytes, indicating its involvement in the transport of mature melanosome to 
keratinocytes (Tomihari et al., 2009, Hoashi et al., 2010, Maric et al., 2013). As other 
pigmentation proteins such as tyrosinase, TYRP1, DCT, and PMEL, the expression of 
GPNMB is regulated by the MITF, a major transcriptional factor involved in cell growth, 
differentiation, and survival of melanocytes (Loftus et al., 2009, Hoashi et al., 2010). 
In this study, GPNMB was identified as a novel target of antibody responses in patients 
suffering from vitiligo by using phage-display technology (Chapter 4). In this chapter, a 
RLBA was employed to study the prevalence of immunoreactivity to GPNMB in a series 
of vitiligo patients, and also to find out if there were any associations of GPNMB 
antibodies with the demographic (e.g., age, gender), clinical features (e.g., vitiligo 
activity, autoimmune disease) or serological details of vitiligo patients. 
 Frequency of GPNMB antibodies 
Firstly, a RLBA was developed which could be utilised to detect and measure GPNMB 
antibodies in human sera. After confirming the specificity of the GPNMB RLBA, it was 
used to analyse 246 vitiligo patient sera for GPNMB antibodies. Of 246 vitiligo patient 
sera analysed by RLBAs, GPNMB antibodies were detected in 37%, while healthy control 
sera demonstrated no antibody reactivity, suggesting a high disease-related specificity. 
The frequency of GPNMB antibodies was relatively high compared to antibody 
frequencies reported for other pigmentation-related proteins, including tyrosinase 
(11%) (Kemp et al., 1997a), TYRP1 (6%) (Kemp et al., 1998b), DCT (6%) (Kemp et al., 
1997b), MCHR1 (16%) (Kemp et al., 2002b), PMEL (6%) (Kemp et al., 1998a),  GTP-




This finding suggests that GPNMB might be a useful serum marker for vitiligo diagnosis 
and evaluation. 
 GPNMB antibody titres and specificity 
In the current work, titration experiments were also performed in order to measure 
GPNMB antibody titres in the 92 patient sera designated as positive for GPNMB 
antibodies. The majority (72/92 = 78%) had GPNMB antibodies at a titre of 1:1000 or 
above. In contrast, previous studies showed much lower titres of antibodies against 
other melanogenic proteins. For example, TH, PMEL, TYRP1 and MCHR1 antibody titres 
ranged from 1:50 to 1:200 (Kemp et al., 1998a, Kemp et al., 1998b, Kemp et al., 2002b, 
Kemp et al., 2011).  
Also, in order to ensure that GPNMB antibody reactivity was specific to the GPNMB, 
absorption experiments were carried out. The absorption experiments showed that all 
the 92 GPNMB antibody-positive patient sera contained GPNMB antibodies that reacted 
specifically with their target autoantigens without cross-reactivity with other vitiligo-
associated autoantigens MCHR1 and tyrosinase, indicating high specificity of GPNMB 
antibodies. Of note, GPNMB exhibits a high amino acid sequence homology with the 
melanosomal structural protein PMEL (Hoashi et al., 2010, Zhang et al., 2013). 
Therefore, GPNMB epitopes may share sequence homology with the antibody binding 
sites on PMEL(Kemp et al., 2001a), although this was not analysed in the current project. 
 Prevalence of GPNMB antibodies in vitiligo sub-types 
Autoimmunity has been strongly proposed to play a potential role in the aetiology of 
non-segmental vitiligo, since this type of vitiligo is frequently correlated with 
autoimmune diseases (Taieb, 2000, Alkhateeb et al., 2003), responds poorly to 
autologous melanocyte grafting (Taieb, 2000), and is well-responsive to 
immunosuppressive therapies (Lepe et al., 2003). Non-autoimmune aetiological 
mechanisms have been suggested to cause segmental vitiligo (Taieb, 2000, Allam and 
Riad, 2013). In keeping with this, GPNMB antibody reactivity was identified in non-




four segmental vitiligo patient samples were available for analysis, a definite conclusion 
cannot be achieved regarding the frequency of GPNMB antibody reactivity in this form 
of vitiligo. 
 Associations of GPNMB antibodies 
Importantly, a comparison of GPNMB antibody-positive and GPNMB antibody-negative 
non-segmental vitiligo patients demonstrated that GPNMB was an antibody target in 
those with and those without concomitant autoimmune disease. This finding is 
consistent with previous studies in which TH antibodies were detected in patients with 
or without accompanying autoimmune disorder (Kemp et al., 2011). However, 
contradictory results have been reported in other studies, in which antibodies to 
melanin-related proteins (TYRP1, DCT and PMEL) were only identified in vitiligo patients 
with other autoimmune diseases (Kemp et al., 1997b, Kemp et al., 1998a, Kemp et al., 
1998b). In addition, Kemp et al. (1997a) and Hedstrand et al. (2001) reported a 
predominant prevalence of tyrosinase and SOX10 antibody reactivity in vitiligo cases 
with additional autoimmune disorders. 
Additionally, when comparing GPNMB antibody-positive and GPNMB antibody-negative 
non-segmental vitiligo patients, the frequency of GPNMB antibodies was not 
significantly correlated with either patient gender, patient age at sampling time, disease 
onset age, disease duration or the occurrence of antibodies against either tyrosinase, 
PMEL, TYRP1, DCT or TH. Such results have also been reported for TH antibodies in 
vitiligo (Kemp et al., 2011).  
In contrast, the findings revealed that the prevalence of GPNMB antibodies was 
significantly increased in the non-segmental vitiligo patient group with active disease. 
However, only 20 cases with stable vitiligo were available for testing, thus further 
verification of this finding is required. These results are consistent with a previous study 
of TH antibodies which were associated with active non-segmental vitiligo (Kemp et al., 
2011). Serological analysis revealed association of MCHR1 antibodies with the presence 
of GPNMB antibodies. Immune reactivity against the receptor had not previously been 




 Development of GPNMB antibodies and potential pathogenicity 
The stimulus for the production of GPNMB antibodies might arise from a genetic 
predisposition to autoimmunity or they may represent a secondary phenomenon 
emerging as a result of damage to pigment cells by other causal factors, albeit they might 
then act to further aggravate vitiligo. However, perhaps, GPNMB antibodies play no part 
in the pathogenesis of vitiligo, but might indicate the existence of autoreactive anti-
GPNMB T lymphocytes that are capable of destroying melanocytes, a scenario that 
merits further investigation. 
Antibody reactivity in patients with vitiligo is most often directed against antigens 
expressed on melanocyte surface (Kemp et al., 2002b). GPNMB primarily localises 
intracellularly mostly within melanosomes, although it can also be expressed on the 
surface of melanocytes (Tomihari et al., 2009) making the protein accessible as a target 
for antibodies that might adversely affect the protein function. Vitiligo-associated 
antibodies can also destroy melanocytes in vitro and in vivo following the injection of 
patient IgG into nude mice grafted with human skin (Gilhar et al., 1995, Essien and 
Harris, 2014). Similarly, in order to ascertain the potential pathogenicity of GPNMB 
antibodies, studies on isolated GPNMB-specific antibodies could be carried out. 
Since GPNMB expression is unrestricted to pigment cells and the protein is detected, for 
instance, in dendritic cells, macrophages and keratinocytes (Tomihari et al., 2009, 
Hoashi et al., 2010, Kramer et al., 2016), any selective destruction of melanocytes in 
vitiligo might occur as the result of the fact that pigment cells are relatively susceptible 
to immune injury, as opposed to, for instance, fibroblasts and keratinocytes (Norris et 
al., 1988). 
 Conclusions 
To conclude, GPNMB has been found as a novel antibody target in vitiligo, and this 
further supports the involvement of autoimmunity in vitiligo aetiology. To the best of 
our knowledge, this finding has not previously been reported. Our finding of significantly 
increased frequency of GPNMB antibodies in patients with actively progressing vitiligo 




























6 Analysis of antibody reactivity against OCA2-encoded P protein in 
vitiligo patients 
 Introduction  
Human skin colour is primarily determined by melanin, the pigment that is formed from 
the amino acid precursor L-tyrosine in the intracellular lysosome-like organelles; 
melanosomes, which are contained in melanocytes (Andrade et al., 2017). In addition to 
the numerous enzymatic proteins, the melanogenic process also requires other 
membrane-bound proteins such as OCA2-encoded P protein (OCA2 protein) (Yamaguchi 
et al., 2007, Andrade et al., 2017). The OCA2 protein is encoded by the OCA2 gene and 
is expressed exclusively in melanocytes as an integral constituent of the melanosome 
membrane (Rimoldi et al., 2014). However, the specific function of OCA2 protein is not 
fully clear. A previous study showed that in OCA2 protein mutant melanocytes, 
tyrosinase was properly glycosylated and functionally active but most of the enzyme was 
never delivered to melanosomes, hence causing disruption in melanin synthesis (Kondo 
et al., 2015). Therefore, the OCA2 protein was hypothesised to be involved in tyrosinase 
trafficking to melanosomes (Kondo et al., 2015). In addition, several studies have 
suggested that the OCA2 protein may be involved in the regulation of pH within 
melanosomes (Puri et al., 2000, Kondo et al., 2015, Andrade et al., 2017), since an 
appropriate gradient of pH is necessary for protein trafficking to their destined 
organelles (Mindell, 2012, Ishida et al., 2013, Kondo et al., 2015). 
In addition to causing disruption in tyrosinase transport to melanosomes, mutations in 
the OCA2 gene are also associated with genetic predisposition to melanoma, type II 
oculocutaneous albinism in humans, and pink-eye dilution in mice (Oetting et al., 2005, 
Ibarrola-Villava et al., 2010, Wang et al., 2015, Andrade et al., 2017). Furthermore, non-
pathological polymorphisms in this gene are associated with normal pigmentation 
variation in different populations, and thus the gene has been considered as a major 
determinant of skin colour (Frudakis et al., 2007, Yuasa et al., 2011, Andrade et al., 
2017). Normal polymorphisms of OCA2 also influence hair and eye colour (Cook et al., 




al., 2012a), and single nucleotide polymorphic alleles of OCA2 that are of low-risk for 
vitiligo are strongly correlated with a high risk of malignant melanoma (Jannot et al., 
2005, Amos et al., 2011, Jin et al., 2012a). In this respect, OCA2 is analogous to the TYR 
gene (Jin et al., 2012a). Both genes also encode melanocyte-specific proteins that can 
be presented to the immune system by HLA-A*02 (Jin et al., 2012a). 
In this project, the OCA2 protein was identified as a potential antibody target following 
rounds of panning against a melanocyte cDNA phage-display library with vitiligo patient 







The main objectives of this part of the project were: 
a) To develop a RLBA to confirm antibody reactivity against OCA2 protein. 
b) To investigate OCA2 protein antibody frequencies in 246 vitiligo patients and 100 
healthy controls using the RLBA. 
c) To determine if antibodies to OCA2 protein were related to any clinical, 







 Experiments and Results 
 Development of an OCA2 protein RLBA  
In order to study the prevalence of antibodies against OCA2 protein in vitiligo patient 
sera, it was first necessary to have OCA2 protein cDNA in a suitable plasmid vector for 
expression of the OCA2 protein, which could then be used as the target antigen to test 
antibody binding in RLBAs. Plasmid pcDNA3.1 (Figure 6.1) was chosen as it contains a T7 
polymerase promoter binding site from which cloned cDNA can be transcribed and 
translated in vitro with the concomitant incorporation of radiolabelled [35S]-methionine. 
The [35S]-OCA2 protein produced in this way can then be used in RLBAs to detect OCA2 
protein antibodies in vitiligo patient and healthy control serum samples. 
6.3.1.1 OCA2 protein cDNA clone confirmation 
The OCA2 protein cDNA cloned into the KpnI-HindIII restriction enzyme sites of 
pcDNA3.1 was obtained from GeneScript (Piscataway, NJ, USA). As a check that the 
recombinant plasmid pcDNA3.1-OCA2 was correct, the plasmid was subjected to DNA 
sequencing (Section 2.17) using primers T7, SP6, OCA2-1-Forward, OCA2-2-Forward, 
OCA2-3-Forward, OCA2-4-Forward, and OCA2-5-Forward (Table 2.5). The results 
verified that the cloned OCA2 cDNA was correct when searched against the GenBank 
database using the network facilities of the NCBI (Bethesda, MD, USA) (Figure 6.2). The 











Figure 6.1: A map of the pcDNA3.1 plasmid vector. 
The map shows restriction enzyme sites and the direction of the T7 promoter in the pcDNA3.1 
plasmid vector. The 2.5-kb OCA2 protein cDNA was cloned between the KpnI and HindIII 







         
       
 
 
Figure 6.2: The cDNA sequence encoding the OCA2 protein. 
The cDNA sequence matched that of the OCA2 protein cDNA Accession Number NM_000275 
when searched against the GenBank database using the network facilities of NCBI (Bethesda, 
MD, USA). The ATG translation start codon and the TAA translation termination codon are 














Figure 6.3: The OCA2 protein amino acid sequence. 





6.3.1.2 In vitro transcription-translation of OCA2 protein cDNA  
Plasmid pcDNA3.1-OCA2 was transcribed and translated in a TnT® T7-Coupled 
Reticulocyte Lysate System, as described in Section 2.19. In order to analyse the 
radiolabelled product qualitatively, a 5-μl aliquot of the in vitro transcription-translation 
reaction was added to 20 μl of 2x Laemmli sample buffer (Section 2.20) and heated to 
100°C for 5 min. A 10-μl sample was then applied to a 10% (w/v) SDS-polyacrylamide gel 
and subjected to electrophoresis (Section 2.20). After drying, the gel was exposed to x-
ray film, which was developed after 24 h (Section 2.20). 
The result showed a protein product with an estimated molecular weight of 88 kDa 
(Figure 6.4). This agrees well with the molecular weight of 89 kDa calculated from the 
amino acid sequence of the protein with 815 residues (Figure 6.3). 
6.3.1.3 Analysis of the immunoreactivity of [35S]-OCA2 protein  
The immunoreactivity of the in vitro translated [35S]-OCA2 protein was analysed in a 
RLBA (Section 2.21) with an anti-OCA2 protein antibody and a panel of antibodies raised 
against proteins unrelated to the OCA2 protein (Table 2.6). The antibodies used were 
PA5-23708 (anti-OCA2 protein), α-PEP7 (anti-tyrosinase), MCHR11-S (anti-MCHR1), 
ab59276 (anti-TH), and α-PEP8 (anti-DCT). They were all used at a 1:100 dilution. An 
immunoprecipitation reaction without any antibodies was also included in each assay 
set, as a background control. From each RLBA, an OCA2 protein antibody index was 
calculated for each of the antibodies tested as: cpm immunoprecipitated by tested 
antibody/cpm immunoprecipitated by the background control. Each antibody was 
tested in four experiments and the mean OCA2 protein antibody index was calculated 
from these values. The OCA2 protein antibody indices of the different antibodies were 
compared using one-way ANOVA, with P values < 0.05 considered significant. 
The results are shown in Figure 6.5, and indicated that the mean OCA2 protein antibody 
index ± SD for each antibody was 28.1 ± 4.98 for PA5-23708, 1.12 ± 0.12 for α-PEP7, 1.09 
± 0.11 for MCHR11-S, 1.15 ± 0.09 for ab59276, and 1.06 ± 0.08 for α-PEP8. In one-way 
ANOVA, the OCA2 protein antibody index of the OCA2 protein antibody PA5-23708 was 




and α-PEP8; P < 0.0001. The result demonstrated a specific immunoprecipitation of [35S]-
OCA2 protein by anti-OCA2 protein antibody, and indicated that [35S]-OCA2 protein 
could be used as a ligand in a RLBAs to detect antibodies against OCA2 protein. 
The OCA2 protein immunoprecipitated in the RLBA by antibody PA5-23708 was also 
analysed quantitatively. Following the RLBA using [35S]-OCA2 protein and antibody PA5-
23708, the protein G Sepharose-OCA2 protein-antigen complexes were suspended in 50 
μl of Laemmli sample buffer, heated at 100°C for 5 min, centrifuged, and the 
supernatant analysed by SDS-PAGE in a 10% (w/v) SDS-polyacrylamide gel (Section 2.20). 
The gel was then subjected to autoradiography (Section 2.20). The results indicated that 
the antibody PA5-23708 immunoprecipitated a protein band of 88 kDa, equivalent in 













Figure 6.4: SDS-PAGE and autoradiography of [35S]-OCA2 protein. 
[35S]-OCA2 protein was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate System using 
plasmid pcDNA3.1-OCA2 as a template for transcription and translation of OCA2 cDNA. For 
analysis, the radiolabelled protein was run in a 10% (w/v) SDS-polyacrylamide gel and 
autoradiographed. The protein molecular weight markers on the gel are Prestained SDS-PAGE 



















Figure 6.5: OCA2 protein RLBA using different antibodies.  
The immunoreactivity of in vitro translated [35S]-OCA2 protein was tested in a RLBA with 
antibodies anti-OCA2 protein (PA5-23708), anti-tyrosinase (α-PEP7), anti-MCHR1 (MCHR11-S), 
anti-TH (ab59276) and anti-DCT (α-PEP8). An immunoprecipitation reaction without serum was 
included as a background control. The mean OCA2 protein antibody index ± SD of four 
experiments is given for each antibody: PA5-23708, 28.1 ± 4.98; α-PEP7, 1.12 ± 0.12; MCHR11-












Figure 6.6: SDS-PAGE and autoradiography of [35S]-OCA2 protein and [35S]-OCA2 
protein immunoprecipitated by anti-OCA2 protein antibody PA5-23708. 
[35S]-OCA2 protein was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate System using 
plasmid pcDNA3.1-OCA2. Subsequently, radiolabelled OCA2 protein was immunoprecipitated in 
a RLBA with anti-OCA2 protein antibody PA5-23708. For analysis, Iimmunoprecipitated proteins 
were run in a 10% (w/v) SDS-polyacrylamide gel and autoradiographed. The results are shown 
for: In vitro translated, non-immunoprecitated [35S]-OCA2 protein (lane 1); [35S]-OCA2 protein 
immunoprecipitated with anti-OCA2 protein antibody PA5-23708 (lane 2). The protein 
molecular weight markers on the gel are Prestained SDS-PAGE Standards, Low Range (Bio-Rad 







6.3.1.4 Analysis of the specificity of the anti-OCA2 protein antibody 
In order to determine the anti-OCA2 antibody PA5-23708 specificity, PA5-23708 was 
used in RLBAs with other radiolabelled antigens and these included tyrosinase, MCHR1, 
TH and DCT. 
Radiolabelled [35S]-tyrosinase, [35S]-MCHR1, [35S]-TH, and [35S]-DCT were produced in a 
TnT® T7-Coupled Reticulocyte Lysate System (Section 2.19) from plasmids pcDNA3-TYR, 
pcMCHR1, pcDNA3-TH and pCMVDTS (Table 2.2), respectively. RLBAs were carried out 
as detailed in (Section 2.21), using these labelled antigens with antibody PA5-23708 at 
a 1:100 dilution. Appropriate positive control antibodies were included at a 1:100 
dilution in each RLBA: α-PEP7 for tyrosinase, MCHR11-S for MCHR1, ab59276 for TH, and 
α-PEP8 for DCT. An immunoprecipitation reaction without antibody was also included 
in each RLBA, as a background control. In each RLBA, an antibody index was calculated 
for each antibody as: cpm immunoprecipitated by tested antibody/cpm 
immunoprecipitated by the background control. Each antibody was tested in four 
experiments and the mean antibody index was calculated from these values. Antibody 
indices were compared using one-way ANOVA with P values < 0.05 regarded as 
significant. 
The mean antibody index ± SD for anti-OCA2 protein antibody in RLBAs against different 
antigens was 26.5 ± 3.94 against OCA2 protein, 1.01 ± 0.05 against tyrosinase, 0.99 ± 
0.11 against MCHR1, 1.06 ± 0.08 against TH, and 1.02 ± 0.10 against DCT (Figure 6.7). In 
one-way ANOVA, the antibody index of the anti-OCA2 protein antibody in the different 
RLBAs was compared; P < 0.0001, indicating there was no significant 
immunoprecipitation of other unrelated proteins. Anti-OCA2 protein antibody PA5-
23708 could be used therefore as a positive control antibody in OCA2 protein RLBAs. 
Additionally, the mean antibody index ± SD for the antibodies α-PEP7 (anti-tyrosinase), 
MCHR11-S (anti-MCHR1), ab59276 (anti-TH), and α-PEP8 (anti-DCT) in RLBAs against 
their cognate antigens was 13.6 ± 1.74, 12.7 ± 1.28, 10.5 ± 1.57 and 11.4 ± 1.24, 







Figure 6.7: RLBAs with anti-OCA2 protein antibody PA5-23708 and different antigens. 
The immunoreactivity of the anti-OCA2 protein antibody PA5-23708 was tested against in vitro 
translated [35S]-OCA2 protein, [35S]-tyrosinase, [35S]-MCHR1, [35S]-TH, and [35S]-DCT) in RLBAs. 
Antibodies anti-tyrosinase (α-PEP7), anti-MCHR1 (MCHR11-S), anti-TH (ab59276), and anti-DCT 
(α-PEP8) were included in the relevant RLBA as positive controls for immunoprecipitation of 
their respective antigens. An immunoprecipitation reaction without any serum was included as 
a background control in each RLBA. The mean antibody index ± SD of four experiments is shown 
for the antibody PA5-23708 in RLBAs against the different antigens; 26.5 ± 3.94 against the OCA2 
protein, 1.01 ± 0.05 against tyrosinase, 0.99 ± 0.11 against MCHR1, 1.06 ± 0.08 against TH, and 
1.02 ± 0.10 against DCT. P < 0.0001 (One-way ANOVA). The mean antibody index ± SD of four 
experiments is also shown for the antibodies anti-tyrosinase (α-PEP7), anti-MCHR1 (MCHR11-
S), anti-TH (ab59276), and anti-DCT (α-PEP8) in RLBAs against their cognate antigens; 13.6 ± 





 Use of the OCA2 protein RLBA to analyse vitiligo patients and control sera for 
OCA2 protein antibodies 
To analyse vitiligo patient and control sera for the presence of OCA2 protein antibodies, 
OCA2 protein RLBAs were carried out using [35S]-OCA2 protein as the radiolabelled 
antigen. The sera analysed were from patients with vitiligo (n = 246) and from healthy 
controls (n = 100). All sera were assayed in duplicate at a final dilution of 1:100. Anti- 
OCA2 protein antibody PA5-23708 was included in each assay set as a positive control 
at a dilution of 1:100. In each assay set, antibody levels were expressed as OCA2 protein 
antibody index. This was calculated for each serum tested as: cpm immunoprecipitated 
by tested serum/mean cpm immunoprecipitated by 100 healthy control sera. Each 
serum was tested in at least three experiments and the mean OCA2 protein antibody 
index was calculated from these values. The upper limit of normal for the assay was 
calculated using the mean OCA2 protein antibody index + 3SD of the population of 100 
healthy controls. Any serum sample with an OCA2 protein antibody index above the 
upper limit of normal was designated as positive for OCA2 protein antibodies.  
The results of the OCA2 protein RLBAs are shown in Figure 6.8. The mean OCA2 protein 
antibody index ± SD for the control group (n = 100) was 1.02 ± 0.11 with a range of 0.75-
1.33. The mean OCA2 protein antibody index ± SD for patients with non-segmental 
vitiligo (n = 231), segmental vitiligo (n = 4), and undetermined vitiligo (n = 11) was 2.14 
± 2.64 (range, 0.77-13.1), 2.05 ± 2.00 (range, 0.95-5.05), and 1.40 ± 1.18 (range, 0.90-
4.95), respectively. The upper limit of normal for the OCA2 protein RLBA was an OCA2 
protein antibody index of 1.34. 
Healthy controls were all OCA2 protein antibody-negative with OCA2 protein antibody 
indices below 1.34. Of the 231 non-segmental vitiligo patients, 52 (23%) were 
considered OCA2 protein antibody-positive (Table 6.1), as their OCA2 protein antibody 
index was above the upper limit of normal value of 1.34. Anti-OCA2 protein antibodies 
were detected in one patient with segmental vitiligo and in one patient with 
undetermined vitiligo sub-type (Table 6.1).  
The prevalence of OCA2 protein antibodies was compared between vitiligo patients and 




were regarded as significant. The results are given in Table 6.1. In comparison with 
controls, a statistically significant increase in the prevalence of OCA2 protein antibodies 
was found in the patient group with non-segmental vitiligo; the P value was < 0.0001. In 
addition, there was a statistically significant increase in the frequency of OCA2 protein 
antibodies in patients with symmetrical or acrofacial vitiligo (Table 6.1). However, in 
most vitiligo sub-type groups, there were too few patients to make statistical analysis 
robust (Table 6.1). There was no difference in OCA2 protein antibody prevalence in 
patients with active or stable vitiligo or in those with or without autoimmune disease 
(Table 6.1). 
To analyse qualitatively, the proteins immunoprecipitated in the OCA2 protein RLBA by 
vitiligo patient and control sera, protein G Sepharose-OCA2 protein-antigen complexes 
were suspended in 50 μl of Laemmli sample buffer, heated at 100°C for 5 min, 
centrifuged and the supernatant recovered for SDS-PAGE in 10% (w/v) SDS-
polyacrylamide gels and subsequent autoradiography (Section 2.20). 
The results indicated that all 54 of the OCA2 protein antibody-positive vitiligo patient 
sera analysed immunoprecipitated a protein band of 88 kDa, comparable to the size of 
OCA2 protein in SDS-polyacrylamide gels. The results for eight OCA2 protein antibody-










Figure 6.8: OCA2 protein RLBA results for vitiligo patient and healthy control sera. 
Vitiligo patient and healthy control sera were evaluated for OCA2 protein antibodies in the OCA2 
protein RLBA. The OCA2 protein antibody indices are shown for sera from vitiligo patients (n = 
246) and healthy controls (n = 100). The OCA2 protein antibody index shown for each serum is 
the mean of three experiments. The mean OCA2 protein antibody index ± SD for the control 
group was 1.02 ± 0.11 with a range of 0.75-1.33. The mean OCA2 protein antibody index ± SD 
for patients with non-segmental vitiligo (n = 231), segmental vitiligo (n = 4), and undetermined 
vitiligo (n = 11) was 2.14 ± 2.64 (range, 0.77-13.1), 2.05 ± 2.00 (range, 0.95-5.05), and 1.40 ± 1.18 
(range, 0.90-4.95), respectively.  The upper limit of normal (mean OCA2 protein antibody index 
+ 3SD of 100 healthy controls) for the OCA2 protein RLBA was an OCA2 protein antibody index 








Table 6.1: OCA2 protein antibody prevalence in vitiligo patients and healthy controls 
 




P value1 P value2 
Vitiligo patient or control group 
Non-segmental vitiligo 52/231 (23%) < 0.0001 - 
Segmental vitiligo 1/4 (25%) ND - 
Undetermined vitiligo 1/11 (9%) ND - 
Healthy controls 0/100 (0%) ND - 
Non-segmental vitiligo sub-type 
Symmetrical (generalised) 38/157 (24%) < 0.0001 - 
Acrofacial 11/42 (26%) < 0.0001 - 
Acral 1/4 (25%) ND - 
Peri-orificial 0/3 (0%) ND - 
Universal 0/1 (0%) ND - 
Symmetrical and peri-orificial 2/10 (20%) ND - 
Symmetrical and acrofacial 0/7 (0%) ND - 
Symmetrical, peri-orificial and 
acrofacial 
0/1 (0%) ND - 
Occupational 0/1 (0%) ND - 
Mixed 0/5 (0%) ND - 
Vitiligo activity 
Active  50/226 (22%) < 0.0001 1.00 
Stable  4/20 (20%) 0.006 
Autoimmune disease 
Present 20/84 (24%) < 0.0001 1.00 
Absent 34/162 (21%) < 0.0001 
 
1P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.24) for 
comparing the prevalence of OCA2 protein antibodies in vitiligo patients and controls. P < 0.05 
was considered statistically significant. 
2P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.24) for 
comparing the prevalence of OCA2 protein antibodies in vitiligo patient groups. P < 0.05 was 
considered statistically significant. 












Figure 6.9: SDS-PAGE and autoradiography of [35S]-OCA2 protein following 
immunoprecipitation in OCA2 protein RLBAs with vitiligo patient and healthy control 
sera. 
Radiolabelled OCA2 protein was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate 
System and then immunoprecipitated in OCA2 protein RLBAs with either vitiligo or healthy 
control sera. For analysis, immunoprecipitated proteins were run in a 10% (w/v) SDS-
polyacrylamide gel and autoradiographed. The results are shown for eight vitiligo patients and 
one healthy control sera: In vitro translated [35S]-OCA2 protein (lane 1); [35S]-OCA2 protein 
immunoprecipitated with: anti-OCA2 protein antibody PA5-23708 (lane 2); sera from OCA2 
protein antibody-positive vitiligo patients (lanes 3-10); sera from healthy control (lane 11). The 








 Determination of OCA2 protein antibody titres in vitiligo patients  
To determine the titres of OCA2 protein antibodies, sera from all OCA2 antibody-positive 
vitiligo patients (n = 54) and healthy controls (n = 10) were analysed in the OCA2 protein 
antibody RLBA at different dilutions including 1:100, 1:200, 1:500, 1:1000, 1:2000 and 
1:5000. For each serum sample tested, an OCA2 protein antibody index (cpm 
immunoprecipitated by tested serum at each dilution/the cpm immunoprecipitated by 
10 healthy control sera at each dilution) was calculated and this was the mean OCA2 
protein antibody index of three experiments.  
The results of the antibody titration experiments are given in Figure 6.10. The titration 
results are also summarised in Table 6.2, and show the serum dilution at which OCA2 
protein antibodies were still detectable at levels higher than the upper limit of normal 
for the OCA2 protein antibody RLBA. Although the titres of OCA2 protein antibodies 
varied between the different vitiligo patients, the majority, 43/54 (80%), had a titre at 








Figure 6.10: OCA2 protein antibody titres.  
The 54 OCA2 protein antibody-positive vitiligo patient sera were analysed in the OCA2 protein 
antibody RLBA at dilutions of 1:100, 1:200, 1:500, 1:1000, 1:2000, and 1:5000. The OCA2 protein 
antibody index (mean ± SD of three exepriments) of each serum at each dilution is shown. (a) 
The results are shown for 12 vitiligo patients. (b) The results are shown for 12 vitiligo patients. 
(c) The results are shown for 12 vitiligo patients. (d) The results are shown for 10 vitiligo patients. 























1The titre of OCA2 protein antibody is shown as the dilution at which immunoreactivity of the 






OCA2 protein antibody 
titre1 
V157, V206 1:100 
V4, V132, V221, V185, V18, V141, V149 1:200 
V166, V189-17 1:500 
V216-18, V111, V5, V54, V36, V15-5, V22-8, 
V38-12, V102-15 
1:1000 
V224-11, V39, V25, V100, V49, V7, V9, V95, 
V76, V118, V155, V16, V133, V234-20, V45-
21, V87, V68, V143 
1:2000 
V172, V121, V82 1:5000 
V237, V62, V27, V241, V73-14, V235, V90, 





 Assessment of the specificity of OCA2 protein antibodies  
In order to determine that OCA2 protein antibodies in vitiligo patient sera reacted 
specifically against the protein OCA2, absorption experiments were performed as 
detailed in Section 2.22. Briefly, serum samples from OCA2 protein antibody-positive 
vitiligo patients (n = 54) and healthy individuals (n = 10) were absorbed with extracts 
prepared from untransfected HEK293 cells or from HEK293 cells transfected with OCA2 
protein, MCHR1 or tyrosinase. Subsequently, duplicate samples of pre-absorbed sera at 
a 1:100 dilution (equivalent to the original sera dilution) were evaluated in the OCA2 
protein RLBA. For each serum sample, an OCA2 protein antibody index (cpm 
immunoprecipitated by tested serum/the cpm immunoprecipitated by 10 healthy 
control sera) was calculated. Serum samples were all tested in triplicate. To compare the 
OCA2 protein antibody index of absorbed against unabsorbed vitiligo patient sera, one-
way ANOVA was used (Section 2.24). P values < 0.05 were considered as significant in 
all tests. 
The absorption experiment results are illustrated in Figure 6.11. There was a statistically 
significant reduction in the OCA2 protein antibody indices by pre-absorption of OCA2 
protein antibody-positive vitiligo patient sera with the OCA2 protein expressed in the 
extracts prepared from HEK293 cells: all P values were < 0.05. In contrast, OCA2 protein 
antibody indices were not significantly decreased after pre-absorption of OCA2 protein 
antibody-positive vitiligo patient sera with extracts made from untransfected HEK293 
cells or HEK293 cells harbouring expressed MCHR1 or tyrosinase: P values were > 0.05.  
Overall, these findings indicated that OCA2 protein antibodies in all OCA2 protein 
antibody-positive patient sera specifically recognised their target autoantigen without 





Figure 6.11: OCA2 protein antibody absorption experiments.  
Serum samples from the 54 OCA2 protein antibody-positive vitiligo patients and 10 healthy 
controls were preabsorbed with extract made from either untransfected HEK293 cells or from 
HEK293 cells expressing OCA2-encoded P protein (OCA2 protein), tyrosinase or melanin-
concentrating hormone receptor 1 (MCHR1). Unabsorbed and preabsorbed sera were then 
analysed in the OCA2 protein RLBA. The results demonstrate the mean OCA2 protein antibody 
index (± SD) of three experiments for unabsorbed and preabsorbed sera. The results are given 
for the 54 vitiligo patients. Comparing the antibody indices of OCA2 protein-absorbed sera with 




 Analysis of vitiligo patient sera for other vitiligo-associated antibodies 
As detailed earlier in Section 5.3.5, RLBAs for tyrosinase, DCT, TYRP1, PMEL, TH, and 
MCHR1 antibodies (Kemp et al., 1997a, Kemp et al., 1997b, Kemp et al., 1998a, Kemp et 
al., 1998b, Kemp et al., 2002b, Kemp et al., 2011) were performed on all the 246 vitiligo 
patient sera. The results are shown in Table 5.3, and used to determine if antibodies to 
OCA2 protein were related to the presence of any antibodies directed against other 
vitiligo-associated autoantigens (Section 6.3.6). 
 Comparison of the demographic, clinical, and serological details of the OCA2 
protein antibody-positive and OCA2 protein antibody-negative non-
segmental vitiligo patients 
In order to compare the details of the demographic, clinical and serological features of 
the OCA2 protein antibody-positive (n = 52) and antibody-negative (n = 179) non-
segmental vitiligo patient groups, Fisher’s exact tests for 2 x 2 contingency tables or 
unpaired t tests were used as appropriate (Section 2.24). P values < 0.05 were 
considered as significant. 
The results are given in Table 6.3. A statistically significant difference was not evident 
between the two cohorts in terms of sex, age of patient, duration of disease, vitiligo 
onset age, activity of vitiligo, the occurrence of other autoimmune disorders, the clinical 
sub-type of non-segmental vitiligo or the prevalence of MCHR1, PMEL, TYRP1, DCT, and 
TH antibodies; P values were all > 0.05, indicating that OCA2 protein antibodies were 
not associated with any of these analysed parameters. However, a statistically 
significant difference was observed between the two groups in terms of the presence of 





Table 6.3: Comparison of the demographic, clinical, and serological details in non-

















Male  27 (52%) 70 (39%) 0.111 
Female  25 (48%) 109 (61%) 
Mean age ± SD (years) 46 ± 17 (14 - 77) 45 ± 17 (0 - 88) 0.702 
Mean onset age ± SD (years) 29 ± 16 (0 - 72) 32 ± 18 (0 - 83) 0.352 
Mean disease duration ± SD 
(years) 
17 ± 14 (0.5 - 51) 13 ± 13 (0 - 71) 0.092 
Non-segmental vitiligo sub-type 
Symmetrical  38 (73%) 119 (66%) 0.401 
Acrofacial  11 (21%) 31 (17%) 0.541 
Vitiligo activity 
Active  49 (94%)  167 (93%) 1.001 
Stable   3 (6%) 12 (7%) 
Autoimmune disease 
Present  19 (37%) 62 (35%) 0.871 
Absent  33 (63%) 117 (65%) 
Serology tests 
Tyrosinase antibody-positive 17 (33%) 25 (14%) 0.0041 
MCHR1 antibody-positive 11 (21%) 40 (22%) 1.001 
PMEL antibody-positive 10(19%) 25 (14%) 0.381 
TYRP1 antibody-positive 14 (27%) 30 (17%) 0.111 
DCT antibody-positive 14 (27%) 29 (16%) 0.101 
TH antibody-positive 11 (21%) 42 (23%) 0.851 
 
1P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.24) for 
comparing the prevalence of demographic, clinical, and serological details in the OCA2 protein 
antibody-positive and the OCA2 protein antibody-negative non-segmental vitiligo patient 
groups. P values < 0.05 were considered significant. 
2P value calculated using Unpaired t tests (Section 2.24) for comparing the age, onset age, and 
disease duration in the OCA2 protein antibody-positive and OCA2 protein antibody-negative 







The specific function of the OCA2 protein remains to be precisely characterised, 
however studies using cultured melanocytes from OCA2 mutant mice propose its 
involvement in the transport of tyrosinase, the precursor enzyme to melanin 
biosynthesis, to melanosomes within melanocytes (Chen et al., 2002, Toyofuku et al., 
2002, Chen et al., 2004, Cook et al., 2009, Rimoldi et al., 2014), and in the regulation of 
melanosomal pH (Puri et al., 2000, Suzuki and Tomita, 2008, Rimoldi et al., 2014). Initially 
in this thesis, OCA2 protein was identified as a novel target of antibody responses in 
patients suffering from vitiligo by using phage-display technology (Chapter 4). 
Therefore, in this chapter, a RLBA was employed to study the prevalence of 
immunoreactivity to the OCA2 protein in a series of vitiligo patients, and also to find out 
if there were any associations of OCA2 protein antibodies with the demographic 
features (e.g., age, gender), clinical features (e.g., vitiligo activity, autoimmune disease), 
or serological details of vitiligo patients.  
 Frequency of OCA2 protein antibodies 
Firstly, a RLBA was developed which could be utilised to detect and measure OCA2 
protein antibodies in human sera. The RLBA proved to be specific for the detection of 
OCA2 protein antibodies. Secondly, the RLBA was used to analyse 246 vitiligo patient 
sera for OCA2 protein antibodies. OCA2 protein antibodies were detected in 54 (22%) 
patients. Although the frequency of OCA2 protein antibodies was relatively low (22%) in 
the vitiligo patients included in the current study, it is not different from other studies 
which have demonstrated a low frequency of antibodies to tyrosinase (11%) (Kemp et 
al., 1997a), TYRP1 (6%) (Kemp et al., 1998b), DCT (6%) (Kemp et al., 1997b), MCHR1 
(16%) (Kemp et al., 2002b), PMEL (6%) (Kemp et al., 1998a), and TH (23%) (Kemp et al., 
2011). Likewise, low frequencies (6-15%) of antibodies against several different 




 OCA2 protein antibody titres and specificity 
To measure OCA2 protein antibody titres, the 54 patient sera positive for OCA2 protein 
antibodies were tested in RLBAs at a series of final dilutions. Although the titres of OCA2 
protein antibodies varied between the different vitiligo patients, the majority, 43/54 
(80%), had a titre at 1:1000 or above, and 13/54 (24%) had a titre above 1:5000. In 
contrast, titres of TH, PMEL, TYRP1, and MCHR1 antibodies in vitiligo patients were much 
lower at 1:200, 1:100, 1:100 and 1:50, respectively (Kemp et al., 1998a, Kemp et al., 
1998b, Kemp et al., 2002b, Kemp et al., 2011).   
Previous analysis has shown that vitiligo patient antibodies against tyrosinase are cross-
reactive with TYRP1 and DCT (Kemp et al., 1997a, Kemp et al., 1997b, Kemp et al., 1998b) 
due to their amino acid sequence homology. In order to ensure that OCA2 protein 
antibody reactivity was specific to the OCA2 protein, absorption experiments were 
performed. The absorption experiments showed that all 54 OCA2 protein antibody-
positive patient sera contained OCA2 protein antibodies that reacted specifically with 
their target antigen with no cross-reactivity to other vitiligo-associated antigens MCHR1 
and tyrosinase. This would be expected due to lack of amino acid sequence similarity of 
the three proteins.  
 Prevalence of OCA2 protein antibodies in vitiligo sub-types 
OCA2 protein antibody responses were detected at slightly higher prevalence (25%) in 
segmental vitiligo patients than in non-segmental vitiligo patients (23%). This contrasts 
with the hypothesis that segmental vitiligo type has a non-autoimmune aetiology, 
whereas non-segmental vitiligo type has an autoimmune aetiology (Taieb, 2000). 
However, samples from only four patients with segmental vitiligo were available for 
testing. Segmental vitiligo mostly presents in children (Halder et al., 1987, Nicolaidou et 
al., 2012, Silverberg, 2015), but children were seen rarely in our clinics as they usually 
present to paediatric dermatology. Additionally, segmental vitiligo less commonly 
present in adulthood and, due to a usually more confined skin area involved, it is less 




vitiligo. Therefore, a definite conclusion cannot be drawn regarding the frequency of 
OCA2 protein antibodies in this vitiligo sub-type.  
 Associations of OCA2 protein antibodies 
A comparison of OCA2 protein antibody-positive and OCA2 protein antibody-negative 
non-segmental vitiligo patients showed that the frequency of OCA2 protein antibodies 
did not correlate with disease activity, a finding contradictory to previous studies where 
a significant increase in TH antibodies was found in vitiligo patients with active disease 
(Kemp et al., 2011). 
In addition, comparing the same two vitiligo groups demonstrated no evident 
correlation between the occurrence of OCA2 protein antibodies and either sex of 
patient, age at sampling time, disease onset age, or disease duration, results consistent 
with previous studies in relation to MCHR1 (Kemp et al., 2002b) and TH (Kemp et al., 
2011) antibodies in vitiligo patients. 
The OCA2 protein was a target of antibodies in vitiligo patients with (24%) and without 
(21%) a concomitant autoimmune disorder and there was no significant difference in 
the prevalence of OCA2 protein antibodies between the two groups, a similar finding to 
a previous study investigated TH antibodies in vitiligo patients (Kemp et al., 2011). 
However, these results contrast to other previous reports in which antibodies against 
melanogenic proteins TYRP1, DCT, and PMEL were only found in patients suffering from 
both vitiligo and other autoimmune diseases (Kemp et al., 1997b, Kemp et al., 1998a, 
Kemp et al., 1998b). In addition, predominant antibody responses against tyrosinase and 
SOX10 were detected in vitiligo patients with accompanying autoimmune diseases 
(Kemp et al., 1997a, Hedstrand et al., 2001).   
In the present work, there was also no apparent correlation between the occurrence of 
OCA2 protein antibodies and MCHR1, PMEL, TYRP1, DCT or TH antibodies. Similarly, no 
association between MCHR1, tyrosinase, TYRP1, DCT, TH, and PMEL antibodies has been 
reported in vitiligo patients (Kemp et al., 2002b, Kemp et al., 2011). However, in this 
work, an association of OCA2 protein antibodies with the presence of tyrosinase 




transporter, is involved in tyrosinase transport and it is analogous to tyrosinase in that 
both proteins can be presented to the immune system by HLA-A*02 (Zhang and Xiang, 
2014). 
 Development of OCA2 protein antibodies 
Owing to the intracellular location of OCA2 protein, OCA2 protein antibodies most likely 
occur by the antigen exposure after the destruction of melanocytes by oxidative stress 
(Kemp et al., 2011) or cytotoxic cells (Palermo et al., 2001, van den Boorn et al., 2009). 
Several hypotheses including neo-antigen formation, exposure of cryptic epitopes and 
protein modification during apoptosis have been put forward about the emergence of 
antibody reactivity to cytoplasmic melanocyte antigens (Namazi, 2007, Westerhof and 
d'Ischia, 2007, Kemp et al., 2011). After processing by dendritic cells, antigenic proteins 
can be presented to either autoreactive T lymphocytes which have escaped clonal 
deletion or to naïve T cells which have not been tolerised against cryptic epitopes 
(Namazi, 2007, Westerhof and d'Ischia, 2007, Kemp et al., 2011). Antibodies might then 
be produced following the triggering of autoreactive B cells by activated CD4+ T 
lymphocytes (Namazi, 2007). 
 Potential pathogenicity of OCA2 protein antibodies 
Generally for autoantigens to be recognised by antibodies, their expression on the cell 
surface is required. However, the OCA2 protein localises on melanosomes contained 
within melanocytes (Sitaram et al., 2009). Interestingly, mutant OCA2 protein has been 
reported to mislocalise to the surface of melanocytes (Sitaram et al., 2009), and could 
therefore be accessible as an antibody target in such cases. However, with restricted 
access to the target antigen in normal pigment cells, OCA2 protein antibodies are 
unlikely to adversely affect the function of the OCA2 protein, and although melanocyte 
destruction by vitiligo-associated antibodies has been demonstrated by both 
complement-mediated activation and antibody-dependent cellular cytotoxicity (Norris 
et al., 1988, Gilhar et al., 1995, Kemp et al., 2011), OCA2 protein antibodies may merely 




OCA2 protein. Indeed, several melanocyte autoantigens that are recognised as antibody 
targets, for example tyrosinase, are also the target of T cell responses in vitiligo skin (Ogg 
et al., 1998, Lang et al., 2001, Palermo et al., 2001, van den Boorn et al., 2009). 
 Conclusions 
The OCA2 protein has been found as a novel antibody target in vitiligo. To the best of 
our knowledge, this finding has not been previously reported.  It requires further 
characterisation, but the finding further supports the involvement of an autoimmune 
mechanism in vitiligo development. Interestingly, in this work, an association was 
evident between OCA2 protein and tyrosinase antibodies. Of particular note, the OCA2 
protein functions in the transportation of tyrosinase, the key enzyme required for 
melanin synthesis, to melanosomes. Therefore, OCA2 protein is a promising antigen 























7 Analysis of antibody reactivity against LaminA in vitiligo patients 
 Introduction  
The nuclear envelope in eukaryotic cells consists of three distinctive membrane 
domains: the outer nuclear membrane, which is linked with the endoplasmic reticulum; 
the membranous wall of the nuclear pore complex, which is situated where the outer 
and inner nuclear membranes fuse to create the pore channel; and the inner nuclear 
membrane, which is connected with a network of proteins, the nuclear lamina (Schoft 
et al., 2003). The Lamins, nuclear intermediate filament proteins, are the major 
structural components of the lamina (Dechat et al., 2000, Wilson et al., 2001, Dittmer 
and Misteli, 2011). In most mammalian cells, the nuclear lamina is composed of three 
major proteins,  Lamins A, B, and C (Hozak et al., 1995) with molecular weights of 60 to 
75-kDa (Heitlinger et al., 1991). The different lamins polymerise to form homopolymeric 
and heteropolymeric 10-nm diameter filaments in the peripheral nuclear lamina (Lin and 
Worman, 1993). They may also assemble into intra-nuclear structures (Dechat et al., 
2000) forming part of a diffuse skeleton spread throughout the nuclear interior (Hozak 
et al., 1995, Dittmer and Misteli, 2011). In addition, according to the reported 
interactions of the lamins with chromatin (Gotzmann and Foisner, 1999), these proteins 
are suggested to be involved in the post-mitotic nuclear reorganisation, such as DNA 
replication, chromatin de-condensation and transcription (Schoft et al., 2003, Wilson et 
al., 2001, Dittmer and Misteli, 2011). 
Recently, LaminA was identified as a target of antibodies in vitiligo patients by proteome 
analysis (Li et al., 2011). Immunoblotting verified that 28.6% of vitiligo patients had 
antibodies against LaminA and that 3.1% of healthy individuals were positive (Li et al., 
2011). Overall, 91.7% of the patients who were positive for LaminA antibodies also had 
active non-segmental vitiligo, and 50% had at least one autoimmune disease (Li et al., 
2011). Furthermore, anti-LaminA, B1, A/C, and ABC antibodies have been reported also 
in patients with systemic lupus erythematosus, chronic autoimmune hepatitis, 
rheumatoid arthritis, linear scleroderma, and autoimmune cytopenias (McKeon et al., 
1983, Wesierska-Gadek et al., 1988, Senecal et al., 1999, Coppo et al., 2004), suggesting 




identified as potential antibody target following rounds of panning against the 






The main objectives of this part of the project were: 
a) To develop a RLBA to confirm antibody reactivity against LaminA. 
b) To investigate LaminA antibody frequencies in 246 vitiligo patients and 100 
healthy controls using the RLBA. 
c) To determine if antibodies to LaminA were related to any clinical, demographic 






 Experiments and Results 
 Development of an LaminA RLBA  
In order to study the prevalence of antibodies against LaminA in vitiligo patient sera, it 
was first necessary to clone LaminA cDNA into a suitable plasmid vector for expression 
of the LaminA, which could then be used as the target antigen to test antibody binding 
in RLBAs. Plasmid pcDNA3 (Figure 7.1) was chosen as it contains a T7 polymerase 
promoter binding site from which cloned cDNA can be transcribed and translated in vitro 
with the concomitant incorporation of radiolabelled [35S]-methionine. The [35S]-LaminA 
produced in this way can then be used in RLBAs to detect LaminA antibodies in vitiligo 
patient and healthy control serum samples. 
7.3.1.1 PCR amplification of LaminA cDNA 
Plasmid pDEST15-LaminA DNA containing LaminA DNA (Figure 7.2) was obtained from 
imaGene GmbH (Berlin, Germany). A sample (50 ng) of pDEST15-LaminA DNA was 
subjected to 35 cycles of PCR amplification in a DNA thermal cycler using the reaction 
conditions given in Section 2.13 with primers LaminA-F and LaminA-R (Table 2.4). To 
check for the correctly sized PCR amplification product, a 5-µl aliquot of the PCR 
amplification reaction was electrophoresed in a 0.8% (w/v) agarose gel (Section 2.11). 
The results are shown in Figure 7.3. The product was visible at approximately 2,000-bp, 
in good agreement with the 1,992-bp DNA fragment that encodes LaminA cDNA. 
The PCR product was purified from a 0.8% (w/v) agarose gel using a Wizard® PCR Preps 
DNA Purification System (Section 2.14) and restricted in a 20-µl reaction with KpnI and 
XbaI (Section 2.12). The restricted LaminA cDNA was re-purified from a 0.8% (w/v) 
agarose gel using a Wizard® PCR Preps DNA Purification System (Section 2.14). Finally, a 
3-μl aliquot of the purified product was analysed by agarose gel electrophoresis in a 
0.8% (w/v) gel (Section 2.11), quantified by spectrophotometry (Section 2.9), and then 













Figure 7.1: A map of the pcDNA3 plasmid vector. 
The map shows restriction enzyme sites and the direction of the T7 promoter in the pcDNA3 












Figure 7.2: A map of the pDEST15-LaminA plasmid. 
The map shows restriction enzyme sites and the direction of the T7 promoter in the pDEST15 
















Figure 7.3: Agarose gel electrophoresis of PCR amplification product from pDEST15-
LaminA.  
Plasmid pDEST15-LaminA was subjected to PCR amplification using oligonucleotide primers 
LaminA-F and LaminA-R. The PCR amplification product was analysed by electrophoresis in a 
0.8% (w/v) agarose gel. The gel image shows: the 1-kb DNA Ladder (500-10,000-bp DNA 
fragments) (lane 1); plasmid pDEST15-LaminA amplified with primers LaminA-F and LaminA-R 








7.3.1.2 Preparation of plasmid vector pcDNA3 
For cloning of the PCR product, 1 μg of plasmid vector pcDNA3 was digested with KpnI 
and XbaI in a 25-μl reaction (Section 2.12). The linearised vector was purified from a 
0.8% (w/v) agarose gel using a Wizard® PCR Preps DNA Purification System (Section 
2.14). A 3-μl aliquot of the purified vector was checked on a 0.8% (w/v) agarose gel 
(Section 2.11), quantified by spectrophotometry (Section 2.9), and then stored at -20°C 
until required for cloning experiments. 
7.3.1.3 Ligation of LaminA cDNA into pcDNA3 
The KpnI and XbaI-restricted LaminA cDNA fragment was cloned into KpnI and XbaI-
digested pcDNA3 by setting up a 20-µl ligation reaction as described in Section 2.15. A 
5-µl aliquot of the ligation reaction was then used to transform 50 µl of chemically 
competent E. coli JM109 cells (Section 2.16), with transformants being selected on LB 
agar (Section 2.5) containing ampicillin at a concentration of 100 µg/ml (Section 2.4). 
Following overnight incubation at 37°C, eight individual bacterial colonies from the 
transformation were purified by streaking on to fresh LB agar containing ampicillin at a 
concentration of 100 µg/ml and subsequently incubating the plates at 37°C overnight. 
7.3.1.4 Screening of E. coli JM109 transformants for recombinant plasmids 
For screening of E. coli JM109 transformants for recombinant plasmids that contained 
the correct LaminA cDNA fragment, eight purified bacterial transformants were 
inoculated separately into 10 ml of LB with ampicillin at 100 µg/ml, and then incubated 
at 37oC overnight. Plasmid DNA was purified from each transformant using a Wizard® 
Plus SV Minipreps DNA Purification System (Section 2.9). Plasmids were then checked 
for the presence of the correctly sized DNA insert by restriction enzyme digestion of a 
0.5-µg sample with KpnI and XbaI in a 25-µl reaction (Section 2.12), followed by analysis 
by electrophoresis in 0.8% (w/v) agarose gels (Section 2.11). The frequency of 
recombinant plasmids was 100%, with 8/8 plasmids having a DNA insert of the correct 










Figure 7.4: Agarose gel electrophoresis of potential recombinant plasmids. 
Plasmid DNA was prepared from eight individual bacterial clones isolated from transformation 
of E. coli JM109 with the ligation reaction of pcDNA3 and LaminA cDNA.  The plasmids were 
restricted with KpnI and XbaI and then subjected to electrophoresis in a 0.8% (w/v) agarose gel. 
KpnI and XbaI-restricted pcDNA3 was included for comparison. The gel shows: the 1-kb DNA 
Ladder (500-10,000-bp DNA fragments) (lanes 1 and 7); KpnI and XbaI-restricted pcDNA3 (lanes 







7.3.1.5 Restriction digest analysis of pcDNA3-LaminA 
One recombinant plasmid from the cloning experiment was designated as pcDNA3-
LaminA (Figure 7.5) and the bacterial strain as JM109 pcDNA3-LaminA. A large-scale 
plasmid preparation of pcDNA3-LaminA from JM109 pcDNA3-LaminA was carried out 
(Section 2.10), and the plasmid then analysed by restriction digestion with KpnI and 
XbaI. The results showed the correctly sized cDNA insert (Figure 7.6). The plasmid 
preparation had a concentration of 1.2 µg/µl and was stored at -20°C until needed. 
7.3.1.6 LaminA cDNA clone confirmation 
As a final check that the recombinant plasmid pcDNA3-LaminA was correct and to verify 
that no sequence errors had been introduced to the LaminA cDNA fragment during PCR 
amplification, the plasmid was subjected to DNA sequencing (Section 2.17) using 
primers T7, SP6, LaminA-555-Forward, LaminA-700-Revesrse, LaminA-1751-Forward, 
and LaminA-1600-Forward (Table 2.5). The results verified that the cloned LaminA cDNA 
fragment was correct on comparison of its sequence with the parent LaminA cDNA in 
pDEST15-LaminA (Figure 7.7) using the Global Alignment tool at the network facilities of 
the EBI-EMBL (Section 2.18). The amino acid sequence of LaminA is given in Figure 7.8. 
7.3.1.7 In vitro transcription-translation of LaminA cDNA  
Plasmid pcDNA3-LaminA was transcribed and translated in a TnT® T7-Coupled 
Reticulocyte Lysate System, as described in Section 2.19. In order to analyse the 
radiolabelled product qualitatively, a 5-μl aliquot of the in vitro transcription-translation 
reaction was added to 20 μl of 2x Laemmli sample buffer (Section 2.19) and heated to 
100°C for 5 min. A 10-μl sample was then applied to a 10% (w/v) SDS-polyacrylamide gel 
and subjected to electrophoresis (Section 2.20). After drying, the gel was exposed to x-
ray film, which was developed after 24 h (Section 2.20).  
The results showed a protein product with an estimated molecular weight of 74 kDa 
(Figure 7.9). This agrees well with the molecular weight of 73 kDa anticipated from the 










Figure 7.5: A map of the pcDNA3-LaminA plasmid. 
The map shows restriction enzyme sites and the direction of the T7 and SP6 promoters in the 
pcDNA3 plasmid vector. The 2.0-kb LaminA cDNA was cloned between the KpnI and XbaI 











Figure 7.6: Agarose gel electrophoresis of plasmid pcDNA3-LaminA.  
Unrestricted pcDNA3-LaminA and plasmid restricted with KpnI and/or XbaI were subjected to 
electrophoresis in a 0.8% (w/v) agarose gel. Unrestricted pcDNA3 and plasmid restricted with 
KpnI and/or XbaI was included for comparison. The gel shows: the 1-kb DNA Ladder (500-10,000-
bp DNA fragments) (lanes 1 and 6); unrestricted pcDNA3 (lane 2); unrestricted pcDNA3-LaminA 
(lane 3); KpnI-restricted pcDNA3-LaminA (lane 4); KpnI-restricted pcDNA3 (lane 5); XbaI-
restricted pcDNA3 (lane 7); XbaI-restricted pcDNA3-LaminA (lane 8);  KpnI and XbaI-restricted 










Figure 7.7: LaminA cDNA sequence.  
The cDNA sequence matched that of LaminA cDNA Accession Number NM170707 when 
searched against the GenBank database using the network facilities of NCBI (Bethesda, MD, 
USA). The ATG translation start codon and the TAG translation termination codon are shown in 















Figure 7.8: LaminA amino acid sequence.  












Figure 7.9: SDS-PAGE and autoradiography of [35S]-LaminA. 
[35S]-LaminA was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate System using 
plasmid pcDNA3-LaminA as a template for transcription and translation of LaminA cDNA. For 
analysis, the radiolabelled protein was run in a 10% (w/v) SDS-polyacrylamide gel and 
autoradiographed. The protein molecular weight markers on the gel are Prestained SDS-PAGE 








7.3.1.8 Analysis of the immunoreactivity of [35S]-LaminA  
The immunoreactivity of in vitro translated [35S]-LaminA was analysed in a RLBA (Section 
2.21) with an anti-LaminA antibody and a panel of antibodies raised against proteins 
unrelated to LaminA (Table 2.6). The antibodies were ab26300 (anti-LaminA), α-PEP7 
(anti-tyrosinase), MCHR11-S (anti-MCHR1), ab59276 (anti-TH) and α-PEP8 (anti-DCT), 
and were all used at a 1:100 dilution. An immunoprecipitation reaction without any 
antibodies was also included in each assay set, as a background control. From each RLBA, 
a LaminA antibody index was calculated for each of the antibodies tested as: cpm 
immunoprecipitated by tested antibody/cpm immunoprecipitated by the background 
control. Each antibody was tested in four experiments and the mean LaminA antibody 
index was calculated from these values. The LaminA antibody indices of the different 
antibodies were compared using one-way ANOVA, with P values < 0.05 considered 
significant. 
The results are shown in Figure 7.10, and indicated that the mean LaminA antibody index 
± SD for each antibody was 37.1 ± 8.85 for ab26300, 1.15 ± 0.10 for α-PEP7, 1.16 ± 0.07 
for MCHR11-S, 1.10 ± 0.11 for ab59276, and 1.02 ± 0.09 for α-PEP8. In one-way ANOVA, 
the LaminA antibody index of LaminA antibody ab26300 was statistically significantly 
higher in comparison to those for α-PEP7, MCHR11-S, ab59276, and α-PEP8; P < 0.0001. 
The result demonstrated a specific immunoprecipitation of [35S]-LaminA by anti-LaminA 
antibody, and indicated that [35S]-LaminA could be used as a ligand in a RLBAs to detect 
antibodies against LaminA. 
The LaminA immunoprecipitated in the RLBA by antibody ab26300 was also analysed 
quantitatively. Following the RLBA using [35S]-LaminA and antibody ab26300, the protein 
G Sepharose-LaminA-antigen complexes were suspended in 50 μl of Laemmli sample 
buffer, heated at 100°C for 5 min, centrifuged, and the supernatant analysed by SDS-
PAGE in a 10% (w/v) SDS-polyacrylamide gel (Section 2.20). The gel was then subjected 
to autoradiography (Section 2.20). The results indicated that the antibody ab26300 
immunoprecipitated a protein band equivalent in size (74 kDa) to that of in vitro 













Figure 7.10: LaminA RLBA using different antibodies.  
The immunoreactivity of in vitro translated [35S]-LaminA was tested in a RLBA with antibodies 
anti-LaminA (ab26300), anti-tyrosinase (α-PEP7), anti-MCHR1 (MCHR11-S), anti-TH (ab59276) 
and anti-DCT (α-PEP8). An immunoprecipitation reaction without serum was included as a 
background control. The mean LaminA antibody index ± SD of four experiments is given for each 
antibody: ab26300, 37.1 ± 8.85; α-PEP7, 1.15 ± 0.10; MCHR11-S, 1.16 ± 0.07; ab59276, 1.10 ± 

















Figure 7.11: SDS-PAGE and autoradiography of [35S]-LaminA and [35S]-LaminA 
immunoprecipitated by anti-LaminA antibody ab26300 
[35S]-LaminA was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate System using 
plasmid pcDNA3-LaminA. Subsequently, radiolabelled LaminA was immunoprecipitated in a 
RLBA with anti-LaminA antibody ab26300. For analysis, immunoprecipitated proteins were run 
in a 10% (w/v) SDS-polyacrylamide gel and autoradiographed. The results are shown for: In vitro 
translated, non-immunoprecitated [35S]-LaminA (lane 1); [35S]-LaminA immunoprecipitated with 
anti-LaminA antibody ab26300 (lane 2). The protein molecular weight markers on the gel are 
Prestained SDS-PAGE Standards, Low Range (Bio-Rad Laboratories Ltd.). The LaninA protein is 









7.3.1.9 Analysis of the specificity of anti-LaminA  protein antibody 
In order to analyse the specificity of the anti-LaminA antibody ab26300, it was used in 
RLBAs with a panel of different radiolabelled antigens including tyrosinase, MCHR1, TH, 
and DCT. 
Radiolabelled [35S]-tyrosinase, [35S]-MCHR1, [35S]-TH, and [35S]-DCT were produced in a 
TnT® T7-Coupled Reticulocyte Lysate System (Section 2.19) from plasmids pcDNA3-TYR, 
pcMCHR1, pcDNA3-TH and pCMVDTS (Table 2.2), respectively. RLBAs were carried out 
as detailed in (Section 2.21), using these labelled antigens with antibody ab26300 at a 
1:100 dilution. Appropriate positive control antibodies were included at a 1:100 dilution 
in each RLBA: α-PEP7 for tyrosinase, MCHR11-S for MCHR1, ab59276 for TH, and α-PEP8 
for DCT. An immunoprecipitation reaction without antibody was also included in each 
RLBA, as a background control. In each RLBA, an antibody index was calculated for each 
antibody as: cpm immunoprecipitated by tested antibody /cpm immunoprecipitated by 
the background control. Each antibody was tested in four experiments and the mean 
antibody index was calculated from these values. Antibody indices were compared using 
one-way ANOVA with P values < 0.05 regarded as significant. 
The mean antibody index ± SD for anti-LaminA antibody in RLBAs against different 
antigens was 38.9 ± 1.38 against LaminA, 0.95 ± 0.01 against tyrosinase, 1.03 ± 0.04 
against MCHR1, 0.97 ± 0.03 against TH, and 0.99 ± 0.02 against DCT (Figure 7.12). In one-
way ANOVA, the antibody index of the anti-LaminA antibody in the different RLBAs was 
compared; P < 0.0001, indicating there was no significant immunoprecipitation of other 
unrelated proteins. Anti-LaminA antibody ab26300 could be used therefore as a positive 
control antibody in LaminA RLBAs. 
Additionally, the mean antibody index ± SD for the antibodies α-PEP7 (anti-tyrosinase), 
MCHR11-S (anti-MCHR1), ab59276 (anti-TH), and α-PEP8 (anti-DCT) in RLBAs against 
their cognate antigens was 13.6 ± 1.74, 12.7 ± 1.28, 10.5 ± 1.57 and 11.4 ± 1.24, 








Figure 7.12: RLBAs with anti-LaminA antibody ab26300 and different antigens. 
The immunoreactivity of the anti-LaminA antibody ab26300 was tested against in vitro 
translated [35S]-LaminA, [35S]-tyrosinase, [35S]-MCHR1, [35S]-TH, and [35S]-DCT in RLBAs. 
Antibodies anti-tyrosinase (α-PEP7), anti-MCHR1 (MCHR11-S), anti-TH (ab59276), and anti-DCT 
(α-PEP8) were included in the relevant RLBA as positive controls for immunoprecipitation of 
their respective antigens. An immunoprecipitation reaction without any serum was included as 
a background control in each RLBA. The mean antibody index ± SD of four experiments is shown 
for the antibody ab26300 in RLBAs against the different antigens; 38.9 ± 1.38 against LaminA, 
0.95 ± 0.01 against tyrosinase, 1.03 ± 0.04 against MCHR1, 0.97 ± 0.03 against TH, and 0.99 ± 
0.02 against DCT. P < 0.0001 (One-way ANOVA). The mean antibody index ± SD of four 
experiments is also shown for the antibodies anti-tyrosinase (α-PEP7), anti-MCHR1 (MCHR11-
S), anti-TH (ab59276), and anti-DCT (α-PEP8) in RLBAs against their cognate antigens; 13.6 ± 






 Use of the LaminA RLBA to analyse vitiligo patients and control sera for 
LaminA antibodies 
To analyse vitiligo patient and control sera for the presence of LaminA antibodies, 
LaminA RLBAs were carried out using [35S]-LaminA as the radiolabelled antigen. The sera 
analysed were from patients with vitiligo (n = 246) and from healthy controls (n = 100). 
All sera were assayed in duplicate at a final dilution of 1:100. Anti-LaminA antibody 
ab26300 was included in each assay set as a positive control at a dilution of 1:100. In 
each assay set, antibody levels were expressed as a LaminA antibody index. This was 
calculated for each serum tested as: cpm immunoprecipitated by tested serum/mean 
cpm immunoprecipitated by 100 healthy control sera. Each serum was tested in at least 
three experiments and the mean LaminA antibody index was calculated from these 
values. The upper limit of normal for the assay was calculated using the mean LaminA 
antibody index + 3SD of the population of 100 healthy controls. Any serum sample with 
a LaminA antibody index above the upper limit of normal was designated as positive for 
LaminA antibodies.  
The results of the LaminA RLBAs are shown in Figure 7.13. The mean LaminA antibody 
index ± SD for the healthy control group (n = 100) was 1.00 ± 0.09 with a range of 0.77 
to 1.23. The mean LaminA antibody index ± SD for patients with non-segmental vitiligo 
(n = 231), segmental vitiligo (n = 4), and undetermined vitiligo (n = 11) was 1.54 ± 1.34 
(range of 0.67 to 10.3), 1.17 ± 0.32 (range of 0.91 to 1.64), and 1.44 ± 1.43 (range of 0.91 
to 5.76), respectively. The upper limit of normal for the LaminA RLBA was a LaminA 
antibody index of 1.29. 
Healthy controls were all LaminA antibody-negative with LaminA antibody indices below 
1.29. Of the 231 non-segmental vitiligo patient sera, 51 (22%) were considered LaminA 
antibody-positive (Table 7.1), as their LaminA antibody index was above the upper limit 
of normal value of 1.29. Anti-LaminA antibodies were detected in one patient with 
segmental vitiligo and in one patient with undetermined vitiligo sub-type (Table 7.1).  
The prevalence of LaminA antibodies was compared between vitiligo patients and 
controls in Fisher's exact test for 2 x 2 contingency tables (Section 2.24). P values < 0.05 




controls, a statistically significant increase in the prevalence of LaminA antibodies was 
found in the patient group with non-segmental vitiligo; the P value was < 0.0001. In 
addition, there was a statistically significant increase in the frequency of LaminA 
antibodies in patients with symmetrical or acrofacial vitiligo (Table 7.1). However, in 
most vitiligo sub-type groups, there were too few patients to make statistical analysis 
robust. There was no difference in LaminA antibody prevalence in patients with active 
or stable vitiligo or in those with or without autoimmune disease (Table 7.1). 
To analyse qualitatively, the proteins immunoprecipitated in the LaminA RLBA by vitiligo 
patient and control sera, protein G Sepharose-LaminA-antigen complexes were 
suspended in 50 μl of Laemmli sample buffer, heated at 100°C for 5 min, centrifuged 
and the supernatant recovered for SDS-PAGE in 10% (w/v) SDS-polyacrylamide gels and 
subsequent autoradiography (Section 2.20). 
The results indicated that all 53 of the LaminA antibody-positive vitiligo patient sera 
analysed immunoprecipitated a protein band of 74 kDa, comparable to the size of 
LaminA in SDS-polyacrylamide gels. The results for six LaminA antibody-positive vitiligo 











Figure 7.13: LaminA RLBA results for vitiligo patient and control sera. 
Patient and control sera were evaluated for LaminA antibodies in the LaminA RLBA. The LaminA 
antibody indices are shown for sera from vitiligo patients (n = 246) and healthy controls (n = 
100). The LaminA antibody index shown for each serum is the mean of three experiments. The 
mean LaminA antibody index ± SD for the healthy control group was 1.00 ± 0.09 with a range of 
0.77 to 1.23. The mean LaminA antibody index ± SD for patients with non-segmental vitiligo (n 
= 231), segmental vitiligo (n = 4), and undetermined vitiligo (n = 11) groups was 1.54 ± 1.34 
(range of 0.67 to 10.3), 1.17 ± 0.32 (range of 0.91 to 1.64), and 1.44 ± 1.43 (range of 0.91 to 
5.76), respectively. The upper limit of normal (mean LaminA antibody index + 3SD of 100 healthy 










Table 7.1: LaminA antibody prevalence in vitiligo patients and healthy controls 
 
Vitiligo patient or control group 
LaminA antibody- 
positive samples 
P value1 P value2 
Vitiligo patient or control group  
Non-segmental vitiligo 51/231 (22%) < 0.0001 - 
Segmental vitiligo 1/4 (25%) ND - 
Undetermined vitiligo (all focal) 1/11 (9%) ND - 
Healthy controls 0/100 (0%) ND - 
Non-segmental vitiligo sub-type  
Symmetrical (generalised) 34/157 (22%) < 0.0001 - 
Acrofacial 10/42 (24%) < 0.0001 - 
Acral 1/4 (25%) ND - 
Peri-orificial 0/3 (0%) ND - 
Universal 0/1 (0%) ND - 
Symmetrical and peri-orificial 3/10 (30%) ND - 
Symmetrical and acrofacial 2/7 (29%) ND - 
Symmetrical, peri-orificial, and acrofacial 0/1 (0%) ND - 
Occupational  0/1 (0%) ND - 
Mixed 1/5 (20%) ND - 
Vitiligo activity  
Active 51/226 (23%) < 0.0001 0.26 
Stable 2/20 (10%) 0.026 
Autoimmune disease 
Present 19/84 (23%) < 0.0001 0.87 
Absent 34/162 (21%) < 0.0001 
 
1P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.24) for 
comparing the prevalence of LaminA antibodies in vitiligo patients and controls. P < 0.05 was 
considered statistically significant. 
2P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.24) for 
comparing the prevalence of LaminA antibodies in vitiligo patient groups. P < 0.05 was 
considered statistically significant. 












Figure 7.14: SDS-PAGE and autoradiography of [35S]-LaminA following 
immunoprecipitation in LaminA RLBAs with vitiligo patient and healthy control sera. 
Radiolabelled LaminA was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate System 
and then immunoprecipitated in LaminA RLBAs with either vitiligo or healthy control sera. For 
analysis, immunoprecipitated proteins were run in a 10% (w/v) SDS-polyacrylamide gel and 
autoradiographed. The results are shown for six vitiligo patient and four healthy control sera: In 
vitro translated [35S]-LaminA (lane 1); [35S]-LaminA immunoprecipitated with: anti-LaminA 
antibody ab26300 (lane 2); sera from LaminA antibody-positive vitiligo patients (lanes 3-8); sera 
from healthy controls (lanes 9-12). The protein molecular weight markers on the gel are 






 Determination of LaminA antibody titres in vitiligo patients  
To determine the titres of LaminA antibodies, sera from all LaminA antibody-positive 
vitiligo patients (n = 53) and healthy controls (n = 10) were analysed in the LaminA 
antibody RLBA at different dilutions including 1:100, 1:200, 1:500, 1:1000, 1:2000, 
1:5000 and 1:10000. For each serum sample tested, a LaminA antibody index (cpm 
immunoprecipitated by tested serum at each dilution/the cpm immunoprecipitated by 
10 healthy control sera at each dilution) was calculated and this was the mean LaminA 
antibody index of three experiments.  
The results of the antibody titration experiments are given in Figure 7.15. The titration 
results are also summarised in Table 7.2, and show the serum dilution at which LaminA 
antibodies were still detectable at levels above the upper limit of normal for the LaminA 
antibody RLBA. Although the titres of LaminA antibodies varied between the different 
vitiligo patients, the majority, 36/53 (68%), had a titre at or above 1:500, and 23/53 






Figure 7.15: LaminA antibody titres.  
The 53 LaminA antibody-positive vitiligo patient sera were analysed in the LaminA antibody 
RLBA at different dilutions including 1:100, 1:200, 1:500, 1:1000, 1:2000, and 1:5000. The 
LaminA antibody index (mean ± SD of three exepriments) of each serum at each dilution is given. 
(a) The results are shown for 12 vitiligo patients. (b) The results are shown for 12 vitiligo patients. 
(c) The results are shown for 12 vitiligo patients. (d) The results are shown for 12 vitiligo patients. 






















1The titre of LaminA antibody is shown as the dilution at which immunoreactivity of the serum 








V214, V215, V211, V230,  V217,  V223,  
V168,  V193 
1:100 
V50, V136,  V134, V200,  V116, V45-21, 
V165,  V197, V77 
1:200 
V186, V19, V115, V141, V40, V124,  V46-
22, V27,  V103, V189-17, V129, V163, 
V172 
1:500 
V151, V213, V61,  V13-4, V120, V142,  
V191, V154, V32, V78, V135,  V192 
1:1000 
V82, V138, V149, V171, V178, V152   1:2000 





 Assessment of the specificity of LaminA antibodies  
In order to determine that LaminA antibodies in vitiligo patient sera reacted specifically 
against the protein LaminA, absorption experiments were performed as detailed in 
Section 2.22. Briefly, serum samples from LaminA antibody-positive vitiligo patients (n = 
53) and healthy individuals (n = 10) were absorbed with extracts prepared from 
untransfected HEK293 cells or from HEK293 cells transfected with LaminA, MCHR1 or 
tyrosinase. Subsequently, duplicate samples of pre-absorbed sera at a 1:100 dilution 
(equivalent to the original sera dilution) were evaluated in the LaminA RLBA. For each 
serum sample, a LaminA antibody index (cpm immunoprecipitated by tested serum/the 
cpm immunoprecipitated by 10 healthy control sera) was calculated. Serum samples 
were all tested in triplicate. To compare the LaminA antibody index of absorbed against 
unabsorbed vitiligo patient sera, one-way ANOVA was used (Section 2.24). P values < 
0.05 were considered as significant in all tests. 
The absorption experiment results are illustrated in Figure 7.16. There was a statistically 
significant reduction in the LaminA antibody indices by pre-absorption of LaminA 
antibody-positive vitiligo patient sera with the LaminA protein expressed in the extracts 
prepared from HEK293 cells: all P values were < 0.05. In contrast, LaminA antibody 
indices were not significantly decreased after pre-absorption of LaminA antibody-
positive vitiligo patient sera with extracts made from untransfected HEK293 cells or 
HEK293 cells harbouring expressed MCHR1 or tyrosinase: P values were > 0.05.  
Overall, these findings indicated that LaminA antibodies in all LaminA antibody-positive 
patient sera specifically recognised their target autoantigen without cross-reactivity 






Figure 7.16: LaminA antibody absorption experiments.  
Serum samples from the 53 LaminA antibody-positive vitiligo patient and 10 healthy control 
were preabsorbed with extract made from either untransfected HEK293 cells or from HEK293 
cells expressing LaminA, tyrosinase or melanin-concentrating hormone receptor 1 (MCHR1). 
Unabsorbed and preabsorbed sera were then analysed in the LaminA RLBA. The results 
demonstrate the mean LaminA antibody index (± SD) of three experiments for unabsorbed and 
preabsorbed sera. The results are given for the 53 vitiligo patients. Comparing the antibody 





 Analysis of vitiligo patient sera for other antibodies 
As detailed earlier in Section 5.3.5, RLBAs for tyrosinase, DCT, TYRP1, PMEL, TH, and 
MCHR1 antibodies (Kemp et al., 1997a, Kemp et al., 1997b, Kemp et al., 1998a, Kemp et 
al., 1998b, Kemp et al., 2002b, Kemp et al., 2011) were performed on all the 246 vitiligo 
patient sera. The results are shown in Table 5.3, and used to determine if antibodies to 
LaminA were related to the presence of any antibodies directed against other vitiligo-
associated autoantigens (Section 7.3.6). 
 Comparison of the demographic, clinical and serological details of the LaminA 
antibody-positive and LaminA antibody-negative non-segmental vitiligo 
patient groups 
In order to compare the details of the demographic, clinical and serological features of 
the LaminA antibody-positive (n = 51) and antibody-negative (n = 180) non-segmental 
vitiligo patient groups, Fisher’s exact tests for 2 x 2 contingency tables or unpaired t tests 
were used as appropriate (Section 2.24). P values < 0.05 were considered as significant. 
The results are given in Table 7.3. A statistically significant difference was not evident 
between the two cohorts in terms of sex, age of patient, duration of disease, vitiligo 
onset age, activity of vitiligo, the occurrence of other autoimmune disorders, the clinical 
sub-type of non-segmental vitiligo or the prevalence of tyrosinase, MCHR1, PMEL, 
TYRP1, DCT, and TH antibodies; P values were all > 0.05, indicating that LaminA 








Table 7.3: Comparison of the demographic, clinical, and serological details in non-












(n = 180) 
P value 
Demographic details 
Male 22 (43%) 75 (42%) 0.871 
Female 29 (57%) 105 (58%) 
Mean age ± SD (years) 48 ± 18 (16 - 83) 45 ± 17 (0 - 88) 0.172 
Mean onset age ± SD (years) 35 ± 18 (6 - 71) 30 ± 17 (0 - 83) 0.112 
Mean disease duration ± SD 
(years) 
14 ± 12 (0.5 - 50) 14 ± 14 (0 - 71) 0.792 
Non-segmental vitiligo sub-type 
Symmetrical  34 (67%) 123 (68%) 0.871 
Acrofacial 10 (20%) 32 (18%) 0.841 
Vitiligo activity 
Active  50 (98%) 166 (92%) 0.201 
Stable  1 (2%) 14 (8%) 
Autoimmune disease 
Present 18 (35%) 63 (35%) 1.001 
Absent 33 (65%) 117 (65%) 
Serology tests 
Tyrosinase antibody-positive 5 (10%) 37 (21%) 0.101 
MCHR1 antibody-positive 13 (25%) 38 (21%) 0.571 
PMEL antibody-positive 5 (10%) 30 (17%) 0.271 
TYRP1 antibody-positive 7 (14%) 37 (21%) 0.321 
DCT antibody-positive 10 (20%) 33 (18%) 0.841 
TH antibody-positive 13 (25%) 40 (22%) 0.711 
 
1P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.24) for 
comparing the prevalence of demographic, clinical, and serological details in the LaminA 
antibody-positive and the LaminA antibody-negative non-segmental vitiligo patient groups. P 
values < 0.05 were considered significant. 
2P value calculated using unpaired t tests (Section 2.24) for comparing the age, onset age, and 
disease duration in the LaminA antibody-positive and LaminA antibody-negative non-segmental 







In most mammalian cells, the nuclear lamina is composed of three major proteins,  
Lamins A, B, and C (Hozak et al., 1995). They are structural proteins that provide stability 
and strength to cells via forming part of a diffuse skeleton spread throughout the nuclear 
interior (Hozak et al., 1995). These proteins are suggested to be implicated in the post-
mitotic nuclear reorganisation like DNA replication and transcription (Wilson et al., 
2001, Schoft et al., 2003, Dittmer and Misteli, 2011). 
LaminA was identified recently as a putative antibody target in vitiligo by proteome 
analysis (Li et al., 2011). The aims of the present study were to investigate the 
prevalence of LaminA antibodies in vitiligo patients, and to find out if there were any 
associations of LaminA antibodies with the demographic (e.g., age, gender), clinical (e.g., 
vitiligo activity, autoimmune disease) or serological details of vitiligo patients. Of 
interest, antibodies against LaminA, B1, A/C, and ABC have been previously reported in 
patients’ sera with rheumatoid arthritis , systemic lupus erythematosus (Senecal et al., 
1999), chronic autoimmune hepatitis (Wesierska-Gadek et al., 1988), linear scleroderma 
(McKeon et al., 1983), and autoimmune cytopenias (Coppo et al., 2004).  
 Frequency of LaminA antibodies 
Firstly, a RLBA was developed which could be utilised to detect and measure LaminA 
antibodies in human sera. After verifying the specificity of LaminA RLBA for the detection 
of LaminA antibodies, RLBA was used to analyse 246 vitiligo patient sera for LaminA 
antibodies. Of 246 patients, LaminA antibodies were found in 22% (51/231) of patients 
with non-segmental vitiligo, 25% (1/4) with segmental vitiligo, and 9% (1/11) with 
undetermined vitiligo. Similar findings have been reported by Li and colleagues (Li et al., 
2011), where 33% (24/72) of Chinese patients with non-segmental vitiligo had antibody 
reactivity to LaminA. However, in the same study, none of 12 of segmental vitiligo 
patients was positive for LaminA antibodies. In contrast to our results, a study conducted 
by Kim and co-workers (Kim et al., 2011) failed to detect LaminA antibodies in sera of 
vitiligo patients of Korean descent. These different findings could be attributed to the 




Although in the current study, the prevalence of LaminA antibodies in vitiligo patients 
was found to be relatively low at 22%, it is similar to other studies which have reported 
a low prevalence of antibodies against tyrosinase (11%) (Kemp et al., 1997a), TYRP1 (6%) 
(Kemp et al., 1998b), DCT (6%) (Kemp et al., 1997b), MCHR1 (16%) (Kemp et al., 2002b), 
PMEL (6%) (Kemp et al., 1998a), and TH (23%) (Kemp et al., 2011). Likewise, Waterman 
and colleagues (Waterman et al., 2010) recently showed low frequencies of antibodies 
in vitiligo patients, ranging from 6 to 15%, against several different autoantigens. These 
results may indicate that vitiligo represents a disorder with a spectrum of pathologies 
that result in similar clinical features instead of being a disease with a single 
pathogenicity (Li et al., 2011). 
 LaminA antibody titres and specificity 
To measure LaminA antibody titres, the 53 patient sera positive for LaminA antibodies 
were tested in RLBAs at a series of final dilutions. Although the titres of LaminA 
antibodies varied between the different vitiligo patients, the majority, 36/53 (68%), had 
a titre at or above 1:500, and 23/53 (43%) had a titre at or above 1:1000. In contrast, 
lower titres of antibodies against other melanogenic proteins such as TH, PMEL, TYRP1, 
and MCHR1 were reported and these ranged from 1:50 to 1:200 (Kemp et al., 1998a, 
Kemp et al., 1998b, Kemp et al., 2002b, Kemp et al., 2011).   
Previous studies have shown that vitiligo patient antibodies against tyrosinase are cross-
reactive with TYRP1 and DCT (Kemp et al., 1997a, Kemp et al., 1997b, Kemp et al., 1998b) 
because of their amino acid sequence homology. In order to ensure that LaminA 
antibody reactivity was specific to the LaminA, absorption experiments were carried out. 
The absorption experiments showed that all 53 LaminA antibody-positive patient sera 
contained LaminA antibodies that reacted specifically with their target antigen with no 
cross-reactivity to vitiligo-associated antigens MCHR1 and tyrosinase. This was as 




 Prevalence of LaminA antibodies in vitiligo sub-types 
An autoimmune involvement has been suggested to contribute to the aetiology and 
pathogenesis of non-segmental vitiligo, as the disease is characterised by a correlation 
with autoimmune disorders, unstable results following autologous melanocyte grafting 
(Taieb, 2000), and a positive response to immunosuppressive treatments (Lepe et al., 
2003). In contrast, non-autoimmune pathomechanisms have been suggested to be 
involved in the development of segmental vitiligo (Taieb, 2000). However, it was found 
that the LaminA antibody response was detectable at a slightly higher frequency (25%) 
in patients with segmental vitiligo than in those with the non-segmental disease sub-
type (22%). However, only a small number of patients with segmental vitiligo, four in all, 
was available.  This was because segmental vitiligo mostly affects children (Halder et al., 
1987, Nicolaidou et al., 2012, Silverberg, 2015), but children present rarely in our clinics 
as they usually go to paediatric dermatology. Additionally, segmental vitiligo is less 
common in adulthood and, due to a usually more confined lesions, it is less likely to 
precipitate a referral to a clinic, than an advancing case of non-segmental vitiligo. 
Therefore, a definite conclusions cannot be made regarding the prevalence of 
immunoreactivity against LaminA in this disease sub-type. 
 Associations of LaminA antibodies 
Previously, antibodies in vitiligo have been reported to occur more frequently in patients 
with active disease (Naughton et al., 1986, Kemp et al., 2011). A recent example of this 
was the finding of the association of TH antibodies with active vitiligo (Kemp et al., 2011). 
A comparison of LaminA antibody-positive and LaminA antibody-negative non-
segmental vitiligo patients showed no statistically significant difference between the 
presence of LaminA antibodies and vitiligo activity. Additionally, comparing the same 
two vitiligo patient groups also demonstrated there was no significant association 
between the presence of LaminA antibodies and the non-segmental vitiligo clinical sub-
type, patient gender, patient age, disease duration or vitiligo onset age, a finding that is 




Past investigations have reported that several melanocyte-specific proteins, including 
TYRP1, DCT, and PMEL are antibody targets in vitiligo patients with accompanying 
autoimmune diseases (Kemp et al., 1997b, Kemp et al., 1998b, Kemp et al., 1998a). In 
addition, antibodies to tyrosinase and transcription factor SOX10 are found 
predominantly in vitiligo patients with autoimmune disorders (Kemp et al., 1997a, 
Hedstrand et al., 2001). However, antibody reactivity to LaminA was detected in patients 
with (19/84 = 23%) and without (34/162 = 21%) a concomitant autoimmune disease, 
and there was no significant difference in the prevalence of LaminA antibodies between 
the two groups. Similar results were found in relation to TH antibodies in vitiligo patients 
(Kemp et al., 2011). 
In the present work, there was also no obvious correlation between the occurrence of 
LaminA antibodies and the presence of tyrosinase, MCHR1, PMEL, TYRP1, DCT or TH 
antibodies. Likewise, no correlation between tyrosinase, MCHR1, TYRP1, DCT, TH, and 
PMEL antibodies has been reported in vitiligo patients (Kemp et al., 2002b, Kemp et al., 
2011). 
 Development of LaminA antibodies and potential pathogenicity 
The question concerning the breakage of self-tolerance resulting in the development of 
antibodies directed to LaminA remains unanswered, although LaminA antibodies have 
been identified in the sera of patients with a variety of autoimmune disorders (Nesher 
et al., 2001). Two hypothesises have been put forward as to how LaminA antibodies 
emerge. One possibility is that many LaminA antibodies are natural antibodies that exist 
in the sera of normal individuals and can react with autoantigens in the absence of 
previous apparent specific antigenic contact (Li et al., 2011). Indeed, antibodies against 
LaminA have been detected in normal sera, albeit at a lower frequency than in vitiligo 
patient sera (Li et al., 2011). However, LaminA antibodies were not evident in the sera 
of the healthy individuals included in this study. Another hypothesis is that the 
emergence of LaminA antibodies in vitiligo patients may be attributed to apoptosis of 
epidermal melanocytes (Li et al., 2011); it has been shown that Lamin proteins 
redistribute from the nuclear lamina to apoptotic blebs during apoptosis of endothelial 




microbodies are not cleared effectively, then their accumulation could result in an 
immune response against the proteins which they contain. Like LaminA, antibodies 
against several other intracellular proteins such as tyrosinase can be found in vitiligo 
patients (Kemp et al., 1997a). Again, however, the processes leading to immune 
responses against such antigens have yet to be clarified. Importantly, although LaminA 
is located intracellularly, the protein also can be expressed on the surface of 
melanocytes since it can be labelled by the lactoperoxidase-labelling technique (Cui et 
al., 1995). This is significant since antibody-mediated melanocyte destruction requires 
the expression of target antigens on the cell surface. As such LaminA may be available 
for binding by antibodies, although any specific LaminA antibody-mediated cytotoxicity 
has yet to be investigated in vitiligo or other autoimmune diseases. 
Of interest, is the question as to whether or not LaminA antibodies play any role in skin 
depigmentation. It is possible that they are an epiphenomenon and do not have a role 
in melanocyte destruction, but nevertheless, indicate the presence of autoreactive T 
cells.  
 Conclusions 
In conclusion, LaminA has been identified as an autoantigen in vitiligo and these results 
further support the possibility that autoimmunity might play a role in vitiligo 
development. However, LaminA antibodies were detected at higher frequency in 
patients with segmental vitiligo, which is suggested to have a non-autoimmune 
aetiology (Taieb, 2000). In addition, since antibodies to nuclear lamins have been 
frequently reported in most sera from patients with other autoimmune diseases (Li et 






















8 General Discussion 
 Discussion of the results 
Vitiligo is the most common pigmentary disease, with an estimated prevalence of 0.4% 
to 2% in various populations (Ezzedine et al., 2015, Picardo et al., 2015). To date, the 
aetiology and pathogenic mechanisms of vitiligo are not completely understood, 
although various hypotheses have been suggested such as genetic vulnerability, 
biochemical and neural abnormalities, dysfunctional melanocytes, and aberrant cellular 
and humoral immune responses (Picardo et al., 2015). Much accumulating and 
convincing experimental and observational evidence suggests a leading role for 
autoimmunity in the destruction of melanocytes in vitiligo. The principal reasons for 
believing autoimmunity is the cause of melanocyte loss in vitiligo are that: 
 Vitiligo patients commonly suffer from other autoimmune diseases such as 
autoimmune thyroid disease, alopecia areata, systemic lupus erythematosus, 
Addison’s disease, rheumatoid arthritis, and type 1 diabetes (Taieb, 2000, 
Alkhateeb et al., 2003, Ezzedine et al., 2015). 
 Autoreactive T lymphocytes and antibodies against melanocyte proteins are 
found in vitiligo patients (Kemp et al., 1997a, Kemp et al., 1997b, Kemp et al., 
1998a, Kemp et al., 1998b, Hedstrand et al., 2001, Lang et al., 2001, Palermo et 
al., 2001, Kemp et al., 2002b, van den Boorn et al., 2009, Kemp et al., 2011, Li et 
al., 2011). 
 Repigmentation occurs in vitiligo patients receiving immunosuppressive 
therapies such as corticosteroids and immunomodulators (Lepe et al., 2003, 
Rodrigues et al., 2017a). 
 Allelic variations in vitiligo patients are present in genes that encode components 
of the immune system (Jin et al., 2012a, Spritz, 2012, Ezzedine et al., 2015). For 
instance, the correlation between specific genetic variations at HLA and 
predisposition to vitiligo (Foley et al., 1983, Yang et al., 2005, Singh et al., 2012a, 




Characterising the autoimmune responses against melanocytes in vitiligo may lead to 
recognising new immune targets that would be useful for developing new therapeutic 
and diagnostic tools, and, possibly, in unveiling the aetiological mechanisms involved in 
the disease. 
The work in this thesis aimed to: (i) describe our Sheffield vitiligo patient cohort with 
regard to demographic and clinical profiles, (ii) identify novel disease autoantigens in 
patients suffering from vitiligo by the application of the powerful tool of phage-display 
technology, (iii) develop a RLBA to detect antibodies in vitiligo patients and measure 
their frequencies, (iv) investigate antibody frequencies against three identified 
autoantigens i.e., GPNMB, OCA2 protein, and LaminA using the RLBAs, and (v) determine 
if antibodies to either GPNMB, OCA2 protein or LaminA were related to any clinical, 
demographic or serological features of vitiligo patients. 
 Vitiligo patient details 
Previous epidemiological studies have disagreed as to whether men and women are 
affected by vitiligo at the same frequency or whether there is a preponderance of 
females (Alkhateeb et al., 2003). Like most studies based on analysis of patient cohorts 
(Martis et al., 2002, Alkhateeb et al., 2003, Dogra et al., 2005, Singh and Pandey, 2011, 
Vora et al., 2014, Lee et al., 2015), an excess of females among our analysed patients 
was observed. This might result from greater cosmetic awareness that prompts women 
to consult a doctor for treatment. The disease onset age was under 40 years in most 
(72%) cases, a finding that differs slightly from most previous studies (Herane, 2003, 
Zhang et al., 2004, Liu et al., 2005, Sehgal and Srivastava, 2007, Taïeb et al., 2007) that 
reported 70-80% of vitiligo cases develop the disease before the age of 30 years. 
Almost all patients (231/246 = 94%) had the non-segmental form of vitiligo. Segmental 
vitiligo most often presents in children and can account for almost a third of paediatric 
cases (Halder et al., 1987, Nicolaidou et al., 2012, Silverberg, 2015). However, children 
were seen rarely in our clinics as they usually present to paediatric dermatology. In 
addition, presentation of segmental vitiligo in adulthood is less common and, due to a 
usually more confined presentation in terms of the area of skin involved, it is less likely 




time of examination, vitiligo was active in most (92%) cases, which is consistent with 
other studies (Chun and Hann, 1997, Dave et al., 2002, Karelson et al., 2009). This finding 
was as expected since non-segmental vitiligo dominated our patient group, and the non-
segmental form is more frequently associated with disease progression than segmental 
vitiligo (Chun and Hann, 1997). 
Our findings confirm previous evidence of correlations between vitiligo and other 
autoimmune disorders (Majumder et al., 1993, Zelissen et al., 1995, Alkhateeb et al., 
2003, Mason and Gawkrodger, 2005, Singh and Pandey, 2011, Vijayalakshmi et al., 
2017). In the present study, several autoimmune diseases were at a higher frequency in 
our vitiligo patient cohort than in the general population. The most frequent 
autoimmune disease was autoimmune thyroiditis, particularly hypothyroidism, and this 
agrees well with previous studies (Alkhateeb et al., 2003, Nejad et al., 2013, Gill et al., 
2016). With respect to vitiligo sub-type, associated autoimmune diseases were more 
frequently (35%) found in patients with non-segmental vitiligo. Three of 11 patients 
(27%) with focal vitiligo had an associated autoimmune disorder, whereas none of the 
four patients with segmental vitiligo had an associated autoimmune disease. This is 
consistent with previous reports in which autoimmune diseases correlated with the non-
segmental form of vitiligo, although our study only included a small number of patients 
with segmental vitiligo (Ezzedine et al., 2011). 
A family history of vitiligo was present in 18.3% of our subjects, consistent with most 
previous studies where the percentage frequency lies between 8% and 30% (Hann et al., 
1997, Dave et al., 2002, Pajvani et al., 2006, Shankar et al., 2012, Silverberg, 2015). In 
addition, family history of other autoimmune diseases was positive in approximately a 
third (37.4%) of our patients, a result that is almost identical to previous studies (Mason 
and Gawkrodger, 2005). This result further indicates that vitiligo may share common 
aetiologic factors with other autoimmune diseases. Indeed, genome-wide association 
studies have identified several susceptibility genes in vitiligo that are also associated 
with other autoimmune diseases (Jin et al., 2012a).  
Collectively, the demographic and clinical profiles of our vitiligo patient group were 




 Identification of novel autoantigens 
Identifying and characterising vitiligo-associated antibody targets accounts for the 
greater part of this thesis. By defining the targets of antibodies in vitiligo, the hope was 
that knowledge would be gained about antibody correlation with disease pathogenesis. 
Furthermore, antibodies in vitiligo may act as potentially useful autoantigen markers for 
pathologically more important involvement of cellular immune reactivity. 
A powerful strategy for identifying vitiligo associated-autoantigens was employed 
herein. A melanocyte cDNA phage-display library was constructed in the phage-display 
vector pJuFo and this was used to screen vitiligo patient IgGs that could bind melanocyte 
peptides. The pJuFo phage-display approach (Crameri and Suter, 1993, Crameri et al., 
1994) was validated previously by the successful enrichment of several different 
autoantigens in vitiligo and other autoimmune diseases (Crameri and Blaser, 1996, 
Crameri et al., 1996, Lindborg et al., 1999, Kemp et al., 2002b, Waterman et al., 2010). 
The present study further demonstrated that the phage-display technique was an 
efficient tool for molecular antigen profiling of the humoral immune response in vitiligo. 
Several putative autoantigens were successfully enriched from the cDNA melanocyte 
library in which they were able to interact with IgG molecules from patients with vitiligo. 
These included proteins that were previously reported as autoantigens in different 
diseases as well as proteins related to melanocyte function. We report the identification 
of a panel of 11 different autoantigens. Four were major melanocyte-specific proteins 
already identified as autoantigens in vitiligo. These were tyrosinase (Baharav et al., 1996, 
Fishman et al., 1997, Kemp et al., 1997a), TYRP1 (Kemp et al., 1998b, Okamoto et al., 
1998), PMEL (Kemp et al., 1998a), and DCT (Kemp et al., 1997b). In addition, HSP90, 
ribosomal protein RPL24, and LaminA, all formerly characterised autoantigens in vitiligo 
(Waterman et al., 2010, Li et al., 2011), were also enriched from the melanocyte peptide 
phage-display library. Most significantly, the screening of the phage-display library led 
to the discovery of four putative novel autoantigens GPNMB, OCA2 protein, MC1R and 
Rab27A. The frequency of immunoreactivity in sera from vitiligo patients against three 
autoantigens, namely GPNMB, OCA2 protein, and LaminA, was investigated using RLBAs 




8.1.2.1 GPNMB antibodies 
GPNMB is localised abundantly in late-stage melanosomes, which are characterised by 
the deposition of melanin pigment, thus, GPNMB might be critical in the functions of 
mature melanosomes, probably their transport to keratinocytes (Hoashi et al., 2010, 
Maric et al., 2013). In the current work, antibody reactivity to GPNMB was found at a 
greater frequency (39% in non-segmental vitiligo patients) than vitiligo-specific 
antibodies against tyrosinase, TYRP1, DCT, PMEL, and MCHR1 (Kemp et al., 1997a, Kemp 
et al., 1997b, Kemp et al., 1998b, Kemp et al., 2002b). None of the segmental vitiligo 
patient sera demonstrated immunoreactivity against GPNMB. This further supports the 
idea that non-autoimmune involvement contribute to the aetiology and pathogenesis 
of segmental vitiligo (Taieb, 2000, Kemp et al., 2011). However, due to the availability of 
only four segmental vitiligo patient sera, definite conclusions were unlikely to be drawn 
regarding the frequency of GPNMB antibodies in this form of vitiligo. Therefore, the 
analysis of a greater number of vitiligo patients with segmental sub-type would be 
necessary to verify this result.  
GPNMB antibodies were found at a significantly higher frequency in vitiligo patients with 
active disease. Such a result was reported for TH antibodies in vitiligo (Kemp et al., 
2011). However, due to the availability of only 20 cases with stable disease, it is 
conceivable that further investigations by including a larger group of patients with stable 
vitiligo are needed to confirm these findings. Interestingly, serological analysis showed 
an association of MCHR1 antibodies with the occurrence of GPNMB antibodies; antibody 
reactivity against the receptor had not been correlated with other antibodies in vitiligo 
before (Kemp et al., 2011). 
8.1.2.2 OCA2 protein antibodies 
Another novel autoantigen detected in this study was the OCA2 protein. The precise 
function of this protein is not entirely clear, although studies suggest its involvement in 
the transportation of tyrosinase to melanosomes as well as in maintaining the pH of 
melanosomes. OCA2 protein antibodies were detected in 22% of vitiligo patients, a low 




reported in earlier studies (Kemp et al., 1997a, Kemp et al., 1997b, Kemp et al., 1998a, 
Kemp et al., 1998b, Waterman et al., 2010, Kemp et al., 2011, Li et al., 2011).  
Unlike GPNMB antibodies, OCA2 protein antibodies were detected at slightly greater 
frequency (25%) in segmental vitiligo patients than in non-segmental vitiligo patients 
(23%). However, again, the availability of only four segmental vitiligo patient sera means 
it is unlikely to firmly conclude that OCA2 protein antibodies are prevalent at higher 
levels in segmental form of vitiligo. Interestingly, an association of OCA2 protein 
antibodies with the occurrence of tyrosinase antibodies was noted. Importantly, the 
OCA2 protein, being a melanosomal membrane transporter, is involved in tyrosinase 
transportation to melanosomes and it is like tyrosinase in that both proteins can be 
presented to the immune system by HLA-A*02 (Zhang and Xiang, 2014). 
8.1.2.3 LaminA antibodies 
A further candidate autoantigen identified in this study was LaminA. LaminA was 
characterised recently as a putative antibody target in vitiligo by proteome analysis (Li 
et al., 2011). It is a structural protein that provides stability and strength to cells and is 
proposed to be involved in the post-mitotic nuclear reorganisation along with other 
nuclear laminar proteins B and C (Hozak et al., 1995, Wilson et al., 2001, Schoft et al., 
2003, Zhu et al., 2015). How this particular protein relates to melanocytes has not been 
reported and the reason for its autoantigenicity remains undetermined, but LaminA as 
wells as other nuclear laminar proteins; B and C, have previously been reported as 
autoantigens in other autoimmune conditions (Wesierska-Gadek et al., 1988, Senecal et 
al., 1999). 
LaminA antibodies were detected in 22% of vitiligo patients. Although the frequency of 
LaminA antibodies is not high, Li et al. (2011) reported similar frequency (28.6%) for 
LaminA antibodies in vitiligo patients. As with OCA2 protein antibodies, the LaminA 
antibody response was detected at a slightly higher frequency (25%) in patients with 
segmental vitiligo than in those with the non-segmental disease sub-type (22%). Again, 
limited numbers of segmental vitiligo patients limit the conclusions that can be made. 
No association was evident between vitiligo activity and LaminA immunoreactivity, a 




Overall, GPNMB, OCA2 protein, and LaminA were antibody targets in both those with 
and those without concomitant autoimmune disease. Similarly, TH antibody prevalence 
did not differ between vitiligo patients with accompanying autoimmune disease and 
those without (Kemp et al., 2011). However, previous studies reported antibody 
detection against TYRP1, DCT, and PMEL only in vitiligo patients suffering from other 
autoimmune disorders (Kemp et al., 1997b, Kemp et al., 1998a, Kemp et al., 1998b). 
Antibodies reactive to tyrosinase, SOX10, and LaminA were also identified mostly in 
patients with both vitiligo and accompanying autoimmune diseases (Kemp et al., 1997a, 
Hedstrand et al., 2001). However, analysis of a larger group of vitiligo patients is needed 
in order to determine whether our results reflect a distinct difference in the pattern of 
GPNMB, OCA2 protein, and LaminA antibody production. 
8.1.2.4 Other autoantigens 
Further autoantigens of note that were identified by using phage-display technology 
included HSP90, MC1R, Rab27A, tyrosinase, TYRP1, DCT, RPL24, and PMEL. HSP90 has 
been characterised as an autoantigen in systemic lupus erythematosus (Conroy et al., 
1994). More recently, HSP90 has also been reported as antibody target in vitiligo by 
using RLBAs, where the majority of vitiligo patients with antibody reactivity to HSP90 
also had an autoimmune disease (Waterman et al., 2010). Therefore, HSP90 antibodies 
are probably markers of autoimmunity, but not specifically associated with vitiligo. 
Indeed, previous studies showed the secretion of HSP70 from stressed melanocyte 
(Denman et al., 2008) and thus, anti-HSP antibodies detected in some patients with 
vitiligo may occur as a result of an immune response to extracellular HSPs (Waterman 
et al., 2010). 
To our knowledge, MC1R is a previously unreported vitiligo autoantigen. The 
melanocyte-specific surface receptor MC1R regulates the amount of melanin and it is 
activated upon binding with its agonist α-MSH (Donatien et al., 1992, McRobie et al., 
2014, Salinas-Santander et al., 2018). When MC1R interacts with α-MSH, melanin 
synthesis is induced (Donatien et al., 1992, Dessinioti et al., 2011, Salinas-Santander et 
al., 2018). Therefore, antibody reactivities to MC1R are likely to affect the receptor 




study investigated the ability of IgG extracted from 41 vitiligo patient sera to block the 
stimulatory effect of α-MSH on the MC1R showed that none of the vitiligo patient IgGs 
was able to inhibit cAMP production stimulated by α-MSH in the human melanocytes 
expressing the MC1R (Agretti et al., 2010). Since only 41 vitiligo patient sera were tested 
for their ability to interfere with α-MSH activity on the MC1R in the study reported by 
Agretti et al. (2010), further investigations including larger numbers of vitiligo patients 
are required in order to identify whether or not antibodies to MC1R have function-
blocking to the receptor affecting its activity in relation to pigmentation. 
The Rab27A, which anchors melanosomes to plasma membrane of melanocytes 
(Yoshida-Amano et al., 2012), has not previously been identified as autoantigen in 
vitiligo, but another GTP-binding protein, namely Rab38, has been reported as an 
autoantigen in vitiligo (Waterman et al., 2010). Rab38 regulates melanogenic enzyme 
trafficking from Golgi apparatus to melanosomes (Wasmeier et al., 2006).  
In the present study, the library screening has provided additional evidence that 
melanocyte-specific proteins tyrosinase, TYRP1, DCT, and PMEL are B cell autoantigens 
in vitiligo (Kemp et al., 1997a, Kemp et al., 1997b, Kemp et al., 1998a, Kemp et al., 
1998b). Tyrosinase, TYRP1, and DCT play a central role in melanin biosynthesis, while 
PMEL is involved in the structural organisation of premelanosomes (Yamaguchi et al., 
2007, Tang et al., 2013, D'Mello et al., 2016). However, usually, these autoantigens have 
been detected at a low frequency, for instance, tyrosinase (11%) (Kemp et al., 1997a), 
TYRP1 (6%) (Kemp et al., 1998b), DCT (6%) (Kemp et al., 1997b), and PMEL (6%) (Kemp 
et al., 1998a). The low prevalence of different autoantigens may signify that vitiligo 
represents a disorder with a spectrum of pathologies, which can result in a similar clinical 
features rather than a disease with a single pathogenicity (Waterman et al., 2010, Li et 
al., 2011). In this respect, vitiligo could be a symptom complex resulting from multiple 
causes (Bystryn, 1989). Genetic factors, oxidative stress, humoral and cellular 
autoimmunity, biochemical and neural abnormalities and melanocyte defect may all 
contribute to the disease, in which autoimmunity reactivities may contribute to a 
greater or lesser degree. 
Interestingly, genome-wide association analyses have discovered several genetic loci 




Andersen, 2017). Almost all of the identified susceptibility genes encode components 
involved in immunoregulation, supporting the autoimmune basis of vitiligo which can 
result from dysregulated immune programming, cellular activation and pigment cell 
target recognition and killing (Jin et al., 2010a, Spritz and Andersen, 2017). Several of 
these loci such as HLA class I and II, PTPN22, GZMB, FOXP3, and CCR6 suggest a role for 
the adaptive immune response. Some of them are associated with other autoimmune 
disorders such as thyroid disease, rheumatoid arthritis, and type 1 diabetes, with which 
vitiligo is epidemiologically associated (Jin et al., 2010a, Spritz, 2012, Ezzedine et al., 
2015, Spritz and Andersen, 2017). In addition, other vitiligo susceptibility genes that 
have been identified by genome-wide association analyses include TYR, OCA2, and 
MC1R, which are involved in melanocyte function (Jin et al., 2010a). These proteins were 
antibody targets in the current study.  
 Antibodies in vitiligo: possible implications  
 GPNMB, OCA2 protein, and LaminA antibodies in diagnosis 
It is clear that the occurrence of antibodies is a feature of vitiligo. Antibodies that are 
highly disease specific do exist in different autoimmune disorders and are likely to reflect 
unique pathological aspects in each case. Such antibodies have proven to be efficient 
diagnostic and prognostic markers. For instance, anti-DNA antibody titres in systemic 
lupus erythematosus patient sera can be correlated with disease activity and the 
presence of anti-Scl70 and anti-centromere protein B antibodies can be predictive tools 
in systemic sclerosis (Riboldi et al., 2005, Nihtyanova and Denton, 2010). Therefore, 
antibodies are likely to be useful diagnostic and prognostic markers in vitiligo, 
particularly in early disease to differentiate melanoma from vitiligo as patients with 
melanoma can demonstrate skin whitening before melanoma detection with a clinical 
manifestation that resembles vitiligo (Picardo et al., 2015), and the significance of early 
treatment for melanoma is well-established (Bishnoi and Parsad, 2018). The presence of 
specific antibodies or increased occurrence of such antibodies can be an indication of 
the involvement of other organs in some autoimmune diseases like antibodies to Sm 




reactivity seems to occur more frequently in active vitiligo with regard to GPNMB 
antibodies, but this was not the case for antibody responses against the OCA2 protein 
or LaminA. However, to verify these findings further investigations of a larger series of 
patients is required. 
 Possible origin of GPNMB, OCA2 protein, and LaminA antibodies 
One of the principal reasons for supporting the autoimmune theory in vitiligo 
pathogenesis is that a variety of antibodies are identified in patients with the disorder. 
However, it is not entirely clear how antibodies originate against cytoplasmic antigens.  
Previous studies have demonstrated that intracellular antigens in cells undergoing 
apoptosis can be contained into apoptotic blebs or microbodies and then released and 
clustered on the cell surface (Herrmann et al., 1998, Casciola-Rosen et al., 1999). Since 
deficiency in taking up apoptotic cell materials has been described in different 
autoimmune diseases, accumulation of cytoplasmic proteins from apoptotic waste 
inside the microbodies can become source for autoantigens that activate dendritic cells 
and trigger immune responses by which antibody production could be stimulated and 
directed against these fragments (Munoz et al., 2010, Mahajan et al., 2016). 
Additionally, accumulating evidence shows that alteration in epigenetic modification, 
such as DNA methylation and histone acetylation, can contribute to the development of 
autoreactive B cells and the induction of antibodies reactive to intracellular antigens 
(Renaudineau et al., 2010, Mahajan et al., 2016). For example, a systemic lupus 
erythematosus-like syndrome has been shown to develop in some patients following 
treatment with drugs such as hydralazine or procainamide, which prevent DNA 
methylation and hence initiate the disorder (Dubroff and Reid, 1980, Mahajan et al., 
2016). 
The intracellular location of GPNMB, OCA2 protein, and LaminA, suggests that the 
development of antibodies to these proteins most likely arises from melanocyte damage 
instigated mainly by non-antibody-dependent processes like oxidative stress or 
cytotoxic T cells (Abdel-Naser et al., 1992, Lang et al., 2001, Schallreuter et al., 2005, 
Dell'anna and Picardo, 2006, Shalbaf et al., 2008, van den Boorn et al., 2009). Several 




intracellular melanocyte proteins, and these include neo-antigen formation, exposure 
of cryptic epitopes and protein modification during apoptosis (Namazi, 2007, Westerhof 
and d'Ischia, 2007, Kemp et al., 2011). Following processing by dendritic cells, antigenic 
proteins can be presented to either autoreactive T cells which evaded clonal deletion or 
to naïve T cells which have not been tolerised against cryptic epitopes (Namazi, 2007, 
Westerhof and d'Ischia, 2007, Kemp et al., 2011). In consequence, antibodies can be 
secreted following autoreactive B cell stimulation by activated autoreactive CD4+ T 
lymphocytes (Namazi, 2007). 
Interestingly, GPNMB has been found to be expressed on the surface of melanocytes, 
albeit to a lesser amount than the intracellular fraction (Tomihari et al., 2009). In 
addition, surface expression of LaminA on melanocytes has been revealed by 
lactoperoxidase-labelling technique, a method that labels only molecules exposed on 
the external surface of cells (Bystryn, 1989, Cui et al., 1995). Also, mislocalisation of 
mutant OCA2 protein to the surface of melanocytes has been reported (Sitaram et al., 
2009). Therefore, these proteins could be accessible as antibody targets in such cases. 
This is important as antibody-mediated melanocyte destruction requires the expression 
of target antigens on the cell surface. As such GPNMB, OCA2 protein, and LaminA may 
be available for binding by antibodies, but antibody-mediated cytotoxicity directed 
against these proteins has to be investigated in vitiligo. 
Antibody production in vitiligo may also arise from other stimuli such as a genetic 
susceptibility to autoimmunity and cross-reactivity with microorganism antigens (Kemp 
et al., 2002b). Equally, antibodies against these proteins might represent an 
epiphenomenon emerging as a result of damage to pigment cells by other causal factors, 
albeit they might then act to further aggravate vitiligo (Kemp et al., 2002b). 
 Possible pathogenic effects of GPNMB, OCA2 protein, and LaminA antibodies 
The presence of antibodies to melanocytes in vitiligo patients suggests that they may be 
involved in the disease pathogenesis. This possibility is supported by the observations 
that most target antigens in vitiligo patients are expressed on the melanocyte surface 
where it is accessible to interact with immune effector mechanisms and that there is a 




(Bystryn, 1989, Cui et al., 1992, Cui et al., 1995, Kemp et al., 2011). However, it is 
presently unknown if antibody abnormalities in vitiligo are a primary or secondary cause 
of the disease. 
GPNMB, OCA2 protein, and LaminA are intracellularly located, although surface 
expression of GPNMB, LaminA, and mutant OCA2 protein on melanocytes has been 
reported (Cui et al., 1995, Sitaram et al., 2009, Tomihari et al., 2009). However, a 
previous study has provided evidence that antibody-mediated protection does not 
terminate at the cell membrane, for instance, antibodies to the intracellular SSA antigen 
in systemic autoimmune diseases can exert their cytopathic immune attack inside the 
cells (Mallery et al., 2010, Racanelli et al., 2011, Yoshimi et al., 2012). Previous studies 
have shown that antibodies targeting specific proteins can alter the activity of such 
proteins. In patients with autoimmune polyglandular syndrome type 1, for example, 
antibodies reactive to TH have been found to have an inhibitory effect on the enzyme 
activity (Hedstrand et al., 2000). Expression of OCA2 protein and GPNMB have been 
detected in cutaneous melanocytes particularly in melanosomes, where they have been 
suggested to play a role in the transportation of tyrosinase to melanosomes and the 
transfer of melanosomes to keratinocytes, respectively (Yamaguchi and Hearing, 2014). 
However, to date, the functions of OCA2 protein and GPNMB in melanin synthesis are 
not clearly characterised and hence conclusions on how antibodies that might affect the 
functions of OCA2 protein and GPNMB could affect melanogenesis and ultimately 
melanocyte behaviour are difficult to be made. In the case of LaminA, it is a structural 
molecule vital in cell stability and post-mitotic nuclear reorganisation (Hozak et al., 1995, 
Schoft et al., 2003, Dittmer and Misteli, 2011), but how this specific protein relates to 
melanogensis has not been reported. 
Other possible pathogenic effects of GPNMB, OCA2 protein, and LaminA antibodies 
include complement binding and antibody-dependent cellular cytotoxicity. However, 
how the interactions between such antibodies and their cytoplasmic antigens occur to 
destroy melanocytes via a cytoplasmic mechanism is difficult to imagine. Although 
melanocyte damage by vitiligo-associated antibodies has been demonstrated by both 
complement-mediated activation and antibody-dependent cellular cytotoxicity (Norris 




antibodies may merely serve as useful markers for melanocyte destruction and/or 
autoreactive T cells that are cytotoxic to melanocytes. Indeed, several melanocyte 
autoantigens that are recognised as antibody targets, for example tyrosinase, are also 
the target of T cell responses in vitiligo skin (Ogg et al., 1998, Lang et al., 2001, Palermo 
et al., 2001, van den Boorn et al., 2009). 
If indeed antibodies to GPNMB, OCA2 protein, and LaminA have cytopathic effects, and 
this remains to be confirmed, the selective damage of melanocytes in vitiligo might 
occur as the result of the fact that pigment cells are relatively susceptible to immune 
injury, as opposed to, for instance, fibroblasts and keratinocytes (Norris et al., 1988). 
Antibodies in vitiligo were capable of destroying pigment cells in vitro (Norris et al., 
1988) and in vivo following the injection of patient IgG into nude mice grafted with 
human skin (Gilhar et al. 1995). However, the exact pathogenic role the GPNMB, OCA2 
protein, and LaminA antibodies play in vitiligo is still unclear. 
 Future Work 
This work could be improved by the analysis of more vitiligo patient serum samples for 
GPNMB, OCA2 protein, and LaminA antibodies. Moreover, in order to extend the 
preliminary findings, additional cases with segmental form of vitiligo as well as subjects 
with stable vitiligo should be tested for the occurrence of antibodies reactive to GPNMB, 
OCA2 protein, and LaminA. Nevertheless, it is unlikely to be able to provide sufficient 
numbers of patients with these categories in the short-term. Other future studies can 
also include: 
 Identification of GPNMB, OCA2 protein, and LaminA antibodies which 
recognise conformation-dependent epitopes 
In the pathogenesis of autoimmune diseases, it is of prime importance for antibodies to 
interact with conformational epitopes. In Graves’ disease and autoimmune 
hypothyroidism, for instance, it is well established that the most prevalent antibodies to 
the thyrotropin receptor and thyroid peroxidase, respectively, and which are 




conformational epitopes (Morgenthaler et al., 1999, Gora et al., 2004). It is likely that 
antibodies that bind to conformational epitopes on the native proteins of GPNMB, OCA2 
protein, and LaminA were not detected in the RLBAs that use recombinant GPNMB, 
OCA2 protein, and LaminA. The prevalence of the humoral immune responses against 
these proteins in vitiligo may, therefore, be underestimated. Identification of antibodies 
that recognise conformational epitopes can be an important future goal. This can be 
undertaken by using GPNMB, OCA2 protein, and LaminA expressed in a mammalian cell 
line in immunoprecipitation assays. Using a mammalian expression system allows the 
production of the native structure of these antigens. A previous study in our laboratory 
identified calcium-sensing receptor antibodies by utilising this technique (Gavalas et al., 
2007). 
 Examination of the possible effects of GPNMB, OCA2 protein, and LaminA 
antibodies on the function of their respective targets 
Antibodies that affect the function of GPNMB, OCA2 protein, and LaminA are more likely 
to play a part in vitiligo aetiology than just being antibodies that bind GPNMB, OCA2 
protein, and LaminA.  For instance, in Graves’ disease, antibodies to thyroid-stimulating 
hormone receptor can mimic the action of thyroid-stimulating hormone by binding to 
the receptor and subsequently stimulate hyperthyroidism (Weetman and McGregor, 
1994, Chistiakov, 2003, Davies and Latif, 2015, Giménez-Barcons et al., 2015). Thyroid-
stimulating hormone receptor mediates the activation of thyroid-stimulating hormone 
to thyroid glands, resulting in thyrocytes growth and proliferation and production of 
thyroid hormone (Chistiakov, 2003, Davies and Latif, 2015, Giménez-Barcons et al., 
2015). In addition, function-blocking antibodies to the acetylcholine receptor, affecting 
the receptor activity have been detected in patients with myasthenia gravis. Antibody 
reactivity to this receptor can interfere with and block binding sites of acetylcholine 
causing receptor functional loss and degradation resulting in myasthenia gravis 
(Hoedemaekers et al., 1997, Meriggioli and Sanders, 2012).  
Antibodies to GPNMB, OCA2 protein, and LaminA might have deleterious effects on the 
functioning of these proteins leading to impaired melanocyte behaviour in vitiliginous 




LaminA are generally located inside the cell, evidence is presented that antibody-
mediated protection does not terminate at the cell membrane, for instance, antibodies 
to the intracellular SSA antigen in systemic autoimmune diseases can exert their 
cytopathic immune attack inside the cells (Mallery et al., 2010, Racanelli et al., 2011).  
Moreover, in patients with autoimmune polyglandular syndrome type 1, for example, 
antibodies reactive to TH have been found to have an inhibitory effect on the enzyme 
activity (Hedstrand et al., 2000). Thus, the effects of vitiligo IgG on the functions of 
GPNMB, OCA2 protein, and LaminA should be evaluated in an in vitro assay (Daubner 
and Fitzpatrick, 1993, Lou et al., 2010). 
 Examination of vitiligo patient lesions for GPNMB, OCA2 protein, and LaminA 
antibodies  
So far, the GPNMB, OCA2 protein, and LaminA antibodies identified have just been 
circulating antibodies in the sera of vitiligo patient. Therefore, further studies on the 
determination of whether patient GPNMB, OCA2 protein, and LaminA antibodies are 
also found in situ, in skin from active vitiligo lesions would be of interest. Moreover, the 
co-localisation of purified vitiligo patient GPNMB, OCA2 protein, and LaminA antibodies 
and expressed GPNMB, OCA2 protein, and LaminA within the same skin tissue sample 
could be evaluated using double indirect immunofluorescence technique. 
 Investigation of cytotoxicity of GPNMB, OCA2 protein, and LaminA antibodies  
In vitro studies have demonstrated that anti-melanocyte antibodies in vitiligo patient 
sera can damage cultured melanocytes, both by complement-mediated damage and 
antibody-dependent cellular cytotoxicity (Norris et al., 1988). In addition, injection of 
IgG molecules from vitiligo patient sera have the ability to destroy melanocytes of the 
human skin grafted onto nude mice (Gilhar et al., 1995). Similar studies would be of 
interest in order to investigate if GPNMB, OCA2 protein, and LaminA antibodies in sera 
of vitiligo patients may able to exert damaging effects on melanin-producing cells by 




 Investigation of T cell responses against GPNMB, OCA2 protein, and LaminA  
A number of studies have reported the occurrence of melanocyte-specific CD8+ 
cytotoxic T lymphocytes circulating in the sera of vitiligo patients. These vitiligo- 
circulating lymphocytes specifically recognise pigment cell differentiation antigens e. g., 
tyrosinase , MelanA/MART-1 and PMEL (Ogg et al., 1998, Lang et al., 2001, Le Gal et al., 
2001, Palermo et al., 2001, Mandelcorn-Monson et al., 2003, Le Poole et al., 2004, 
Garbelli et al., 2005, Le Poole and Luiten, 2008, van den Boorn et al., 2009). These 
cytotoxic T cells are characterised by high expression of the skin-homing receptor 
cutaneous lymphocyte-associated antigen (Lang et al., 2001). In addition, their numbers 
are associated with both disease activity and extent supporting a critical role for the 
involvement of cell-mediated immunity in vitiligo (Lang et al., 2001). Thus, further 
studies that would be of special importance are to investigate into T cell reactivities to 
GPNMB, OCA2 protein, and LaminA, since antibodies to GPNMB, OCA2 protein, and 
LaminA might be just markers of autoreactive anti- GPNMB, OCA2 protein, and LaminA 
T lymphocytes in vitiligo patients. 
 Overall conclusions  
The work in this study has concentrated on describing the demographic and clinical 
profiles of our Sheffield vitiligo patient cohort as well as on identifying and characterising 
putative antibody targets in vitiligo patients. The demography and comorbidities for 
vitiligo patients in Sheffield were generally in accordance with finding from elsewhere 
in the world, supporting a role for autoimmunity in the development and progression of 
vitiligo. Several novel autoantigens were identified by using the phage-display 
technology and the immunoreactivity of three potential autoantigens (GPNMB, OCA2 
protein, and LaminA) against a panel of vitiligo patient sera were confirmed by using the 
RLBA. 
However, the relationship between antibodies reactive to GPNMB, OCA2 protein, and 
LaminA, and indeed all vitiligo-associated antibodies, and the disease pathogenesis still 
remain to be determined. The likelihood that the GPNMB, OCA2 protein, and LaminA 




autoreactive anti-GPNMB, OCA2 protein, and LaminA T lymphocytes ought to be 
investigated. Regardless of whether or not they are directly pathogenic, antibodies to 
GPNMB, OCA2 protein, and LaminA may act as potential markers for epidermal 
melanocyte disruption in vitiligo and, therefore, further characterisation of them will be 
helpful in further elucidating the causative role of autoimmunity in vitiligo.  
As is true for most autoimmune disorders, the answer to several key questions is 
unknown. Characterising the specificities of antibodies in vitiligo as well as the detection 
of their expression in vitiligo lesions may help resolve the questions as to whether: (i) 
the melanocyte antibodies are a cause or a result of the disease, (ii) there is a primary 
defect in the immune system such as tolerance breakdown that results in autoimmune 
responses to melanocytes and to the subsequent damage of these cells, (iii) or there is 
an initial injury to pigment cells that leads to release of melanocyte antigens and to the 
subsequent stimulation of an immune response to such antigens. In any one of these 
cases, once pigment cells are injured, release of other antigens could exaggerate 
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